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Summary
We have undertaken a mutagenic and cell biological study o f the properties o f the rat insulin like growth 
factor binding protein-2 (IGFBP-2). This 32kDa protein belongs to a family o f six high affinity IGFBPs 
(IGFBP 1-6) which are well characterised in both rodents and humans.
In initial studies we mutated two highly conserved proline residues in the N-terminal region of 
IGFBP-2 to create the mutant proteins P20A-IGFBP-2 and P22A-IGFBP-2 and expressed these proteins 
along with wild type rat IGFBP-2 in the baculovirus/insect cell system. We found that this expression 
system was able to produce correctly folded, functional rat IGFBP-2 and using solution phase equilibrium 
binding techniques we demonstrated that the affinity o f these mutated proteins for both IGF-I and IGF-II 
was similar to that of the wild type protein. We conclude that, although highly conserved in all IGFBP 
species, these proline residues are not involved in the IGF ligand binding site o f rat IGFBP-2.
In order to investigate the biological functions of IGFBP-2 in the regulation of IGF action we 
undertook experiments to establish a cell culture model in which the appropriate components of the IGF 
axis were present to allow such an investigation to take place. In initial experiments we screened several 
cell lines for the presence of cell or extra-cellular matrix associated IGFBP-2 (a phenomenon which 
limited reports in the literature had previously described). For one of these cell lines Clone 9 - a cell line 
derived from rat liver- we demonstrated clearly by Western blotting, ligand blotting and 
immunoprecipitation the association of IGFBP-2 with the surface of the cell line although experiments to 
determine the chemical nature of this interaction proved inconclusive. In addition to the demonstration of  
cell membrane associated IGFBP-2 we also identified the presence of IGF-I receptor on these cells and we 
were also able to show that these cells secrete IGF-I (but not IGF-II) into the surrounding medium.
The identification of these components of the IGF axis in Clone 9 cells encouraged us in 
biological experiments to examine the possible modulatory role of cell-membrane associated and secreted 
IGFBP-2 on the modulation o f IGF-I activity at the IGF-I receptor. We initially established that Clone 9 
cells do indeed respond to exogenous IGF-I both in short term signalling events (acute tyrosine
10
phosphorylation of a 180kDa protein) and in longer term metabolic/mitogenic assays as determined by 
MTT-formazan dye conversion.
Further, we demonstrate, by the use of the IGF-I analogue des(l-3) IGF-I (which does not interact with 
IGFBPs but retains wild type potency at the IGF-I receptor) that IGF-I activity is inhibited both acutely 
and in longer term assays by the presence of IGFBP-2. We postulate that the former inhibition may be due 
to the association of IGFBP-2 with the plasma membrane of Clone 9 cells while the latter may be more 
related to the accumulation o f IGFBP-2 in the conditioned medium.
In order to further test and clarify this hypothesis we finally report on some preliminary 
experiments aimed at stably transfecting Clone 9 cells with sense or antisense IGFBP-2 constructs. Initial 
characterisation of mixed populations of such cells show no difference in basal growth rates between 
control, antisense and sense transfected cells although we observed reduced secretion of IGFBP-2 into 
conditioned medium by antisense transfected cells. We believe that the use o f these cells will aid in the 
clarification of the role of IGFBP-2 in the regulation of the autocrine and perhaps paracrine role of IGF-I. 
In the final chapter of this thesis we expand on those areas o f the current work which we feel would 
benefit from further research
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OVERVIEW
Insulin-like growth factors (IGFs) were first discovered while investigating the mode o f action of 
pituitary growth hormone (GH) (Salmon and Daughaday, 1957). Many o f the in vivo growth effects 
attributed to GH were demonstrated to be not due to the direct interaction of GH with its own receptor, but 
the result of the GH-stimulated increase of a circulating plasma factor, IGF-I, which subsequently exerted 
potent metabolic and mitogenic effects at the tissue level. For this reason IGF-I is often referred to as 
somatomedin (i.e. mediator of somatotropin, which was the name traditionally attributed to GH) (Van 
Wyk et al., 1974). Since they were discovered, many studies have been undertaken to characterize IGF 
molecular features and to highlight the complexity o f their regulation and the multiplicity o f their 
functions.
There are two IGF peptides, IGF-I and -II, which share similar structure and which are related to 
insulin. IGF-I and n  are both widely expressed in the tissues but they show a distinct hormonal regulation, 
tissue specificity and dependence on physiological status. Both IGF-I and -II seem to exert their 
physiological action through the cell membrane IGF-I receptor, but they can also bind IGF-n and insulin 
receptors. The local concentration of IGFs and the abundance of the receptors on the cell membrane are 
not the only factors that influence IGF biological action as the actual bioavailability o f the peptides also 
plays a major role. In fact in the plasma and tissues only a small percentage of IGFs are present in a free 
form with the bulk of hormone complexed with a family o f IGF-binding proteins (IGFBPs).
The IGFBP family comprises 6 well characterised members each of which binds IGF-I and -II with a 
different affinity. IGFBPs can be found ubiquitously in the organism, although they have a different tissue 
specificity and regulation o f gene expression.
When IGFBPs were first identified in the plasma they were believed to function mainly as carrier 
proteins as it was shown they significantly increase IGF half-life in blood and regulate IGF distribution to 
the tissues. Lately when IGFBPs were found to be expressed in virtually all body tissues and in vitro cell 
cultures it became the general opinion that IGFBPs exerted an inhibitory effect on IGF action by 
sequestering the peptides from interaction with IGF-I receptor.
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However as research continued, an increasing number of studies reported that in some cell 
systems IGFBPs displayed an IGF enhancing effect. This observation implies that, although IGFBPs 
generally reduce IGF bioavailability, in some cases IGFBPs may somehow augment IGF’s interaction 
with its receptor. It became clear that the in vitro determined affinity constants o f IGF for IGFBPs or for 
the receptor might not give a real picture o f what happens in a biological context. In fact the association of 
IGFBPs with the cell surface or the extracellular matrix (ECM), the presence in biological fluids and cell 
conditioned media of specific IGFBP proteases and the occurrence of postranslational modifications of 
IGFBP molecules can significantly affect the IGF-binding affinity and therefore have a considerable 
impact on IGF action. Many more questions still need to be answered in order to highlight the precise 
mechanism by which IGFBPs dynamically modulate IGF bioavailability. In addition, the well reported 
IGF-independent effects that IGFBPs seem to exert by directly interacting with cell membrane proteins is 
also worth further investigations.
The apparent redundancy o f six IGFBPs for one common function (i.e. binding IGFs) is unusual 
and alternative functions have been postulated. One hypothesis is that each IGFBP member, at the 
molecular level, plays a specific biological role. Alternatively the final IGFBP biological effect could 
result from a reciprocal modulation between IGF, IGFBP and the environment and therefore the same 
IGFBP may exert different actions in different biological contexts. Additional information on the 
molecular features of IGFBPs and on the IGF-IGFBP-environmental axis will be important for 
understanding the mechanism involved in the widely described but never elucidated IGF enhancing effect 
of IGFBPs. Again, the existence of two IGFs and two IGF receptors might look unnecessary duplication 
as both growth factors seem to signal only through the IGF-I receptor.
These are just some aspects of the complexity o f the IGF-IGFBP axis which stimulated our interest 
and led to our work into this research area.
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1. INTRODUCTION
1.1 Insulin-like growth factors (IGFs)
Insulin-like Growth Factors, IGF-I and IGF-II, are small polypeptide hormones structurally and 
functionally related to insulin Despite many similarities with insulin, IGFs show a distinct biological 
action and play specific roles in the organism.
1.1.1 IGF STRUCTURE
IGFs are single chain, basic polypeptide hormones o f about 7.5 kDa (Daughaday and Rotwein, 
1989; Rotwein 1991). The mature protein, based on the similarities with insulin, can be divided into 4 
distinct domains:
•  A and B domains correspond to the a and b chains of the mature insulin molecule The B domain 
contains the N-terminus of the IGF molecule. The A and B domains of IGF-I and II share 70% 
identity, while the overall amino acid sequence homology between IGF A-B domains and insulin a-b 
chains is as high as 50% (Phillips et al., 1998).
•  a 12 residue C domain (8 residues in IGF-II) which links the A and B domain and corresponds to the 
peptide that connects the a and b chain in pro-insulin. (De Meyts et al., 1994)
•  and a 8 amino acid D domain (6 residues in IGF-II) which represents the C-terminus o f the IGF 
molecule (De Meyts e t al., 1994).
In addition some incompletely processed high Mr IGF-I and n  have been described. A 12-18 kDa 
pro-IGF-I retains part of the signal peptide (Goldstein and Phillips, 1989; Acquaviva et al., 1982; 
Goldstein and Phillips, 1991). Instead the so-called “big IGF-II” is an immature IGF-II molecule with a 
carboxyl terminal extension due to the incomplete cleavage of the E domain that is present in pro-IGF-II. 
A big IGF-II form referred to as (El-21) is one o f the factors which is associated with the appearance of 
hypoglycemia in non islet cell tumors (Hizuka et al., 1998).
IGF and insulin are also very similar in 3-D structure and they have 3 similar disulfide bridges 
(De Meyts et al., 1994).
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In Fig 1.1.1 the tertiary structure of IGF-I, proinsulin, insulin and relaxin, all members of 
insulin/IGF peptide hormone family is compared (Fig from De Meyts et al., 1994, with permission).
1.1.2 IGF RECEPTORS
Two IGF receptors, IGF-IR and Man6P/IGF-IIR are present at the cell surface, but most of the 
biological actions attributed to IGF-I and -II appear to be mediated by the IGF-IR
1.1.2a Type 1 IGF-I receptor or IGF-IR
IGF-I receptor (IGF-IR) has a wide distribution in tissues and cell cultures (as has the insulin 
receptor, IR). It is believed that IR has a predominant metabolic effect, while IGF-IR is mainly 
mitogenic/transforming/antiapoptotic (Sepp-Lorenzino, 1998). i) The structural similarity between the two 
receptors; ii) the fact that they coexist in many cell lines; iii) the possibility that insulin or IGF-I cross- 
reacts with IGF-IR or IR respectively; iv) the naturally occurring formation of IR-IGF-IR hybrids and v), 
the overlapping pathways activated by the two receptors are some of the difficulties involved in trying to 
identify where insulin and IGF-I receptor signals diverge.
IGF-IR binds IGF-I with high affinity (k  ^ lO^M), IGF-II with 10 fold lower affinity and it can 
also bind insulin weakly (with 500-1000 fold lower affinity than for IGF-I) (Nissley et al., 1991). IGF-I 
receptor is an a 2p2 heterotetrameric glycoprotein, very similar to the insulin receptor (IR) (De Meyts et 
al., 1994). The extracytoplasmic a  subunit (Mr 130kDa) represents the ligand binding domain and it is 
disulphide bonded to the P subunit (Mr 95kDa) which is responsible for signal transduction (Moss and 
Livingston, 1993; Alexandrides et al., 1993). The P subunit is formed by a short extracellular domain, a 
single membrane-spanning domain, a juxta-membrane domain, an ATP binding site and a tyrosine kinase 
domain. Extensive mutagenic studies of the p subunit led to the identification of sequences and domains 
which are specifically involved in either the mitogenic, transforming or antiapoptotic function of the 
receptor or identified regions required for IGF-IR internalization after ligand binding (Sepp-Lorenzino, 
1998).
Unlike other growth factor receptors, IGF-IR is a constitutive dimer (De Meyts et a l ,  1994), 
being formed by two functional a-P halves linked to each other by disulphide bridges. The receptor 
activation only occurs when the 2a  subunits are bridged through the ligand molecule. There are 2 binding
15
Fig 7.7.7
Comparison of tertiary structure of members 
of insulin/IGF peptide hormone family
B30
A21
insulin Proinsulin
IGF-
Computer modeling of tertiary structure of insulin, proinsulin, IGF 
and relaxin. These peptides together with IGF-II, invertebrate 
bombexin and molluscan insulin-like peptide form a family of 
peptide hormones.
(From De Meyts et al., 1994, with permission)
Relaxin
domains in each a  subunit and each IGF-IR binds one IGF molecule with high affinity and a second one 
with 10 times lower affinity causing curvilinear Scatchard plots. The concentration of the ligand might 
modulate effectiveness o f signalling as the binding o f a second molecule to the receptor causes the release 
o f the first ligand molecule in a negative cooperativity manner (De Meyts et a l, 1994). Ligand binding at 
the extracellular a  subunit results in the activation of the tyrosine kinase domain of the J3 subunit which 
gives rise to a reciprocal (3 subunit transphosphorylation and to tyrosine phosphorylation o f signal 
mediator proteins, such as IRS-I and She and Crk (Rubin and Baserga, 1995). Each one of these proteins 
can then bind several other protein substrates so that the signal cascade proceeds down the pathway but it 
is also propagated horizontally to other pathways. Probably the most important pathway through which 
IGF-I exert its mitogenic effects is the activation of the ras-raf-MAP kinase pathway. IGF-IR does not 
activate ras directly but the activated IRS-I, She and Crk bind Grb-2 protein which finally binds mSOS 
and the signal continues through ras and the MAP kinase pathway. Activated IRS-I also binds p85 subunit 
o f the phosphatidyl-3 kinase (PI 3K) and stimulates the activity of p i 10 catalytic subunit o f PI 3K. The PI 
3 kinase pathways might be involved in the survival-promoting action of IGF-I activating Akt pathways 
(Dudek et al., 1997). A diagram of IGF-I signal transduction pathways is shown in Fig. 1.1.2. a.
As indicated above, through the activation o f cytoplasmic protein mediators, the signal can 
spread horizontally leading to the simultaneous activation of multiple signal pathways which share 
common mediators. It is note-worthy that not only do many pathways share the same mediators, but that 
signal initiated from different receptors might be transduced through the same pathway and still produce 
different specific effects. Therefore in cells which express a variety o f receptors there must be a way for 
each receptor to exert specific effects. It has been suggested that each receptor might activate a still 
unidentified characteristic mediator or perhaps may activate common mediators in a unique manner 
(Rubin and Baserga, 1995). Moreover De Meyts et a/. (1994) suggest that the consideration of quantitative 
and time related aspects of signalling events might help to answer these questions.
1.1.2b Type 2 IGF receptor or IGF-IIR
The IGF-IIR is a monomeric, 260kDa glycoprotein homologous to the cation-independent 
mannose 6-phosphate receptor which is involved in trafficking of the lysosomal enzymes (Jones and 
Clemmons, 1995a; Sepp-Lorenzino, 1998). The IGF-II/Man-6-P receptor consists o f 15 extracellular
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contiguous repetitive domains (each o f 150aa in length) (Marron-Terada et al., 1998) and a short 
cytoplasmic domain which does not have tyrosine kinase activity. IGF-II/Man-6-P receptor is also present 
on other organelle membranes and its function as a carrier in the delivery o f newly synthesized lysosomal 
enzymes is well known. The receptor situated on the membrane of Golgi vesicles binds the mannose 
residues of the newly synthesized lysosomal enzymes and delivers them to the endosomes. From there the 
receptor-enzyme complex reaches the lysosomes where the acidic pH allows the enzymes to dissociate 
from the IGF-II/ Mannose 6 phosphate receptor and the unoccupied membrane-bound receptor can then be 
recycled through the Golgi network (Brown et al., 1986).
Two distinct forms of Man-6-P receptors (215kDa and 46kDa as described in Clone 9 rat liver cells) are 
present on the cell surface and become internalized after binding Man-6-P containing proteins, but only 
the 215kDa form is able to bind IGF-II (Matovcik et al., 1990).
The binding, to IGF-IIR/Man-6-P, o f some ECM glycoproteins, or renin (Faust et al., 1987) proliferin 
(Lee and Nathans, 1988), thyroglobulin (Herzog et al., 1987) and the latent form of transforming growth 
factor-p (TGF-P) (Purchio et al., 1988) has been reported. In this last case the latent form of the TGF-P 
after binding to IGF-IER/Man-6-P receptor is cleaved and becomes active (Dennis and Rifkin, 1991).
Cell membrane IGF-Il/Man-6-P receptor binds IGF-II peptide with high affinity (0.017-0.7nM) (Nissley et 
al., 1991), has 500-1000 fold lower affinity for IGF-I and it does not bind insulin (Jones and Clemmons, 
1995a). Man-6-P and IGF-II are competitors for binding to the receptor. After ligand binding has occurred 
the membrane bound receptor is internalized and IGF-II degraded at a lysosomal level (Oka et al., 1985). 
The extracellular portion of the receptor can be proteolytically cleaved and reaches the circulatioa 
Whether or not this circulating molecule has a role in the regulation of IGF-II is not clear (LeRoith, 19%). 
The biological function of IGF-II/Man-6-P receptor also remains unclear. There is a general agreement on 
its function as a scavenger receptor. In IGF-IIR knock out mice 100% of foetuses died at 15 days of 
gestation (Lau et al., 1994; Wang et al., 1994). W^hen IGF-IIR and IGF-II genes are both deleted some of 
the foetuses carried on gestation till birth and one pup reached adulthood. These data seem to indicate that 
at least in the foetus IGF-II clearance through IGF-II receptor is essential (Filson et al., 1993).
It is also believed that most of the biological functions attributed to IGF-II are mediated through the IGF- 
IR. Nevertheless, there are some reports on IGF-n actions mediated through the IGF-IIR. In a rat
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neuroblastoma cell line which expresses both IGF receptors and responds to IGF-I or II with an increased 
cell proliferation, IGF-I treatment also increased the secretion of IGFBP-4 into the conditioned medium. 
In contrast IGF-II decreased IGFBP-4 secretion by 50%. Treatment o f the cells with anti IGF-IIR antibody 
alone caused a 70% inhibition o f IGFBP-4 secretion and the effect was greater if  IGF-II was present at the 
same time. These authors conclude that in this cell line IGF-II acts in part through IGF-I R and in part 
through IGF-II R (Ceda et al, 1991). A signal pathway has never been identified for IGF-D/Man-6-P 
receptor, but the receptor is reported to be coupled with GTP binding proteins. When IGF-II binds to the 
receptor it stimulates the binding o f GTPyS to G& and inhibits the GTPase activity. The observed Ca^ 
influx stimulated by IGF-n in 3T3 fibroblasts could be mediated through IGF-II/Man-6-P receptor and the 
coupled GTP-binding proteins (Nishimoto et al., 1987 and 1989; Murayama et al., 1990; Kojima et al., 
1988). Recently it has been reported that IGF-II promotes exocytosis o f insulin in pancreatic cells through 
Man-6-P/IGFUR. This effect is independent from Ca^ influx and is mediated by the phosphorylation of 
protein kinase C (Zhang et a l ,  1997).
1.1.3 IGF FUNCTIONS
Many similarities between IGF and insulin functions can be reasonably expected considering the 
already mentioned molecular homology between the peptides and their receptors. In addition it has been 
shown that the two receptors can form IR-IGF-IR hybrids in vivo (De Meyts et a l ,  1994) and that a low 
affinity cross-binding between IGF-I and IR or insulin and IGF-IR occurs when the ligands are present at 
high concentration. Furthermore once activated the two receptors seem to share common mediators of 
signal transduction. Despite these considerations it must be pointed out that IGF and insulin have 
developed specific biological roles.
Insulin is a typical endocrine factor. It is produced by J3 cells in the pancreas then enters the 
circulation and reaches the target organs -mainly liver, muscle and adipose tissue- where it stimulates 
anabolism via glucose and amino acid uptake.
IGF-I has an endocrine mode of secretion in the liver where it is primarily under GH control and 
this provides the main source of circulating IGF-I. Typical o f an endocrine hormone is also the negative
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regulation of pituitary GH secretion that is triggered by increased IGF-I plasma concentration (Phillips et 
al., 1998). Conversely, unlike typical endocrine hormones, IGF-I is also expressed in many organs and 
tissues in an autocrine/paracrine fashion. In some cases as in the epiphyseal growth plate (Jennische et al., 
1992), in the ovary (Giudice, 1992) and kidney (Chin et al., 1992) this local production is under GH 
regulation, while in other cases, such as in the uterus (Murphy et al., 1987), IGF-I expression is GH- 
independent. In some pathological states GH regulation o f hepatic IGF-I production can be overcome by 
inhibitory factors. An abnormally low plasma insulin concentration or a restricted availability o f energy 
and protein (in particular essential amino acids) negatively regulate IGF-I despite normal levels o f GH 
(Phillips et al., 1998). The design of the IGF-I gene allows the alternative usage of promoters and 
initiation transcription sites, includes multiple sites of polyadenylation together with alternative splicing 
and variations in mRNA stability offering many opportunities for the regulation o f IGF-I production 
(Phillips et a l,  1998).
Unlike IGF-I, IGF-H secretion occurs in an autocrine/paracrine GH-independent mode (Jones and 
Clemmons, 1995a). IGF-II is the predominant IGF in fetal life, after birth its concentration decreases 
while GH concentration rises and stimulates a concomitant increase in IGF-I. In rat, IGF-I becomes the 
major species in adult plasma (Phillips et al., 1998) while in humans IGF-II is the predominant hormone 
(Gargosky et al., 1990; Suikkari and Baxter, 1992). In the fetus IGF-I is GH independent and its 
responsiveness to GH becomes gradually effective in postnatal life (Jones and Clemmons, 1995a).
IGFs are involved in fetal growth and development. IGF-I, -II and IGF-IR are expressed in rat embryos as 
early as the 8-cell stage (Heyner et al., 1989; Heyner and Garside, 1994). Targetted disruption of the IGF-I 
gene in mice produces a phenotype o f 60% weight at birth, variable postnatal lethality and delays in 
ossification (Baker et al., 1993), whereas IGF-II knockout mice are 60% smaller than normal pups, but are 
otherwise proportionate and vital (DeChiara et al., 1990; DeChiara et al., 1991). Homozygous IGF-IR 
deficient mice only weigh 45% of normal mice. They present abnormalities in various organs and die at 
birth (Liu et al., 1993). The disruption of IGF-I and IGF-IR genes did not further reduce the weight o f the 
embryos. In contrast when the IGF-H gene was disrupted in combination with either IGF-I or IGF-IR 
genes the weight of the embryos dropped to 30% indicating that some o f the growth promoting effect of 
IGF-II is not mediated through IGF-IR (Liu et al., 1993). IGF-IIR knock out mice die in utero, but the
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double suppression of IGF-DR gene and IGF-H gene rescues the mice which show 60% of normal weight 
at birth and are mostly viable (Filson et al., 1993).
1.1.3a The in vivo biological effects o f IGFs 
are mainly:
•  an anabolic insulin-like effect (stimulation o f glucose uptake and glycogen synthesis) on fat and 
muscle cells (Froesch et al., 1985)
•  a growth promoting effect consisting essentially in mediating the GH-stimulated body weight gain 
and skeletal elongation (Salmon and DuVall, 1970)
•  stimulation of cell proliferation in a variety o f organs and tissues (Davoren and Hsueh, 1986; Davoren 
eta l., 1985; Kasson and Hsueh, 1987; Rechler et al., 1976; Conover et al., 1985).
1.1.3b In vitro IGF action 
can be summarized as:
•  promotion of the cell cycle progression from the Go\Gl to the S phase, resulting in DNA synthesis 
and cell proliferation. IGFs stimulate a mitogenic response in many cell types whereas in 
haematopoietic cells and in some carcinoma cell lines they can function as survival factors preventing 
apoptosis. Proliferation and apoptosis signals may share some common pathways as they both induce 
similar changes in the morphology o f the cells (chromatin condensation, loss o f cell-cell contact 
inhibition, nuclear disintegration). This is supported by the observation that overexpression of 
proteins normally associated with cell proliferation can cause apoptosis (Hartwell and Kastan, 1994; 
Steller, 1995; Askew et a l ,  1991; White et a l ,  1991). The anti-apoptotic effect o f IGF might 
represent the result o f two opposite effects, one promoting apoptosis and the other cell proliferation. 
However IGF-I has been shown to support viability in non proliferating cells in culture (Carlsson- 
Skwirut et al., 1989; Beck, 1994; Bozyczko-Coyne et al., 1993; LeRoith et al., 1993; Svrzic and 
Schubert, 1990) suggesting that stimulation o f cell proliferation and anti apoptotic action may be two 
distinct signals (Rubin and Baserga, 1995)
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•  Stimulation of cell differentiation in osteoblasts (Sara and Hall, 1990), chondrocytes (Geduspan and 
Solursh, 1993 ), adipocytes and neural cells (Pahlman e ta l ,, 1991)
• Induction of an acute insulin-like effect on protein and carbohydrate metabolism, especially in 
myoblasts (Dimitriadis et al., 1992)
• Regulation of hormone secretion or induction o f chemiotactic migration in specific cell types. (Stracke 
et al. 1989; El-Badry et al., 1990).
The wide range of IGFs actions is controlled by the availability of the hormones and their receptors. Many 
factors can affect this equilibrium but it is believed that a major role is played by a family o f IGF binding 
proteins.
1.2 Insulin-like growth factor-binding proteins (IGFBPs)
The IGF binding proteins (IGFBPs) constitute a family o f 6 well characterized proteins that bind 
IGFs with high affinity, but do not bind insulin. IGFBPs are identified with a progressive number from 1 
to 6 which represents the chronological order of their discovery. IGFBP Mr ranges between 24 and 40 kDa 
and all members share many similarities in terms o f molecular structure, IGF-binding, biological function, 
gene organization and evolution.
The structure and the functions of insulin-like growth factor binding proteins have been reviewed by Jones 
and Clemmons (1995a) in a comprehensive and detailed manuscript. It is the intention of the present 
introduction to give special emphasis to the literature published in the last four years.
Recently a new group of low affinity IGF binding proteins has been described which comprises 
mac25, CTGF, nov, and cyr6\. As these proteins share some structural similarities with IGFBPs and can 
bind weakly to IGFs, they were initially named IGFBP-7, 8, 9 and 10 respectively. However at the fourth 
IGF Symposium (Tokyo) it has been recommended to group these proteins in the IGFBP superfamily 
under the heading of lGFBP-related proteins. Further elucidation of the molecular and biological features 
o f these proteins is necessary for their definitive classification (Baxter et al., 1998).
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For simplicity, only the 6 high-affinity IGFBP members will be considered in this introduction 
while characteristics of the IGFBP-related proteins compared to IGFBP (1-6) will be described separately.
1.2.1 IGFBP STRUCTURE
Analyzing the aligned amino acid sequences o f the 6 IGFBPs it appears that they all have 16-18 
cysteine residues in conserved positions. Based on cysteine distribution and on sequence homology, the 
IGFBP molecule can be divided in 3 distinct regions (Fig 1.2.1):
•  an N-terminal region which typically contains 12 cysteine residues (exceptions are human and rat 
IGFBP-6 that lack 2 and 4 Cys residues respectively) (Shimasaki et al. 1991)
• a central region which is virtually cysteine-free (except in human, bovine and rat IGFBP-4 which 
contain 2 Cys (Landale eta l., 1995).and
• a C-temunal region which contains the remaining 6 cysteines.
The N terminal and C terminal regions are well conserved among different classes of IGFBPs and 
between different animal species (50% and 80% homology respectively). The conserved homology 
suggests that these two regions might be structurally/functionally essential for the biological activity o f  
IGFBPs. The observation that both the N terminus and the C terminus of IGFBPs are involved in IGF- 
binding and that the C-terminus is necessary for the association o f IGFBPs with the cell surface or the 
extracellular matrix, seems to support this hypothesis.
In contrast the central region is not conserved among different IGFBPs and it is considered as a 
hinge domain which connects the N- and C-terminal ends of the molecule. The central region of some 
IGFBPs is a target of specific IGFBP proteases which regulate IGFBP bioavailability (Lee et al., 1997; 
Clemmons, 1997; Zheng et al., 1998a). A schematic diagram of IGFBP general structure is shown in Fig.
1. 2. 1.
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Fig 1.2.1
3 domain structure of IGFBPs
N- terminal region- 12 Cys
C- terminal region- 6 Cys J  hiSh structural homology 
Central region-Cys-free, no sequence homology
The high number of Cys residues indicates that IGFBPs are probably highly structured and that the 3-D 
structure might be important for the functionality o f these proteins. It is believed that most, i f  not all, the 
cysteines are engaged in disulfide bridges. The demonstration that the 18 cysteines in hIGFBP-3 (Sommer 
et al. 1991) and at least 16 cysteines in hIGFBP-1 (Brinkman et al., 1991a) are disulphide bonded supports 
this assumption. Links between Cys56-Cys69 and Cys63-Cys89 were identified in rat IGFBP-3 with peptide 
mapping procedures (Hashimoto et a l ,  1997). Recently Kalus et al.(1998) analyzed IGFBP-5 region 
between Ala40 and lie92 and concluded that the formation of disulphide bridges between Cys 47-Cys60 and 
Cys54-Cys80 are the most likely to form and they correspond exactly to the cysteine pairs reported by 
Hashimoto in IGFBP-3.
However it was not clear whether the disulphide links were established intra domain or if  they 
cross-linked the N terminus and C terminus domains. The observation that it was possible to isolate the N- 
terminal region of the IGFBP molecule without reduction of the disulfide bridges suggested that the N- 
terminal and the C-terminal regions were not linked by S-S bridges (Sommer et al., 1991). Recently this 
result has been confirmed by Forbes et al. (1998) using CnBr digestion and SDS-electrophoresis under 
non reducing conditions. This indicated that none of the Cys residues of the N terminus of IGFBP-2 is 
engaged in an interdomain disulphide bridge. In addition the authors assigned the S-S bond pattern in the 
C-terminus of bIGFBP-2 as (Cys186 -Cys220 ; Cys231 -Cys242; Cys244-Cys265) showing that all 6 C-terminal 
Cys residues are engaged in disulphide bonds within the same domain.
An almost contemporary paper showed that no disulfide bonds linked the N-terminal and C-terminal 
regions of hIGFBP-6 and provided also a partial identification of the disulfide bridge pattern (Neumann et 
a l, 1998). In this work hIGFBP-6 fragments resulting from a partial digestion with trypsin or 
chymotrypsin were purified by reverse-phase HPLC under denaturing conditions (6M urea and lOmM 
DTT), but unexpectedly these reducing and denaturing conditions did not break S-S bridges and allowed 
the purification of disulfide bonded peptides. The authors propose that the location of disulphide bonds 
redefines the 3-domain structure and rearranges the conformation of IGFBP-6 within 4 subdomains, 2 in 
the N-terminus and 2 in the C-terminus The first subdomain includes the first 6 cysteine residues (29, 32, 
40, 44, 57, 63) of N-terminal IGFBP-6 which appear to be all engaged in 3 disulfide bridges. The second 
subdomain results from the connection of Cys104with either Cys71, Cys78or Cys84; the C-terminus third
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subdomain is structured around a Cys1 “ -Cys190 bridge and the last subdomain is formed by the link 
between either Cys201 or Cys234 with Cys212 or Cys214.
Before the publication of these data, the lack of information on IGFBP crystallographic structure made 
investigation of the molecular functional domains of the IGFBPs extremely difficult. In fact any cleavage 
or mutation of the IGFBP molecule could have interfered with the correct formation of disulphide bonds 
causing major changes in the tertiary structure and any loss of biological function of the modified IGFBP 
molecule could have made the results difficult to interpret. Instead Forbes and Neumann’s work supports 
the idea that IGFBP tertiary structure folds separately within the N-terminus and the C-terminus forming 
two distinct domains whose structure and functions can be studied, at least in part, independently.
The high degree of sequence homology between IGFBPs o f different animal species and among 
different IGFBP family members supports the hypothesis that all 6  IGFBP genes are derived from a 
common ancestral gene. IGFBP genes are closely linked to Homeobox (Hox) genes. HOX genes encode 
for transcription factors and are located on the same chromosome regions as the IGFBP genes. In humans 
IGFBP- 1 and 3 and the HOX A cluster genes are located on chromosome 7; IGFBP2 and 5 and HOX D 
cluster on chromosome 2; IGFBP4 and HOX B cluster on chromosome 17; and finally IGFBP6  and HOX 
C cluster on chromosome 12 (Lee et al. 1997). It is believed that originally a single copy o f IGFBP and 
HOX ancestral genes were associated on the same chromosome before they underwent duplication and 
dispersion to the current chromosomal loci (Lee et al. 1997). It has been suggested that after a first step of  
duplication and translocation the fate of the IGFBP-1-3 and 2-5 genes (all containing 18 Cys) diverged 
from IGFBP4 and 6  (which have 20 and 16 Cys, respectively). Subsequently other round of duplications 
and translocations gave rise to the current locations. It has been speculated that the duplication of a 2 
gene-cluster gave rise to the current location of the IGFBP1-3 pair on chromosome 7 and the IGFBP 2-5 
gene cluster on chromosome 2. The duplication of clustered genes might explain some structural and 
functional similarities between IGFBP 1 and 2 and between IGFBP-3 and 5. The first two proteins share 
the presence in the molecule of an RGD sequence for integrin-binding and their concentration in serum is 
subjected to metabolic regulation, whereas IGFBP3 and 5 show high protein homology and are growth 
related (Collett-Solberg and Cohen, 1996). Despite the high degree o f similarities each IGFBP developed 
specific features in relation to postranslational modification and functions.
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IGF-RELATED PROTEINS OR LOW AFFINITY IGF-BINDING PROTEINS
Mac25 (product of mac25 cDNA), TAF (tumor-derived adhesion factor), PSF(prostacyclin- 
stimulating factor) are different names initially attributed to the same protein. Mac25 is structurally related 
to IGFBPs as it conserves 11 of the 12 cysteine residues present in the N-terminus of IGFBPs, and is 
capable of binding to IGF-I and -II, although with relatively low affinity. Due to these features mac25 was 
provisionally named IGFBP-7 (Oh e ta l ,  1996).
The connective tissue growth factor (CTGF), nov and cyr61 are instead three different proteins 
encoded by a family o f immediate-early genes. As for mac25, the N-terminal region of these proteins are 
homologous to IGFBPs, while the C-terminus is not conserved. As CTGF expressed in baculovirus was 
demonstrated to bind IGF-I and -II with low affinity it was designated IGFBP- 8  (Kim et al., 1997). The 
remaining two proteins (nov and cyr 61) were only proposed as candidate members of the IGFBP family 
on the basis o f their structural homologies (Baxter et a l ,  1998).
However i) the lack of the cysteines in a conserved location in the C-terminal region of mac 25 
(Hashimoto et al., 1997); ii) the lower amino acid identity o f mac25 with IGFBP (1-6) compared to the 
sequence homology among the 6  traditional IGFBP members; iii) the low binding affinity for IGF-I and - 
II displayed by mac25, iv) the ability o f mac25 to bind insulin with high affinity, a property shared with 
the N-terminus o f IGFBP-3,(Yamanaka et al., 1997) and v) the location of mac25 gene on a chromosomal 
site which does not contain a HOX gene cluster suggests that further investigation is needed to enable a 
correct classification of the IGFBP-related proteins (Lee et al., 1997).
25
Table 1.2.1 (based on Jones and Clemmons, 1995a; LeRoith, 1996; Hodgkinson et al., 1994 and Swiss- 
Prot sequence data base)
Characteristics IGFBP-1 IGFBP-2 IGFBP-3 IGFBP-4 IGFBP-5 IGFBP- 6
N  residues
human 234 289 264 237 252 249
rat 247 270 265 233 252 252
Mr theoretical 
human 27903 35137 31660 27934 28553 30570
rat 29628 32883 31680 27745 28428 30298
SDS-page 30 32 39-41 24-28 30 30
(non reducing)«  
phosphorylation + + +
Glycosylation - - N N O O
RGD sequence + + - - - -
Heparin-bind S S S + L nd S+S+L Nd
(S= short; L=long) 
Other basic aa seq. 
Heparin binding +/- +
215-232
++ +
210-218
++ Nd
Cell surf, associat. + + + - + -
proteolysis - + + + + Nd
IGF-I-IGF-II
preference >IGF-II >IGF-II >IGF-II »IG F -II
Chromosomal 
localiz. (human) 7p 2 q 7p 17q 2 q 1 2
HOX gene 
association HOXA HOXD HOXA HOXB HOXD HOXC
nd=not determined
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1.2.1.1 PHOSPHORYLATION
As indicated in table 1.2.1 IGFBP-1, 3 and 5 are serine phosphorylated in their central domain 
(Coverley and Baxter, 1997). However this post-translational modification has been shown to have 
functional significance only in hIGFBP-1, which is phosporylated on serine residues at position 101 (70% 
of total phosphorylation), 169 (25%), 119 (5%) (Lee et al., 1997). Phosphorylated hIGFBP-1 displays 4-6 
fold higher affinity for IGF than the non phosphorylated isoform (Jones and Clemmons, 1995a). Rat 
IGFBP-1 is phosphorylated at Ser 107 (non homologous to human phosphorylated serines) and at Ser 132 
(possibly corresponding to human residue Ser119), but unlike the homologous human protein this post- 
translational modification does not affect the affinity for IGF-I (Peterkofsky et al., 1998).
The phosphorylation reaction occurs inside the cell, but the protein kinase responsible for IGFPB-1 
postranslational modification has not been identified. Based on the sequences flanking the target serine 
residues, IGFBP-1 could be a suitable substrate for members of the casein kinase family and indeed casein 
kinase 2 was shown to phosphorylate IGFBP1 in vitro (Jones and Clemmons, 1995a). Rat IGFBP-1 
phosphorylation is carried out in two different cellular sites, the c/s-Golgi and the trans Golgi network, 
and together with casein kinase 2, the Golgi casein kinase has been implicated. (Peterkofsky et al., 1998). 
The observation that the ratio between phosphorylated and non phosphorylated hIGFBP-1 varies in 
different biological fluids and in physiological and pathological states suggested that this postranslational 
modification might have a regulatory role. It was reported that smooth muscle cells showed an increase 
IGF-I stimulated thymidine uptake when treated with non phosphorylated IGFBP-1 and a decrease when 
treated with the phosphorylated form (Busby et al., 1988a; Jones and Clemmons, 1995a). Proliferating 
endometrial cells normally secrete non-phosphorylated IGFBP-1, but after medroxyprogesterone induction 
of luteinization, the cells produce phosphorylated IGFBP-land undergo growth arrest (Frost and Tseng,
1991). IGF potentiating effects o f the non phosphorylated form of IGFBP-1 have also been described in in 
vivo experiments, while the phosporylated isoform of IGFBP-1 did not display a potentiating action 
(Jyung et a l ,  1994). It was hypothesized that phosphorylated IGFBP-1 could sequester IGF-I from the 
receptor because o f its higher affinity and therefore inhibit the effects o f the growth factor. Conversely the 
non phosphorylated IGFBP-1, which binds IGFs with lower affinity, could enhance IGF-I stimulated 
action perhaps by providing a reservoir of growth factors that can be released (Jones et al., 1991).
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However it should be borne in mind that the non phosphorylated isoform retains a high affinity for IGF 
with a Kaof 3.1-4.6 xlO9 (NT1) (Koistinen et al., 1993a and b), although it appears reduced in comparison 
to the phosphorylated form. In addition there are examples in the literature that contradict the generalized 
regulatory role attributed to phosphorylation. Both IGFBP-1 isoforms purified from amniotic fluid were 
able to block IGF-I binding to human fetal fibroblasts and to enhance IGF-mediated thymidine 
incorporation (Koistinen et al., 1993a). In addition non phosphorylated IGFBP-1 was shown to inhibit 
IGF-stimulated cell growth in vitro (Burch et al., 1990; Grellier et al., 1996; Figueroa et al., 1993) and in 
vivo (Motani et al., 1995; Cox et al., 1994). In conclusion the discrepancy in results derived from different 
experimental systems leaves the role of IGFBP-1 phosphorylation in vivo unclarified (Lee et a l ,  1997). 
Perhaps the observation that it is the non-phosphorylated form that associates to cells may also be relevant 
for the interpretation of the function of phosphorylation on IGFBP-1 biology (Chan and Spencer, 1997).
hIGFBP-3 is secreted as phosphorylated protein and the modification principally occurs at serine 
111 and 113 (Hoeck and Mukku, 1994). In vitro phosphorylation of IGFBP-3 can be obtained by protein 
kinase A and C and by casein kinase 2. The phosphorylation does not affect IGF-binding but it might 
affect its ability to associate to the cell membrane and to bind to ALS (acid labile subunit) (Coverley and 
Baxter, 1997).
Phosphorylation of IGFBP-5 is poorly reported.
1.2.1.2 GLYCOSYLATION
As shown in table 1.2.1, IGFBP-3 and -4 are N-glycosylated, while IGFBP5 and 6  are O- 
glycosylated.
IGFBP-3 is subjected to various degrees of glycosyl-substitution and contains three N- 
glycosylation sites, 89NAS, 109 NAS, 172NAS (Wood et al., 1988) in the central region of the molecule. 
IGFBP-3 migration pattern in electrophoresis is represented as a doublet with an apparent Mr of 53- 
46kDa, compared to the theoretical Mr of 29kDa (Jones and Clemmons, 1995a). The biological 
significance of glycosylation is undetermined The presence or absence of glycosyl residues in IGFBP-3 
does not appear to affect IGF-binding nor the formation o f the tertiary complex with IGF-I and ALS 
(Sommer e t al., 1993). Similarly both glycosylated and non glycosylated forms of IGFBP-3 can bind to 
heparin and be eluted from a heparin affinity column with 0.3-0.5M NaCl (Smith et a l ,  1994).
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Glycosylation of IGFBP-3 does not seem to be required for association to cell surfaces, as deletion of the 
central region of the molecule, which carries the 3 glycosylation sites, does not affect binding to cell 
membranes (Firth et a l ,  1998).
IGFBP-4 is also N-glycosylated. In SDS gel electrophoresis under non reducing conditions, 
IGFBP-4 typically migrates as a double band with an apparent Mr of 28 and 24 kDa. Treatment with N- 
Glycanase reduces the intensity o f the 28kDa band and at the same time increases the intensity o f  the 24 
kDa band (Cheung et a l ,  1991). Partial sequencing of the two bands show that they are indeed the same 
protein (Ceda et a l,  1991). The biological significance of this postranslational modification is unknown, 
but it is of interest to note that the 28kDa IGFBP-4 is slightly more resistant to proteolysis compared to the 
non-glycosylated form (Chemausek et a l ,  1995).
IGFBP-5 is commonly described in literature as an O-glycosylated protein, but no precise details 
o f this postranslational modification are available. In a recent report the comparison between theoretically 
calculated and spectrometrically analyzed mass of a C-terminal IGFBP-5 fragment shows a difference of 
about lOOODa (Standker et a l ,  1998). The authors suggest that O-glycosylation at threonine 152could 
account for this difference and that it might involve one hexose, one N ’ acetylhexosamine and 2 
N ’acetylneuraminic acid residues similarly to O-glycosylation described for IGFBP- 6
Glycosylation of hIGFBP- 6  has been the object o f a detailed study recently published by 
Neumann et a l  (1998). It was noted that IGFBP- 6  displays a considerable heterogeneity o f glycosylated 
isoforms, five different sites of glycosylation were identified on Ser or Thr residues of the central region 
o f the IGFBP- 6  molecule. Only Thr126appeared to be glycosylated in all major isoforms, whereas 
substitutions at Ser144 Thr145 Thr146 Ser152were variable. The number of carbohydrate residues was 
estimated between 8  and 16 in the major isoforms.
The significance o f the glycosyl-substitution is unknown. It was noted that Ser and Thr residues 
involved in glycosylation of hIGFBP- 6  were not conserved in mouse and rat sequence and that these 
proteins display a lesser extent of glycosylation. Though, similarly to IGFBP-4, the glycosylated form of 
IGFBP- 6  appears to be less susceptible to chymotrypsin and trypsin digestion in comparison with the non 
glycosylated form, indicating that this post-translational modification might be biologically relevant 
(Neumann et al., 1998).
29
1.2.1.3 RGD SEQUENCE
An arginine-glycine-aspartic acid (RGD) sequence is present in the C-terminal region of rat, cow 
and mouse IGFBP-1 (Brewer et a l ,  1988; Hynes, 1992; Lee et a l ,  1997) and in human, rat and chicken 
IGFBP-2 (Landale et al., 1995; Schoen et al., 1995). The RGD sequence is a consensus recognition 
sequence for a family o f cell membrane proteins, the integrin receptors. Integrins are involved in a 
multiplicity o f cellular biological events among which the interaction between cells and extra cellular 
matrix (ECM) and cell migration are the best known. IGFBP-1 binds to a 5Pi integrin (fibronectin 
receptor) through its RGD sequence as first shown by the work of Jones et al (1993b). In order to prove 
IGFBP-1 binding to integrin, membrane proteins of CHO transfected cells expressing IGFBP-1 were 
iodinated and the cell lysates were applied to an IGFBP-1 affinity column and eluted with a competing 
RGD-containing peptide. Subsequently the eluted material was immune-precipitated with an antibody 
against the a 5 or P! integrin subunit and separated by electrophoresis. The direct autoradiography led to the 
identification of 2 single protein species with a Mr of 135 and 130 kDa (under reducing conditions). In 
contrast the use o f an RGE containing peptide was unable to displace the CHO membrane proteins bound 
to the IGFBP-1 chromatographic column demonstrating that the RGD sequence of IGFBP-1 was 
specifically involved in the interaction with the cell membrane. In addition the use antibodies to a 2, a 3, cXy 
subunits under identical condition to the anti a 5 antibody did not lead to the precipitation of any CHO 
membrane protein showing that IGFBP-1 binds specifically to the a 5 integrin subunit. Further support for 
these conclusions came from the demonstration that the anti a 5 antibody could co-precipitate IGFBP-1 
bound to a 5 integrin on the cell membrane of the IGFBP-1-transfected CHO cells. In contrast when CHO 
cells were transfected with WGD-IGFBP-1 (which had the R of the RGD sequence substituted with W) 
the anti a 5 antibody was unable to co-immune precipitate WGD-IGFBP-1. Additional proof of the 
interaction of IGFBP-1 with a 5Pi integrin derives from the effect that the binding protein exerts in cell 
culture and in vivo experiments which will be reported in a later section..
Despite the presence of an RGD sequence in the C-terminal region o f IGFBP-2, at the present 
time there are no reports showing IGFBP-2 binding to integrin receptors. Iodinated membrane proteins
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from pSMC culture (pig smooth muscle cells expressing IGFBP-2) applied to an IGFBP-2 affinity column 
did not bind to the column. However the same cell lysate applied to an IGFBP-1 column led to the 
purification of asfr integrin following elution of the column with RGD peptide (Gockerman et al., 1995). 
Moreover in functional bioassays IGFBP-2 failed to stimulate cell migration of pSMC (Gockerman et al.,
1995) and wound healing (Galiano et al., 1996) under the same experimental conditions which permitted 
the stimulating effect o f IGFBP-1.
The presence of an RGD sequence is not per se a guarantee of heparin binding as several RGD 
containing proteins do not bind integrins (Gockerman et a l ,  1995) and, in addition, integrins can bind 
proteins which lack an RGD sequence. Nevertheless, IGFBP-2 binding to integrins cannot be excluded as 
at least 6  different integrins recognize the RGD sequence and not all o f them have been tested for binding 
IGFBP-2. Therefore it is possible that IGFBP-2 did not bind integrins expressed on pSMC cells (a 5Pi is 
the most abundant, although small amounts of otv|33, a 3Pi 0 4  Pi are also present) or that the expression of 
these integrins was quantitatively below the sensitivity o f  the detection system. Moreover the inability to 
detect any effect o f IGFBP-2 on cell migration or wound healing does not exclude an efficient binding of 
IGFBP-2 and integrins. In fact the conditions and cell types used can affect the results of this type of 
bioassay even for known integrin -binding proteins. For instance Jackson and Yee (1995) were unable to 
demonstrate any binding of exogenous or endogenous IGFBP-1 to a 5Pi integrin expressed on the surface 
o f MDA-MB-231 (human breast tumour) and MG-63 (human osteosarcoma ) cells. IGFBP-1 was also 
unable to compete cell attachment on fibronectin-coated plates. An indication of a potential functional role 
o f IGFBP-2 RGD sequence was reported by Delhanty and Han (1993) who showed that wt IGFBP-2 
potentiated IGF-II-stimulated mitogenesis in sheep choroid plexus cells whereas an RGE-IGFBP-2 mutant 
was ineffective. In conclusion, although the presence o f an RGD sequence is neither necessary or 
sufficient for integrin binding the possibility that IGFBP-2 might bind to integrin needs further 
investigation.
1.2 .1 .4  HEPARIN-BINDING MOTIFS
Indications that the IGFBPs could bind to heparin were noted by researchers investigating the 
translocation of IGFs from the circulation to tissues. IGFs present in the plasma are mostly associated with 
IGFBP-3 and ALS (acid labile subunit) protein in a stable 150kDa complex which cannot leave the
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circulation. It was observed that heparin could liberate IGF from the complex (Clemmons et a l., 1983). 
Heparin, produced by mast cells and stored in cytoplasmic granules, is released into the circulation during 
the inflammatory process . In these conditions heparin could function to liberate IGF from the 150 kDa 
complex and favour its delivery to the tissues. It was shown that IGFBPs bound to heparin and it was 
hypothesized that IGFBPs could also bind to GAGs (glycosaminoglycans) which are structurally related to 
heparin. GAGs are normal components of the cell surface and extracellular matrix and are believed to be 
involved in the translocation of IGFs to extravascular tissues. As it has been shown that IGFs can localize 
to specific cell types that do not express IGF mRNA but synthesize IGFBPs it was postulated that 
ECM/cell surface-associated IGFBPs could direct IGF to specific cell types within the tissue (Jones et al., 
1993a). While postulations about the biological meaning o f the binding between IGFBPs and heparin were 
under investigation, this chemical property started to be exploited as an affinity chromatography step in 
the protein purification process for IGFBPs (Bar et a l ,  1987).
Rat and human IGFBPs (1-6) (except rat and human IGFBP-4 and rat IGFBP-6) were found to 
have at least one heparin-binding consensus sequence (Hodgkinson et al., 1994). Cardin and Weintraub 
(1989) identified, two heparin binding sequences: XBBXBX and XBBBXXBX ,where B represents any 
basic amino acid (mainly Arg and Lys) and X  is unassigned.
hIGFBP-3 has 2 heparin binding motifs, one in the central region at position 148-153, , and one 
in the C-terminal region at position 219-226 (Firth et a l ,  1998). Both the central and C-terminal domain 
seem to account for IGFBP-3 ability to bind to heparin although to a different extent In fact the deletion 
o f  the central domain of IGFBP-3 induced a reduction o f heparin-binding, while the deletion of the C- 
terminus completely abolished the binding (Firth et a l ,  1998). The heparin binding sequence in the C- 
terminal domain is included in a region formed by 10 basic amino acids between residues 215 and 232. An 
homologous basic amino acid-rich 201-218 sequence exists in IGFBP-5 and has been shown to be 
important for heparin/GAGs association. The 201-218 sequence of IGFBP-5 was able to compete with 
IGFBP-3 and IGFBP-5 for binding to fibroblast ECM indicating a possible role of these 18 residue 
homologous sequences in heparin/ECM binding (Parker et al., 1996). In agreement with this hypothesis 
the substitution of the amino acids 228 KGRKR of IGFBP-3, included in the 215-232 sequence, with the
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corresponding MDGEA sequence of IGFBP-1 caused a reduction in heparin affinity and abolished 
binding to the cell surface (Firth et al., 1998).
hIGFBP-5 was first reported to have 3 heparin binding domains: two overlapping short heparin 
binding sequences (132-137 135-140) located in the central region of the molecule, while a third long-type 
sequence (205-212) heparin binding domain is in the C-terminal region of hIGFBP-5 (Hodgkinson et a l ,
1994). In region 132-140 the two overlapping short consensus sequences form a VKKDRRKKLT 
sequence in which the BBXB heparin binding motif is in actual fact lost and it can therefore be considered 
as a basic amino acid rich region and not as an heparin binding sequence. An additional short heparin 
binding motif is identifiable at the 119-124 (PKHTRI) region of hIGFBP-5 (Parker et al., 1996). The basic 
amino acid residues of the heparin binding sequence are believed to establish ionic bonds with the 
negative sulfate groups of heparin and possibly the same kind of interaction would also permit IGFBP-5 
binding to the cell surface/ECM GAGs. In the attempt to test if  the theoretically predicted heparin binding 
sequences were really responsible for IGFBP-5 binding to heparin and/or to GAGs several engineered 
IGFBP-5 constructs were prepared. An IGFBP-5 C-terminal 201-218 peptide, which contains 10 basic 
amino acids in a stretch of 18 residues and includes the long heparin binding sequence, was show to bind 
to heparin in ligand blot. A peptide with similar charge/mass ratio (containing 6 basic residues out o f 11) 
spanning from residue 133 to 143 of IGFBP-5 central region performed less efficiently in heparin ligand 
blot (Andress, 1995). The 201-218 IGFBP-5 peptide was also demonstrated to compete IGFBP-3 or 5 
binding to ECM although less efficiently than intact IGFBP-3 or 5. Instead the 131141 IGFBP-5 peptide (7 
basic amino acids out of 11), was considerably less effective in competing IGFBP-3 or 5 binding to 
fibroblast ECM. (Parker et al., 1996). Thus it appears that heparin binding of IGFBP-5 depends in part on 
electrostatic interactions between basic amino acid of IGFBP-5 and heparin/GAG sulfated groups and in 
part on the specific position of the basic amino acids in the IGFBP sequence. As for IGFBP-3, the C- 
terminal region o f IGFBP-5 seems to have a important role in heparin binding. The full length IGFBP-5 
showed higher heparin affinity with respect to a corresponding C-terminally deleted molecule, as 
measured with [H]3 heparin ligand blot or by the NaCl concentration required for the elution o f the 2 
molecules from heparin-Sepharose beads (Andress, 1995). However, despite the lower affinity for heparin,
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the C-terminus truncated IGFBP-5 was able to bind to osteoblast monolayers where it exerted a mitogenic 
effect similar to intact IGFBP-5. (Andress and Bimbaum, 1992).
IGFBP-3 and 5 are the only IGFBPs that bind to fibroblast ECM. An 18 amino acid sequence rich in basic 
residues is present in IGFBP-5 (sequence 201-218), and in IGFBP-3 (215-232 sequence), but no 
equivalent can be found in IGFBP-1, 2 or 4. The above experiments indicated that these 18 amino acid 
sequences o f IGFBP-3 and 5 were involved in heparin/GAGs binding. To further characterize the role o f  
the 201-218 sequence of IGFBP-5 in heparin binding, the effect o f the mutation of combinations of 
several basic residues within the 201-218 region was assayed. The basic residues ^ K , 206K, ^ R , and21 *K 
were suggested to be the most important for binding to fibroblast ECM (Parker et al. , 1996) and in a later 
study the same authors (Parker et al., 1998), concluded that the residues 214R and ^ R  are the two key 
residues for binding to the ECM of pSMC (pig smooth muscle cells). However the involvement of the 
heparin binding sequence in heparin and GAGs association was questioned by the finding that mutation of 
2 basic residues within the sequence did not affect IGFBP-5 affinity for heparin whereas the mutation of  
other basic residues outwith the heparin binding motif, but inside the 201-218 sequence, did affect the 
binding (Arai et al., 1996). In agreement with this result it has been reported that an IGFBP-5 derived 
peptide containing a short heparin binding sequence was unable to compete with IGFBP-5 for binding to 
pSMC ECM (Parker et al., 19%).
Lastly heparin and ECM binding sites might not be identical as it was observed that a 131' 
141 IGFBP-5 derived peptide containing 6 basic residues out of 11 was able to associate to ECM but not to 
heparin (Arai et al. 1994a; Parker et al., 19%).
As heparin inhibits IGFBP-5 binding to IGF-I (Arai et al., 1994a) it was determined if  the amino acid 
residues involved in heparin binding were also involved in IGF binding. First, IGFBP-5 analogs with 
mutated basic amino acid residues were tested for their affinity for IGF-I and showed no significant 
differences compared to wild type IGFBP-5 (Arai et al., 1996). Next, the IGF-I affinity shift evident for 
wild type IGFBP-5 bound to heparin was evaluated and the impact of the basic amino acid mutations on 
this shift tested. Residues 211, 217 and 218, which do not significantly affect heparin binding nor IGF- 
binding, appeared to be involved in the shift of IGF affinity for the IGFBP-5-heparin complex (Arai et al.,
1996). Interestingly IGFBP-3 which has a sequence equivalent to 201-218 is not subjected to IGF affinity
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shift after complexation with heparin. In addition, IGFBP-1, 2 or 4 binding to 125I IGF-I was not affected 
by the addition of heparin (Arai et al., 1994a).
Furthermore the IGFBP-5 201-218 sequence also seems to be involved in the recently described 
binding of plasma IGFBP-5 with PAI (plasminogen activator inhibitor) (Nam et a l ,  1997) and with ALS 
(acid labile subunit) and similarly the homologous 215-232 sequence of IGFBP-3 is involved in the 
binding with ALS and plasminogen (Campbell et al., 1998). The 210-218 IGFBP-5 and 215-232 IGFBP-3 
sequences have also been recently shown to contain the NLS (nuclear localization sequence) a bipartite 
consensus motif that allows the intranuclear localization of both binding proteins (Schedlich et al., 1998)
1.2.1.5 IGFBP PROTEOLYSIS
Proteolytic events have been described for all IGFBPs. Among many examples the proteolysis o f  
circulating IGFBP-3 during pregnancy has been extensively studied.
IGFBP-3 is the most abundant IGF-binding protein in human plasma and it is easily detected in ligand blot 
as a typical 38.5-41.5kDa doublet band. However after the 6th week o f pregnancy the IGFBP-3 doublet 
becomes progressively fainter until it disappears and it regains normal levels only 5 days post-partum 
(Giudice et al., 1990). Similarly, in rat serum IGFBP-3 can hardly be detected after day 18 of pregnancy 
(Davenport et a l ,  1992). It has also been demonstrated that the observed decline of IGFBP-3 in blood was 
due to a serum proteolytic activity which gave rise to IGFBP-3 fragments undetectable on ligand blot 
because o f their decreased affinity for IGF. With IGF affinity cross-linking experiments it was shown that 
IGFBP-3 fragments retain some IGF binding capacity. The size of the fragments derived from the 
incubation of iodinated recombinant hIGFBP-3 with human term pregnancy serum was electrophoretically 
estimated at 29 and 22-17 kDa (Giudice et al., 1990). The reduced affinity for IGFs that occurs for 
IGFBP-3 after proteolytic cleavage might have the function o f improving the bioavailability o f the growth 
factors for the increased pregnancy demand and fetal growth (Hossenlopp et al., 1990).In addition Booth 
et al. (1996) propose a functional role for IGFBP-3 fragments on IGF passage through capillary walls.
The enzymes responsible for IGFBP-3 degradation in human and rat pregnancy serum, MMP-1 
and MMP-2, are cation-dependent serine proteases belonging to the matrix metallo proteinase (MMP) 
family which includes MMP-1 (collagenase), MMP-2 (gelatinase A), MMP-3 (stromolysin 1) and MMP-9
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(gelatmase B). These collagenases have a role in inflammatory process and metastasis invasion (Collet- 
Solberg and Cohen, 19%). Increased MMP activity during pregnancy might be due to a decline in the 
concentration of a tissue specific metallo proteinase inhibitors (TIMP). MMPs, unlike other serine 
proteases are not specific and degrade other IGFBPs in addition to IGFBP-3 (Clemmons, 1997). A small 
amount of proteolysed IGFBP-3 is present in normal adult rat (Lee and Rechler, 1995), but serum 
proteolytic activity can be considerably increased in stress conditions (late pregnancy, malnutrition, severe 
illness, malignancy and major surgery) (Jones and Clemmons, 1995a; Phillips et al., 1998)
Plasmin and thrombin were also demonstrated to cleave IGFBP-3, but they are mainly located in 
vessels walls rather than in plasma (Clemmons, 1997; Zheng et al., 1998a). Interestingly while heparin 
binding protects IGFBP3 from proteolysis by plasmin and pregnancy serum, it exerts a stimulatory action 
on thrombin activity. The modulation of the activity o f different proteases might be another control point 
for IGF transport out of the circulation (Booth e t al., 1996).
Prostate specific antigen (PSA) is a kallikrein-like protease that is also able to degrade IGFBP-3 
and 5, but not IGFBP-1, 2, 4 or 6 (Collett-Solberg and Cohen, 1996). This enzyme is found in seminal 
plasma and is present in high concentration in the blood of patients with disseminated prostate cancer 
(Clemmons, 1997).
y-nerve growth factor is another kallikrein which is potently active on IGFBP-4 and 6 and 
consequently enhances IGF action showing an interaction between different growth factors (Collett- 
Solberg and Cohen, 1996)
In IGFBP-1 there is present one PEST (proline, glutamine, serine, threonine) domain which 
might increase the susceptibility o f the protein to proteolysis. This sequence is only found in IGFBP-1, but 
other sequences in the central region o f all IGFBPs are targets of protease action.
Pregnancy serum also degrades IGFBP-2, -4 and 5 (Davies et al., 1991b; Claussen et al., 1994). 
More than one proteolytic enzyme seems to be involved in this process as supported by the fact that the 
addition of specific inhibitors differentially affects the degradation of single IGFBP species. Recently a 
novel disintegrin-like MMP which cleaves IGFBP-3, -4 and -5 has been identified in pregnancy serum 
(Kubler et a l ,  1998). IGFBP proteolytic enzymes are also produced by cells in culture for example pSMC 
secrete 3 different proteases for IGFBP-2, IGFBP-4 and IGFBP-5 respectively (Rees et al., 1998).
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The action of proteases in cell culture can be modulated in various ways. Interestingly 
complexation of IGFBP-5 with IGFs protects it from enzymatic digestion (Collett-Solberg and Cohen, 
1996; Arai et al., 1994b; Zheng et al. 1998a) whereas IGFBP-4 proteolysis occurs at a very low rate in 
conditioned medium of human decidua and rat neuroblastoma cells (Myers et a l, 1993, Chemausek et al.,
1995) unless IGF is added. A change in conformation due to IGF binding might be responsible for both 
these opposing effects. IGFBP-5 is also protected by proteolysis when it is associated to the ECM 
(Clemmons, 1997; Nam eta l., 1997).
Cathepsin D is also able to proteolyse IGFBP-1 through 5, but its physiological significance is uncertain. 
In fact cathepsins are a family o f lysosomal enzymes and although they can be found in the conditioned 
medium of prostate and breast cancer cells, they are active only at a pH ranging between 4 and 5.5 
(Collett-Solberg and Cohen, 1996)
1 .2 .1 .6  AFFINITY FOR IGFs
A large amount of data has been collected on the affinity o f each IGFBP for IGF-I or -II and 
these data are summarized in table 1.1.2
The general consensus is that IGFBP-1 and 4, have equal affinity for IGF-I or -II, while for IGFBP 2, 3, 5, 
the preferential binding to IGF-II in comparison to IGF-I is variously reported. Indisputable is IGFBP-6 
higher affinity (20-100fold) for IGF-II (Drop et al., 1992; Oh et a l ,  1993; Roghani et a l ,  1991).
Many studies have investigated the IGF-binding domain on IGFBPs although the absence of information 
on IGFBP tertiary structure rendered these investigations very difficult. The possibility o f defining the 
IGF binding site by using mutated or truncated IGFBPs was limited by the fact that loss o f IGF-binding 
ability could either be due to the effect o f the introduced modification or simply a consequence o f major 
changes in the tertiary structure of the IGFBP molecule. During recent years a conspicuous amount of data 
have been accumulated alternatively supporting the hypothesis that the IGF-binding domain was located 
either in the N-terminus or in the C-terminus of the IGFBP molecule.
In favour of the primary role of the N-terminal domain of IGFBP there was the observation that 
the N-terminus retained IGF-binding capacity when isolated from the rest o f the molecule, while deletion 
or alteration of the N-terminal domain caused complete loss of IGF-binding. Similar results were obtained
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by different researchers with different IGFBPs. An IGFBP-1 molecule deleted of the first 60 N-terminal 
amino acids was unable to bind IGF-I in ligand blot (Brinkman et a l, 1991a). Mutation of IGFBP-1 Cys 
residues at position 16 or 35 into serines (Powell et al., 1989) or 38 into Tyr (Brinkman et a l ,  1991a), 
caused a complete loss o f IGF binding. This is likely to be due to a major change in the molecular 
integrity rather than to the loss of a residue essential for IGF binding. In contrast point mutations 
introduced in the N-terminus of the molecule or even the mutation of Cys 34 to Tyr did not affect IGF 
binding, suggesting that Cys34 may not be involved in maintaining IGFBP-1 tertiary structure (Brinkman 
et a l ,  1991a). The comparison of proteolytic fragments from the digestion of IGFBP-3 with plasmin, 
thrombin or pregnancy serum showed that the most of the N-terminus containing peptides retained IGF 
binding affinity in ligand blot, while only a few C-terminal fragments, starting approximately around 
residue 150, displayed IGF binding (Booth et a l ,  1996). Accordingly a naturally occurring 30 kDa N- 
terminal proteolytic fragment (1-160) of IGFBP-3 was capable of IGF binding, but a smaller 16 kDa (1- 
95) N-terminal fragment was not (Mohseni-Zadeh and Binoux, 1997b). In affinity cross-linking 
experiments it was found that the N-terminal or the N-terminal linked to the central region o f IGFBP-3 
maintained IGF-binding affinity (Sommer et a l ,  1991; Hashimoto et a l ,  1997; Firth et a l, 1998). The 
affinity o f the N-terminus (1-93) or the N-terminus+central region (1-186) was also quantified in a 
competitive solid phase assay and determined to be respectively 4% and 12.5% of wtIGFBP-3 IGF- 
binding ability (Hashimoto et a l ,  1997). The discrepancy o f the IGF-binding ability o f small fragments 
might depend on the detection method. In general the reduced affinity of the fragments becomes 
undetectable in ligand blot, while it can be revealed with 125IIGF-I or II cross-linking techniques. Hobba et 
a/. (1996) reported that iodination of Tyr 60 residue of bIGFBP-2 decreased IGF-affinity. Two years later 
the same authors confirmed the importance of Tyr60 showing that this Tyr was the only residue, within the 
Val59 and Arg 63 region of bIGFBP-2, whose mutation caused a reduction in affinity for IGF-I and II 
(Hobba et a l,  1998). Further support to the primary role played by the N-terminal domain in IGF binding 
is provided by Kalus et a l  (1998). The authors found that of three proteolytic fragments corresponding to 
the C-terminus, the central region and the N-terminus of hIGBBP-5, only the latter retained the ability to 
bind to IGF-I or -II. In particular the IGF binding domain seems to be confined to an Ala^-Ile92 mini­
fragment of IGFBP-5 which appears to be sufficient to start the IGF-binding process with a very high
38
association constant. However this mini-IGFBP-5 fragment dissociates from IGF very quickly, so that its 
affinity is 10-200 fold reduced compared with the full length IGFBP-5. Therefore the higher affinity o f the 
full length IGFBP-5 must be due to some additional binding interactions established by the central and/or 
the C-terminal regions that may have the effect o f stabilizing the IGF-IGFBP-5 complex. Similar 
conclusions were drawn by Qin e t al. (1998) who expressed isolated domains of IGFBP-4 as GST fusion 
proteins and found that i) C-terminal domain was unable to bind IGFs, ii) the deletion o f the central region 
(which in IGFBP-4 contains two additional Cys residues) did not affect the affinity, iii) N-terminus of 
IGFBP-4 truncated at various length retained binding capacity but with a substantially lower affinity 
compared to the full length protein
Other studies supported the C-terminal domain as the candidate for the location of the IGF 
binding domain. A 21kDa fragment corresponding to 148-270 of rIGFBP-2 retained a low affinity for 
IGF-I or-II, (Wang et al., 1988). An IGFBP-1 molecule lacking the 20 C-terminal amino acids was unable 
to bind IGF in ligand blot. However point mutation introduced in the C-terminus of IGFBP-1 did not 
affect IGF binding and only the substitution of Cys 226 with a Tyr or the introduction of an amino acid 
negatively charged in the vicinity led to formation of dimers and loss of IGF binding (Brinkman et al., 
1991b). A 14kDa carboxyl-terminal fragment of IGFBP-2 isolated from human milk retained considerable 
affinity for IGF-II in RLA assay (Ho and Baxter, 1997a).
In conclusion the cooperation of both the N-and C-terminal domains of IGFBPs appears to be 
needed for IGF binding. Moreover it should be pointed out that despite the high homology between 
IGFBPs, each IGFBP species shows different affinity for IGF-I and II. Therefore it is possible that in each 
IGFBP the relative contribution of a defined part of the molecule might vary. Furthermore, the observation 
that truncation or mutation of the IGFBP molecule differentially affected the affinity for IGF-I or -II gave 
rise to the hypothesis that binding sites for the two peptides might be overlapping but not identical. 
Iodination of bIGFBP-2 Tyr60 residue (Hobba et al., 1996) or its mutation to Phe caused 8 fold reduction 
in affinity for IGF-I and 4 fold reduced affinity for IGF-II (Hobba et al., 1998). A bIGFBP-2 molecule 
whose 62 C-terminal residues were deleted had a general reduction in affinity for both IGFs, but the loss 
o f affinity for IGF-II was more dramatic (Forbes et al., 1998). In cross-linking affinity labeling assays an 
IGFBP-3 lacking the C-terminal domain showed a big reduction in affinity for both IGFs but IGF-II
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binding was most compromised (40 fold reduction, compared to 20 fold reduction in affinity for IGF-I). 
Moreover while the mutation of 253KED sequence in the central region of IGFBP-3 into RGD affected the 
affinity for both IGFs (a 4-6 fold reduction), the substitution of 228KGRKR sequence with MDGEA in C- 
terminal region of IGFBP-3 caused nearly no changes in IGF-I affinity, but a 3 fold reduction for IGF-II 
(Firth et al., 1998). Similarly a 14 kDa C-term fragment of hIGFBP-2 had only 10 fold lower affinity for 
IGF-II compared with wt IGFBP-2, while its binding capacity for IGF-I was much more seriously 
compromised (Ho and Baxter, 1997a).
Finally some reports have described equivalent effects on IGF-I and IGF-II affinity following IGFBP 
modifications. For example a 21kDa fragment corresponding to the 148-270 C-terminus of rIGFBP-2 
bound IGF-I or-II equivalently, although with low affinity (Wang et al., 1988). Similarly Qin et al. (1998) 
found that the N-terminal fragments of IGFBP-4 had a similarly decreased affinity for 125I IGF-I or -II in 
ligand blots.
In summary, from the comparison o f studies undertaken by different laboratories, it appears that 
in some IGFBP species, the C-terminal region might contain determinants which are specifically 
important for IGF-II binding, while the N-terminal region might be involved in more fundamental aspects 
of the binding mechanism which applies to both IGF-I and -II.
1.2.2.IGFBP FUNCTIONS
1 .2 .2 .a ln  vivo
1.2.2. a. 1 Serum transport and storage of circulating IGF
Ternary complex Perhaps the most intensively studied function o f IGFBPs is as a carrier o f IGFs. 
Just after IGFs were discovered as a biological mediator of GH action, it became clear that the growth 
factors were not present in plasma as free form. 90-96% of IGF-I and II are bound in a 150kDa complex 
together with IGFBP-3, a 46-53 kDa N-glycosylated acid stable protein, and to ALS, an acid labile subunit 
of the complex (Clemmons, 1997). ALS is a glycoprotein with an apparent Mr o f 84-86 kDa and a 
characteristic leucine-rich domain which is believed to facilitate protein-protein interaction (Leong et al.,
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1992). Liver is the main source o f plasma IGF, IGFBP-3 and ALS. The proteins are released into the 
circulation where i) IGF combines with IGFBP-3 in a dimer complex and ii) subsequently binds to the 
ALS subunit forming a stable 150 kDa ternary complex (Jones and Clemmons, 1995a). ALS is present in 
excess in the blood (290nM), while IGFBP-3 is totally saturated with IGF so that the growth factors and 
the binding protein have almost equimolar concentration in the circulation(120-150nM) (Phillips et al., 
1998). The assumption that virtually all plasma IGF and IGFBP-3 are complexed with ALS in the 150kDa 
complex, has now been challenged. Collet-Solberg et al. (1998) described three blood association proteins 
(APs), with a Mr of 70, 100, 150kDa, able to bind IGFBP-3 and they propose that part of IGFBP-3 in the 
serum is associated to these APs and part with ALS. Campbell et al. (1998) suggest an intriguing 
hypothesis based on the observation that IGFBP-3 binds to plasminogen and that the complex, present in 
normal plasma, is able to bind IGF-I with high affinity (IQ 0.47 nM). The theory that all IGFBP-3 present 
in the plasma is bound to ALS (88kDa) and IGF is based on gel filtration studies which simply show that 
plasma IGFBP-3 is engaged in a 150 kDa complex. However as plasminogen (97-92 kDa) has a Mr 
similar to ALS, it is possible that part of the 150 kDa is in actual fact formed by IGFBP-3, IGF and 
plasminogen On the other hand an IGFBP-3-ALS-plasminogen trimeric complex would not form as both 
ALS and plasminogen interact with the 215-232 heparin binding sequence in the C-terminus o f IGFBP-3.
The belief that IGFBP-3 could not form a binary complex with ALS has been questioned by a 
number o f studies proving that binding between IGFBP-3 and ALS in the absence o f IGFs could indeed be 
detected using several techniques (Lee and Rechler, 1995; Hashimoto et al., 1997; Collett-Solberg et al., 
1998). Moreover the 150 kDa complex was also found in ovary follicular fluid demonstrating that it is not 
characteristic of the plasma only (Cwyfan Hughes et al., 1997), neither is its formation an exclusive 
property o f IGFBP-3, as IGFBP-5 has recently been reported to form a 150 kDa complex with ALS and 
IGF in serum (Twigg and Baxter, 1998).
The 150kDa complex represents a storage form of IGF-I/II in the body. The renal clearance of 
the 150kDa complex is limited and extravascular passage is impeded resulting in an increased plasma half 
life o f 12-15 hours compared to free IGFs (10 min) and free IGFBP-3 (1-2 hours) (Jones and Clemmons, 
1995a). It is o f fundamental importance that the relative concentration of all components of the ternary 
complex is maintained in equilibrium as indicated by the fact that hepatic production of these three
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components is subjected to positive GH regulation. It is worthwhile to note that an increased availability 
of free IGFs, e.g. after an injection of IGF peptide, would cause an acute hypoglycemic effect if  it was not 
buffered by IGFBP (Collett-Solberg and Cohen, 1996). Any change in relative concentration of one o f the 
components of the complex is followed by an adjustment of the concentration o f the other components. 
For instance any rise in plasma IGFs stimulates an increase of IGFBP-3, while ALS is available in excess. 
Subsequently, in order to maintain constant the concentration of 150kDa complex, IGF, which negatively 
regulates GH secretion, indirectly inhibits ALS secretioa Equilibrium is then restored because a larger 
proportion of binary complex IGF-IGFBP-3 is formed and quickly cleared from the circulation 
(Clemmons, 1997). The physiological function of this circulating store of IGF is not fully understood but 
there are indications which suggest that it might represent a body reservoir to be used in catabolic 
conditions. In fact it has been observed that in stress states (eg late pregnancy-Hossenlopp et al., 1990; 
Giudice et al., 1990; Lasarre and Binoux, 1994; diabetes- Bang et al., 1994; Bereket et al., 1995; 
malnutrition-Pucilowska et al., 1993, severe illness- Davies et al., 1991a; malignancy- Muller et al., 1993 
and major surgery Davenport et al., 1992) IGFBP-3 is specifically cleaved by serum proteases into a 30 
kDa fragment still able to form the ternary complex but with a 20-30 fold decreased affinity for IGF 
(Binoux et al., 1991). The growth factors can then be easily released from the ternary complex and 
equilibrate with lower Mr IGFBPs or with the extra vascular tissues (Martin and Baxter, 1992).
IGF-IGFBP binary complex The small portion of IGFs, less than 10 %, which is not included in 
the trimeric complex forms a 40-50kDa dimeric complex, while only 0.4% is in a free form (Chan and 
Spencer, 1997). However, although in normal conditions most of IGFs are bound to the 150kDa complex, 
in pathological conditions the concentration of the trimeric complex can decrease to favor smaller Mr 
complexes between IGF and different classes o f IGFBPs (Hardouin et al., 1989; Zapf et al., 1990; Martin 
and Baxter, 1992). IGFBP-1, -2 and, to lesser extent, IGFPB-4 are present in plasma in significant 
concentration, while IGFBP-5 and 6 levels are very low and their role in the physiological regulation of 
circulating IGF is unclear (Clemmons, 1997). Unlike the 150kDa complex, the binary complex o f IGFs 
with IGFBP-1, -2 or -4 can cross capillary barriers, and may be facilitating the delivery o f the growth 
factors to peripheral tissues (Bar et a l ,  1990a). IGFBP 1 and 2 can actively influence IGF bioavailability 
especially in pathological conditions. Both proteins are present in the plasma in unsaturated form
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(McCusker et al., 1988) and although they are 10 times less concentrated (2-15 nM -Murphy, 1998) than 
IGFBP-3 and have 5-10 fold lower affinity for IGFs, they are available to bind any IGFs liberated from 
the 150 kDa complex. The movement of IGF from the high to the low Mr complex is not lully elucidated 
and no answers have been found to explain why some IGF circulates free despite the presence of 
unsaturated IGFBPs (Murphy, 1998).
IGFBP-1 IGFBP-1 is metabolically more responsive than IGFBP-3 with only a 14 min half-life 
in the circulation (Lee et al., 1997). The IGF-IGFBP-1 complex is not comparable to the 150kDa trimeric 
complex and its rapid and dynamic regulation is exploited to modulate IGF bioavailability in specific 
physiological or pathological states. Liver is the main source of plasma IGFBP-1 in males and non 
pregnant females. Liver production of IGFBP-1 is mainly under insulin negative regulation. Insulin causes 
a fall in IGFBP-1 concentration within 15mia of administration which, together with the lack of effect o f 
cyclohexamide (a translation inhibitor) treatment suggests that no transcription factor synthesis is required 
for the inhibition to occur (Phillips et al., 1998). Moreover insulin seems to be able to stimulate IGFBP-1 
capillary transport, further contributing to decreased IGFBP-1 plasma concentration (Bar et al., 1990b). In 
a parallel fashion insulin up-regulates IGFBP-3 and increases IGF-I concentration (Phillips et al., 1998) 
Thus in normal conditions, GH positively regulates the concentration of plasma 150 kDa complex either 
by acting directly or controlling insulin levels, which also suppress IGFBP-1 concentratioa As the 
IGFBP-1 gene is subjected to negative insulin regulation through an IRE (insulin responsive element) 
region located at the transcription start site (Lee et al., 1997), IGFBP-1 protein levels are readily 
influenced by changes in nutritional status. The postprandial rise in insulin level causes 4-5 fold decrease 
in IGFBP-1 concentration. Conversely fasting for 12-16 hours stimulates a 4-6 fold increase in IGFBP-1 
concentration, due to suppression o f insulin levels (Busby et al., 1988b). A decrease of plasma levels o f  
150kDa complex and an increase in IGFBP-1 is typical o f diabetes and GH deficiency (Graubert et al., 
1991).
IGFBP-2. IGFBP-2 is the most abundant IGFBP in serum after IGFBP-3. Like IGFBP-1, 
IGFBP-2 in plasma is present in unsaturated form, but it is less responsive than IGFBP-1 to metabolic 
changes and it has a longer half life (90min) (Jones and Clemmons, 1995a). Nutrition is a weak regulator 
of IGFBP-2 concentratioa Severe protein deprivation can increase (30-40%) the IGFBP-2 le v e l, but only,
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after 5-6 days (Clemmons et al., 1991; Straus and Takemoto, 1990). GH directly down-regulates the 
concentration o f the binding protein, whereas IGF-II potently increases IGFBP-2 levels. A  decrease in the 
150 kDa complex concentration and a compensatory increased level of IGFBP-2, is the typical plasma 
pattern o f patients affected by non-islet cell tumor hypoglycemia (LeRoith, 1996). This tumor produces an 
high level o f big IGF-II, an IGF-II variant with C-terminal 21 amino acid extension represented by 
uncleaved residues of the E domain. The origin of hypoglycemia associated with this tumor is not clear as 
IGF-II concentration is not always high in these cases. It has been proposed that an impaired formation of 
the 150 kDa complex might be the cause of hypoglycemia (Hizuka et a l, 1998). In this type o f tumor GH 
is usually at low level (because IGF-II inhibits pituitary GH secretion) and as consequence IGF-I, IGFBP- 
3 and ALS are low and this could be limiting for the formation of the 150kDa complex.
The relative abundance of the IGFBPs does not only change in pathological conditions but also in 
different physiological states.
1.2.2. a. 2 IGFBPs in foetus and pregnancy
In human foetal serum IGF-II, IGFBP-2 and IGFBP-1 concentrations are high, whereas IGF-I 
and IGFBP-3 are low. Under GH stimulation IGF-I starts to increase around birth as does IGFBP-3 whose 
concentration is veiy low in young children, then it increases and reaches its peak at mid puberty and only 
starts to decline after age 30. Conversely post natal levels o f IGF-II, IGFBP 1 and 2 decline (LeRoith, 
1996, Clemmons, 1997, Lee e ta l ,  1997).
During pregnancy the maternal endometrium secretes into the amniotic fluid an extremely high 
quantity o f IGFBP-1 which causes IGFBP-1 levels in maternal plasma to double, although they are still 
one order of magnitude lower then in the amniotic fluid. Foetal plasma concentration of IGFBP-1 is 
between the levels in amniotic fluid and maternal plasma, and it starts to be highly expressed in fetal 
hepatocytes only in the perinatal period. The localized, time-regulated and substantial changes in the 
expression of IGFBP-1 during pregnancy suggests a specific role for this protein. One hypothesis is that 
IGFBP-1 is involved in the process of trophoblast invasion of maternal endometrium. This occurs in a 
series of subsequent steps: i) cell attachment, ii) local matrix proteolysis, iii) cell migration and cessation 
of these activities. It has been observed that high levels o f IGF-II are expressed at the invading front 
resulting in a stimulation of trophoblast cell proliferation and migratioa Thus IGFBP-1 could act by
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inhibiting IGF-II interaction with the receptor and therefore reduce trophoblast invasion. On the other 
hand IGFBP-1, through its interaction with cell membrane a 5Pi integrin, has been shown to stimulate of 
CHO cells and long-term passaged cytotrophoblast migration in culture conditions (Jones et al., 1993b; 
Irving and Lala, 1995). It is likely that the combination of the two opposite effects o f IGFBP-1 on cell 
migration would result in a final inhibiting effect in vivo (Lee et al., 1997). Recently, Irwin and Giudice, 
showed that freshly isolated cytotrophoblasts were inhibited in the invasion of human endometrial cells 
(decidualized in vitro) when IGFBP-1 was expressed, but not when IGFBP-1 expression was suppressed 
by insulin. The authors suggest that in this case IGFBP-1, by binding to the integrin receptor, restrains 
trophoblast invasiveness acting in a fibronectin-like fashion (Irwin and Giudice, 1998).
1.2.2.a.3 Wound healing
In a rabbit ear dermal ulcer model IGFBP-1 has been described to promote wound healing when 
locally applied in combination with IGF. This is another effect o f IGFBP-1 which occurs through the 
interaction of its RGD sequence and integrin receptor. IGFBP-1 or IGF alone were ineffective as were the 
combination of IGF-I-IGFBP-2-, IGF-I-WGD-IGFBP-1 (an IGFBP-1 analog with a point mutation of the 
first amino acid of the RGD sequence) and D es(l-3) IGF-I-IGFBP-1, demonstrating that binding between 
the growth factor and the binding protein-1 and the integrity o f IGFBP-1 RGD sequence were essential for 
this effect (Galiano et al., 1996). A role for IGFBP-1 in wound healing has also been studied in humans, 
rats and in diabetic rabbits (Kratz et al., 1994; Jyung et al., 1994; Tsuboi et al., 1995).
1.2.2.a.4.Foetal development
The deletion of IGF-I and II mouse genes by homologous recombination produced animals of 
normal features, but reduced in size (DeChiara et al., 1990; Powell-Braxton et al., 1993) indicating the 
involvement of the two peptides in foetal development. A  role for IGFBPs in foetal development was also 
postulated, acting either through the modulation of IGF action or in an IGF-independent fashion. IGFBP 
expression in rat and mouse embryos has been determined and a specific spatio-temporal expression 
pattern was observed (Baker et al., 1993; Powell-Braxton et al., 1993; Cerro et al., 1993; Green et al., 
1994; Schuller et al., 1993; Streck et a l ,  1992; Wood et a l ,  1992). In particular, IGFBP-2 and-5 
expression appears to be localized in the same or adjacent tissues (Green et a l ,  1994; Schuller et al., 1993)
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suggesting a complementary role of these two binding proteins in specific tissues (Allan et al., 1999). The 
targeted disruption of the IGFBP-2 gene in mice did not produce any apparent phenotypical alteration 
(Wood e t al., 1993). This result, while suggesting a functional redundancy between the 6 IGFPBs, does 
not exclude a specific role for each IGF-binding protein in the development of normal embryos.
1.2.2.a.5 delivery to specific tissue
It is believed that IGFBPs can play a role in IGF transcapillary transport. Low Mr IGF-IGFBP 
complexes can cross capillary barriers (Jones and Clemmons, 1995a) and a specific role for endothelium 
associated IGFBP-3 fragments has been proposed (Booth et al., 1996). IGFBP-1 has been identified in 
peritoneal fluid whose composition is believed to be similar to interstitial fluid. It is not known if  the 
passage o f IGFBP-1 to the extravascular compartment occurs by passive leakage from the blood or if  it 
involves an active/regulated transport which would further support the hypothesized role o f IGFBP-1 in 
the interstitial space (Lee et al., 1997). During the acute phase response in CNS injury, IGF-II is rapidly 
mobilized from the central nervous fluid to the damaged neural parenchyma, in the absence o f increased 
local mRNA expression. It has been proposed that IGFBP-2, which is the most abundant IGFBP species in 
the CNS and whose local expression also increases, might play a specific role in IGF-II transportation in 
the wounded site (Walter et al., 1999; Walter et al., 1997).
1.2.2. a. 6 organ specific functions.
IGF growth promoting and metabolic action is widely expressed throughout the organism, but it 
might play a specific role in defined organs where the modulation by IGFBPs will significantly influence 
IGFs biological effects. However the widely spread tissue production of the 6 binding proteins, the 
contemporary presence o f growth factors and proteases make the investigation of IGFBP effects on a 
single organ very complex. For this reason much of the knowledge on the biology o f IGFBPs derives from 
studies carried out in suitable vitro models.
1.2.2.b in v itro
Both stimulating and inhibiting effects on IGF action have been attributed to IGFBPs in different 
cell culture systems. It is generally believed that soluble IGFBPs have an inhibiting effect on IGF action as
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they display high affinity for IGFs and prevent the growth factors from interacting with IGF-IR. In 
contrast, most o f the IGF-potentiating effects attributed to IGFBPs refer to cell surface or to ECM- 
associated IGFBPs. Although exceptions to this generalization have been reported, it is becoming apparent 
that the soluble and immobilized forms o f the same IGFBP can have quite different biological actions.
The nature of the interaction between IGFBPs and the cell surface or the ECM has not been fully 
elucidated. As mentioned in the previous sections the presence of the RGD sequence in IGFBP-1 and 2 
suggests a possible interaction of these IGFBPs with integrin receptors. Alternatively (or in addition to the 
RGD sequence) IGFBPs might bind to the ECM or the cell surface through a heparin binding motif 
(present in all IGFBPs) or through an 18 amino acid region rich in basic residues (only in IGFBP-3 and 5). 
It has been proposed that in this case the binding would occur via GAG components of the ECM or the 
cell surface. However the molecular features of this interaction are not completely clarified. It remains to 
be explained why, although all IGFBPs display at least a heparin binding sequence, different IGFBPs 
show a preferential binding to the cell surface or the ECM or why some IGFBPs do not seem to bind 
either the cell surface or the ECM. The understanding of the mechanisms involved in this association 
would be useful for a better interpretation of the contradictory effects displayed by the IGFBPs in a variety 
o f  biological assays
1.2.2.b.l IGFBP-1
Either IGF- inhibiting or potentiating effects have been attributed to IGFBP-1. as reviewed by 
Jones and Clemmons (1995a); LeRoith (1996);Collett-Solberg and Cohen (1996), and Lee et al. (1997).
Inhibition of IGF action.
In general i f  IGFBP-1 is phosphorylated or present in at least 4:1 excess o f IGFs, it exerts an 
inhibitory effect on IGF action (Clemmons, 1997). Phosphorylated IGFBP-1, which has higher affinity for 
IGF-I, decreased IGF-I-stimulaled DNA synthesis in human fibroblasts, but after dephosphorylation 
IGFBP-1 potentiated IGF action (Busby et a l., 1988a; Jones and Clemmons, 1995a). If a high enough 
molar excess of protein is used, there is no requirement for IGFBP-1 to be phosphorylated in order to exert 
inhibition on IGFs. In MCF7 cells IGFBP-1 inhibits IGF-I stimulated growth, preventing the 
phopshorylation of the IGF-IR by IGF-I (Yee et al., 1994). In the same breast cancer cell line IGFBP-1
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also inhibits estrogen or serum-stimulated cell growth (Figueroa et a l ,  1993). When added in excess, 
IGFBP-1 has also been reported to inhibit: i) AIB uptake in JEG-3 choriocarcinoma cells (Ritvos e t al., 
1988), ii) 3[H] thymidine incorporation in pSMC (Busby et al., 1988a) and in MG63 osteosarcoma cells 
(Campbell and Novak, 1991) and iii) glucose uptake in 3T3/Balb fibroblasts (Okajima et al., 1993).
Potentiation of IGF action.
In contrast when the non-phosphorylated isoform o f IGFBP-1 is used, or when the binding 
protein is added at low concentrations, an IGF potentiation is generally obtained. IGFBP-1 enhanced IGF- 
I, but not IGF-II, stimulated proliferation in human keratinocytes and skin fibroblasts (Kratz et al., 1992) 
and increased DNA synthesis in human, mouse and chick embryo fibroblasts (Elgin et al., 1987). In 
contrast to the above mentioned inhibitory effect o f IGFBP-1 in pSMC, this binding protein was reported 
to increase 4.8-fold the IGF-I-stimulated 3[H]thymidine uptake, while IGFBP-2 only increased IGF action 
2.2-fold under the same conditions (Boumer et a l ,  1992).
IGFBP-1 interaction with integrins.
The interaction of the C-terminal RGD sequence of IGFBP-1 with the cellular a 5Pi integrin 
(fibronectin receptor) on the cell surface has been described (Jones et al., 1993b). Post-translational 
modifications might influence this binding as it has been reported that only the phosphorylated form of 
IGFBP-1 can associate to the cell surface (Chan and Spencer, 1997).
IGFBP-1 stimulates cell migration in CHO cells (Jones et al., 1993b) and in pSMC cells seeded on 
fibronectin coated plates (Gockerman et a l, 1995).
The RGD sequence appears to be essential for this stimulation to occur as demonstrated by the inhibition 
o f the IGFBP-1-stimulated cell migration by a competitive RGD peptide or by the inability o f a WGD- 
IGFBP-1 mutant to stimulate cell migration. It has been shown that fibronectin-a5Pi inhibits cell 
migration in CHO cells overexpressing a 5Pi integrin (Giancotti and Ruoslahti, 1990) and although it is 
involved in cell adhesion, it does not facilitate cell migration in pSMC cells (Clark, 1993). Therefore 
IGFBP-1 stimulation of cell migration could result from its competition on fibronectin to a 5Pi integrin. 
(Gockerman et a l,  1995).
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IGF-I and II alone are also potent stimulators o f pSMC cell migration on fibronectin coated plates. In this 
case IGFBP-1 exerts an inhibiting effect on IGF-stimulated migration by antagonizing the binding o f the 
growth factors to IGF-IR and consistently it fails to affect des(l-3)IGF-I action in this assay system. 
(Gockerman e ta l ,  1995).
Cell migration is a complex phenomenon resulting from the interaction between several growth factors, 
the cells and the extracellular matrix (Gockerman et al., 1995). Therefore a combination of factors, 
including the integrin type expressed on the cell surface and the cellular substratum, can affect the ability 
o f a molecule to stimulate cell migratioa
Thus on vitronectin coated plates IGF-I also promotes pSMC cell migration, but in this case the 
contemporary stimulation of the IGF-IR by IGF-I and the ligand occupancy o f OvP3 integrin (vitronectin 
receptor) seem to be necessary. The prevention of these events by the addition of IGFBP-1 in the former 
case or ocvP3 integrin competitors (such as echistatin and kistrin),in the latter case, inhibits IGF-I- 
stimulated cell migration (Jones et al., 1995b; Jones et al., 1996).
Integrms that have been considered principally as adhesion molecules, are now increasingly reported to be 
involved in cellular signaling events. Integrin a  subunit is responsible for ligand specificity, while the P 
subunit determines the signal specificity. This means that the stimulation by different ligand molecules 
can lead to the same cellular response. Integrin p subunit does not have tyrosine kinase activity, but (at 
least for Piand p3) can associate with ppl25FAK (focal adhesion kinase). This kinase is activated by 
phosphorylation and concentrates around the focal adhesion area, which represents the integrin- 
cytoskeletal transmembrane linkage. Other proteins have been reported to become phosphorylated in 
response to integrin signalling such as IRS-I, Grb2, and MAP kinases suggesting a convergence between 
integrin and IGF-IR signalling (Vuori and Ruoslahti, 1994; Schlaepfer et al., 1994; Chen et al., 1994; 
Morino et al., 1995). Importantly, treatment with lOOnM insulin, a dose that would be able to stimulate 
the IGF-IR, stimulated phosphorylated IRS-I to associate to the a vP3 receptor (Vuori and Ruoslahti, 1994)
IG FBP-2
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A detailed description of IGFBP-2 interaction with the cell membrane/ECM and its biological function in 
cell culture systems will be described in the last paragraph o f this literature review as it relates to the 
principle investigation of the current thesis.
1.2.2. b. 2. IGF BP-3
IGFBP-3 biological functions include an inhibitory and a potentiating effect o f IGF action, as 
well as an IGF independent effect. Data reported in the literature are often contradictory and the attempt to 
deduce some general properties o f IGFBP-3 behavior in the different cell systems is difficult. However it 
seems clear that IGFBP-3 interaction with the cell surface/or ECM, and possibly the different methods by 
which this takes place, can largely influence the IGFBP-3 effect. In the past five years IGFBP association 
with the cell membrane or with the ECM has been extensively investigated. IGFBP-3 and 5 were the most 
thoroughly studied binding proteins with this respect for two main reasons: i) first because in various cell 
cultures a significant part of IGFBP-3 and 5 appears to be bound to the cell surface/ECM, ii) second, and 
probably more important, because the study o f cell surface/ECM association represents a new promising 
approach for understanding the mechanisms by which IGFBP-3 and 5 can either potentiate IGF action or 
act in an IGF-independent fashion. The molecular aspects of IGFBP cell surface/ECM-association have 
not been fully identified, however the two most popular theories propose either GAGs or protein 
molecules as cell membrane mediators of IGFBP binding.
A summary of some o f the studies in support or in contradiction of the role played by GAGs in IGFBP-3 
association to the cell membrane will be introduced before the description of the biological effects o f  
IGFBP-3. The interaction of IGFBP-3 with a putative membrane IGFBP-3 receptor protein and IGFBP-3 
nuclear translocation will be mentioned in the section dedicated to IGFBP-3 (IGF-independent) effects.
It was shown that heparin could release cell-associated IGFBPs into the culture medium (Martin 
e t a l ,  1992b). Heparin is very similar to heparan sulfate, one of the GAGs present on the cell membrane 
and the ECM. Both are polymers formed by highly sulfated iduronic acid-N-acetylglucosamine 
disaccharide repeat units. Thus it was hypothesized that the mechanism by which heparin displaced cell- 
associated IGFBP was a specific competition between heparin and the cell membrane heparan sulfate. It 
was subsequently shown that heparin displacement of fibroblast or rat glioma cell-associated IGFBP-3 is
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likely to be due to the direct binding between heparin and IGFBP-3 which possibly masks the binding 
sites necessary for IGFBP-3 association to the cell surface (Yang et al., 1996). Oh et al.(1992) showed 
that the treatment with IGF-I but not with [QAYL]IGF-I (which has lower affinity for IGFBP and normal 
affinity for IGF-IR), released membrane-associated IGFBP-3 into the medium o f cultured human breast 
cancer Hs578T cells. However the association of IGFBP-3 with GAGs does indeed occur (Arai et al., 
1994a) and thus it was investigated whether these polymers were responsible for IGFBP-3 association to 
the cell monolayer. In human skin fibroblasts and rat glioma cells, heparan sulfate and chondroitin sulfate 
account for all o f the cell membrane associated GAGs. Pretreatment o f the cell monolayer with 
heparitinase (which degrades heparan sulfate GAGs), or heparinase (which preferentially degrades highly 
sulfated GAGs like heparin and heparan sulfate) or ABC chondroitinase (which digests chondroitin 
sulfate) did not decrease 125I IGFBP-3 binding to the cell monolayers (Yang et al., 1996). Similar 
enzymatic treatments and also the addition of sodium chlorate to the culture medium failed to affect 125I 
IGFBP-3 binding to Isikawa endometrial cancer cells (Karas et al., 1997). Taken together these data 
indicate that the interaction of IGFBP-3 to the cell surface cells is unlikely to occur via GAGs. In contrast, 
Smith et al. (1994) showed that sodium chlorate treatment, which inhibits the enzyme responsible for 
sulphation of GAGs (Hoogewerf e t al., 1991), reduced the binding of exogenously added IGFBP-3 to rat 
Sertoli cells in a dose dependent manner.
Several reports show that not only does 125I IGFBP-3 associate to the cell membrane, but, after incubation 
at 37°C, it becomes internalized (Yang et al., 1996; Karas et a/., 1997) through an endocytotic process 
which can be inhibited by incubating the cells at low temperature (Smith et al., 1994). Internalization and 
lysosomal degradation of cell associated IGFBPs could represent an additional aspect o f the complex 
modulation o f the IGF-IGFBP axis.
Inhibition of IGF action.
As reviewed in Clemmons (1997), IGFBP-3 added in excess to Balb/c3T3 cells in culture inhibited the 
insulin-like actions o f IGF-I (Okajima et al., 1993). In chick fibroblasts IGFBP-3 decreased IGF-I DNA  
synthesis (Blat et al., 1989) and in rat granulosa cells the steroidogenesis and the cAMP rise stimulated by 
IGF-I was inhibited by exogenous IGFBP-3 (Bicsak et al., 1990). IGFBP-3 inhibited collagen synthesis in 
rat and mouse osteoblasts and IGF-I stimulated glucose uptake in pig fat cells (but it was ineffective on
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insulin-stimulated glucose uptake). It was proposed that the increased concentration of IGFBP-3 in the 
conditioned medium in mouse embryo fibroblasts could account for the density dependent inhibition of 
cell growth (Blat et al., 1994). Nickerson et al., (1997) reported that in MCF7 cells 72h incubation with 
IGFBP-3 caused a reduction of 3[H]thymidine uptake and a 3.5 fold increase in the number of apoptotic 
cells. IGFBP-3 also antagonized the antiapoptotic effect o f IGF-I, but not of R3IGF-I, an IGF-I analog 
with full affinity for IGF-IR and reduced affinity for IGFBPs. This indicates that the apoptotic effect of 
IGFBP-3 in this cell line derives from its ability to prevent IGF interaction with IGF-IR. In a human 
glioblastoma cell line, A172, the induction o f p53 gene expression caused apoptosis and the stimulation of  
IGFBP-3 gene promoter and protein expression. It has been shown that in this cell line the addition of 
recombinant IGFBP-3 causes apoptosis but it remains to be demonstrated if  the p53-induced apoptosis is 
mediated through the increase of endogenous IGFBP-3 (Shen and Glazer, 1998). Karas et al. (1997) 
showed that in Isikawa endometrial cancer cells membrane-associated IGFBP-3 inhibited short (IGF-IR 
and IRS-I phosphorylation) and longer term (induction of c-fos, increased API binding to TRE 
oligonucleotides) signalling events.
IGF-potentiating action.
When either human recombinant glycosylated or non glycosylated IGFBP-3 was incubated with 
bovine fibroblasts, it associated to the cell monolayer and constituted an additional low affinity binding 
site for 125I IGF-I. After 72h pre-incubation of the cells with IGFBP-3, the AIB and thymidine uptake 
stimulated by IGF-I, insulin and [QAYLJIGF-I was potentiated (Conover, 1992). Cell responsiveness to 
the growth factors correlated with their affinity for IGF-IR, independently from their affinity for IGFBP- 
3. It could be hypothesized that IGFBP-3 localizes IGF-I on the cell membrane and slowly releases it to 
the receptor, thus preventing the IGF-IR down regulation induced by an excess of IGF. However the 
potentiation of insulin and [QAYL]IGF could not be explained with this model.
IGF-independent effects.
Several lines of evidence have been collected in favor of an IGF-independent effect o f IGFBP-3 
in some cell culture models.
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Oh et al. (1993c) reported that IGFBP-3 binds to the Hs578T cell surface and inhibits cell proliferation 
stimulated by IGF-I, but not by IGF analogs with reduced affinity for IGFBP-3. By cross-linking 125I 
IGFBP-3 to the cell monolayer and subsequently immune precipitating the cell lysate with anti IGFBP-3 
antibodies 3 cell surface proteins (20, 26 and 50 kDa) with IGFBP-3 binding properties were identified 
(Oh et al., 1993b). The authors propose that the IGFBP-3 inhibitory effect on cell proliferation could be 
mediated through a specific IGFBP-3 receptor. In 1995 the same authors showed that substances that 
inhibited Hs578T cell growth, such as TGF(32 (tumor suppressor growth factor), antiestrogens and retinoic 
acid, induced an increase of IGFBP-3 expression. TGF|32-induced growth arrest was reversed by 60 % by 
transfecting the cells with antisense IGFBP-3. IGF-II and Leu27 IGF-II (which has full affinity for IGFBP- 
3 and reduced affinity for IGF-IR) were able to reverse TGFf32 stimulated growth suppression, but 
[QAYLL]IGF-II (which has full affinity for IGF-IR and reduced affinity for IGFBP-3) did not. These data 
indicate that the mechanism by which TGF(32 determines the reduction of the cell growth cannot be 
explained by the simple increase in IGFBP-3 and subsequent sequestration of IGFs from IGF-IR, and 
suggests that IGFBP-3 acts in an IGF-independent fashion (Oh et al., 1995). Further support for this 
hypothesis came from a study where it was shown that IGF-IR-negative mouse fibroblasts, transfected 
with human IGFBP-3, displayed lower growth rate compared to the controls (Valentinis et al., 1995). 
Moreover several reports have shown that IGFBP-3 fragments derived by limited plasmin proteolysis, 
despite their reduced affinity for IGF, inhibited IGF-stimulated mitogenesis and even the mitogenic effect 
o f insulin (Oh, 1997). In the prostate cell PC-3, IGFBP-3 fragments derived by plasmin digestion 
displayed opposite biological effects. Intact IGFBP-3 was able to increase cell proliferation and 1_ 
169IGFBP-3 fragment was almost three times more effective than the wild type molecule. This effect is 
probably due to a modulation of endogenous IGF-II-induced cell proliferation as it is markedly reversed 
by aIR-3, an anti IGF-IR monoclonal antibody. In contrast 195IGFBP-3 fragment, derived from further 
digestion of the 1-169 peptide, reduced cell proliferation to 50% of basal levels. This fragment (that does 
not bind IGF-II), was able to reverse IGF-II induced cell proliferation even when the accessibility o f IGF- 
IR was blocked with the addition odR3 (Angelloz-Nicoud et al., 1998). These data confirm previous work 
o f the same research group which described the growth inhibitory effect o f 195IGFBP-3 fragment in mouse 
fibroblasts with targeted disruption of IGF-IR gene (Mohseni-Zadeh and Binoux, 1997a).
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The same authors also showed that intact IGFBP-3 is able to inhibit both IGF-I and des(l-3)IGF-I 
proliferative activity. The authors propose that in this case IGFBP-3 might bind directly to IGF-IR 
preventing its interaction with the IGF peptides (Mohseni Zadeh and Binoux, 1997b).
An alternative method of interaction between the cells and IGFBPs has recently been described 
for IGFBP-3 and 5 which were shown to translocate to the cell nucleus. With immunofluorescence 
IGFBP-3 was detected in the nucleus of proliferating human keratinocytes and laser scanning confocal 
microscopy confirmed that the binding protein was present in the nucleus and not in the perinuclear spaces 
(Wraight e t a l ,  1998). Nuclear uptake of fluorescently labelled IGFBP-3 and 5 was demonstrated in 
proliferating human breast cancer cells after 90’minutes whereas no nuclear uptake was observed after the 
addition of equivalent amount of labeled IGFBP-1 and 2 although all labeled proteins were shown to 
associate to the cell membrane (Schedlich et al., 1998). Both IGFBP-3 (Radulescu, 1994) and 5 contain a 
NLS sequence (nuclear localization signal) inside the C-terminal 18 residue sequence (215-232 for 
IGFBP-3 and 210-218 for IGFBP-5) that is also involved in heparin/GAGs and ALS binding. The NLS 
motif is a bipartite nuclear targeting sequence found in many nuclear proteins and consists o f 2  basic 
residues followed by an interval of 10-11 amino acids and then at least 3 basic residues within the next 5 
positions. Substitution of the (^KGRKR) IGFBP-3 sequence with the corresponding (MDGEA) IGFBP- 
1-derived sequence abolishes nuclear uptake (Schedlich et a l ,  1998). In contrast to the IGFBP-3 
internalization by endocytosis reported by Smith (1994), IGFBP-3 nuclear localization does not seem to 
be affected by lysosomotropic inhibiting agents nor by microtubule disrupting agents, suggesting the 
internalization and translocation occurs through an alternative pathway (Schedlich et al., 1998). Nuclear 
translocation has been described also for insulin, platelet derived growth factor and fibroblast growth 
factor which stimulate cellular responses either by an indirect signal pathway or directly through nuclear 
targeting. A similar possibility could exist for IGFBP-3 and the choice between one or the other pathways 
might depend on the cell cycle phase (Schedlich et al., 1998), as nuclear localization seems to occur only 
in cells in mitotic phase at the cytokinesis stage (Wraight e t al., 1998). In particular nuclear targeting 
could explain some o f the cellular growth inhibitory effects o f IGFBP-3 which do not appear to be IGF- 
mediated (Wraight et a l, 1998).
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Finally although IGFBP-3 preferentially binds to the cell surface, but it can also associate to 
ECM, although less potently in comparison with IGFBP-5 (Jones et al., 1993 a; Imai et al., 1997).
1.2.2. b. 3IGFBP-4
IGFBP-4 modulation on IGF action is mainly inhibitory, as reviewed in Jones and Clemmons 
(1995a) and Clemmons (1997).
Inhibition of IGF effects
In rat Leydig cells IGF-I enhances hCG-stimulated steroidogenesis and IGFBP-4 inhibits the 
effect o f the growth factor (Lin et al., 1993). IGFBP-4 inhibits human osteosarcoma cell growth and 
glycogen synthesis, when added in excess over IGF-I and IGF-II (Kiefer et al., 1992) and an inhibitory 
effect on DNA synthesis has been reported also in colon carcinoma cells (Culouscou and Shoyab, 1991). 
In the B104 neuroblastoma rat cell line IGFBP-4 inhibits IGF-I stimulated, but not des(l-3)IGF-I- 
stimulated, 3[H] thymidine uptake (Cheung et al., 1991). IGFBP-4 antagonized IGF-I- stimulated A IB 
uptake or DNA synthesis in fibroblasts and in porcine smooth muscle cells (pSMC). The level o f this 
inhibition was affected by specific IGFBP-4 proteases released in the conditioned medium by cultured 
pSMC and human fibroblasts (Cohick et al., 1993; Conover et al., 1993a). The principal cleavage site at 
which proteases produced by B104 neuroblasts cleave IGFBP-4, is located between K120 and H121, 
while a secondary cleavage site lies between M131-K132 (Chemausek et al., 1995). The exposure o f rat 
IGFBP-4 to human fibroblasts also causes proteolytic degradation and a cleavage site after M135 residue 
has been described. Consistently rat IGFBP-4 mutated in the vicinity o f 132-135 sequence appeared more 
potent in inhibiting IGF-stimulated DNA synthesis in human fibroblasts (Conover et al., 1995). The 
ability o f IGFBP-4 or various IGFBP-4 derived or mutated proteins to antagonize IGF-H-stimulated 
proliferation in human osteosarcoma cells was tested. The inhibitory effect correlated with the affinity of 
each IGFBP-4 form for IGF-II. Thus IGFBP-4 and H74P IGFBP-4 mutant had equal affinity for IGF-II 
and the highest inhibitory action. A C-terminus-deleted IGFBP-4 molecule had reduced affinity for IGF-II 
and is also less potent in reducing the effect o f the growth factor. In contrast the N-terminus 171 IGFBP-4,
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which binds IGF-II very weakly, and the C-terminus of the molecule, which shows no affinity for IGF-II, 
were not effective in inhibiting IGF-II stimulated cell growth (Qin et al., 1998).
1.2.2.b.4 IGFBPS
IGFBP-5 shares structural and functional similarities with IGFBP-3 and, like IGFBP-3, can exert 
an inhibitory or enhancing effect on IGF action or may even have an IGF-independent function. The 
biological action of IGFBP-5 varies substantially depending on whether the binding protein is present in 
soluble form in the conditioned medium or is associated with the solid phase on the cell membrane or 
ECM. A summary o f the data in this area will precede the description of the functions of IGFBP-5 in cell 
culture. As for IGFBP-3, it is believed that IGFBP-5 might either bind to GAGs or to the proteins 
normally present on the cell surface or on the ECM
IGFBP-5 has been shown to interact with ECM proteins, such as type IV collagen and type III 
collagen, fibronectin and laminin, (listed in decreasing order of affinity), while it does not bind to 
vitronectin, type I, V and VII collagen (Jones et al., 1993a). Moreover as IGFBP-5 binds to heparin 
(Andress, 1995), it was investigated if  GAGs, which are structurally related to heparin, were also involved 
in the in IGFBP-5 interaction with the ECM/cell surface. It was found that the binding o f IGFBP-5 to 
ECM prepared from human fibroblast or to mesangial cell monolayer was inhibited by high salt 
concentration, competed by heparin and decreased by enzymatic degradation o f GAG residues with 
heparinase (Jones et al., 1993a; Arai et al., 1996 and Abrass et al., 1997). It was also shown that IGFBP-5 
bound to plates coated with a purified heparan sulfate proteoglycan, tenascin, and the binding was reduced 
by heparinase treatment (Arai et al., 1996). These results support the hypothesis that IGFBP-5 binding to 
the ECM occurs at least in part via GAGs, as well as through direct binding to ECM proteins. Andress 
(1995) tested if  GAGs were also involved in the association IGFBP-5 with the cell membrane. Both 
IGFBP-5 and its C-terminal-truncated variant1169 IGFBP-5 bound to osteoblast-like cell membranes and 
became internalized. The binding was inhibited by high salt concentration and competed by heparin> 
heparan sulfate> dermatan sulfate in decreasing order for both proteins, although higher salt and heparin 
concentration were required to displace 1169 IGFBP-5 compared to wild type protein. However, these 
results derived from a direct competition between the above molecules and the cell membrane GAGs,
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were questioned by the inability o f the heparinase or sodium chlorate treatment of the cell monolayers to 
affect IGFBP-5 binding to the cell membrane. By cross-linking IGFBP-5 or 1169 IGFBP-5 to osteoblast 
monolayers, it was found that the tracer proteins formed a complex with a 420kDa Triton-extractable 
membrane protein and this protein was then purified from a cellular extract on an IGFBP-5 affinity 
chromatography column. The affinity labeling was greater for IGFBP-5 than for its truncated variant and 
the formation o f the complex was not affected by heparinase or chondroitinase pretreatment of the cell 
monolayer. In contrast IGFBP-5 and 1169IGFBP-5 failed to cross-link to any protein of an ECM 
preparation. In conclusion, while IGFBP-5 association to the ECM might involve GAG interactions, the 
binding to osteoblast cell surfaces was mediated by a 420kDa protein, which would serve as an IGFBP-5 
specific receptor. Its functions as a receptor were further investigated in a recent study by the same author 
(Andress, 1998). The treatment with IGFBP-5 or with the 201-218 peptide derived from IGFBP-5, caused 
an increased serine phosphorylation of the 420kDa protein which in addition displayed some kinase 
activity itself as it was able to induce serine phosphorylation o f casein in vitro.
When a nuclear localisation sequence (NLS), similar to the one described for IGFBP-3, was 
identified also in IGFBP-5 (Schedlich et al., 1998), an alternative route for IGFBP interaction with cells 
emerged. In IGFBP-5 the nuclear translocation sequence is located in the 201-218 region which is also 
involved in the binding to heparin, ALS and PAL More details on nuclear translocation have been 
described in the section detailing the IGF- independent effects o f IGFBP-3.
Finally it is important to remember that the microenvironment can modulate the IGF-IGFBP axis 
in many different ways. For example,
-While IGFBP-3 preferentially binds to the cell surface, IGFBP-5 preferentially binds to the 
ECM (Jones et al., 1993a, Imai et al., 1997)
-When IGFBP-5 is bound to heparin or to the ECM its affinity for IGFs is decreased 8-15 fold 
while IGFBP-3 affinity for IGFs shows a 12-fold decrease when the binding protein is associated to the 
cell surface, but not when it is bound to ECM (McCusker et al., 1990; Arai et al., 1996; Arai et al., 
1994a).
-In many cell culture conditions extensive proteolytic activities degrade IGFBP-5 and the 
resulting fragments show a reduced binding for IGFs (Camacho-Hubner et al., 1992).
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-The proteolytic activity is generally inhibited when IGFBP-5 is bound to the ECM or to IGF-I 
(Jones et a l ,  1993a; Camacho-Hubner et a l ,  1992 and Sunic et a l ., 1998).
IGF inhibiting effects.
IGFBP-5 inhibited IGF-I and H-stimulated DNA and glycogen synthesis in human osteosarcoma 
cells (Kiefer et a l,  1992). Moreover IGFBP-5 decreased the IGF-I stimulated steroidogenesis in Leydig 
cells (Ling et a l ,  1993).
In some of the models used to investigate the biology o f this binding protein it was noted a 
correlation existed between the occurrence o f apoptosis and the increased expression of IGFBP-5. 
Guennette and Tenniswood (1994) reported that IGFBP-5 expression increases in involuting prostate and 
suggest that the binding protein associated with the ECM would prevent IGF interaction with the IGF-IR 
and therefore the subsequent delivery o f IGF survival signals. A contemporary increase in IGFBP-5 
expression and in apoptotic cell number was also noted in finasteride or castration-induced prostate 
involution, although differential staining for DNA breakage or for IGFBP-5 expression did not overlap 
within the same tissue sections (Thomas et a l ,  1998). A correlation between IGFBP-5 expression and 
apoptosis was also observed in atretic follicles (Erickson et al., 1992) and in rat involuting mammary 
gland (Tonner eta l., 1997).
IGF potentiating effects
Potentiating effects o f IGFBP-5 have been reported by several authors in fibroblasts, bone cells 
and smooth muscle cells (SMC).
ECM-associated IGFBP-5 enhanced human fibroblast growth in response to IGF-I treatment, 
while the binding protein in the CM was degraded to a 21kDa fragment lacking of potentiating effects 
(Jones et a l ,  1993a). In human glioblastoma cells (T98G) endogenous IGFBP-5 was associated with the 
cell membrane and showed 5 fold higher affinity for IGF-II, than for IGF-I. Zn^  induced a reduction in 
the affinity o f membrane-associated IGFBP-5 for IGFs but at the same time it stimulated retention of 
IGFBP-5 on the cell surface. In this system Zn^ was able to potentiate IGF action in the absence o f  
exogenously added IGFBP-5. Therefore the Zn^potentiating effect might derive from a facilitated release 
of IGF from the cell surface-associated IGFBP-5 to the IGF-IR (Sackett and McCuscker, 1998). In bone
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cells, as well as in smooth muscle cells, IGFBP-5 has been reported to have alternatively an effect 
promoting cell proliferation or cell differentiation. In human osteoblast-like cells both IGFBP-5 and its 
carboxy-truncated 23kDa fragment enhanced IGF-I and IGF-II stimulated mitogenesis. IGFBP-5 
stimulated cell proliferation in the absence of exogenous or endogenous IGFs (Andress and Bimbaum,
1992). During the differentiation process in MC3T3-E1 mouse osteoblasts, IGFBP-5 secretion increases in 
the initial cell proliferation period and it reaches its peak at transition with the start of differentiation, then 
it declines. In contrast, it has been noticed that in rat osteoblasts, growth factors which stimulated cell 
proliferation, such as FGF, TGFp and PDGF, decreased the expression o f IGFBP-5, IGF-I and IGF-II 
(Canalis and Gabbitas, 1995; Canalis et al., 1993), while factors that stimulated cell differentiation, 
(namely IGFs and retinoic acid), increased IGFBP-5 expression (Conover and Kiefer, 1993; Dong and 
Canalis, 1995; Gabbitas and Canalis, 1998). Cortisol which is an inhibitor of multiple parameters of bone 
formation, including cell proliferation, reduced IGFBP-5 expression and its deposition onto the ECM 
(Gabbitas et al., 1996).
As with bone cells, also in smooth muscle cells (SMC) contrasting results have been published 
suggesting that IGFBP-5 potentiated either the proliferating or the differentiating effect o f IGF peptides. 
In pSMC transfected with IGFBP-5 cDNA the expressed protein accumulated in the ECM more 
abundantly than in the control cells and it potentiated the IGF-I stimulation o f DNA synthesis. Conversely, 
the transfection of pSMC cells with IGFBP-5 mutants which have reduced ECM binding affinity, resulted 
in an inhibition of IGF-I stimulated 3[H]Thymidine uptake (Parker et al., 1998). The presence in 
conditioned medium of a low level o f intact IGFBP-5 with high affinity for IGF, together with the 
presence of abundant intact ECM-associated IGFBP-5 with reduced affinity for IGFs appears to be the 
condition required for the binding protein to exert an IGF potentiating effect. The authors propose that 
IGFBP-5 should be included in the group of the crinopectins, molecules which interact with proteoglycans 
and facilitate the interactions between the growth factors and their receptors (Parker et al., 1998).
Similar results in terms of potentiation of IGF stimulated 3 [H]thymidine uptake were obtained in SMC 
when monolayers were incubated for 48h with IGFBP-5, but not after a 24h incubation period. It was 
suggested that, in order to achieve an IGF enhancing effect IGFBP-5 required to be proteolyzed into a 
21kDa fragment, which retained the ability to associate to the ECM but had greatly reduced affinity for
59
IGFs. This theory is further strengthened by the observation that a proteolysis resistant IGFBP-5 mutant in 
the same culture conditions revealed an IGF inhibitory effect (Duan and Clemmons, 1998). In this latter 
study it was shown that IGFBP-5 and IGF expression is high in proliferating cells and declines when cells 
reach confluence. In contrast other authors report that in L6A1 muscle cells (Ewton et a l., 1998) and in C2 
mouse myoblasts (Rousse et al., 1998) IGFBP-5 expression increases during cell differentiation.
Rousse e t a/. (1998) showed that in the same C2 cell line, stably transfected with antisense IGF-II, 
IGFBP-5 expression was indeed increased during myogenic differentiation, but this phenomenon was 
independent from the differentiation process and directly regulated by IGF-IR activation. In contrast, 
evidence o f a direct involvement of IGFBP-5 in myogenic differentiation was provided by studies 
showing that C2 myoblasts overexpressing IGFBP-5 failed to differentiate, while the transfection o f the 
cells with antisense IGFBP-5 causes earlier differentiation.(James et al., 1996).
In L6A1 cells IGFBP-5 expression was higher in differentiating cells and the binding protein 
showed an inhibitory effect on IGF stimulated proliferation and a potentiating effect on cell differentiation 
stimulated by IGF-I but not IGF-II (Ewton et al., 1998).
Finally it should be pointed out that in many experimental models the IGF-IGFBP axis cannot 
really be considered as an isolated system. For example recent work showed that the SMC phenotype can 
be substantially influenced by the type o f substrate the cells are cultured on. On laminin and collagen the 
cells display a dedifferentiated phenotype, while on fibronectin the cells show a synthetic phenotype and 
respond to growth factor stimulation with an increased cell proliferation or migration. Cells cultured on 
fibronectin produced 4 times more IGFBP-5, than cells cultured on laminin/collagen. Moreover the 
addition of exogenous IGFBP-5 did not affect cells seeded on fibronectin whereas it markedly increased 
IGF-I-stimulated DNA synthesis in cells plated on laminin/ collagen. Thus it appears that ECM proteins, 
by interacting with cell membrane integrins, can influence the IGF-IGFBP-5 axis. In particular this study 
showed that ligand occupancy o f a v(33 by vitronectin or thrombospondin induces IGF signalling events 
which lead to the stimulation o f cell proliferation or cell migration (Zheng et al., 1998b).
IGF-independent actions.
IGFBP-5 and an IGFBP-5 derived peptide containing the 201-218 sequence were shown to 
stimulate cell proliferation in mesanglial cells (MC), but in the presence of IGF-I, IGFBP-5 reduced IGF-
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induced cell migration. MC cells express and integrins. The addition of kistrin, a disintegrin 
which binds to a vp3 integrin, abolished IGF-I induced migration, but not migration stimulated by 201-218 
peptide. Therefore it seems that IGF and IGFBP-5 stimulate cell migration through 2 different 
mechanisms (Abrass et al., 1997).
1 2.2.b.IGFBP-6
Due to its low affinity for IGF-I, IGFBP- 6  inhibitory effect is mainly restricted to IGF-II action.
Inhibition of IGF effects.
In the ovary FSH and LH stimulate IGFBP- 6  secretion which in turn inhibits IGF-I stimulated 
steroidogenesis, although less potently then IGFBP-2 or 4 (Jones and Clemmons, 1995a). IGFBP- 6  
inhibits IGF-II, but not IGF-I, induced differentiation in myoblasts (Bach et al., 1994). In MC3T3-E1 
osteoblasts IGFBP- 6  reduced the basal level o f 3[H] thymidine uptake, abolished the IGF-II-induced 
increase in thymidine incorporation, but inhibited only 40% of the IGF-I induced effect. The higher 
affinity o f IGFBP- 6  for IGF-II compared to IGF-I probably accounts for the difference in inhibitory 
strength. (Srinivasan et al., 1996). As described for other IGFBPs, IGFBP- 6  expression can be subjected 
to TGFp regulation which has been shown to decrease IGFBP- 6  mRNA in osteoblasts (Gabbitas and 
Canalis, 1997).
IGFBP- 6  secretion in keratinocytes, myoblasts and neuroblastoma cells increases when cells 
undergo growth arrest Retinoic acid in neuroblastoma cells induces differentiation, reduces IGFBP2 and 4 
expression, but increases IGFBP- 6  expression, whose function might be to sequester endogenous IGF-II 
from the interacting with IGF IR in these cells (Chambery et al., 1998). From in vitro and in vivo studies 
some indications suggest that through the same mechanism IGFBP-6 , which is expressed in a range of cell 
tumours (breast carcinoma, prostate carcinoma, endometrial carcinoma, neuroblastoma) might play a 
growth inhibition role (Sheikh et al., 1993; Bach and Rechler, 1996; Drivdahl et al., 1995; Gong et al., 
1992; Babajko andBinoux, 1996).
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1.2.2. b. 6.IGFBP-2
An IGF-inhibitory effect is generally attributed to IGFBP-2, however a correlation between 
IGFBP-2 plasma concentration and cell proliferation in patients affected by cancer has been reported in 
vivo and a few enhancing effects have also been described in vitro. As for other IGFBPs the association of 
IGFBP-2 to the cell membrane or to the ECM might be biologically significant and a review o f the 
information available in the literature will precede the description of IGFBP-2 effects in cell culture.
As described above, IGFBP-2 has an RGD sequence in the C-terminus o f the molecule, but 
unlike IGFBP-1 which was shown to bind to a 5(3] integrin, no binding to integrin has been demonstrated 
for IGFBP-2. Although the possibility that this binding occurs cannot be excluded, alternative mechanisms 
o f  interaction between IGFBP-2 and the cell membrane have been investigated. IGFBP-2 is secreted in 
many tissues and cell lines, but its association to the cell membrane has been poorly reported. Within the 
rat brain only in the olfactory bulbs is IGFBP-2 largely bound to the cell membrane, although it is 
produced throughout the whole brain (Russo et al., 1997). Similarly in non small cell lung cancer 
(NSCLC) and small cell lung cancer (SCLC) derived cell lines which both secrete IGFBP-2, the 
association of the binding protein with membranes is more abundant in SCLC cell lines (Reeve et al.,
1993). The association of IGFBP-2 with the cell membrane was demonstrated with several different 
assays. Many studies were carried out with [125I] IGFs affinity labeling experiments where the 
radiolabelled growth factors were cross-linked either to cell membrane preparations or directly to cell 
monolayers which produced IGFBP-2. The electrophoretic resolution of the cross-linked material revealed 
two bands corresponding to the complexes between tracer and the IGF-I or -II receptors, and their 
appearance was competed by cold IGFs or des(l-3)IGF-I. In addition a band o f approximately 40 kDa was 
apparent, which was competed by cold IGF-I or -II, but not by insulin or des(l-3)IGF-I which do not bind 
IGFBPs (Reeve e t al., 1993; Russo et al., 1995; Bradshaw et al., 1999). Based on the size of the protein, 
the IGF competition pattern and the IGFBP expression profile o f the cells used in the experiments, this 
membrane-associated IGFBP was inferred to be IGFBP-2. More direct evidence of the presence o f an 
IGFBP species on the cell membrane came from a direct 125I IGF-I ligand blot of cell membrane 
preparations (Russo et al., 1995). The actual identification of the membrane associated IGF-binding 
protein species as IGFBP-2 was achieved with an anti IGFBP-2 Western blot of a crude membrane
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preparation (Reeve et al., 1993) or by immune precipitation o f solubilized membranes with anti IGFBP-2 
antibodies (Reeve et al. 1993; Bradshaw et al., 1999). The next step was to try to identify the nature of the 
IGFBP-2 binding molecule on the cell membrane. Arai et al. (1996) showed that IGFBP-2 could bind to 
heparin Sepharose only when it was precomplexed with IGF-I or II and this binding could be competed by 
cold heparin or heparan sulfate, but only weakly by chondroitin sulphate A, dermatan sulphate or 
chondroitin sulphate C. It was also shown that IGFBP-2 bound to human fibroblast ECM and IGF-II was 
able to increase the binding by 18-fold. These results conflict with a later study carried out by Russo et al. 
(1997) who showed that IGFBP-2 could bind to heparin, heparan sulphate, chondroitin sulphate, keratan 
sulphate and aggrecan (a proteoglycan containing chondroitin and keratan sulphate residues) in the 
absence o f IGFs. The discrepancies between the two studies could derive from the different type of assays 
or from the different IGFBP-2 species used in these experiments. The treatment of aggrecan-coated plates 
with chondroitinase or keratanase decreased IGFBP-2 binding, supporting the hypothesis that GAG 
residues of aggrecan played a part in this interactioa Consistently, NaCl and heparin were able to inhibit 
cross-linking of ,25I IGF-I with soluble or membrane-associated IGFBP-2, while RGD peptides were 
ineffective, suggesting that the RGD sequence of IGFBP-2 is not involved in the interaction with the cell 
membranes and that probably the binding is not mediated by integrins (Russo et al., 1997 Bradshaw e t al., 
1999). Finally it was demonstrated that in solubilized membrane preparations (from rat olfactory bulbs) an 
anti IGFBP-2 antibody was able to coimmuno-precipitate IGFBP-2 complexed with an unidentified 
molecule. The complex was separated in electrophoresis and the molecule bound to IGFBP-2 appeared to 
be a proteoglycan which migrated with an apparent Mr o f about 200kDa which was recognized in Western 
blot by anti chondroitin sulphate antibodies (Russo et al., 1997).
In conclusion IGFBP-2 was shown to associate to the ECM and the cell membrane and some 
indications support the hypothesis that this binding is mediated by GAGs.
Inhibitory effects of IGF action.
In most of the cell culture systems studied, IGFBP-2 accumulates in the conditioned medium 
where it binds to IGFs with high affinity and inhibits IGF action by preventing the interaction o f the 
growth factors with the IGF-I receptor.
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In rat calvaria cells IGFBP-2 reduced basal, and IGF-I-stimulated, 3[H]thymidine uptake and 
collagen synthesis (Feyen eta l., 1991). In porcine muscle satellite cells, multiple passaging culture caused 
reduced cell division and myotube formation accompanied by an increased secretion of IGFBP-2, which 
may reduce endogenous IGF-I activity (Fligger et al., 1998). The addition of equimolar concentrations of 
soluble IGFBP-2 and IGF-II to the NSCLC cell line caused a reduction in DNA synthesis compared with 
IGF-n treatment alone. However no differences between the two treatments were revealed in the SCLC 
cell line. Consistently, soluble IGFBP-2 was less efficient in antagonizing IGF-II binding to SCLC cells, 
in which IGF-II tracer bound to IGF-IIR and to cell surface associated IGFBP-2, in comparison to NSCLC 
cells in which radiolabelled IGF-II mainly associated to IGF-IR (Reeve et al., 1993).
The addition of plasminogen to neuroblastoma cell cultures caused proteolysis o f IGFBP-2 which 
resulted in 4-5 fold reduction o f the affinity of the binding protein for IGF-II. In these cells IGFBP-2 is the 
major regulator of IGF-II action as it is more abundant than IGFBP-4 and it has higher affinity for IGF-II. 
Plasminogen also induced a mitogenic effect in neuroblastoma cells which was inhibited by blocking IGF- 
II with a specific antibody. This led to the conclusion that the plasminogen mitogenic effect derived from 
the increased bioavailability o f IGF-II following the degradation of IGFBP-2 (Menouny et al., 1997).
In IEC- 6  rat intestinal cells, 3 [H] thymidine uptake and 14C leucine incorporation were stimulated 
more potently by des(l-3)IGF-I and QAYL-IGF-I (IGF analogs with wild type affinity for the IGF-IR and 
reduced affinity for IGFBPs) than the wild type IGFs. This suggested that the endogenously secreted 
IGFBP-2 could account for the observed difference in IGF activity (Park et al., 1992). Treatment of the 
same cell line with Na butyrate caused apoptosis and stimulated the expression of some genes, including 
IGFBP-2, believed to be involved in the apoptotic process (Guo et al., 1998). The inhibition of IGFBP-2 
expression by the transfection of IEC- 6  cells with an anti-sense IGFBP-2 construct, stimulated and 
increased cell proliferation in comparison with the control cells (Corkins et al., 1995).
Analogous experiments were undertaken in kidney fibroblasts stably transfected with an IGFBP- 
2 expression vector. The cell growth rate of cells transfected with IGFBP-2 was reduced compared to the 
control cells and the inhibition was reversed by IGF-I and II and even more potently by LongR3 IGF-I 
which has reduced affinity for IGFBPs. The anti-proliferating effect o f IGFP-2 was confirmed when the
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medium conditioned by IGFBP-2-transfected kidney fibroblasts was applied to choriocarcinoma cells, 
causing a reduction of cell proliferation (Hoflich et al., 1998)
A recently published study analyzed the correlation between the level of expression of IGFBP-2 
and growth rate in C6  rat glioma cells transfected with anIGFBP-2 expression vector (Bradshaw et al, 
1999). That IGFBP-2 might play a role in the regulation o f cell proliferation was suggested by the 
observation that in primary glia cells, which have a regulated growth, IGFBP-2 is highly expressed, 
whereas in glioma cells, proliferation rate is high and IGFBP-2 expression level is low. Moreover in a 
previous report the authors showed that the addition of IGFBP-2 to primary glia cells caused an inhibition 
o f IGF stimulated 3[H]thymidine uptake. Therefore it was expected that the higher the expression of 
IGFBP-2 in C6  transfected clones, the lower was the rate of cell proliferation. Surprisingly the growth rate 
o f cloned cells that expressed the highest level o f IGFBP-2 did not differ from control cells, while an 
inhibition of cell proliferation became evident in clones expressing lower levels o f the binding protein. 
Other parameters were also analyzed and interesting observations were recorded. First, the clones that 
expressed IGFBP-2 at the highest level displayed a concomitant upregulation of the endogenous IGF-I 
mRNA and it is possible that this cell compensation mechanism limited the effect o f IGFBP-2 on cell 
proliferation. Second, the transfection of glioma cells with IGFBP-2 vector affected the expression pattern 
o f other endogenously produced IGFBPs. For instance, in the clones with lower growth rate and moderate 
IGFBP-2 expression levels the appearance of a new 29kDa binding protein (possibly IGFBP-5) was noted 
both in the conditioned medium and associated to the cell membranes. Although transfected clones 
moderately expressing IGFBP-2 showed a decrease in cell proliferation it is possible that the effect was 
due to the induction of IGFBP-5 expressioa It was concluded that factors other than the equilibrium 
between IGF-I and IGFBP-2 were involved in growth regulation (Bradshaw et al., 1999).
Some studies on the effect o f retinoic acid on cultured cells also support the inhibitory role of 
IGFBP-2. In a bovine mammary gland cell line, MAC-T, cultured in 1%FBS, retinoic acid inhibited cell 
proliferation and the expression of IGFBP-3, while it stimulated an increase in IGFBP-2 levels in the 
conditioned media and on the cell surface. Retinoic acid-induced growth inhibition was reversed by IGFs 
and even more efficiently by des(l-3)IGF-I indicating that at least in part the retinoic acid effect was 
mediated by the increased secretion of IGFBP-2 (Woodward et al., 1996). It should be mentioned that in
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other cell lines, eg. neuroblastoma cells, retinoic acid depressed IGFBP-2 expression (Chambery et al., 
1998).
Potentiating effects on IGF action.
Little evidence has been reported on a possible IGFBP-2 enhancement on the IGF effect. As 
indicated above, a correlation between high IGFBP-2 expression level and active tumour processes has 
been reported by several authors (Elmlinger et al., 1998, Mishra et al., 1998; Cohen et al., 1993; Fuller et 
al., 1999; Ho and Baxter, 1997; Kanety et al., 1993, Kanety et al., 1996; Karasik et al., 1994). Recently it 
was shown that in both normal and malignant colorectal tissue, IGFBP-2 is proteolysed into a 22 and 
30kDa fragments, but mRNA and protein expression of IGFBP-2 is significantly increased in malignant 
tumour areas (Mishra et al., 1998). Elevated IGFBP-2 concentration was noted in the serum of patients 
suffering from T cell leukemia (Blum et al., 1993; Mohnike et al., 1996). In a leukemic T cell line Molt4, 
the addition of IGF-II caused an increase in IGFBP-2 mRNA and protein secretion. Conversely, blocking 
endogenous IGF-II with an anti IGF-II antibody caused partial inhibition of the growth rate and the 
complete cessation of IGFBP-2 secretion (Elmlinger et al., 1998). In neuroblastoma cells endogenous 
IGF-II mediates cell proliferation under the regulation of IGFBPs. It has been suggested that a partial 
proteolysis o f IGFBP-2 could facilitate the release of IGF-II from the binding protein enabling the growth 
factor to stimulate cell growth (Menouny et al., 1997).
In non tumour models IGFBP-2 was able to increase 2.2 fold the IGF-I stimulated 3[H] thymidine 
uptake in pSMC (Boumer et al., 1992) while in microvascular epithelial cells, a partially purified 
preparation of the binding protein increased IGF-I stimulated AIB uptake (Bar et al., 1989).
IGF independent effects.
To our knowledge the only report on the possible IGF-independent effect o f IGFBP-2 was 
published on UMR10601 rat osteoblasts-like cells.
IGF-I and -II treatment of these cells did not stimulate cell proliferation and decreased the GH 
binding with endogenous GHR. In contrast, both IGFBP-2 and -3 at l|ig/m l stimulated GH binding to its 
receptor and displayed a marked mitogenic activity on these cells (Slootweg e t al., 1995).
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In conclusion it would appear that IGFBP-2 displays mainly an anti proliferating effect whether 
present as a soluble form in the conditioned medium or associated to cell membranes.
1.3. Aims and objectives
At the beginning of our studies, an important scientific debate in IGFBP research was focused on 
the attempt to define the relative contribution of the N-terminal or C-terminal IGFBP domain to IGF 
binding. Observing the aligned N-terminus sequence o f different species and different classes o f IGFBPs, 
we noticed a group of very conserved proline residues (corresponding to residues at position 2 0 , 2 1  and 2 2  
in rat IGFBP-2. See Fig. 3.1.3.2). We hypothesized that these amino acids might have escaped 
evolutionary re-modelling because they were involved in a specific biological function. Therefore we 
started our project testing what effect on IGF-binding was exerted by the introduction of two point 
mutations in that region of the rat IGFBP-2 sequence (section 3.1 of the results chapter). IGFBP-2 was 
initially chosen among other IGFBPs because we considered that its lack o f post-translational 
modifications and the availability o f commercial reagents (antibodies, purified IGFBP-2) could facilitate 
protein expression and identification. Each of two conserved N-terminal proline residues at position 20 
and 22 were substituted with an alanine. The two mutants and the wild type proteins were produced with 
the baculovirus expression system and called P20A, P22A and wt IGFBP-2, respectively. Finally we 
compared IGF affinity of the wild type IGFBP-2 and its two mutants using the charcoal binding assay.
Although the IGF-binding site of IGFBPs still remains incompletely characterised, while we were 
working at our project, research had been making a remarkable progress and in the scientific literature a 
large amount of new intriguing findings in the IGFBP field were published. It became clear that in a 
biological context IGFBP activity did not only depend on affinity between IGF and IGFBPs, but was 
influenced by multiple factors (association with cell surface/ECM and proteolytic activities). Therefore we 
refocused our studies investigating other features of IGFBP-2 that could be relevant in understanding its 
biological function.
The best known effect of IGFBPs is an inhibition of IGF action. However, IGF- 
enhancing/independent effects have also been described for some IGFBPs and their association with the 
cell membrane/ECM appeared to be required for the occurrence of these effects. As far as IGFBP-2 is
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concerned, its inhibitory action has been widely described, whereas only a very few studies reported its 
possible IGF-potentiating effect. However, a correlation between tumour cell proliferation and high 
IGFBP-2 expression level has been observed in an increasing number of studies. In addition, Guennette 
and Tenniswood (1994) theorized a model to explain the specific role played by different IGFBPs during 
the involution of the prostate gland. In this model it was postulated that IGFBP-5, which is expressed 
when the prostate undergoes involution, could exert a pro-apoptotic role by sequestering the IGFs in ECM 
and preventing their binding to IGF-IR. Conversely, IGFBP-2, which is constantly expressed before and 
during the involution process, could associate to the cell membrane and facilitate IGF interaction with its 
receptor allowing the delivery of a cell survival signal. Studies such as these led us to investigate 
alternative functions of IGFBP-2 in a suitable cell culture system.
As for other IGFBPs association with the cell membrane seemed to play a key role in IGF- 
potentiating effects, we first worked to identify a cell line in which IGFBP-2 binding to the plasma 
membrane could be demonstrated (section 3.3.1 o f the results chapter). In this chapter the possibility that 
IGFBP-2 could bind to plasma membrane integrin receptors through its RGD sequence was also 
considered. RGD stands for arginine, glycine, aspartic acid and it is a recognition sequence for integrin 
receptors. To test if  IGFBP-2 RGD sequence was involved in plasma membrane binding we also 
expressed and purified a PGD IGFBP-2 mutant, whose RGD sequence was altered by the substitution of 
the arginine residue with a proline and it was used as negative control in integrin-binding experiments.
After screening several cell lines and using various techniques, we succeeded in detecting the 
association of endogenous IGFBP-2 to plasma membranes of a rat liver cell line, Clone 9 cells.
We then demonstrated that this cell line is responsive to IGF stimulation and that it secretes IGF-I 
endogenously (section 3.3.2 o f the results chapter).
Therefore Clone 9 cells met all the requirements as a suitable model for studying IGFBP-2 
modulation o f IGF action in vitro. In the last part of our project (section 3.3.3) we proceeded to the 
transfection o f Clone 9 cells with an antisense IGFBP-2 construct. Our aim was to compare wild type and 
antisense IGFBP-2 transfected cells with respect to their responsiveness to endogenous or exogenous IGF 
stimulation.
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2. MATERIAL AND METHODS
General laboratory chemicals and reagents
General reagents were supplied by BDH (Poole, Dorset, UK) and by Fisher Scientific 
(Loughborough, Leicestershire, UK). Unless specified otherwise, most of the other chemicals were from 
Sigma (Poole, Dorset, UK). Cell culture media and supplements were supplied by Gibco BRL, Life 
Technologies (Paisley, UK) or Sigma, and molecular biology reagents were from Boehringer Mannheim 
(East Susan, UK) or Promega (Southampton, UK). Cell culture plasticware was supplied by Costar 
(Bucks, UK) or Greiner Labortechnik (Stonehouse, Glos., UK). Water was tissue culture grade from Life 
Technologies or double distilled tap water. Unless otherwise stated, all centrifugations of Eppendorf tubes 
were carried out with bench top microfuge (MSE microcentaur), while centrifugations necessary for cell 
culture routine mantainance and experimental work were conducted in a MSE mistral 2000 centrifuge 
(MSE Loughborough, Leicestershire, UK).
2.1 Construction of P20A and P22A IGFBP-2 mutants, expression ofwt 
IGFBP-2 and mutated proteins and assessment of their affinity for IGFs
2.1.a Composition of buffers, solutions, cell culture media used in molecular biology methods and 
a description of general techniques
TBE xlO: 1M Tris-HCl, 0.9M Boric acid, 0.01M EDTA, pH 8.4
TAExlO: 0.4M Tris, 0.2M Na acetate, 0 .01M EDTA, pH7.2 with glacial acetic acid.
5xQrange G loading buffer: 20ml 500 mM EDTA, 20g Ficoll, water to 100ml, Grange G 
(approximately 0 . lg)
TE buffer (lOmM Tris-HCl, pH 8.0, ImM EDTA). Autoclaved
Restriction digestion. A typical restriction digestion would be performed in excess of enzyme: 
20(il reaction volume containing lpgDNA, 2pi xlObuffer (containing 0.5mg/ml BSA), lOunits enzyme.
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Endonuclease enzymes and appropriate lOx buffers were supplied by Boehringer or Promega. Digestions 
were incubated at recommended temperature for l-2 h.
A s  arose sels
1% w/v high gelling temperature agarose (Promega) contained lxTBE buffer and 0.5pg/ml of 
ethidium bromide (Biorad, Hertfordshire,UK ). Before loading, DNA samples, typically in 10-15pl 
volume, were mixed with 2-3 pi orange G loading buffer. DNA size markers used were X DNA/Hind HI 
fragments and cpX174 RF/Haelll fragments (Life Technologies). Electrophoresis was performed in 
0.5xTBE for 90-120min at 80V using Electro4 or mini gel Hybaid (Ashford, Middlesex, UK) apparatus.
1% w/v low melting point agarose (Sigma) was dissolved in lxTAE buffer and 0.5pg/ml 
ethidium bromide was added. Gels were electrophoresed in lxTAE buffer as described above. Low 
melting point agarose gels were used for DNA inserts, that were to be excised from the gel and extracted 
with GenecleanRII kit (Anachem, Luton, UK) following the instructions described by the manufacture. 
Electrophoresed DNA was visualised on a Herolab transilluminator (Mididoc, gel documentation analysis 
system and EASI store software Herolab Molekulare Trenntechnik,)
QUIA quick se l extraction filters (Qiagen, Crawly, West Sussex, UK): this kit was used either to 
purify linearized and dephosphorylated DNA plasmids in solution or to extract DNA inserts from high 
gelling point agarose gels. Purification was performed as recommended by the manufacturer.
Lisation a typical ligation reaction would be performed in 15pi volume containing: 1.5pl xlO 
ligation buffer (500mM Tris-HCl (pH7.5), lOOmM MgCl2, lOOmM DTT, lOmM ATP, 250pg/ml BSA); 
100-200ng of linearized, dephosphorylated plasmid DNA, 100-200ng o f DNA insert with compatible 
restriction enzyme ends and 15U T4DNA ligase (0.5 pi o f high concentration T4DNA ligase from New 
England Biolab, Hitchin, Hertfordshire, UK). Reactions were incubated at 16°C overnight.
Competent cells JM109 (Promega) was the strain of Escherichia coli (E. coli) used for general 
transformations to clone DNA inserted in pGEM and pALTER plasmids. This strain is endA 1, recA 1, 
gyrA96, thi, hsdRXl (r^ m ^ , relA \,supE44,X~A(lac-proAB),\F’,traD36, proA+B+, laclqZAM15],
LB (Luria Bertaini) medium: lOg Peptone, 5g yeast extract, 5g NaCl, H20  to llitre, pH7.5 and 
then autoclaved. Powders for bacteriological purposes were from Oxoid (Hampshire, UK). If antibiotic 
supplementation was required, medium was cooled to 55°C before drug addition. For the most commonly
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used media, ampicillin or tetracycline was added to LB medium to a final concentration of 125pg/ml and 
12.5 pg/ml respectively.
LB-asar plates 15g of agar were added to llitre LB medium, pH adjusted to 7.0 and autoclaved. 
Drugs, if  required, were added, at the concentration indicated above, when LB-agar solution reached 
55°C. Agar was immediately poured onto 10 cm Petri dishes and, after setting, dried in a flow cabinet. 
Plates were stored at 4°C for up to one month (wrapped with foil for those plates which contained 
tetracycline).
Antibiotic stock solutions: ampicillin (125mg/ml), gentamycin (7mg/ml) and kanamycin 
(lOmg/ml) were dissolved in water and filter-sterilized. Tetracycline was dissolved in 80% ethanol at 
12.5mg/ml. All solutions were stored at -20°C in the dark.
SOC medium: 2g Tryptone, 0.5g yeast extract, lm l o f 2M NaCl and 0.25ml 1M KC1 were added 
to 97ml H20 ,  stirred until dissolved, autoclaved then cooled to RT. Then, lm l o f 2M Mg** stock (prepared 
as followed: 1M MgCl2* 6H20 ,  1M M gS04» H20 ,  filtered sterilized) and lm l of 2M glucose (filter 
sterilized) were added. The volume was adjusted to 100ml (pH7.0) and the solution was filter sterilized 
through a 0 .2 pm filter unit
Transformation For a typical transformation, aliquots of JM109 competent cells would be thawed 
on ice for approximately lOmin. lOOpl of cell suspension would be placed in prechilled polypropylene 
tubes and after the addition of 50ng of plasmid DNA, tubes would be mixed and incubated on ice for 
30min. Tubes were incubated at 42°C for 50seconds and immediately chilled on ice for 2min. After the 
addition of 900pi LB medium to each tube, cells would be left to recover at 37°C for lh  with shaking. 
lOOpl of cell suspension would be plated onto LB-agar plates in the presence or absence o f appropriate 
drug selection and plates incubated at 37°C for 18-24h.
Minipreps Typically minipreps were prepared as follows, although some minor difference were 
adopted when following protocols recommended by different manufactures. 1.5ml o f overnight bacterial 
cultures were centrifuged for 5min at 13000rpm on a bench top micro centrifuge (MSE microcentaur 
centrifuge). Cell pellets were resuspended in lOOpl of prechilled solution I  (25mM Tris- pH8.0, lOmM 
EDTA, 50mM glucose 2mg/ml lysozyme), mixed by vortexing and incubated on ice for 30min. 200pl of 
solution II (1% SDS, 0.2M NaOH), stored at RT, was added to the tubes, which were then gently mixed
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by inversion and incubated on ice for a further 5min. Finally 150jil of prechilled solution III (3MNa 
acetate pH 4.8) was added. Tubes were mixed vigorously and a copious precipitate formed. After 45min 
incubation on ice and 5min centrifugation at 130001pm, 400pl of the resulting supernatant was transferred 
to fresh tubes, avoiding the white precipitate. The addition of 2.5 volume o f 100% ethanol and the 
incubation of the sample at -70°C  for 30min-lh, would then lead to DNA precipitation. Tubes were then 
centrifuged for lOmin at 13000rpm, ethanol was immediately aspirated, pellets washed with 70% ethanol 
and dried in a vacuum. Pellets were resuspended in 30pl RNAse (20|ig/ml in H20 ) .
If DNA was to be further purified phenol/chloroform extraction was undertaken before ethanol extraction. 
In this case the 400pi supernatants (resulting from the centrifugation which follows the addition of 
solution III) was supplemented with lm l of phenol:choloroform:isoamyl alcohol (25:24:1), mixed for 
lm in and centrifuged at 12000x g for 5min. After transferring the upper aqueous phase to fresh tubes, lml 
o f chloroform:isoamyl alcohol (24:1) was added. Mixing o f the samples, centrifugation and transfer of the 
upper aqueous phase was repeated as before. DNA was precipitated and pelletted as described above.
Ultraclean mini plasmid prep kit (MoBio Laboratories, Solana Beach, Ca) was used in later 
experiments. The procedure used was that recommended by manufacture.
M axivrevs (QUIAGEN tips 500) were prepared following the method described by the 
manufacture
2.1.1. Site directed m utagenesis to create the cDNA encoding for P20A and 
P22A IGFBP-2 mutants
In order to introduce the mutations necessary for creating P20A and P22A mutants at specific 
sites in the IGFBP-2 cDNA, we employed the Promega “Altered sites11 IT’ in vitro mutagenesis system. 
This technique exploits the hybridization between the wild type gene and a single stranded oligonucleotide 
which has a sequence complementary to the wt gene, but which carries alteration of a few base pairs at the 
site of mutagenesis. Overview o f the method: the IGFBP-2 gene was cloned in pALTERexl plasmid 
which contains an inactivated ampicillin resistance gene and an active tetracycline resistance gene. In each 
mutagenesis reaction, three different oligonucleotides were used: i) one oligo to introduce the desired 
mutation (P20A or P22 A), ii) one oligo to repair the ampicillin resistance gene, and iii) one oligo to knock
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out the tetracycline resistance gene. T4DNA polymerase was used to fill the gaps between the 
oligonucleotides, by using plasmid single strand DNA as template, and DNA ligase was used to seal 
together the newly synthesised DNA fragments. As a result, wt-mutant hybrid DNA duplex was obtained. 
In order to avoid the host-directed mismatch repair system which would repair the unmethylated newly 
synthesised DNA strand, the hybrid duplex was amplified in a A. coli mutS strain (ES 1301). Due to the 
semi-conservative mode of DNA replication, wt and mutated plasmids would theoretically be amplified at 
the same ratio. The introduction of ampicillin selection allowed an increase in the yield o f mutated DNA  
over the wt.
PGEM 7Zf(+/-) rat IGFBP-2 was a kind gift o f Dr Sean Guenette, John Wayne Cancer Institute Los 
Angeles.
The recombinant plasmid was amplified in JM109 cells under ampicillin selection. A description of 
methods followed for plasmid transformation into JM109cells, mini and maxi preps is as reported above.
IGFBP-2 cloning into pALTER exl. The rat IGFBP-2 cDNA was excised from the pGEM vector 
as a BamHI-Xbal fragment, separated in a low melting point agarose gel and extracted using the 
Geneclean kit. BamHI-Xbal digested pALTERex-1 plasmid was phenol/chloroform extracted and ethanol 
precipitated. pAlter-IGFBP-2 resulting from ligation was transformed into JM109 cells, and grown on 
tetracycline plates for 48h at 37°C. Single colonies were picked and grown in LB-tet medium. Mini and 
maxi preps were prepared (pALTERex 1 -IGFBP-2 stock solution was present at 436pg/ml in TE buffer)
Mutasenetic primers. For the construction of either P20A or P22A mutations, 2 base pairs of the 
wt DNA IGFBP-2 sequence were substituted. Mutagenic oligos contained 15 nucleotides of flanking 
sequence at either side of the 2 base mismatch to allow sufficient hybridisation to the IGFBP-2 sequences. 
The mutagenic oligos were designed in such a way as to create SacI or PvuII restriction endonuclease sites 
for P20A and P22A respectively. 33-mer mutagenic oligonucleotides P20A (IGFBP-2) primer GGG CGC 
GTC GGG TGG AGC TCC GCA GGC GGC CAG and P22A (IGFBP-2 ) primer GGC GCA GGG CGC 
GTC AGC TGG GGG TCC GCA GGC(altered bases shown in blue) were supplied, lyophilised from 
Cruachem Ltd (Glasgow, UK). Each oligonucleotide was resuspended in H20  at lpg/ml.
5'phosphorylation o f  oligonucleotides, lp g  (lp l) o f each oligonucleotide was incubated at 37°C 
for 30min in the presence of 2.5|il of kinase buffer xlO, 0.5U (0.5|il)T4 polynucleotide kinase, 2.5pl of
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lOmM ATP (in a final volume of 25pl). Kinase was then heat inactivated at 70°C for lOmin and the 
reactions stored at -20°C.
Alkaline denaturation reaction. 6 pl of pALTER exl-IGFBP-2 template (2.5pgDNA) was 
incubated for 30min at 37°C with lp l o f 4M NaOH and lp l o f 2mM EDTA (in a final volume of 20pi). 
2pi o f 3M Na acetate (pH4.8) was added and DNA was precipitated at -70°C  for 30min with the addition 
o f 75pl o f 100% ethanol. After centrifugation at 13000rpm for 15min and washing the pellet with 200pl of 
prechilled 70% ethanol, samples were recentrifuged at 13000rpm for 15min. The supernatants were 
discarded, pellets were vacuum dried and resuspended in lOOpl TE. DNA denaturation was checked on a 
1% agarose gel.
Annealins reaction. lOpl of alkaline denatured ds DNA template, lp l Amp-repair Oligo, lp l Tet- 
knockout Oligo, lp l of phosphorylated mutagenic nucleotides (P20A and P22A) diluted 1:3, 2pl of 
manufacture’s xlO annealing buffer to a final volume of 20pl, were incubated for 5min at 75°C in a water 
bath. The water bath was then switched off until the temperature reached 45°C (approximately 30min) and 
finally tubes were put on ice until RT was reached. The following were added on ice: 3pi synthesis xlO 
buffer, lp l (5-10units) T4 DNA polymerase, lp l (l-3units) T4 DNA ligase in this order and finally H20  to 
30 pi. Tubes were then incubated for 90min at 37°C.
Transformation o f  ESI 301 mutant competent cells. ES1301(/acZ53, mwtS201::Tn5, thyA36, rh&- 
5, metB 1, deoC, IN (rmD-rmE) is a mismatch repair minus strain o f E.coli. High efficiency competent 
ES1301 cells were provided with the Promega Ultrasites-II kit. For transformation 1.5pl of P20A or P22A  
mutagenesis reaction (approximately lOng of template DNA) was used and the general protocol described 
earlier was followed, except that after the addition of DNA cells were incubated on ice for only lOmin. 
After the cells had recovered at 37°C for 30min with shaking, 500pl o f each culture was transferred to a 
fresh tube containing 4.5ml LB-Amp medium and grown overnight at 37°C with shaking.
Plasmid mini prep. Miniprep preparation, phenol/chloroform extraction and ethanol precipitation 
of DNA were undertaken following the protocol described above.
Transforming P20A and P22A IGFBP-2 mutant DNAs into JM109 cells. The yield of P20A and 
P22A mutated DNAs obtained from ES1310 mini prep preparations was estimated on a 1% agarose gel. 5-
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lOng of DNA was transformed into JM109 competent cells and the cells were grown overnight on LB- 
Amp plates at 37°C. Minipreps were prepared and the presence o f P20A and P22A mutations was verified 
by restriction digestion with SacI or PvuII respectively. Resulting fragments were separated on 
electrophoresis and the result is shown in Fig 3.1.1.
2.1.2 Expression of wt, P20A and P22A IGFBP-2 mutated proteins
We expressed IGFBP-2, P20A and P22A proteins with the Bac-to-Bac™ baculovirus expression 
system (Life Technologies). In this system the gene to be expressed is cloned into baculovirus and the 
recombinant virus is used to infect insect cells which express the recombinant protein.
An overview of the system is shown in Fig 2.1.2
Wt and mutant IGFBP-2 genes were cloned into the donor plasmid, pFastBac, down stream of the 
polyhedrin promoter o f AcNPV (Autographica califomica nuclear polyhedrosis virus) baculovirus. In 
nature, the polyhedrin promoter is activated in the very late phase of baculovirus infection of insect cells 
(occluded cycle). In this phase virus DNA particles are packaged in polyhedrin protein and stored as 
occlusion bodies. However, the expression of polyhedrin protein is not essential under in vitro conditions 
where the virus can replicate and infect neighbouring cells even if  the polyhedrin gene is substituted with 
a heterologous gene. In pFastBac donor plasmid, the polyhedrin promoter and the gene of interest are 
located in an expression cassette flanked by the right and left arm of bacterial transposon gene, Tn7. When 
pFastBac is transformed into E. coli DHlOBac cells, a helper plasmid (pMON7124) provides the functions 
necessary to transpose the gene of interest from pFastBac to a baculovirus shuttle vector, (the bacmid, 
pMON14272), contained in the cells. Routinely bacmid can be propagated in E coli DHlOBac cells as a 
large, low copy number plasmid which confers on the cells kanamycin resistance and the ability to 
ferment lactose. The bacmid possesses a gene encoding for lacZa  peptide which compensates the for lacZ 
deletion in the bacterial chromosome. Therefore, on BluoGal-IPTG plates, DHlOBac colonies appear blue. 
Moreover the bacmid has inserted inside lacZa gene, a mini-atfTn7attachment site for Tn7 bacterial 
transposon. Inside DHlOBac cells the mini-Tn7 element of pFastBac (including the gene of interest and 
the protein expression cassette) is transposed at the bacmid mini-a//Tn7 site. The insertion of the mini-Tn7 
element into the bacmid causes the disruption of the reading frame of lacZa peptide. Therefore on
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BluoGal-IPTG plates, colonies containing recombinant bacmid will appear white, allowing an easy 
selection from the background o f blue colonies containing non recombinant bacmid.
Finally, recombinant bacmid is purified and used to transfect a monolayer of Sf9 insect cells. Viral stock 
is harvested from the supernatant o f transfected cells and is utilised to infect fresh insect cells in order to 
obtain the expression of the protein of interest.
Cloning wt IGFBP-2. P20A and P22A into pFastBac. IGFBP-2, P20A and P22A inserts were 
obtained by digesting approximately 20pg of pALTER recombinant vectors with 4pi (=40units) of EcoRl 
at 37°C 2 h in a final volume of 60pl with appropriate lx  diluted buffer. DNA inserts were separated in a 
1% low melting point agarose gel and extracted with the Gene clean kit.
Analogously, 20 pg of pFastBac plasmid were prepared for the ligation reaction by digestion with 1.5 pi 
EcoRl with subsequent dephosphorylation, phenol-chloroform purification and ethanol precipitation. 
Relative amounts of pFastBac, wtIGFBP-2, P20A and P22A DNAs were estimated on a 1% agarose gel, 
and 2pg of pFastBac were ligated to 2pg of either wt or mutated IGFBP-2 fragments following the general 
protocol described earlier. Ligation products were transformed into JM109 cells under ampicillin 
(lOOpg/ml) selection. Minipreps of the DNA were prepared and an EcoRl digestion was performed to 
detect the recombinant clones. Orientation o f the recombinants was verified by a Hindlll restriction 
enzyme digest; Hindlll cuts in the polylinker sequence o f pFASTBac and at one end of IGFBP-2. Maxi 
prep DNA was then prepared for each one of the mutants or wt IGFBP-2 proteins.
Transposition. LB agar plates (5g peptone, 2.5g yeast extract, 5g NaCl, 6g agar in 500ml H20 ,  
pH 7.0) supplemented with 50pg/ml kanamycin, 7pg/ml gentamycin, 10jig/ml tetracycline, lOOpg/ml 
Bluo-Gal and 40fig/ml IPTG, were prepared and stored in the dark at 4°C for a maximum of 2 weeks. 
DHlOBac cells were transformed with lng of wt IGFBP-2, P20A or P22A DNA. The general protocol 
was followed, with the exception that after transformation 900fil o f SOC, instead of LB, medium was 
added and that the cells were recovered for 4 h at 37°C with shaking. Each culture of transformed cells 
was serially diluted with SOC medium ( 1 0 1, 10'2 ,10'3 ) and lOOpl of each dilution was plated onto Bluo- 
Gal/IPTG plates under drug selection (kanamcin, gentamycin, tertacycline). After 24h incubation at 37°C, 
10 large white colonies within a background of small blue colonies were picked, and to confirm the white 
phenotype, they were re-plated on fresh plates.
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Confirmation by PCR that white colonies contained DNA inserts of the correct size. The PCR
mix solution was prepared as follows: 15pi M13Reverse primer, 15pi Forward primer, 75pl 25mM 
MgCl2, 75pl xlO buffer (500mM KC1, lOOmM Tris-HCl pH 9, 1% TritonX-100), 5pl dNTP (25mM), 
37.5pl DMSO, 527.5pl H20  and aliquoted into 25pl/tube. The universal primers, forward and reverse, 
were synthesised by Cruachem. They were received lyophilized and resuspended at lpg/pl in H20  A 
single white colony was swirled in the tube. As negative controls, a blue colony, two minus DNA samples 
and pFastBac-IGFBP-2 were included. Finally, 0.5 pi TAQ polymerase was added and the PCR reaction 
was performed as follows (94°Cx2min) xlcycle; (94°Cx45sec, 62°Cx45sec, 72°Cxlmin) x30 cycles and 
(72°Cx5min) xlcycle. The presence of inserts was detected by running PCR products in a 1% agarose gel. 
With the pUC/M13 amplification primers (that are directed at sequences on either side of mini -att Tn7 
site within the Lac Z a  gene) the expected sizes of PCR products were: Bacmid alone »  300 bps, bacmid 
transposed with pFastBac »  2300 bps. From blue colonies a 300bps product was obtained, while 
recombinant bacmids, obtained from white colonies on IGFBP-2, P20A or P22A plates, migrated between 
the 2300 and 4361 size markers, indicating the presence of the inserts (2300bp of bacmid transposed with 
pFastBac + « lOOObp of wt or mutated IGFBP-2 inserts).
High Mr plasmid (Bacmid)mini preps. From each o f the wt IGFBP-2, P20A, P22A DHioBac 
plates a single colony with confirmed white phenotype was picked and cultured at 37°C for 24 h in 2ml of 
LB medium supplemented with kanamycin, gentamycin and tetracycline (at the same concentration 
reported above for the plates). High Mr bacmid mini preps were prepared following the protocol 
recommended by Life Technologies. Briefly: pellets o f bacterial cultures were gently resuspended in 
300pl of solution I (15mM Tris-HCl, lOmM EDTA pH 8.0, 100pg/ml RNase A). 300pi solution II (0.2N  
NaOH, 1% SDS) was added and tubes were gently mixed. After a 5min incubation at RT, 300pl o f 3M 
potassium acetate (pH5.5) was added and tubes were incubated on ice for lOmin. After a lOmin 
centrifugation at 13000rpm, supernatants were carefully transferred to fresh tubes, which already 
contained 0.8ml of isopropanol and these were mixed by inversion and incubated on ice for lOmin. After a 
15min centrifugation at 13000rpm, the supernatants were carefully aspirated, the pellets were washed with 
0.5ml 70% ethanol and centrifugation was repeated for 5min as before. Supernatants were carefully 
aspirated and the pellets air dried. In order to avoid damage to the high molecular weight (Mr) DNA,
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pellets were resuspended in 40pi of TE buffer by keeping the tubes on ice for lOmin, and flicking them 
very gently every 2 min. 5 pi aliquots for each recombinant Bacmid were stored at -20°C.
Transfection of Sf9 cells with recombinant Bacmid DNA. Sf9 insect cells (>97% viable) were 
grown in suspension to mid log phase. Cells were then resuspended at 4.5x105 cells/ml in SF900II 
medium containing 50U/ml penicillin and 50pg/ml streptomycin. 2ml of cell suspension was placed in 
each well o f a 6well plate and cells were left to attach for lhr at RT. In a tube, lOOpl of SF900II medium 
without antibiotics was mixed with 5pl o f each recombinant Bacmid (i.e. carrying either IGFBP-2, P20A  
or P22A DNA). At the same time lOOpl of SF900H medium without antibiotics was mixed with 6pl of 
Celfectin (Life Technologies) and then added to recombinant bacmid and incubated at RT for 25min. 
Wells containing cell monolayers were washed with 2 ml o f SF900II without antibiotics. Transfection was 
performed in the following order: i) 0.8ml of SF900 II was added to each tube containing 200pl of lipid- 
DNA complexes and the contents mixed, ii) Following complete removal of wash medium from one well, 
the cell monolayer was overlaid with lm l of transfection mixture and the incubation was left for 5h at 
27°C. The transfection mixture was then removed and 2ml of SF900II medium with antibiotics was added, 
and the plate was incubated for 72h at 27°C. After this incubation period, the supernatants containing 
recombinant viruses were harvested. Supernatants from 2 wells were pooled, centrifuged at lOOOrpm for 
5min, transferred to a 15ml tube wrapped with foil and stored at 4°C. lOOpl of this sample was assayed for 
protein expression by Western blot.
Vims amplification . In order to obtain a large volume of high titre viral suspension necessary to 
innoculate 50-100ml of insect cell cultures, the supernatants harvested after 48h from insect cells 
transfected with recombinant bacmids underwent several rounds of amplification. Insect cells were seeded 
at confluence density on 6 well plates or flasks. The viral innoculum was diluted in a volume of SF900II 
just sufficient to cover the cell monolayer, which was then incubated for lh  at RT. The innoculum was 
discarded, fresh SF900II medium was replaced and cells were incubated for 48hr at 27°C. Supernatants 
were harvested, centrifuged at lOOOrpm for 5min to eliminate residual cells, transferred to bottles wrapped 
with foil and stored at 4°C.
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Virus titration Titration of virus was performed with the BacPAK™ baculovirus rapid titer kit 
(Clontech, CA USA, supplied by Cambridge Bioscience, Cambridge, UK) following procedures 
recommended by the manufacturer.
Insect cell culture. The Sf9 insect cell line was originated from pupal ovarian tissue of 
Spodoptera frugiperda (armyworm) and it has been selected for its high susceptibility to Baculovirus 
infection. We received as a gift from Life Technologies a frozen vial o f cells already adapted to serum free 
conditions. We expressed IGFBP-2 in Sf9 cells in serum free medium (SFM), protein free (SF900-Q 
Gibco) conditions for several reasons: i) as IGFBP-2 is a secreted protein, we intended to recover the 
expressed protein directly from the supernatant of a culture o f insect cells grown in suspension. The 
manufacturing company (Life Technologies) that commercialises the Bac-to-Bac expression system 
claims that, in SF conditions, the recombinant secreted protein represents the major protein species in the 
insect cell supernatant, so that further purification might not be required; ii) serum bovine IGFBPs would 
contaminate the recombinant protein preparation and the separation between rat and bovine IGFBPs 
would require a laborious reverse-phase chromatography step; iii) protease activity contained in the serum 
could potentially degrade the expressed protein.
Sf9 insect cell culture was initiated directly in suspension, thawing 1.7xl07 cells in 40ml of SF900-II 
medium (without addition of antibiotics or antimycotics) in a 50ml spinner flask (Techne, Cambridge, 
UK). Cells were routinely grown at 27°C, with stirring at 75rpm using a Techne MCS-104S biological 
stirrer placed inside the incubator. Cell viability was checked every day with Trypan blue staining (0.5% 
Trypan in PBS, mixed at 1:2 with the cells). Cell viability was consistently over 99%, with the larger cell 
clusters depositing on the bottom of the flask. These were routinely removed by aspiration. Cell density 
was maintained between 0.5 and 2 x 106cells/ml.
It is recommended to use SFM-adapted cells only for a low number of passages (12-15), as 
culture of insect cells in SFM in suspension has been reported to decrease cell viability and foreign protein 
expression (Clemm, 1994). For this reason we made frozen stocks o f early passage cells. Cells were 
harvested in mid log phase with a viability >97%. After 5min o f centrifugation at lOOOrpm, the cells were 
resuspended at a density o f 1-2 x l0 7cells/ml in medium containing 7.5% DMSO and 92.5% of a 1:1 mix
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o f  fresh and cell-conditioned SF900-II medium. Vials were wrapped in cotton wool, placed in a 
polystyrene box, stored at -70°C  overnight and then transferred to liquid nitrogen.
For protein production, a 50ml suspension culture of SF900II medium containing 2 xlO6 cells/ml of Sf9 
cells in log phase was infected with a variable volume of virus innoculum. Virus infection was performed 
at a multiplicity o f infection (MOI) of 5 using the following formula: 
innoculum required (ml): desired MOI(pfu/ml) x (total number of cells)
titer o f viral innoculum (pfu/ml)
During the infection, samples were taken at 8 hr intervals to check the cell viability and cultures were 
harvested when the viability dropped below 80%. The samples were also analysed on Western blots for 
the expression and possible degradation of the protein, in an attempt to optimise the harvesting time.
Insect cells were separated from the media by centrifugation at 3000rpm for 2 min, supernatants were 
concentrated on Millipore tubes (Ultraffee-20) by centrifugation at 1700xg for 2hr at 4°C, and stored at -  
70°C.
2.1.3. IGF-affinity studies on the wt, P20A and P22A IGFBP-2 proteins
IGF peptides
Recombinant human IGF-I and n  (animal/media grade) and Des(l-3)IGF-I (receptor grade) were 
obtained from GroPep Pty Ltd (Adelaide, Australia). Peptides were received lyophilized and were 
resuspended at a concentration of 1 mg/ml in lOmM acetic acid, aliquoted, snap frozen and stored at -  
20°C.
Radionucleotides
Iodinated IGFs and IGFBP-2 were kindly provided by Dr J.Beattie. 2.5jig IGF-I, IGF-II or 
IGFBP-2 were iodinated to a specific activity o f 50-lOOp.Ci/ug as described in Borromeo et al, 1996.
Charcoal binding assay
This assay was carried out as in Conover (1989). Typically, triplicate IGFBP samples were added 
to RIA tubes and appropriate volumes of assay buffer (50mM Tris-HCl, 0.5% BSA, pH7.4) were added to
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make the volume up to lOOpl. An additional lOOpl of assay buffer was then added. If competitive studies 
were to be undertaken, the latter lOOpl of buffer would contain cold IGF-I or IGF-13, at various 
concentrations. After the addition o f further lOOpl of assay buffer containing 25000cpm of 125I IGF-I or 
IGF-II tracer (giving a total volume o f 300|d/tube), samples were vortexed and incubated overnight at 
4°C. The charcoal buffer (1% activated, neutralized charcoal, 0 .2 mg/ml protamine sulphate in ice cold 
assay buffer) was prepared freshly in considerable excess to allow good mixing of the charcoal in 
suspension and 600pi was quickly added to each sample tube. Samples were vortexed before and after a 
lOmin incubation at 4°C during which free IGF binds to the charcoal, while IGF-IGFBP complexes 
remain in solution. To separate free from IGFBP-complexed 125I IGF tracer, samples were centrifuged at 
3000rpm (171 lxg) for 15min at 4°C and, after immediate decanting of the supernatants, pellets were 
counted in Packard Auto-gammaR ycounter (Packard Instruments Meriden, CT, USA).
Creating an IGF-I and IGF-II binding curve for wt or IGFBP-2 mutated proteins. In a preliminary 
experiment we tested the IGF-binding capacity o f equal volumes o f each protein preparation containing 
either wt IGFBP-2, P20A, or P22A, and the resulting IGF-I and IGF-II binding curves were plotted. 
Concentrated baculovirus protein preparations were diluted 1:500 in assay buffer and different volumes of 
these samples (0,10, 20, 30, 40, 50, 60, 70, 80, 90,100, 150, 200pi) were added to RLA tubes. In each tube 
the volume was brought up to 200pl with assay buffer. Finally, approximately 25000cpm of 125I IGF-I or 
II in lOOpl assay buffer was added and the assay was completed as described above. The radioactivity of  
the pellets was measured with a gamma counter. The amount of 125I IGF-I or II that, in the absence of 
IGFBPs, was bound to charcoal pellets was defined as the blank value and counts of all other sample 
pellets were subtracted from this blank value. 125I IGF-I and 125I IGF-II binding curves were plotted as 
shown in Fig 2.1.3 a, b. The X axis indicates the volume of the wt IGFBP-2, P20A, P22A preparations. 
The Y  axis, tracer binding is expressed as % of the blank value (labelled “% added”). For each IGFBP the 
linear part of the binding curve was identified, where the amount o f bound tracer increased linearly with 
the volume of IGFBP preps. For each protein a 20pl volume o f the 1:500 diluted protein preparations was 
chosen for subsequent competition experiments.
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2 . 1.3.1 Competition studies using the charcoal binding assay
Competition studies were established to determine the affinity of wt IGFBP-2, P20A and P22A 
for IGF-I or IGF-II. Based on the results o f the previous experiment (see Fig 2.1.3.a. and b), wt IGFBP-2, 
P20A or P22A preparations were diluted 1:2500 with assay buffer and, lOOpl were added to RIA tubes. 
lOOpl of assay buffer +/-increasing amount of cold IGF-I, IGF-II was added, lmg/ml IGF-I and II stock 
solutions in lOmM acetic acid were appropriately diluted to obtain a final concentration of 0.25, 0.5, 1, 
2.5, 5, 10, 25, 50ng/ml. Finally, approximately 25000cpm of 125I IGF-I or IGF-II in lOOpl of assay buffer 
were added so that wt IGFBP-2, P20A and P22A proteins were each tested for all combinations of  
competitive binding (IGF-I v 125I IGF-I; IGF-II v  125I IGF-I; IGF-II v  125I IGF-II and IGF-I v 125I IGF-II). 
The blank value for each of 125I IGF-I and 125I IGF-II tracers was determined and the radioactivity 
measured in all other charcoal pellets was subtracted from the appropriate blank as described above. 1251 
IGF-I/II binding of wt or mutated IGFBP-2 proteins in the absence of cold IGFs was designated the 
control value. The residual tracer binding in the presence of cold IGF competitors was expressed as a 
percentage of control value ( 1 0 0 %).
2.2 IGF-II affinity chromatography purification of wt IGFBP-2 and PGD 
IGFBP-2 mutant
Column preparation
The column was performed following the recommendations described in “Affinity 
chromatography. Principle and methods” hand book (Pharmacia LKB biotechonology Cat.N 18-1022-29). 
500ug of activated CM Sepharose 4B (Cat N. 17-0490— 01 Pharmacia Biotech, Uppsala Sweden) was 
washed in a sintered glass filter with 150ml of ImM HC1. 0.9mg of rhIGF-II (media grade GroPep) was 
dissolved in coupling buffer (0.1M NaHC03, pH 8.0) and mixed with the gel end over end for lhr at RT. 
Sepharose gel coupled with IGF-II was placed into a Biorad plastic column and, after discarding the 
excess coupling buffer, was washed first with 100ml of 0.05M Tris, 0.5M NaCl pH 8.0, then with 100 ml 
of 0.05M formate, 0.5M NaCl, pH 4.0. Excess activated CM groups were blocked with 0 .1M Tris-HCl pH 
8.0 and the column re-equilibrated in 50mM Tris, 0.5M NaCl, 0.01% sodium azide pH 7.4. The column 
volume was lml.
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Purification of wt IGFBP-2 and PGD IGFBP-2
Protein purification was performed following the method described by Carr et al. (1994). 800pl 
IGF-II-coupled Sepharose gel, prepared as described above, was equilibrated with 10ml 0.5M NaCl, 
50mM Tris pH 6.5. 2- 4ml of concentrated insect cell culture supernatant containing IGFBP-2 or PGD- 
IGFBP-2 was applied to the column. The gel was mixed gently with the sample several times and 
incubated overnight at 4°C. Unbound protein solution was run through the column, reapplied twice and 
finally harvested and kept at -20°C  to be analysed for the residual presence o f IGFBPs. The column was 
washed with 10 ml 0.5M NaCl, 50mM Tris pH 6.5 (the first lm l of the flow through was retained for 
analysis). 6  ml of 0.5M acetic acid pH3 was incubated with column gel for lOmin before starting the 
elution. 6 x lm l fractions were collected in Eppendorf tubes already containing 300-360(j.l 2M Tris base 
necessary for immediate pH buffering to pH 7.0. Fractions were kept on ice and the column washed with 
10ml 0.5NaCl, 50mM Tris pH 6.5. Subsequently, alternate washes with 5ml of 0.1M Tris, 0.5 NaCl, pH 
8.5 and 5 ml of 0.1M Na acetate, 0.5M NaCl, pH 4.5 were repeated twice. For storage the column was 
equilibrated in 50mM Tris, 0.5 M NaCl, 0.01% sodium azide, pH 7.4 and kept at 4°C.
IGFBP-2 or PGD-IGBP-2 fractions eluted from the affinity column were analysed for their total protein 
content by Coomassie blue or Silver staining gels and the presence of purified proteins was confirmed by 
anti IGFBP-2 Western and ligand blots (as described below). Measurement of protein concentration was 
estimated by reading spectrophotometrically the absorbance at 280nm, as commercial protein assay kits 
were unsuitable due to the high concentration of Tris added to neutralise acidic fractions.
General techniques for protein analysis.
Sodium dodecvl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE was 
carried out following the method described by Laemmli (1970). Separating gels contained 7.5% or 12% 
total acrylamide (2.7% Bisacrylamide cross-linker), 375mM Tris-HCl (pH8 .8 ), 0.1%SDS (w/v). 
Polymerisation was initiated with ammonium persulphate (Biorad) and Temed. Stacking gels were 4% 
acrylamide, 125mM Tris HC1 (pH6 .8 ), 0 .1% SDS. Samples for analysis were mixed 1:1 with 62.5mM  
Tris-HCl (pH6 .8 ), 0.1% SDS, 10% glycerol and 0.05% bromophenol blue. For reducing conditions 5% 2- 
mercaptoethanol was included in the sample buffer. Electrophoresis was performed at constant voltage
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(150V) on a Biorad mini protean n  apparatus in tank buffer consisting of 25mM Tris-HCl, pH 8.3, 
192mM glycine, 0 .1% SDS.
Coomassie blue staining. This technique was employed to visualise protein bands after 
electrophoretic separation and to estimate their relative concentration.
Gels were stained in 5% methanol, 7.5% acetic acid, 0.3% Comassie blue R250 by shaking gently for 
approximately lhr at RT. To enable the detection o f protein bands from the stained background, gels were 
washed for lOmin in 5% methanol, 7.5% acetic acid, then fresh solution was replaced and gels destained 
overnight For further analysis, gels were dried between cellophane sheets with Hoefer Easy breeze gel 
dryer equipment. Alternatively, i f  direct autoradiograhy was to follow, gels were placed on filter paper 
(Biorad), covered by Saran film and dried on a Hoefer (Hoefer scientific instruments, S.Francisco, CA) 
dual temperature slab gel drier at 80°C for 2h and then at RT until completion.
Silver staining. This is a very sensitive technique which was adopted to detect proteins of low 
abundance. After electrophoresis, gels were sequentially washed at RT, with gentle agitation, in 100ml of 
sol. 1 (50% methanol, 10% acetic acid, 40% H20 )  for 30min (or overnight), 100ml o f sol. 2 (5% methanol, 
7% acetic acid, 8 8 % H20 )  for 30min and with sol. 3 (2.5% glutaraldehyde, 97.5% H20 )  for a further 
30min. To completely eliminate glutaraldehyde, extensive washing in H20  (8 x 15min) over a period of 2 
hours was carried out. Gels were then incubated in DTT 0.5mg/100ml H20  for 30min and with 100ml of 
0.1% A gN 0 3 for a further 30min. During this last incubation, developing solution (150ml of 3% Na2C 0 3 
supplemented with 70|j.l o f 40% formaldehyde) and stop solution (5ml of 2.3M citric acid) were prepared. 
At the end of the 30min incubation in A gN 03, gels were quickly rinsed with water for 30sec and then 
incubated with 25ml of developing solution. The solution was discarded when brown colouration 
developed. A second wash with 25ml of developing solution was repeated for 30seconds. The remaining 
100ml of developer was added and development of gels kept under observation. The reaction was stopped 
by the addition of 5ml stop solution, when brown coloured protein bands were clearly visible over the 
increasingly dark background. Gels were then rinsed in water and dried between cellophane sheets as 
described for Coomassie staining.
Electrotransfer. As an alternative to direct gel staining, proteins separated by electrophoresis were 
transferred from the gel to either Hybond-C extra or Hybond-PVDF (Amersham) membranes. In the latter
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case membranes required lOsec pre-wetting in methanol and subsequent 5min rinsing in H20  before use. 
Gel sandwiches (fibre pad, filter paper, gel, membrane, filter paper, fibre pad) were assembled under 
transfer buffer (25mM Tris, 192mM glycine, 20% methanol) in a bath and then located in the Biorad mini 
transblot apparatus equipped with an ice pack. Protein electrotransfer was performed at a fixed voltage 
(100V) for lh, unless otherwise indicated. Blotted proteins were usually visualised by Ponceau staining, as 
described below. Membranes were then either blocked for ligand or Western blotting for immediate 
analysis or dried and stored between filter paper in a plastic bag at 4°C, for later analysis. Dried PVDF 
membranes were moistened for 1 0 sec in methanol before being further processed.
Ponceau S staining. Sigma Ponceau S concentrated solution (Ponceau S, 2% w/v, in TCA, 30% 
w/v, and sulphosalicylic acid, 30% w/v), diluted 1:10 with water, was applied to the membranes for lOmin 
for visualisation of protein bands. After washing with water, the membranes were dried and stored or 
directly incubated in blocking buffer for further analysis by ligand or Western blotting.
1251 IGF-I ligand blotting. 125I IGF-I ligand blotting was performed essentially as described by 
Hossenlopp et al. (1986).
After transfer, membranes were washed with 50ml 3% NP40 Tris-saline solution (lOmM Tris, 60mM  
NaCl 0.05% sodium azide) for 30min, with 50 ml 1% BSA Tris-saline solution for 2h and finally with 
50ml 0.1% Tween 20 Tris-saline solution for lOmin. Approximately 1.5-2 x 106cpm 125I IGF-I in 1.5ml of 
1% BSA, 0.1% Tween 20 Tris-saline solution was added to a plastic bag containing each blot and 
incubation was continued overnight at 4°C. Blots were then washed twice for 15min in 50ml 0 .1% 
Tween20 Tris-saline solution and three times for 15min in 50ml Tris-saline solution. After drying, 
membranes were exposed to autorad films (Hyperfilm |3max, Amersham) in a 18x24 radiographic cassette 
(Genetic Research Instrumentation Ltd. Essex, UK) at -70°C  for 4-10 days. The films were bathed in 
GBX Kodak developer for approximately 3min followed by a quick rinse in water, moved to fixer solution 
for 5min and then extensively washed in tap water.
As an alternative to autoradiographs, dried blots were exposed to a Molecular Dynamics Phospho-imager 
screen for 2 days at RT and the resulting image would be visualized with the Phospholmager 445SI 
software.
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Western blotting. Typically, blotted membranes were blocked in 3% BSA TBS-T (20mMTris- 
HC1, 137mM NaCl, pH 7.6 supplemented with 0.1% Tween) for lhr at RT or overnight at 4°C. After 
rinsing in TBS-T, membranes were incubated with the first antibody for lhr at RT in a plastic bag 
containing approximately 1.5ml of 1-3% BSA TBS-T. The dilution and the exact nature of first antibody 
varied as specified in each experiment. Blots were washed x2 quickly, x l  for 15min and x2 for 5min with 
TBS-T, with shaking. HRP-conjugated second antibody, was added to 50ml of 5% skimmed dried milk 
TBS-T in which each membrane was incubated for lh  at RT, with gentle agitatioa After washing in TBS- 
T, as described above, protein detection would be performed with Enhanced Chemi-Luminescence 
technique (ECL™. Amersham, Buckinghamshire, UK) by exposing blots for various lengths of time to 
Hyperfilm™ ECL™ (Amersham). Finally the films would be processed as described above in developer 
and fixer.
2.3.Studies on biological features of IGFBP-2
2.3.1.Studies on IGFBP-2 association to the cell surface 
Cell lines
The Clone 9 epithelial cell line was derived from Rat Sprague Dawley liver and is listed in the 
European collection of cell culture with ECACC code No.88072203. Cells were supplied frozen from the 
European Collection of animal cell culture (ECACC, Salisbury, Wiltshire, UK). Clone 9 cells were grown 
at 37°C, 5% C 0 2, in 75-225cm2 plastic flasks containing 20-40ml of complete medium (Ham’s F12 
medium with 2mM glutamine, 10% foetal bovine serum (FBS), supplemented with lOOU/ml Penicillin G 
and 100[ig/ml Streptomycin sulphate). At confluence cells were washed with HBSS and detached from the 
plastic surface by a few minutes incubation at 37°C in the presence of 3-7ml of xlTrypsin-EDTA solution 
(0.5g/mlTrypsin and 0.2g/ml EDTA, obtained by diluting xlO concentrated solution with HBSS). 15-20ml 
of 10% FBS F12 medium were added to inactivate trypsin, then cells were harvested in 50ml centrifuge 
tubes and centrifuged at lOOOrpm for 5min. Supernatant was discarded and cell pellets resuspended in 
complete medium. Cells were routinely passaged 1 : 1 0  and fed with fresh medium every 3 days after 
washing with HBSS.
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The MC3T3-E1 osteoblastic cell line was a kind gift o f Dr. Simon Butterwith (Roslin Institute, 
Edinburgh)
MC3T3-E1 cells, that have a fibroblastic phenotype, were derived from newborn mouse calvarial cells by 
Sudo et al. (1983). Cells were routinely cultured at 37°C in 1 0  % new bom calf serum (NCS) 
DMEM(41965-039 Life Technologies) supplemented with penicillin and streptomycin, as described 
above. Cells were passaged at confluence as for Clone 9 cells.
The A10  smooth muscle cell line (available in ECACC No CRL1476), derived from rat thoracic 
aorta, was a kind gift of Dr C. Delves (Glaxo-Wellcome, Stevenage, UK). A 10 smooth muscle cells were 
routinely cultured in DMEM supplemented with 20% heat inactivated (56°C for 30 min) FBS and 
antibiotics, as described above. Cells were passaged 1:10 as described for Clone 9 cells.
The 3T3F442A preadipocyte cell line was purchased from Dr Howard Green at Harvard Medical 
School, Boston, MA USA. Cells were routinely cultured in DMEM 10% NCS in the presence of penicillin 
and streptomycin and incubated at 37°C al 1 0 % C 0 2. If grown in this medium and passaged when 
subconfluent, 3T3F442A cells maintain an undifferentiated, fibroblastic phenotype. As at confluence 
confluent cells tends to detach from the plastic surface and as cells appeared to be very sensitive to 
dehydration, care was taken to carry out experiments at 70-80% cell confluence and to promptly replace 
medium or washing solutions.
The Dx3 human melanoma cell line was a kind gift o f Dr C. Delves (Glaxo-Wellcome, 
Stevenage, UK). Cells were routinely cultured in DMEM supplemented with 10% heat inactivated FBS 
(56°C for 30min) penicillin and streptomycin. At confluence cells were passaged 1:10 by washing with 
PBS first and then incubating for lmin at 37°C with one part of trypsin and 4 parts of Versene (Life 
Technologies)
The K562 human erythroleukemia cells were a kind gift o f Dr C. Delves (Glaxo-Wellcome, 
Stevenage, UK). These cells were grown in suspension in 50% RPMI-50%DMEM supplemented with 
10% FBS and antibiotics.
87
Antibodies:
Polyclonal, rabbit, anti bovine IGFBP-2 antibody was from Upstate biotechnology (supplied by 
TCS Biologicals Ltd, Buckingham UK). Obtained from the same source were i) rabbit polyclonal anti-rat 
IRS-I (Pleckstrin homology domain), and ii) 4G10 anti-phosphotyrosine monoclonal antibody.
Anti-rIGFBP-5, sheep polyclonal antiserum was a gift from Dr E. Tonner, Hannah Research 
Institute, Ayr, UK.
Anti-h IGF-II polyclonal antiserum (rabbit) was from GroPep.
Anti-hIGF-I was a gift from NIDDK (Bethesda Maryland, USA).
Enzyme-conjugated antibodies, anti-rabbit, anti-sheep or anti-mouse HRP-conjugated, were from
Sigma.
2.3.1 .a Screening of different cell types and different m ethods to detect the 
association of exogenously added rat recombinant IGFBP-2 with the cell 
surface.
2.3. La. I Use of an immunoistochemical technique (anti IGFBP-2) to detect recombinant 
rIGFBP-2 or PGD-IGFBP-2 mutant binding to Dx3 cell monolayers
96 well plates (Life Technologies Maxisorp Nunc immuno-plates) were coated with 2p.g/well
fibronectin or with 2.5pg/well poly L-lysine and incubated at 37°C for lh  (or at 4°C overnight). After
washing the wells three times with PBS, Dx3 cells were plated at lxlO 5 cells/well in IOOjj.1 of 1% BSA,
O.lmM Mg"^ DMEM and allowed to attach for lhour at 37°C. In order to test the background binding of
recombinant IGFBPs to plastic, cells were omitted in some wells. After washing the plate twice with PBS,
0.5-2fig/well o f recombinant IGFBP-2 or PGD-IGFBP-2 in lOOpl of 1% BSA, O.lmM Mg^/DMEM was
added to cell monolayers or control wells. The binding reaction was allowed to proceed for lh  at 2
different incubation temperatures, 21°C or 4°C, as IGFBPs could be internalised after association with the
cell membrane. Cells were washed three times with ice cold PBS, and fixed for lOmin on ice with 4%
paraformaldehyde, which also has cross-linking properties. After extensive washing, non-specific binding
sites were blocked with 1% BSA for 45min at RT. For immune-detection o f bound IGFBP, anti IGFBP-2,
diluted at 1:2500 in 1% BSA PBS, was added and incubated overnight at 4°C. After 3 washes with PBS,
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the second antibody, anti rabbit HRP (Ig HRP-iinked F(Ab)2  fragment, code NA9340, Amersham) diluted 
at 1:20000 in 1% BSA PBS was added and incubation was allowed for lh  at RT. After 5 washes with 
PBS, the presence of immuno reactive IGFBP-2 proteins was revealed with Sigma Fast™ ODP peroxidase 
substrate system (code P 9187). One o-phenylenediammine dihydrochloride and one urea hydrogen 
peroxide tablet were dissolved in 20ml H20 . 200pl/well o f this solution was added, then plates were 
incubated in the dark for 30min and the colourimetric reaction was measured with the spectrophotometer 
at 450nm.
2.3-l.a. 2.1251 IGFBP-2 binding toAlO and Clone 9 cell surface in competition with cold 
IGFBP-2
Clone 9 and A10 cells were plated on 24 well plates at density o f 0 .8x l0 4 and 2 .2xl04 cell/well 
respectively and allowed to reach confluence. In some cases cells were omitted, but wells were treated 
exactly in the same way as follows. After washing twice with HBSS, cells were serum-starved in F12 or 
DMEM containing 0.01% BSA and incubated overnight at 37°C. Supernatants were removed and cell and 
control wells were washed with ice cold Hepes binding buffer (H.b.buffer): 20mM Hepes, 118mM NaCl, 
5mM KC1, 1.2mM M gS04, 8 .8 mM dextrose (D glucose), 0.1% fatty acid free BSA, pH 7.4 (as in Yang et 
al., 1996). 85000cpmof 125I IGFBP-2, dissolved in H.b. buffer, was added to monolayer or control wells in 
the presence or absence o f 0.1 pg or lp g  of cold IGFBP-2 (in a total volume of 200pl/well) and incubation 
was continued for 3h at 8 °C. Wells were washed 3 times with ice cold H.b.buffer and residual 
radioactivity was removed from monolayers and control wells with 500pi IN NaOH. After monitoring 
cell lysis microscopically, supernatants were transferred to RIA tubes and radioactivity determined by y- 
counting.
2.3. l.a.3 Stripping endogenous IGFBP-2 potentially bound to the cell membrane before 
incubating cells with 125I IGFBP-2.
Clone 9 and A10 cells were plated in 6  well plates and grown with serum containing medium till 
confluence. Some o f the control wells did not contain cells, but they were treated identically. After 
washing with HBSS, cells were incubated for 24h in SFM containing 0.01%BSA. Stripping of 
endogenous IGFBP potentially associated to cell membranes was performed as in Andress (1995). After
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washing with SFM, wells were sequentially rinsed with i) 2 ml of ice cold 2M NaCl, 20mM Na acetate, 
pH4.0, ii) 2ml ice cold 2M NaCl, 20mM Hepes, pH 7.5 and iii) PBS. Cell monolayers were then incubated 
for 2h at 4°C with 150000cpm125I IGFBP-2 dissolved in 20mM Hepes, 0.1% BSA, pH7.0 in the presence 
or in the absence of l |ig  of cold IGFBP-2. After rinsing the wells three times with ice cold PBS, residual 
radioactivity was extracted with 500jil/well IN NaOH shaking for lh  at RT and radioactivity detected by 
y-counting.
2.3.1. a. 4.1251 IGFBP-2 binding to cell monolayers cultured on positively charged plates
In our attempt to minimise 125I IGFBP-2 non specific binding to plastic, Clone 9 cells were 
cultured on positively charged 6  well plates (PrimariaR plates code 3846 Becton Dickinson labware 
supplied by Fred Baker Scientific, Cheshire,UK) and grown until they became confluent. Monolayer and 
cell-free control wells were washed 3 times with PBS and incubated for 4h at RT with 500jil Hepes 
b.buffer containing 70000cpm o f 1251 IGFBP-2 in the presence or absence o f 25jxg of cold IGFBP-2. After 
washing, 500p.1 IN NaOH/well was added and plates were shaken for lOmin. Supernatants were 
transferred to RIA tubes and radioactivity determined by y-counting..
2.3.1. a. 5 1251 IGFBP-2 binding to cells in suspension
In an attempt to decrease 125I IGFBP-2 non specific binding to plastic, the cell membrane/plastic 
surface ratio was increased by using a high density cell suspension placed in RIA tubes. A10 and 
3T3F442A cells were plated in 10cm dishes and grown at 37°C till 80-90% confluence. Dishes were 
washed twice with cold SFM, scraped into 5ml SFM and sequentially passed through an 18G and 23G 
needle. Cell suspensions were washed in H.b. buffer, centrifuged at 1700xg for 5min, resuspended at 
lxlO 6 cells/100pl H.b buffer and placed in RIA tubes. A10 cells were incubated with 6000 cpm of 125I 
IGFBP-2 in the presence or absence o f O.lor lp.g/ml cold IGFBP-2 (in a total volume of 300pl 
H.b.buffer). 3T3F442A cells were incubated with 160000cpm of 125I IGFBP-2 and cold competitor was 
added at 0.3(a.g/ml or 3|xg/ml. During the 3h incubation at 8 °C, cell suspensions were mixed from time to 
time. Tubes were centrifuged at 1700xg for lOmin at 4°C and radioactivity in both pellets and 
supernatants was determined by y-counting.
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2.3. l.a. 6 125I IGFBP-2 ligand blots on Clone 9 andMC3T3-El cell membrane preps.
Clone 9 and MC3T3-E1 membranes were prepared as described in paragraph 2.3.l.b. Membrane 
samples were electrophoresed, blotted and processed for ligand blotting as described in paragraph 2 . 2  with 
the exception that, instead of IGF-I, 125I IGFBP-2 was used as probe for detection of a possible binding 
partner present in membrane preparations.
2.3. l.a. 7 1251 IGFBP-2 cross-linking to Clone 9 membranes treated (+/-) sodium chlorate.
Clone 9 cells were plated onto 10cm dishes and grown to confluence in the presence or absence 
of 30mM Na chlorate. Plasma membranes prepared from treated and untreated cells were cross-linked 
with 125I IGFBP-2 following the method described in paragraph 2.3. l.b. 1
2.3. l.a .8 Preliminary study to detect exogenous/endogenous IGFBP-2 binding to Clone 9 cell 
extracellular matrix..
ECM preparation was obtained following the method described by Jones et al., 1993. Clone 9 and 
MC3T3-E1 cells were plated on positively charged PrimariaR 6  well plates (described above) and grown at 
37°C. When confluence was reached, wells were washed twice with ice cold PBS. Cell membranes were 
dissolved by shaking the plates for lOmin on ice with 500|il/well o f 0.5% Triton X-100 in PBS, pH7.4 and 
removed. Nuclei and cytoskeleton elements were then removed with 500pl/well of 25mM NH4 acetate 
pH9.0 shaking the plates on ice for lOmin. The residual ECM-coated plates were used immediately. 
70000cpm 125I IGFBP-2, in 50Qpl Hepes binding buffer, were added to ECM coated or cell-free control 
wells and incubated for 48h at 4°C. Supernatants were then aspirated and wells washed three times with 
PBS. Residual radioactivity was removed either with IN NaOH or 2% SDS and determined by y-counting. 
Alternatively samples from each step of ECM preparation described above were electrophoresed on a 12% 
gel, blotted and processed for either 125I IGF-I or 125I IGFBP-2 ligand blot. In this last case half o f the blot 
was incubated with 125I IGFBP-2 tracer in the presence of 25pg cold IGFBP-2.
2.3. l.a. 9.alntegrin studies: Fibronectin binding assay on K562 cells using IGFBP-1 as 
competitor
96 well/plates (Maxisorp) were coated with 2pg/well fibronectin as described in 2.3.l.a. 1. After 
washing in HBSS 0.5mM MnCl2, K562 cells were resuspended in the same medium at a density o f 6 x l0 5
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cells/ml. lOOfil of cell suspension was incubated for 3hr at RT in the presence of either 2pg IGFBP- 
l(Sigma); 2p.g (IGF-I-IGFBP-1 complex), 20(j.g RGD, 20pg RGE, 1,2,5,10,20pg 4B4 Ab; 10,20pg mouse 
IgG] Isotype Ab or PBS. For each condition tested, 50jil/well o f cell suspension were plated in duplicate 
onto fibronectin plates. Cells were left to adhere for 30min at 37°C, washed twice with PBS and fixed 
with 100% ethanol for 30min. After cell staining with 0.1% crystal violet for lh  at RT, plates were rinsed 
with tap water and lysed with 50pl of 0.5% Triton and shaken for lOmin. 150|il o f water was added and, 
after mixing, the absorbance was read at 570nm
2.3. l.a. 9. b Integrin studies: cell adhesion test on IGFBP-2 and IGFBP-1 coated plates
After trypsinisation, Dx3 cells were resuspended at lx l0 6cells/ml in DMEM in the presence or
absence o f ImM Mg4*. lOOjol of cell suspension was plated on Maxisorp plates coated with 10-50-100- 
500pg/well of IGFBP-2 or non phosphorylated IGFBP-1 (Sigma) and allowed to attach for lhour at 37°C 
or 2hr at 4°C. After careful washing with PBS cells were fixed with 37% formaldehyde for 30min at 4°C. 
After washing with PBS for 5min, cells were stained with crystal violet and lysed as described above. 
Absorbance was determined at 570nm.
2.3 .1.b Detection of endogenous IGFBP-2 associated to the cell surface.
Cell membrane preparation
Cell membranes were prepared from cell monolayers as in Woodward et al. (1996).
Typically cells would be plated on 20x10cm Petri dishes in complete medium and incubated at 37°C till 
confluence. After washing twice with 10 and 5ml of HBSS, cells were grown overnight at 37°C in 5ml of 
serum free medium (which has the same composition as complete medium, except serum was substituted 
with 0.01% BSA). The following procedures were all carried out on ice and using ice cold solutions. After 
washing twice with PBS and rinsing quickly with 5ml of hypotonic buffer (ImM EDTA, ImM NaHC03, 
pH7.4), cell plates were incubated for 10-20min with 3ml/plate of hypotonic buffer supplemented with 
proteases inhibitors (2mM PMSF, 3uM leupeptin, 16uM aprotinin, 500mM N aV 04). Cells were scraped 
from all plates, pooled and kept on ice. Residual cells were harvested by washing each plate with 2ml 
hypotonic buffer (with protease inhibitors) which were pooled with the rest o f cell lysate and then
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homogenized for lOsec at half maximal speed with a Polytron homgenizer (Kinematica, Luzern 
Switzerland). A lOmin centrifugation at lOOOxg at 4°C removed the nuclear fraction. Supernatant was 
transferred to 2x30ml tubes (Nalgene, Rochester, NY, USA) and centrifuged at 15000xg (13000rpm in 
SS34 rotor) at 4°C for lOmin to remove lysosomal contamination. This supernatant was transferred to 
50ml Sorval tubes and ultracentrifiiged at 50000xg (26000rpm on A641 rotor, Beckman) at 4°C for 1.30h. 
After careful removal of the supernatant, the small, transparent, lipidic pellet was resuspended in a small 
volume (200-300pi) o f lOmM Tris pH7.4 supplemented with proteases inhibitors (as for hypotonic 
buffer). Membrane preps were frozen in liquid nitrogen and stored at -20°C. Protein concentrations were 
assayed on the day o f the experiment and the membrane preparation further diluted as required.
2.3. l.b. 1 125I  IG F cross-linking studies on Clone 9 and MC3T3E1 cell membranes
125I IGF-I and IGF-II cross-linking experiments were carried out adapting the method described 
by Reeve et al. (1993).
400 pg/tube of membranes were resuspended in Tris buffer (5mM Tris pH 7.4 , 0.5% fatty acid 
free BSA) and, after the addition of cold competitors (lp g  IGF-I/n, desIGF-I, or lOpg insulin), the 
volume was adjusted to 500pl. An additional 500pl of Tris buffer containing lxlO 6 cpm of 125I IGF-I or 
IGF-II was added to each tube followed by a 3hr incubation at RT with rotation. Membranes were pelleted 
at 14000rpm at 4°C for lOmin, and after aspirating radioactive supernatant, the pellet was counted and 
washed with lml of Tris buffer. Centrifugation was repeated, supernatants discarded and, after recording 
the c.p.m., pellets were resuspended in lm l of ice cold Tris buffer (without BSA) for the cross-linking 
reaction. 40mM Disucciminidyl suberate (DSS) in 100% DMSO anhydrous was prepared freshly and kept 
at RT 50 pi of this solution was added to each membrane sample and incubated on ice for 15min. The 
cross-linking reaction was quenched by the addition of 200pi o f stop solution (50mM Tris pH 7.4, 5mM 
EDTA) and tubes were centrifuged at 14000rpm for lOmin at 4°C. Radioactive supernatants were 
separated carefully (after recording supernatant and pellet counts), and cross-linked pellets were 
resuspended in 2x reducing SB, boiled for 3min and run in 12% or 7.5% acrylamide SDS gel.
A recombinant rIGFBP-2 sample was included in the cross-liking reaction as control. Our preparation of  
IGF-ff affinity chromatography purified IGFBP-2 contained high concentrations of Tris-base used to
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neutralize the pH. Primary amines found in Tris would interfere with the DSS cross-linking reaction, 
therefore we drop-dialysed 10-20 pi o f 170pg/ml IGFBP-2 on 0.025p Millipore membrane disks (cat 
VSW 02500) against 70ml water for 15min and replaced once for a further 15min. lOpl of dialysed 
IGFBP-2 was incubated with 50pl of IGF tracer (dissolved in 5mM Tris pH7.4, 0.5% fatty acid BSA as 
described above) and rotated for 3h at RT. The cross-linking reaction was performed by adding 2.5pi o f  
DSS solution directly to the tubes (containing 0.5% BSA). After 15min incubation on ice, the reaction was 
quenched with lOpl of stop solution and the white pellet resuspended. 20pl of this suspension were mixed 
with 20pl o f reducing 2x SB.
2.3. l.b. 2 Detection of IGFBP-2 associated to Clone 9 membranes by 125IIGF-I ligand blot and 
anti IGFBP-2 Western blot.
Crude preparations o f Clone 9 cells were electrophoresed on a 12%acrylamide gel under non 
reducing conditions and after transfer blotting, membranes were processed for 125I IGF-I ligand blotting or 
Western blotting according to the general procedure described in paragraph 2.2. For anti IGFBP-2 
Western blotting, the first antibody (rabbit anti bovine IGFBP-2) was diluted 1:2000 and anti rabbit HRP- 
conjugate second antibody was diluted at 1:5000. Incubation and dilution buffers have been described 
earlier.
Sheep anti rIGFBP-5 immune serum (1:1000) was used as negative control in Western blotting 
experiments (data not shown). In this case second antibody was 1:20000 dilution of anti-sheep HRP- 
conjugate antibody (Sigma).
2.3. l.b. 3 Anti IGFBP-2 and 5 immune-precipitation (IP) of solubilized Clone 9 and MC3T3-E1 
membrane preps. Detection ofprecipitated proteins by 125I IGF-I ligand blot.
Buffer A (50mM Tris-HCl pH 7.4, 150mM NaCl, 0.01% NaN3) and buffer B (20mM Tris-HCl 
pH 7.5, lOmM MgCl2, 0.2% BSA) were prepared.
800pg of Clone 9 or MC3T3-E1 membranes were resuspended in a final volume of 400pl o f buffer A 
supplemented with protease inhibitors (0 .8 mg/ml pepstatin, 2 mg/ml aprotinin, 2 mg/ml leupeptin,) and 
with detergents (1% Triton-XlOO, 1% Na-Deoxycholate). Membrane samples were allowed to solubilize 
by rotating at 4°C for lhr. 400pi of buffer B was added and insoluble debris was removed by
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centrifugation at 14000rpm for 30min at 4°C. Supernatants were transferred to fresh tubes and lOpl o f anti 
IGFBP-2 antibody or lOpl of anti IGFBP-5 anti serum were added. To pellet the immune-precipitated 
complexes, 50 pi of Pansorbin were added, tubes were rotated for lh  at 4°C and centrifuged at 6500 rpm 
for lOmin at 4°C. Supernatants were aspirated and pellets were washed 3 times with 1ml buffer A 
(without protease inhibitors or detergent). Pellets were mixed with 50pl of 2x non reducing SB, incubated 
for 30min on ice, boiled for 3min, electrophoresed on a 12% gel and finally processed for 1251 IGF-I 
ligand blot.
As a control for the immune-precipitation reaction, i) lOpl o f 70pg/ml IGFBP-2 and lOpl of baculovirus 
expressed, non purified, IGFBP-5 (a kind gift o f Dr E. Tonner) were dissolved in 200pl of buffer A in the 
presence or in the absence of 4 pi o f anti IGFBP-2 or anti IGFBP-5 antibodies, ii) 4 pi o f anti IGFBP-2 or 
anti IGFBP-5 was diluted in 200pl of buffer A in the absence of IGFBPs. 200pi of buffer B was added to 
all control samples, which were rotated overnight at 4°C. Pansorbin precipitation was performed as 
described for membrane samples. (Only some o f these controls are shown).
2.3.2 Clone 9 cell responsiveness to IGF stimulation.
2.3.2.1. Signalling studies
Clone 9 cells were plated in 10cm dishes in 10% FCS Ham’s F12 and incubated at 37°C in 5% 
C 0 2 until confluence was reached. Cells were then washed with HBSS and serum starved overnight in 
5ml of 0.01% fatty acid free BSA in Ham’s F12. Lysis buffer was prepared fresh on the day o f the 
experiment, by thawing a 20ml aliquot of buffer (50mM Tris HC1 pH7.4, 1% NP40, 0.25% Na- 
deoxycholate, 150mM NaCl, ImM EDTA, aliquoted in 20ml and stored at -20°C) and adding 200pl 
N aV 04 (stock solution lOOmM in water, stored at -20°C), 20pl leupeptin and 20pl aprotinin (stock 
solutions lmg/ml in water, stored at -20°C) and 20pl PMSF (1M solution in 100% Ethanol prepared 
fresh). Stock solutions of IGF-I, IGF-II (lmg/ml in lOmM acetic acid), des (1-3) IGF-I (0.5mg/ml in 
water) and insulin lmg/ml (in lOmM HC1) were diluted in 5ml SFM at concentrations specified for each 
experiment. Cells were washed with 5ml of pre-warmed HBSS, then 5ml o f pre-warmed medium with or 
without hormones was added and incubated at 37°C for 2 - 1 0 min as indicated for each experiment. 
Medium was discarded, and plates placed on ice and immediately rinsed with 10ml of ice cold PBS.
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Washing was repeated once and PBS aspirated completely. 300pi of cell lysis buffer was added to each 
dish and cells scraped and collected in a 1.5ml tube and kept on ice. Cell lysates were rotated end over end 
for 20min at 4°C, then centrifuged at lOOOOxg at 4°C for lOmia Supernatants were transferred to fresh 
tubes and protein concentration determined with BCA protein concentration kit (Pierce).
All samples were normalized by adding an appropriate volume of lysis buffer. A 20 pi sample was mixed 
with 20pl of 2x reducing SB, run in a 7.5% gel and blotted on nitrocellulose membranes. The first 
antibody, 4G10 anti phopsho-tyrosine monoclonal antibody was diluted 1:1000-1:4000 (as indicated in 
figure legends) and the second antibody, anti mouse HRP-conjugate, at 1:1000-1:2000. Western blot was 
performed following the general description as in Methods section 2.2.
Membranes were also examined by anti IRS-I Western blotting. Anti-IRS-I, (rabbit polyclonal IgG) 
(Upstate biotechnology cat. N. 06-524), was diluted at 1:1000 in 1% BSA TBS-T. Second antibody, anti 
rabbit HRP-conjugate was diluted at 1:5000 in 5% skimmed dried milk in TBS-T.
2.3.2.2. M T T  assay
This assay is based on the conversion of MTT, a water soluble tetrazolium salt, to water insoluble 
formazan by mitochondrial dehydrogenases. MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide; thiazolyl blue), added to the cell culture as a yellowish solution, is reduced in mitochondria 
where it accepts electrons from ubiquinone and cytochromes b and c (Kieman, 1981). Reduction opens the 
tetrazolium ring and MTT is converted to a purple insoluble formazan. Solubilization of formazan is 
obtained with isopropanol and the spectrophotometrical absorbance is a function o f the converted dye 
concentration. The MTT method has been used in place of thymidine uptake, for cell counting, or for 
measurement of cell cytotoxicity and it monitors both the metabolic and mitogenic activity o f  cells 
(Mosmann, 1983).
The cell density to be used in the following experiments was established in preliminary studies.
Clone 9 cells were trypsinized from a 225cm2 flask, pelletted by centrifugation at 1000 rpm for 
5min, washed in 0 .1% FCS Ham’s F 1 2  and recentrifuged. Cell pellets were resuspended in 10ml o f 0.1% 
FCS Ham’s F12 then cells were counted and diluted to 1.2x 105cells/ml. In a 96 well plate, 50pl of cell 
suspension was plated in rows proceeding from well 1 to 1 2  and coining back from 1 2  to 1 in the next 
row, in order to obtain an homogeneous distribution o f cells within the columns. Moreover during the
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plating procedure, care was taken to mix the cell suspension frequently but gently, by inverting the tube. 
After plating, cells were incubated at 37°C overnight to allow cell attachment. IGF-I, IGF-II, des (1- 
3)IGF-I or insulin were diluted in 0.1% FCS Ham’s F12 to required concentrations as indicated for each 
experiment. For each treatment a column of 8  replicate wells was used. 50pl o f 0 .1% FCS Ham’s F 1 2  with 
or without hormone supplementation was added to each well and cells were incubated for 24 or 48 hours 
at 37C, 5% C 0 2. lOpl of MTT solution (5mg MTT/ml in RPMI without phenol red, filtered and stored at 
4°C in the dark) was added and cells were incubated at 37°C for a further 3hr. The water insoluble 
formazan dye which formed was dissolved with 150pl o f 0.05M HC1 in isopropanol by thorough 
trituration. Absorbance was determined at 620 n m .
2 . 3.2.3 Characterisation of IGF production by Clone 9 cells
4 x 225 cm2 flasks of confluent Clone 9 cells were washed with HBSS twice and incubated in serum free, 
protein free Ham’s F12 medium for 48h. 100ml o f CM was harvested, centrifuged at 3000rpm to eliminate 
cell debris and the supernatant was freeze dried overnight (Heto freeze drier). Lyophilised medium was 
dissolved in 5ml of water and dialysed against lOmM phosphate for 48h at 4°C. After dialysis, CM was 
again freeze dried and resuspended in 1ml o f water, giving a 1 0  fold concentration from the original 
medium.
Detection of IGFs by western blotting was performed as described by Hizuka et al. (1998). 15pl of Clone 
9 CM sample, and 10, 100, lOOOng of hIGF-I or hIGF-II were run under non reducing conditions in a 16% 
acrylamide SDS gel and then transferred as described above. First antibody, either anti IGF-I or anti IGF- 
II, was diluted at 1:1000 in 1% BSA TBS-T. In both cases, the second antibody was anti rabbit HRP 
diluted at 1:5000. Buffers, incubation conditions and detection are described elsewhere (Methods section 
2.2).
2.3.3 Development of a cellular model to investigate IGFBP-2 biological functions
2.3.3.1 Cloning IGFBP-2 and IGFBP-5 into the pcDNA3 expression vector, in sense and 
antisense orientations.
pcDNA 3 plasmid (Invitrogen), a CMV-based mammalian-expression vector was a kind gift from Dr M  
Travers.
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The cloning of IGFBP-2 and IGFBP-5 cDNAs into pcDNA3 and the restriction digests of the 
recombinant plasmids to check the orientation o f the inserted DNA, were performed following the general 
procedures described in paragraphs 2.7.<xand 2.1.1. Briefly: 2pg of pcDNA3 was digested with EcoRl, 
treated with alkaline phosphatase (Boehringer) and purified with Quiaquick gel extraction filters. IGFBP-2 
and IGFBP-5 cDNA inserts were prepared from 10pg of clones contained in the recombinant pGEM 7Zf 
(+/-) plasmid by an EcoRl digestion and purified on a 1% agarose gel. IGFBP-2 and IGFBP-5 inserts 
were excised from the gel and purified on Quiaquick gel extraction filters. After checking the relative 
amount of DNA on agarose gel, a 1:1 and 1:10 ratio between EcoRl-digested pcDNA3 and IGFBP-2 or 
IGFBP-5 inserts were chosen for ligation. Following transformation with the ligation products, JM 109 
competent cells were grown on LB-agar plates under ampicillin selection. 10 single colonies from each 
plate were picked and DNA plasmid minipreps were prepared (with UltraClean mini plasmid prep kit, 
MoBio laboratories, Solana Beach, Ca). The miniprep DNAs were analyzed on a 1% agarose gel after 
being digested with EcoRl to check the size o f any released inserts and with Hind ID to assess the 
orientation of the inserts with respect of the cytomegalovirus promoter (Fig 3.3.3.1). Maxipreps were 
prepared for either orientation of pcDNA-IGFBP-2 and 5.
2.3.3.2 Preliminary experiments to evaluate the growth rate in Clone 9 cells transfected with 
sense/antisense IGFBP-2 in comparison to wt cells transfected with vector alone 
Transfection of Clone 9 cells with pcDNA3 constructs 
We transfected Clone 9 cells with sense/antisense IGFBP-2; sense/antisense IGFBP-5 or pcDNA3 vector 
alone and created 5 different Clone 9 cell subtypes.
Clone 9 cells were plated in 60mm dishes at 2 .5xl05cells per dish and grown in complete medium. After 
24h incubation at 37°C, the cells reached 50% confluence and were transfected with pcDNA3 vector 
alone; sense/antisense IGFBP-2 or sense/antisense IGFBP-5. Lipofectin (Life Technologies) was used to 
promote the transfection, which was performed following the instructions described by the manufacturer. 
The incubation of cells with the DNA-Lipofectin mix was carried out for 6 h, after which the supernatants 
were removed the cells were allowed to recover for 48h at 37°C with 10% FBS F12 Ham’s medium 
supplemented with penicillin and streptomycin. The cells were then passaged 1:5 to fresh 60mm dishes
98
and, as pcDNA3 confers neomycin resistance, transfected cells were selected with 400|a,g/ml of a 
neomycin analogue, G418 (Geneticin, Life Technologies). Few cells from each transfection survived 
G418 selection, but after a recovery period they started to proliferate, forming distinct foci. Drug selection 
was maintained for one month. Subsequently the G418 concentration was reduced to 200pg/ml for 2-3 
days , then the drug was omitted for a further 1 - 2  days and the cells were frozen in liquid nitrogen.
MTT assay on Clone 9 cells transfected with sense or anti sense IGFBP-2 or pcDNA3 vector alone.
Frozen vials of Clone 9 cells, which were transfected with pcDNA3 vector alone, sense or antisense 
IGFBP-2, were thawed and grown for 2 passages under drug selection (400pg/ml o f G418)
The MTT assay was carried out substantially as described in paragraph 2.3.2.2. For each cell line, 7 plates 
(21 in total) were prepared. Each cell line was trypsinized, washed and resuspended at 6x l0 4 cell/ml in 
0.1% FBS. lOOpl/well o f each cell suspension were placed in 24 of the 96 wells o f a plate. Cells were 
grown at 37°C, 5 %CC>2. After 4h, one plate for each cell line was supplemented with 1 0 pl/well o f MTT 
solution (5mg/ml of MTT in RPMI w/o phenol red). These plates were further incubated for 3h to allow 
formazan production by the cells. The dye produced was solubilised by the addition of 150pl o f  
isopropanol 0.05M HCl/well and absorbance was determined at 620nm. The remaining plates were 
identically processed every 12hours, over a period o f 72h.
2.3.3.3.1251 IGF-I charcoal binding assay on CM samples from Clone 9 cells transfected with 
sense/antisense IGFBP-2 or pcDNA vector alone.
Clone 9 cells transfected with sense/antisense IGFBP-2 or pcDNA3 expression vector were 
grown in 10cm dishes in 10% FBS Ham’s F12. At confluence the cells were washed with HBSS and 
grown for 24h in 5ml of SFM. Conditioned media was harvested and the IGF-binding capacity of 
increasing volumes (from 10 to 200pl) o f each CM was assessed in our charcoal binding assay following 
the general procedure described in Materials and Methods (paragraph 2.1.3).
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3. RESULTS
3.1 Construction of P20A and P22A IGFBP-2 mutants, expression of wt 
IGFBP-2 and mutated proteins and assessment of their affinity for IGFs
3.1.1 Site-directed m utagenesis to create P20A and P22A IGFBP-2 mutants
We used the Promega “Altered sites” system to mutate the wt rat IGFBP-2 cDNA and create 
P20A and P22A mutants, which encode proteins where the proline residues, at position 20 or 22 of the 
mature protein were substituted with alanine residues. For P20A, the triplet CCC, at position 256-258 of  
rat IGFBP-2 cDNA was substituted with CGT. This modification of the original sequence also created a 
novel restriction site for the restriction endonuclease Sacl.
Similarly, for the construction of P22A DNA, the triplet CCC at position 262-264 o f rat IGFBP-2 cDNA  
was replaced with GCT. This modification formed a novel restriction site for the PvuII restriction 
endonuclease. Fig 3.1.1 shows a 1% agarose gel o f wt and mutated IGFBP-2 DNAs (inserted in pALTER 
ex-1 plasmid) digested with Sacl and PvuII endonucleases.
On the same figure two diagrams illustrate the DNA restriction sites for each of the mutants and the 
expected size of the fragments resulting from endonuclease digestion.
There are no Sacl sites in pALTER exl. One restriction site for Sacl, at about position 930 bps, is present 
in wt IGFBP-2 DNA, therefore digestion with Sacl results in a linearization of pALTER-IGFBP-2. As the 
mutation introduced at the triplet 256-258 of IGFBP-2 DNA for the construction of P20A mutant created a 
new recognition site for Sacl, an additional fragment of about 670 bps was released following the 
digestion.
There are no PvuII restriction sites in the IGFBP-2 cDNA, but this endonuclease cleaves pALTERexl 
plasmid at three sites, demonstrated by the 3 fragments that originated from the digestion of pALTER- 
IGFBP-2. The mutation of IGFBP-2 DNA at the triplet 262-263 created a novel restriction site for PvuII 
and, as expected, we saw 4 fragments resulting from digestion with this endonuclease.
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3.1.2 Expression of wt, P20A and P22A IGFBP-2 mutated proteins
We chose to express wt IGFBP-2 and P20A and P22A mutants in insect cells using the 
baculovirus expression system. We initially considered expressing the protein in procaryotes (E.coli), as 
IGFBP-2 is not post translationally modified and bacterial expression o f IGFBP-3 had been reported in the 
literature (Mohseni Zadeh and Binoux, 1997a,b). However, IGFBPs being highly disulphide bonded (9 S- 
S bridges), we expected that complicated purification, denaturation and refolding steps would be required 
in order to yield a functional protein. The Baculovirus expression system offered the advantage of being 
able to harvest the recombinant protein in a soluble form directly from the insect cell conditioned medium, 
as these cells are able to utilise mammalian signal peptide and secrete the protein.
Following the construction of recombinant baculoviruses carrying either wt IGFBP-2, P20A or P22A 
mutant DNAs, the expression of the encoded proteins was obtained by infecting Sf9 insect cells, as 
described in Mats and Meths. To detect the presence o f wt IGFBP-2, P20A or P22A proteins in the insect 
cell supernatants, equal volumes o f the concentrated conditioned media were electrophoresed on a 1 2 % 
gel under non reducing conditions. Proteins were transferred to Hybond-C extra membranes, which were 
processed fo r1251 IGF-I ligand blot, as described. The same membranes were subsequently reused for anti 
IGFBP-2 Western blot and protein bands were revealed by ECL technique. Wt IGFBP-2, P20A, P22A 
proteins were all detected by anti-IGFBP-2 antibody (Fig 3.1.2 b) and they appeared as a major band of 
approximately 36kDa. A lower intensity band of smaller Mr is detectable in the P20A preparation and it 
probably represents a proteolytic fragment of P20A. 125I IGF-I ligand blots (Fig.3.7.2,a) demonstrated that 
not only are insect cells able to secrete the binding proteins, but that probably wt IGFBP-2, P20A and 
P22A are also correctly folded as they retain IGF-binding ability. No smaller Mr bands are detected with 
125IGF-I ligand blot technique. In both Western and ligand blot, P20A was the most concentrated sample 
followed by P22A and wt IGFBP-2. This result gives a preliminary indication that the 2 mutations 
introduced in IGFBP-2 did not affect IGF-I binding. In fact, band density detected with the IGF-I ligand 
blot, which partly depends on the affinity o f the binding proteins for IGF-I, substantially replicated the 
picture obtained with anti IGFBP-2 Western blot, which is not affected by the IGF binding characteristics 
of the proteins.
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F i g  3 . 1.2 
Expression of wt IGFBP-2 , P20A and ’22 A mutants
125i IGF-I ligand blot
BP-2 P20A P22A BP-2 P20A P22A BP-2 P20A P22A
1 Ml 0.5 jul 0 .25  jlxI
a )  D etection o f protein expression in  concentrated supernatants o f insect 
cells cultures transfected with either IGFBP-2, P20A or P22A recom binant 
baculovirus. Equal volum e o f each sample was run in a 12% gel under non 
reducing conditions. Proteins were then transferred to nitrocellulose m em branes 
and ,25I IGF-I ligand blot was carried out as described in M ats & M eths
Anti IG FBP-2 W estern blot
BP-2 P20A P22A BP-2 P20A P22A BP-2 P20A P22A
1 pl 0.5 pi 0.25 pi
b) This picture shows the sam e m em brane blot utilized above subsequently 
processed for an anti IGFBP-2 W estern blot.
Fig 3 . 1.2
Expression of wt IGFBP-2, P20A and P22A
C om assie blue staining
SM IG FBP-2 P20A  P22A Sf9 uninf
Silver staining
IGFBP-2 P20A P 22A  Sf9 uninf SM
Detection o f protein expression in concentrated supernatants o f insect cell cultures 
transfected with e ither IGFBP-2, P20A or P22A recom binant baculovirus. A sam ple 
o f concentrated supernatant o f non-infected Sf9 cells (Sf9 uninf.) is also included as 
a control. Equal volum es o f each sam ple were run in a 12% gel under non reducing 
conditions. The arrow in Fig.c) indicates the location o f the putative IGFBPs
According to the manufacturers (Life Technologies), if  insect cells are grown in serum-protein- 
free medium, recombinant secreted proteins can represent up to 95% of the total protein concentration of 
culture supernatants, provided that conditioned media are harvested before cell lysis occurs (Guide to 
baculovirus expression vector systems (BESV) and insect cell culture techniques-Instruction manual- 
GD3CO BRL). We assayed the level o f purity of recombinant proteins in the concentrated insect cell 
supernatants by Coomassie and silver staining.
As shown in Fig 3.7.2.C, under our experimental conditions, Coomassie staining revealed that in each 
protein preparation the recombinant IGFBP protein was the predominant band. However it is difficult to 
estimate the relative concentration of the IGFBPs among all other contaminant bands. In silver staining 
(Fig 3.7.2.d), which is a more qualitative technique, a much higher number of protein bands was detected 
and it became difficult to identify clearly the band corresponding to the recombinant IGFBP.
3.1.3. IGF-affinity studies on the wt, P20A and P22A IGFBP-2 proteins
3.1.3.1 C om petition  studies with charcoal binding assay
As described in the Materials and Methods section (paragraph 2.1.3), in a preliminary study we 
constructed an 1251 IGF-I and ,25I IGF-II binding curve for wt IGFBP-2, P20A and P22A in order to 
analyse the relative binding capacity o f equivalent amounts of recombinant protein preparations. On the 
basis of these data we were able to choose the appropriate volume of IGFBP preparations to be used in the 
subsequent competition study. Two criteria influenced this choice: i) the volume chosen for each IGFBP 
preparation should lie in the linear part of the IGF-binding curve ii) this amount of IGFBPs should bind a 
relatively low percentage of IGF tracer (approx. 20%). These conditions would guarantee that in the 
competition studies IGFBP would be saturated with 125 I IGF-I or II so that the addition of cold IGF 
competitor would displace tracer from the binding protein.
The competition studies aimed to determine the relative affinity o f wt IGFBP-2, P20A and P22A for IGF-I 
or IGF-II. Fixed volumes of recombinant IGFBP-2, P20A or P22A preparations were incubated with a 
fixed amount of 125IIGF-I/II tracer competed by increasing concentrations o f cold IGF-I or IGF-II (0.25, 
0.5, 1, 2.5, 5, 10, 25, 50ng/ml). Different ranges of cold IGF competitors were tested in previuos
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experiments which showed similar results with respect of the affinity of IGFBP-2 and its 2 mutants for 
IGFs. Data presented here show the results o f a single experiment which was chosen as representative 
example. The competition curves obtained are shown in Fig. 3.1.3.1a, b, c and d. Data were plotted as 
follows: on the X axis the increasing concentration of cold IGF (ng/ml) is plotted: on the Y axis is 
reported the amount of bound tracer expressed as % of cpm controls (control= tracer+IGFBP in the 
absence o f cold IGF, as described in Material and Methods). From these graphs, the IC50 values 
(concentration of cold IGF-I or n  able to displace 50% of the tracer) were graphically derived. For all 
proteins, IC50 values fell in a range of 4-6ng/ml, except for wt IGFBP-2 where slightly lower 
(IC5o=2.5ng/ml) values were found when cold IGF-II was used as competitor of either IGF-I or IGF-II 
radioligand. Although this observation is not statistically significant, it is in agreement with the work of 
Oh et al. (1993a) who previously reported a 2 fold higher affinity o f hIGFBP-2 for IGF-II in comparison 
to IGF-I.
Data were analysed statistically with GENSTAT 5 version 4.1.
First, all competition curves (Fig. 3.1.3.1a, b, c and d) were smoothed by fitting into g-logistic 
curves and unnormalised analysed as A620 versus the log of the concentration, using non linear 
regression analysis. The IC50 values were calculated based on these fitted curves and they all ranged 
between 2.4 and 6.5 ng/ml (and again the lowest IC50 values (2.4 and 2.9ng/ml) were displayed by wt 
IGFBP-2 when cold IGF-II was used to compete either IGF-I or IGF-II tracer). A general analysis o f  
variance (up to the second level o f interactions) was applied to the IC50 data. None of the factors (protein, 
cold, and radiolabelled tracer), or the two level interactions between them, was significant.
Data were also transformed according to Scatchard’s equation (Scatchard, 1949) and plotted as follows: 
the amount of bound IGF-I or n  (B) was expressed in pM on the X  axis, while on the Y axis the ratio 
between bound and free IGF-I or II (B/F) was plotted. A linear regression analysis with groups was 
applied to the transformed data and the gradient of the slopes (representing the Kd value of IGFBPs for 
IGF-I or II) shown to be not significantly different.
In conclusion, our analysis show no evidence that single mutations o f the conserved prolines 
located at position 20 or 22 of rat IGFBP-2 affect IGFBP-2 binding to IGF-I or II.
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Fig 3 . 1. 3.1
Affinity studies of wt IGFBP-2, P20A and P22A for 
IGF-I or IGF-II
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Charcoal binding assay. Radio-labelled IGF-I or-II (25000cpm/tube) was incubated with a fixed 
amount of the insect cell supernatant containing either •  wtIGFBP-2, ■ P20A or A P22A. The tracer 
was competed with increasing amount of cold IGF-I or -II, as indicated on the x axis. Data on the y 
axis express tracer binding as % of control samples (IGFBP+ tracer in the absence of cold 
competitor). Each point shown in the graphs represents the mean of three replicates.
3.1.3.2. DISCUSSION
While the IGFBP binding site on the IGF molecule has been extensively studied and fairly well 
characterized (Bayne et al., 1988; Baxter et al., 1992; Heding et al., 1996) the identification of IGF 
binding sites on IGFBP is still the object o f study and debate. Site-directed mutagenesis, deletion of 
protein domains and the utilisation of naturally occurring proteolytic fragments were some o f the 
strategies employed to identify that the IGF binding site is either in the N-terminus or C-terminus o f  
IGFBP molecules. Contradictory results for the involvement of one or other domain were reported by 
different groups o f researchers (Brikman et al., 1991a; Lalou et al 1996; Hashimoto et al. 1997; Firth et 
al., 1998; Ho and Baxter 1997a; Forbes et al., 1998). It is now generally believed that although either one 
or the other domain of IGFBPs might play a pivotal role in IGF binding, both the N- and C-terminus of  
IGFBPs are necessary to achieve the typical high affinity binding to IGFs (Kalus et al., 1998; Qin et al., 
1998). The occurrence of binding in multiple steps or the existence o f distinct binding sites for IGF-I or 
IGF-n has also been proposed (Roghani et al., 1991; Ho and Baxter, 1997a; Forbes et al., 1998).
As far as IGFBP-2 is concerned, studies aiming to identify the IGF binding site have been 
published only very recently and its location in either the N- or C-terminal domain has been supported. 
Hobba et al. (1996 and 1998) showed that iodination of a tyrosine residue at position 60 or its substitution 
with an alanine caused a 4 and 8 fold decrease in the affinity for IGF-II and IGF-I respectively. On the 
other hand Ho and Baxter (1997a) showed that a 14kDa C-terminal fragment of IGFBP-2 retained IGF 
binding capacity, while the deletion of the most C -terminal 62 residues severely compromised IGF 
binding (Forbes et al., 1998).
At the time we started our research much o f this information was not available, neither was it 
known if  the N-terminus and the C-terminus of IGFBPs represented two distinct domains or if  they were 
cross-linked through disulphide bonds forming a functionally indivisible domain. Observing the aligned 
sequences o f different IGFBPs (Fig 3.1.3.2), we noticed that at position 20, 21 and 22 of mature IGFBP-2 
there was a group o f three prolines, well conserved among IGFBP species. We hypothesised that these 
proline residues might have been preserved from changes throughout evolution because they played a 
functional role and perhaps had a part in IGF-binding, the best known of the IGFBP functions. Therefore 
we decided to investigate if  single mutations of proline residues at position 20 or 22 of the wt IGFBP-2
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protein affected its affinity for IGF-I or -II. Our results indicate that the substitution of these prolines with 
alanine residues has no effect on IGF-I or IGF-II binding.
Other data from our competition studies indicate the relative affinity o f wt IGFBP-2 for IGF-I or IGF-II. 
Although when calculated from the raw data, the IC5o value of IGFBP-2 for IGF-I (in the presence of 
either 125I IGF-I or 125I IGF-II) was double that of the IC50 value for IGF-II (in the presence of either the 
radio-ligands), the statistical analysis o f the results o f the competition binding studies, revealed no 
significant difference in affinity o f any of the wt or mutant IGFBP-2 proteins for either of the growth 
factors. A higher affinity o f IGFBP-2 for IGF-II in comparison to IGF-I has been reported in the literature. 
IGFBP-2 preference for IGF-II was found to be as high as 20-30 fold or as little as 2-4 fold (Rosenfeld et 
al. 1989; Roghani et al., 1991; Oh et al., 1993a). Discrepancies could be due to different experimental 
conditions employed. When biological fluids are used as a source of IGFBP-2, it is possible that the 
presence of contaminant IGFBPs with very high affinity for IGF-II might have influenced the results. Vice 
versa, the method utilised for IGFBP-2 purification may have caused loss o f its preference for IGF-II. Our 
data fall in the same order of magnitude of those obtained by Oh et al. (1993a) who found that hIGFBP-2 
IC50 values for IGF-I were respectively 5.5 and 9.5ng/ml when 1251 IGF-I or II were used, while the IC50 
values for IGF-II were respectively 5.0 and 6.5ng/ml w hen1251 IGF-I or II were used.
During the course of our studies, research in this area made remarkable progress and new lines of 
investigation were opened as it became clear that in a biological context the interaction between IGFs and 
their binding proteins was not simply a matter of affinity, but was in fact the result o f an intricate 
equilibrium between multiple factors. For instance specific IGFBP proteases present in biological liquids 
or the association of IGFBPs with the cell surface/ECM were shown to significantly affect IGFBP affinity 
for IGFs. Moreover it was found that IGFBPs could exert not only an inhibitory but also an enhancing 
modulation of IGF action or even an IGF-independent effect. Therefore we decided to continue our studies 
on IGF-IGFBP-2 interactions in a cell culture model which would offer a more biological context
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3.2 IGF-I! affinity chromatography purification of wt IGFBP-2 and PGD 
IGFBP-2 mutant
With a view to future studies aiming to investigate the biological functions of IGFBP-2 in a cell 
culture system, we proceeded to purify wt IGFBP-2 from the concentrated insect cell supernatant.
Fig 3.2 a and b show the purification of IGFBP-2 following the processing of concentrated insect cell 
supernatant on an IGF-II affinity chromatography column. Samples from each purification step were 
electrophoresed on a 12% gel and protein bands were detected by Coomassie blue staining (Fig 3.2.sl). 
Most o f the contaminant proteins present in the starting material were recovered in the unbound and 
washing fractions, while fractions eluted with 0.5M acetic acid pH 3, principally contained a 36kDa 
protein and a lower Mr species. The identity o f the eluted protein and a proteolytic fragment from this 
protein was confirmed with an anti IGFBP-2 Western blot (Fig 3.2. b) which also showed the enrichment 
in IGFBP-2 concentration in the first elution fractions compared with the starting material.
In addition, we also expressed and purified the PGD-IGFBP-2 mutant, which was generated through site 
directed mutation of the wt IGFBP-2 cDNA by Dr G. Allan in our laboratory. The C-terminal RGD 
integrin-binding sequence was mutated to PGD in order to investigate the possible involvement of the 
RGD sequence in IGFBP-2 association with the cell surface. Similarly to the corresponding wt protein, 
PGD-IGFBP-2 was purified on an IGF-II affinity column. Purification steps, as analysed by Coomassie 
blue staining and anti IGFBP-2 Western blot, are shown in Fig 3.2 .c and 3.2.d respectively.
As an example of the degree o f purification achieved with IGF-II affinity chromatography, a silver stained 
gel o f the purification steps of P20A IGFBP-2 is also shown in Fig 3.2.e,
106
Fig 3.2
IGF-II affinity chrom atography purification 
o f rat IGFBP-2
i.c.s ub w l w2 1 2 3 4 5
(b)
IGF-II affinity chrom atography purification steps o f IGFBP-2.
Concentrated insect cell culture supernatant (I.c.s) w as loaded onto the the IGF-II affinity colum n, 
the unbound material (ub) was co llected  and the colum n was w ashed tw ice with the equilibrating  
buffer. Elution was performed with 0.5M  acetic acid and the first 5 fractions were analysed for the 
presence o f  IG FBP-2. Sam ples were taken from each purification step and electrophoresed on a 
12% gel under non denaturing conditions.C om assie blue gel staining is show n in the top picture. 
An anti IGFBP-2 Western blot is shown in the bottom picture.
Fig 3.2.
IGF-II affinity chrom atography purification 
o f PGD-IGFBP-2
SM i.c.s ub w l w2
(d)
250
98
64
IGF-II affinity chromatography purification of PGD-IGFBP-2.
Concentrated insect cell culture supernatant (I.c.s) w as loaded onto the the IGF-II affinity colum n, 
the unbound material (ub) w as collected  and the colum n w as w ashed tw ice with the equilibrating 
buffer Elution was performed with 0.5M  acetic acid and the first 5 fractions were analysed for the 
presence o f  PG D -IG FBP-2. Sam ples were taken from each purification step and electrophoresed  
on a 12% gel under non denaturing conditions.C om assie blue gel staining is show n in the top picture. 
An anti IGFBP-2 Western blot is shown in the bottom picture.
Fig 3.2
P20A affinity chrom atography purification
(e)
SM  i.c.s. ub wl 1 2 3 4 5
P20A-IGFBP-2 purification steps on an IGF-II affinity chromatography 
column.
Concentrated insect cell culture supernatant (i.c .s) w as loaded onto the IGF-II affinity colum n, 
the unbound material (ub) w as collected  and the colum n w as w ashed tw ice with equilibrating  
buffer (the first ml run through the colum n was collected , w l) .  Elution w as performed with 0.5M  
acetic acid and the first 5 fractions (1-5) were harvested. Sam ples were taken from each  
purification step and electrophoresed on a 12% gel under non denaturing conditions.
Protein bands were then detected by silver staining.
The arrow indicates the location o f the putative P20A -IG FB P-2
3.3.Studies on biological features of IGFBP-2
We focused our research on the investigation of possible IGFBP-2 functions other than simple 
inhibition o f IGF action. As already mentioned in the introduction chapter, it is believed that IGFBP 
association to the cell surface could be important for the IGF-potentiating or IGF-independent effects 
described for some IGFBPs (De Mellow and Baxter, 1988, Conover, 1992). Although IGFBP-2 
principally shows an IGF-inhibiting effect (Clemmons, 1997), it has been hypothesised that cell 
membrane-associated IGFBP-2 could in fact facilitate IGF binding to IGF-IR (Guenette and Tenniswood, 
1994). We aimed to establish an experimental model which would allow us to investigate the biological 
role of cell-associated IGFBP-2.
Although IGFBP-2 is produced by many tissues and cell lines, at the time as this study was undertaken, its 
interaction with the cell surface had been described in only a very few cell types.
•  In section 3.3.1 we tried to identify a cell line on which IGFBP-2 binding with the cell surface could 
be demonstrated. Two opposite approaches were followed in these studies: the addition of exogenous 
recombinant rat IGFBP-2 to cultured cells {section 3.3.1. a.), or the detection o f endogenous IGFBP-2 
naturally associated with cell surface (section 3.3.l.b). Membrane-bound IGFBP-2 was demonstrated in 
Clone 9 cells.
•  In section 3.3.2 we then focused on finding a system to reveal Clone 9 cell responsiveness to IGF and, 
at the same time, the influence that soluble or monolayer associated IGFBP-2 exerts on IGF action
•  In section 3.3.3. we constructed a model suitable
-to study biological functions o f IGFBP-2 in Clone 9 cells under basal 
conditions
-or to investigate the specific effect o f cell membrane-associated IGFBP-2 on IGF 
stimulation.
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3.3.1.Studies on IGFBP-2 association to the cell surface
3.3.1 .a Screening different cell types and different methods to detect the 
association of exogenously added recombinant rat IGFBP-2 with the cell 
surface.
In this part of the project we tried to determine if  exogenous recombinant IGFBP-2 could 
associate with the cell surface. Intuitively this would appear the most direct way to demonstrate such 
binding and many studies published on IGFBP-3 and -5 association with the cell surface (Smith et al:, 
1994; Karas et al., 1997; Yang et al., 19% Abrass et al. 1997; Andress, 1998) or to ECM (Parker et al., 
1996; Arai et a l ,  1996) utilised this approach. To our knowledge no published reports demonstrated 
evidence o f exogenous IGFBP-2 binding to membranes o f cultured cells, but we had no reason to believe 
this technique would be unsuitable for this purpose. Moreover, if  radioactive IGFBP-2 was used as a 
probe, the method could achieve the sensitivity necessary to detect the very small amount of binding 
protein that we expected to be associated with the cell surface. On the other hand, a possible drawback of  
this method could be that in cell lines naturally producing IGFBP-2, cell surface binding sites could be 
already saturated by the endogenous protein.
Unexpectedly, we found many difficulties associated with the use of recombinant IGFBP-2 and we failed 
to obtain convincing proof o f exogenous IGFBP-2 binding to cell surfaces. Therefore, here (table
3.3. La. 1-5) we present only a brief description of the rationale and results of the experiments which 
represent to a large extent attempts to overcome technical problems. A detailed description of every single 
experiment can be found in the Materials and Methods chapter, while an overall discussion o f the results is 
presented at the end of this section.
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Table 3.3. l.a. 1-5
Cell txpe Rationale and Results
EXPERIMENT 3.3.1 .a. 1 Use o f  an im m unohistochem ical technique (anti IG FBP-2 antibody) 
to d e tec t recom binant rIGFBP-2 o r  P G D -IG F B P-2 m utant binding to D x3 ce ll m onolayer
Dx3,
human skin melanoma 
cells, express a nP3 and 
a vp3 integrins on the cell 
membrane
This experiment was undertaken as part of studies on IGFBP-2 interaction 
with integrins (Exp. 3.3.1.a.9). Dx3 cells were chosen as, once IGFBP-2 
binding to the cell surface had been demonstrated, it would have been 
possible to further investigate if  and OvP3 integrins were involved in 
IGFBP-2 binding. Use o f an immune detection technique, could 
potentially be exploited to detect membrane association o f both wt and 
PGD IGFBP-2.
Results:
-The addition of recombinant IGFBP-2 or its mutant PGD IGFBP-2 led to 
a background binding which was much higher in cell-free compared to 
cell-coated wells.
Therefore wt or PGD IGFBP-2-binding detected with this method seems to 
be due to a direct association of the binding proteins to tissue culture 
plastic.
EXPERIMENT 3.3 .l .a .2 . 1251 IG FBP-2 binding to  A 1 0  a n d  Clone 9  ce ll surface in 
com petition with co ld  IGFBP-2
A10,
rat smooth muscle cells
Clone 9,
adult rat liver cells
Both cell lines naturally 
secrete IGFBP-2
IGFBP-2 association with the cell surface had been described in the 
literature to a limited extent (Reeve et al., 1993, Russo et al., 1997). In 
both cases, IGFBP-2 was endogenously produced by the cells. We thought 
that an IGFBP-2 secreting cell line may be more likely to express also the 
appropriate binding sites on the cell surface 
Results:
-The background o f IGFBP-2 tracer bound to plastic was higher than the 
amount of tracer bound to cells.
-Cold IGFBP-2 did not displace the tracer.
-To test the method, we also tried to detect1251 IGF-I tracer binding to cell 
membranes (IGF receptors (including possible IGFBPs associated to the 
membranes). In this case i) cold IGF-I effectively competed the tracer 
binding and ii) the back ground radioactivity was slightly lower in the 
absence than in the presence of the cells.
EXPERIMENT 3.3. l.a . 3 S tripping endogenous IG FBP-2 po ten tia lly  bound to the cell 
m em brane before incubating the cells with 125I  IGFBP-2
A10
Clone 9
The inability to detect any binding of IGFBP-2 tracer to the cell surface 
could be due to the saturation of the binding sites by endogenous IGFBP-2 
(especially in Clone 9 cells where IGFBP-2 secretion is high).
Results
-Despite stripping treatment, tracer bound in the presence of cells did not 
exceed tracer background bound to plastic.
-Cold IGFBP-2 was unable to displace the tracer
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Cell type Rationale and Results
EXPERIMENT 3.3.1. a. 4.1251 IGFBP-2 binding to cell monolayers cultured on positively charged 
plates
Clone 9 It has been described that positively charged plates reduce the background
binding of IGFBP-5 to plastic surface to <3%, compared to 15% for 
negatively charged plates (Jones et al, 1993). We tested if  these plates 
were suitable to reduce also 125I IGFBP-2 binding background
Results
-background of IGFBP-2 tracer bound to positively charged plastic was 
still higher than the tracer bound to cell monolayer 
-Cold IGFBP-2 was unable to displace tracer.
EXPERIMENT 3.3. l.a. 5 1251 IG FBP-2 binding to cells in suspension
To reduce the background tracer binding to plastic plates and increase the 
cell surface available, cells, scraped from dishes and resuspended at high 
density in tubes, were incubated w ith1251 IGFBP-2 tracer in the presence 
or absence of cold IGFBP-2
Results
-background o f IGFBP-2 residue in the no-cell tubes was higher than in 
cell pellets containing tubes.
-cold IGFBP-2 was unable to displace the tracer from the cell pellet, 
conditioned medium, 
therefore cell surface 
binding sites may be 
available for tracer 
binding
A10
3T3F442A, 
mouse preadipocytes. 
These cells were chosen 
because they do not 
secrete IGFBP-2 into the
3.3. l.a . 6 1251 IGFBP-2 ligan d  blots on Clone 9 a n d  M C 3T 3-E l cell m em brane preps.
Enriched plasma membrane preparations, obtained from Clone 9 or MC3T3-E1 cells as described 
in Materials and Methods, were electrophoresed on a 10% gel and blotted. After transfer, membranes were 
probed with radio-labelled IGFBP-2 and exposed to direct autoradiography (Fig 3.3.1 .a6 ). To test i f  the 
method was suitable to detect proteins known to be IGFBP-2 binders, an anti-IGFBP-2 antibody was 
included as a positive control. No obvious band appeared at 150kDa, although in a previous 7.5% gel (data 
not shown) the anti IGFBP-2 antibody was revealed as one major 150kDa band and 2 fainter bands with 
higher Mr. Conversely, in both Clone 9 and MC3T3-E1 ECM tracks, the IGFBP-2 tracer clearly detected 
a doublet o f approximately 34-36kDa. The different intensity o f the bands in the two cell types could be 
due to different protein concentration in the membrane preps or to a difference between cell types. It is o f
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Fig i .i .y .a .6
125 IIGFBP-2 ligand blot of 
Clone 9 and MC3T3-E1 plasma membranes
SM a B P 2  Clone 9 M C 3T3
1251 IGFBP-2 Ligand blot o f CIone9 and MC3T3-E1 
plasma membranes.
M em branes were prepared as described in M ats & M eths, 
electrophoresed in a 10% gel and blotted onto H ybond C -extra 
m em branes. Blots were further processed for ,2:>I IGFBP-2 ligand 
blot and finally exposed to an autoradiograph film  for 10 days.
An anti IGFBP-2 antibody was included as a control o f the method. 
The arrow indicates the expected position o f  the anti IGFBP-2 
band (aB P-2).
interest that, among several other bands, a 34-36kDa doublet was also visible with Ponceau S staining. If 
the double band displayed by IGFBP-2 ligand and by Ponceau S staining represented the same protein/s, 
the abundance o f this protein would be high. Furthermore, in the other half o f the same blot, lpg/m l of 
cold IGFBP-2 was included during incubation with 125I IGFBP-2, but no competition was observed (data 
not shown) suggesting that perhaps the binding o f the tracer to these 2 bands was not specific.
In conclusion the nature o f the 34-36kDa doublet protein detected by 1251 IGFBP-2 ligand blot on Clone 9 
and MC3T3-E1 membranes, remains unknown.
3.3 .1 .a. 7 125 I  IGFBP-2 cross-linking to C lone 9 m em branes trea ted  + /-  sodium  chlorate.
As Russo et al. (1997) showed that IGFBP-2 bound to rat olfactory bulb plasma membranes 
through the mediation o f glycosaminoglycans (GAGs), we tried to see if  similar evidence could be 
obtained in Clone 9 cells. We prepared plasma membranes from Clone 9 cells cultured in routine 
conditions or in the presence o f 30mM NaC104. This reagent is known to inhibit membrane GAG 
sulphation which in some cases results in a reduction o f GAG binding capacity (Hoogewerf et al., 1991). 
In order to test if  NaC104-treated plasma membranes showed a reduction in 125I IGFBP-2 binding, both 
normal and treated plasma membranes were incubated with the tracer. In addition, as it was also 
conceivable that membrane association o f 125I IGFBP-2 was mediated by membrane proteins, we added 
DSS, an homobifunctional cross-linking agent, to stabilize this potential binding. Cross-linked samples 
were analysed by electrophoresis performed either under reducing or non reducing conditions. Samples of 
IGFBP-2 tracer alone self cross-linked in the presence or absence o f heparin were also included. With 
these controls we intended to check if  the cross-linking reaction led to the formation o f i) IGFBP-2 dimers, 
whose occurrence during protein purification has been reported (Boumer et al., 1992), or ii) putative 
aggregates between IGFBP-2 tracer and a GAGs, like heparin. The DSS cross-linking agent is active on 
primary amines, therefore it could stabilise IGFBP-2 dimers, i f  present, but it was expected to foil to cross­
link heparin and IGFBP-2. As shown in Fig 3.3.1.a7  under non reducing conditions 125I IGFBP-2 tracer 
migrated as a single band o f approximately 36kDa and no dimer forms were detected. Under reducing 
conditions 125I IGFBP-2 migrated with an apparent Mr o f 34kDa, and two additional bands were apparent. 
One, just below the main 34kDa band, was present in all samples run under reducing conditions. The 
other, an approximately 19kDa band, appeared in all tracks with the exception o f the tracer under non
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Fig 3.3.1.a J
125 I IGFBP-2 cross-linking to 
Clone 9 plasma membranes
C lone9 Clone9  
+
Na chlorate
tracer tracer
+
heparin
C lone9 C lone9 tracer tracer 
+ +
Na chlorate heparin
cross-linked with 1251 IGFBP-2 cross-linked with 125 1 IGFBP-2
Non reducing conditions ELECTROPHORESIS reducing conditions
M em brane preps from  Clone 9 cells cultured in the presence or in the absence o f 
30mM  sodium  chlorate, were cross-linked w ith 125 I IGFBP-2. As control, the 
cross-linking reaction was done with IG FBP-2 tracer alone or in the presence o f 
heparin. Sam ples were then electrophoresed on a 12% gel under reducing or non 
reducing conditions and dried gels were exposed  to direct autoradiography.
reducing conditions. The addition o f heparin to tracer sample during the cross-linking reaction, did not 
change the pattern o f IGFBP-2 tracer bands either under non reducing or non reducing conditions but it 
decreased their intensity. The lower intensity may be explained by the appearance o f a large Mr aggregate 
at the top o f the gel in which the tracer was partially sequestered.
In the tracks o f Clone 9 membranes, irrespective o f  the treatment o f  cells with 30mM sodium chlorate, the 
pattern o f the bands was virtually identical to tracer control lanes. This suggests that the bands shown were 
just a residue o f the added tracer which was not cross-linked, but bound or just physically trapped in the 
membrane pellets or associated to the tube walls and resolubilised in the sample buffer. The most evident 
difference between membrane and tracer electrophoretic patterns was the lack o f  the 19kDa band in 
IGFBP-2 tracer (with or without heparin) run under non reducing conditions. The only other difference 
between tracer and membrane lanes was the presence, at the top the gel o f all membrane tracks in both 
reducing and non reducing conditions, o f a large Mr aggregates. We conclude that IGFBP-2 cannot be 
cross-linked to Clone 9 membranes by using DSS.
3.3. J.a.8  P relim inary study to de tec t exogenous/endogenous IG FBP-2 binding to Clone 9 cell 
extracellu lar m atrix
In the first part o f this experiment we simply compared 125I IGFBP-2 binding to ECM coated or 
empty wells. Positively charged plates were utilised for this experiment and Clone 9 and MC3T3-E1 ECM 
coated wells were prepared from cell monolayers as described in the Materials and Methods section. After 
a 48 hour incubation with 125I IGFBP-2 and following extensive washing o f the plates, residual 
radioactivity was extracted either with IN NaOH or with 2% SDS and determined by y counting (data not 
shown). No differences in 125I IGFBP-2 binding to the two ECM types, nor between the reagents used to 
remove the radioactivity, were observed. Despite the use of positively charged plates, the background 
radioactivity associated with the plastic was higher than the radioactivity associated with the ECM, 
therefore it was impossible to draw any information on IGFBP-2 binding to Clone 9 and MC3T3-E1 
ECM.
In the second part o f the experiment, we investigated i f  any endogenous IGFBPs were present in 
Clone 9 ECM and, if  this was the case, what kind o f ECM molecule IGFBPs were bound to. Clone 9 cell
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monolayers were sequentially treated with 0.5% TritonX-100 to solubilize the cell membranes and with 
25mM NH4 acetate pH9.0 to eliminate nuclei and cytoskeleton. Finally, the extracellular matrix was 
extracted with non reducing Laemmli sample buffer. Samples from each step o f ECM preparation and 
samples o f concentrated Clone 9 membrane preparation were electrophoresed, blotted and further 
processed for 125I IGFBP-2 or 125IIGF-I ligand blots as shown in. Fig 3.3.1. a  8  a and b respectively.
With the 125I IGF-I ligand blot we aimed to detect the presence o f natural IGFBPs possibly present on 
Clone 9 ECM. This experiment is presented in this section because the same samples were also analysed 
by 125I IGFBP-2 ligand blot in the attempt to detect the ECM molecule capable o f binding the tracer. We 
considered that it would be informative to compare the results obtained by the 2  techniques side by side. 
As shown in Fig 3.3.1.a. 8 b (right hand side blot), radiolabeled IGF-I in both 0.5% Triton-extracted 
membrane and ECM preparations bound to a low Mr band (<30kDa), possibly an IGFBP proteolytic 
fragment with residual IGF-binding ability. In the ECM track a fainter but distinct double band, that 
migrated at approximately 32-34kDa, appeared and a feint shadow suggests it was possibly present also in 
the plasma membrane track. The band size, which corresponds to IGFBP-2, and the feet that IGFBP-2 is 
the only binding protein detectable in Clone 9 conditioned medium (CM) by ligand blot, suggests that this 
double band might represent, at least in part, IGFBP-2. However, we cannot exclude that the double band 
detected by 125I IGF-I tracer represents an IGF-binding protein species, distinct from IGFBP-2, which is 
undetectable in CM, but is associated with Clone 9 cell membranes or ECM.
After the demonstration in Clone 9 ECM of an IGFBP, which we believed to be IGFBP-2, we attempted 
to identify the ECM molecule capable o f IGFBP-2 binding, by 125I IGFBP-2 ligand blot. The blot was 
divided in two halves and incubated with IGFBP-2 tracer in the presence or in the absence o f cold IGFBP- 
2. As shown in Fig 3.3.1. a. 8.a), the left half membrane gave an image identical to the right part, but 
fainter as tracer binding was specifically competed by cold IGFBP-2. Along with samples o f ECM 
preparation steps, a control sample o f concentrated Clone 9 plasma membranes was included. 
Concentrated and 0.5% Triton-extracted membrane samples showed a very similar pattern, confirming the 
efficiency o f  the treatment with the detergent. In these tracks 125I IGFBP-2 detected a multiplicity o f  
bands, amongst which three darker areas appeared at about 50kDa, 34kDa and 28kDa. No bands were
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detectable in NH^acetate-extracted samples corresponding to Clone 9 nuclei and cytosketelons. In the 
ECM sample track a distinct double band o f approximately 32-34kDa appeared.
Interpretation o f the bands detected by 125 I IGFBP-2 ligand is not easy as the use of this technique to 
identify IGFBP-2 binding molecules within a complex protein mix, such as membrane or ECM 
preparations, is novel and does not give guarantees on detection specificity. As will be discussed later, it 
was surprising to observe that 125I IGF-I and 125I IGFBP-2 ligand blots gave virtually the same picture.
3.3.1. a. 9 Integrin binding studies
Table 3.3. l.a .9  summarises preliminary studies undertaken to investigate the interaction between IGFBP-2 
and integrins.
Cell type Description of the experiment
EXPERIMENT 3.3. l.a.9 a Fibronectin binding assay on K562 cells using IGFBP-1 as competitor
K562. The ability o f IGFBP-1 to inhibit K562 cell adhesion
erythroleukemia cells, express asPi integrin to fibronectin coated wells was tested 
on the cell membrane
EXPERIMENT 3.3.1. a. 9 b Cell adhesion test on IGFBP-2 and IGFBP-1 coated plates
Dx3, The ability o f Dx3 cells, which express a wider range
human skin melanoma cells, express a nP3 o f integrins on their surface, to adhere to IGFBP-1 or
and OvP3 integrins on the cell membrane IGFBP-2 coated wells was tested
In order to establish if  the fibronectin binding assay was a suitable method to investigate IGFBP-2 
interaction with integrins, IGFBP-1, which is known to bind to a 5Pi integrin, was utilised in a preliminary 
study. The fibronectin binding assay is based on the ability o f various molecules to inhibit cell adhesion on 
a fibronectin substrate by binding and occupying cell surface a 5Pi integrin (fibronectin receptor). 
Undifferentiated K562 human erythroleukemia cells were employed as they express as Pi integrin (Conrad 
et al., 1994; Zheng et al., 1994). In addition to IGFBP-1, an RGD containing peptide and an anti P! 
integrin subunit antibody were used as competitors of cell attachment, while an RGE containing peptide 
and a mouse isotype antibody were used as negative controls. Duplicate values and the pattern o f the 
positive controls were not consistent (except for RGD peptide which clearly inhibited cell attachment)
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(Data not shown). Therefore no conclusions could be drawn on the effect o f IGFBP-1 on K562 cell 
adhesion to fibronectin coated plates under our experimental conditions.
These experiments were highly consumptive o f reagent, as inhibition of cell adhesion requires microgram 
quantities of competing protein. Therefore a different approach was attempted in the next series of  
experiments
In this case Dx3, a cell line derived from a human melanoma, was chosen because it expresses a wider 
range of integrin receptors, including a nPi and 0 1 ^ 3  (vitronectin receptor) integrins (Helfrich et al., 1992; 
Townsend et al., 1999) and therefore could be more suitable for the initial screening. The ability o f  the 
cells to adhere directly to IGFBP-2 or IGFBP-1-coated wells was tested. We found no differences in the 
number o f cells attached on plastic alone or on IGFBP-1 or IGFBP-2 coated wells.
3.3.l.a. 10 DISCUSSION
The common feature o f the experiments presented in this section was the attempt to identify 
IGFBP-2 association to plasma membranes or ECM by the addition o f exogenous recombinant protein. 
The experiments described above failed to provide a conclusive answer on this matter and a general 
discussion of all results will be presented
Negative results could be due to the inability o f IGFBP-2 to bind to cell membrane/ECM in the cell lines 
tested, because the binding sites were either absent, or saturated by endogenous IGFBPs. Alternative 
explanations could be that IGFBP-2 binding to cell surface/ECM could have occurred if  different 
experimental conditions (incubation buffers, time and temperature) had been employed, or that it did 
occur, but the analytical methods we adopted failed to detect it. As no reports were available in the 
literature, we tested IGFBP-2 association to the cell surface by using the same conditions described for 
IGFBP-3 and IGFBP-5. It should be pointed out that even in the case o f IGFBP-3, whose ability to bind to 
the cell surface is well documented in the literature, only 6-9% o f the added 125 I IGFBP-3 binds to cell 
monolayers o f fibroblast and rat glioma cells (Yang et al., 1996). Therefore, the use o f the correct 
experimental conditions might be crucial to the success o f  the experiment.
One o f the major technical problems was that the background binding o f IGFBP-2 to plastic plates or 
tubes was higher in the absence than in the presence o f cell membrane or ECM preparations. Therefore,
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although specific binding o f recombinant IGFBP-2 to cell membrane/ECM could possibly occur, it would 
be undetectable, as it would be masked by the high background. Despite this high background problem, 
when radiolabelled IGFBP-2 was used as a probe, an indication of binding specificity could be deduced if  
cold IGFBP-2 displaced the tracer in a dose dependent manner. Unfortunately, in most cases the addition 
of cold IGFBP-2 foiled completely to affect tracer binding. This could have happened because IGFBP-2 
tracer binding was not specific in the first place or simply because o f the presence on the plastic surface of  
a large amount o f unsaturated binding sites, which would sequester cold IGFBP-2 and prevent it from 
competing the tracer. An alternative explanation may be that the concentration o f cold IGFBP-2 estimated 
to be 10-50 fold higher than tracer concentration might not be sufficient for displacement. Russo et al. 
(1997), showed IGFBP-2 associated to olfactory bulb cell membranes through GAGs. Protein interaction 
with GAGs can range from high to low affinity and specificity (Kjellen and Lindahl, 1991), but is 
generally a high capacity type o f binding, due to the relative abundance o f GAG compared to the ligand. 
As a consequence, displacement o f the IGFBP-2 tracer might require an extremely high concentration of  
cold protein. As already mentioned in table 3.3.1.a., when we incubated Clone 9 and A10 monolayers with 
125I IGF-I to test if  the method was able to detect specific binding, we obtained tracer binding only slightly 
higher than the background, but the addition o f cold IGF-I successfully competed the tracer.
Many different methods have been used in an attempt to overcome the problem outlined above.
1) The use o f positively charged (Primaria) plates has been described to reduce the background 
binding o f IGFBP-5 to plastic (Jones et al, 1993a), but it did not appear to resolve the problem in our case 
(Exp. 3.3.1.a.4 and 3.3.2.a.8). Similarly, Parker et al. (1996) demonstrated IGFBP-5 binding to fibroblast 
ECM prepared on Primaria plates, but recently reported that non specific binding o f IGFBP-5 to pSM cell 
ECM coated plates was as high as 50% and consequently they developed an extraction method to 
overcome the problem (Parker et al., 1998).
2) In order to increase the ratio between cell membranes and plastic surface available for tracer 
binding we incubated 125I IGFBP-2 tracer with a high density A10 or 3T3F442A cell suspension instead of 
cell monolayers (Exp. 3.3.1.a  5). After discarding the radiolabelled IGFBP-2 supernatants, residual 
radioactivity in plastic tubes did not vary in the presence or in the absence o f cell pellets. The addition of 
cold IGFBP-2 during the incubation of cells with tracer was unable to compete 1251 IGFBP-2 binding. In
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conclusion, we were unable to demonstrate IGFBP-2 binding to the plasma membrane o f A10 and 
3T3F442A cells although we cannot exclude that the binding did occur.
3) Saturation of cell surface binding sites by naturally produced IGFBP-2 could be responsible 
for the failure o f exogenous IGFBP-2 to bind to the cell surface. Therefore we tried to use a cell line 
which does not produce IGFBP-2 (ExpJ.5. l.a. 5) and, in addition we tried to strip the endogenous protein 
from plasma membranes o f cells that naturally produced IGFBP-2 (Exp. 3.3. l .a  3).
Previous work carried out in our laboratory demonstrated that in 3T3F442A cell conditioned medium the 
principal IGFBP detectable by 125 I IGF-I ligand blot was a 40kDa protein (which co-migrated with 
IGFBP-3 bands in mouse serum control), followed by a 24kDa IGFBP (probably IGFBP-4, which co­
migrated with a mouse serum control). No proteins co-migrating with the 32kDa IGFBP-2 band o f mouse 
serum were found in 3T3F442A conditioned medium by ligand blotting. Therefore, we considered that 
these cells could be used as a control cell line to test IGFBP-2 binding to cell membranes in the absence of 
endogenous protein. Again, the high background o f radioactive IGFBP-2 bound to plastic made the results 
uninterpretable. We cannot exclude the possibility that endogenous IGFBP-3 might be associated with 
3T3F442A cell membranes and compete with IGFBP-2 binding. This would imply that IGFBP binding to 
cell membranes is not specific. Testing this hypothesis was beyond our purpose and we did not pursue the 
investigation further.
As the only reports o f IGFBP-2 association to cell membranes available in literature referred to 
the detection o f the endogenous proteins, in rat olfactory bulbs (Russo et a l., 1997), and a small cell lung 
cancer (SCLC) cell line (Reeve et al, 1993), we focused our research on IGFBP-2 producing cell lines. We 
hypothesised that IGFBP-2 secreting cells might be more likely to express specific IGFBP-2 binding sites 
on their membranes, though these studies by Russo and Reeve showed that IGFBP-2 secretion by the cells 
did not necessarily imply its association to the membranes.
To test i f  IGFBP-2 binding to Clone 9 and A10 cell membranes might be inhibited by 
endogenous IGFBP-2 that had saturated the available binding sites, we treated the cell monolayers with 
20mM sodium acetate, pH4 and 2M NaCl as described by Andress (1995) for stripping IGFBP-5 from 
mouse osteoblasts. Once more, after the stripping treatment and incubation with 125I IGFBP-2, the amount 
of tracer bound to the cell monolayer failed to exceed the radioactive background measured in cell-free
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wells. No differences were observed between the two cell lines, or when cold IGFBP-2 was co-incubated 
with the tracer.
Although the results o f the first group o f experiments (from 3.3. l.a. 1 .to 3.3. l.a .5) were 
uninterpretable due to the high background binding o f 125 I IGFBP-2 tracer to plastic, we had evidence 
(from experiments that will be presented in section 3.3. l.b )  that endogenous IGFBP-2 was associated to 
cell membranes. Therefore we examined i f 1251 IGFBP-2 would be better exploited as a probe on protein 
blots or in cross-linking experiments.
In a preliminary experiment (data not shown), we assessed if  the 1251 IGFBP-2 ligand blotting 
technique was suitable for detecting an IGFBP-2 binding molecule by including in the gel an anti IGFBP- 
2 antibody as a positive control, along with A10 and Clone 9 membrane samples. As the antibody control 
displayed a faint band at the expected size and the membrane samples also showed a band at the edge of  
the migration front, we were encouraged to repeat the experiment at a higher %  acrylamide gel. We 
attempted to employ the 125I IGFBP-2 ligand blotting technique to identify a putative IGFBP-2 binding 
molecule on Clone 9 and MC3T3-E1 cell membranes (Exp. 3.3.1.a.6  and 3.3.1.a8), but results were not 
completely consistent and difficult to interpret. In Fig 3.3.1.a.6  a doublet of approximately 34-36 kDa 
represents the only band detected by ,25I IGFBP-2 in each membrane track. The incubation o f the other 
half o f the blot with cold IGFBP-2 failed to compete the tracer (data not shown). In Fig 3.3. l.a.8.a, 
IGFBP-2 tracer detected many protein bands in both concentrated or 0.5% Triton extracted Clone 9 
plasma membrane tracks. Moreover, tracer binding was specifically competed by high concentration of 
cold IGFBP-2 (25ug). Some o f the differences between the two experiments can be explained, as the 2 
blots are not directly comparable. In feet in Fig 3.3. l.a .6  the membrane proteins were electrophoresed on a 
10% g e l , while in Fig 3.3.1.a.8 a) a 12% gel was used. The 28kDa protein band was possibly absent on 
the 10% gel due to its small size. Also, it is possible that the 50 kDa band present in the 12% gel might be 
undetectable in the 10% blot due to the darker background o f the film (two different film types were 
used). In Fig 3.3.1.8 a the doublet 32-34 kDa band detected by IGFBP-2 tracer in the membrane samples, 
was also present on the ECM sample track. It is surprising to note that when the same ECM preparation 
samples that were used for 125I IGFBP-2 ligand blots, were probed with 125I IGF-I (shown on the right 
hand side, Fig 3.3. l.a .8 b) a very similar picture was produced.
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No convincing conclusions can be derived from these experiments.
An interesting interpretation o f these results may be that, despite a small difference in 
electrophoretic migration which could be explained by experimental variability, the 36 or 34kDa bands 
(single or double), detected with both IGF or IGFBP-2 ligand blotting techniques might represent the same 
protein/s and, more precisely, endogenous IGFBP/s present in membrane or ECM samples. This would 
imply that 125I IGFBP-2 binds to blotted IGFBPs (including IGFBP-2). The hypothesis could be tested by 
including an IGFBP-2 control in the blot, but such a control is not presented as the possibility that IGFBP- 
2 tracer would bind to cold IGFBP-2 was totally unexpected. Moreover, when IGFBP-2 tracer was 
incubated with DSS in cross-linking experiments (Exp.3.3.1.a7), no formation o f dimer/polymer 
aggregates was observed.
Nevertheless, the recurrent appearance o f 34-36 kDa bands in membrane/ECM samples analysed by either 
125I IGF-I or 125I IGFBP-2 ligand blotting (Fig 3.3. l.a .8) is at least a surprising coincidence.
With regard to the IGFBP-2 cross-linking experiment (Exp. 3.3.l .a  7), here we would like to 
explain the rational o f the experiment. Sodium chlorate, which is a potent inhibitor o f sulphate 
adenylyltransferase, reduces sulfation of GAGs, without interfering with their synthesis (Hoogewerf et al., 
1991). NaC104 treatment was reported to effectively reduce binding o f some proteins to cell surfaces 
(Hoogewerf et al., 1991, Roghani and Moscatelli, 1992). Treatment o f cell monolayers or with NaC104 or 
glycanases (heparinase, heparitinase, chondroitinase) are the most commonly used methods used to 
investigate IGFBP interaction with GAGs. Smith et al. (1994) provided some evidence o f  sodium chlorate 
inhibitory effects on recombinant IGFBP-3 binding to Sertoli cell membranes. The only work that 
investigated the nature o f IGFBP-2 binding to plasma membranes (Russo et al., 1997) showed that 
IGFBP-2 binds to rat olfactory bulb cell membranes specifically through chondroitin sulfate and keratan 
sulfate. Contradictory evidence on IGFBP-2 binding to GAGs in vitro have been reported in the literature 
(Arai et al., 1996 Russo et al., 1997). The ability to bind to heparin and other GAGs in vitro has been 
demonstrated for most IGFBP species (Arai et al., 1994a), and, at least for IGFBP-5, it has been shown 
that heparinase treatment decreases the ability o f  the protein to bind to fibroblast ECM (Arai et al., 1996). 
On the other hand, IGFBP-3 and -5 have been shown to interact with proteins (“receptors”) on the cell 
membrane (Oh et al., 1993b; Andress, 1995). It should also be considered that all membrane GAGs,
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except hyaluronic acid, are bound to a core protein to form proteoglycans and protein interaction with 
membrane proteoglycan can involve the carbohydrate and the protein part, as shown in the binding of 
thrombin to thrombomodulin (Kjellen and Lindahl, 1991). Therefore, it cannot be excluded that IGFBP-2 
association with plasma membranes involves both GAGs and proteins (which may be the protein part of a 
proteoglycan). We tested possible protein-protein binding by 125I IGFBP-2 cross-linking to Clone 9 
membranes. As already mentioned in 3.3.1.a.7, the DSS cross-linking agent preferentially links NH2- 
primary amine groups (Partis et al., 1983) and, as we expected, was unable to covalently link heparin 
(included as a GAG control) and IGFBP-2 in a complex o f expected the Mr 38-40kDa. Instead formation 
o f  high Mr aggregates was observed. Although it cannot be excluded that the bands on the top o f  the gel 
contained 1251 IGFBP-2 cross-linked with a high Mr membrane protein, it is more likely that they are non 
specific aggregates commonly observed in cross-linking experiments. If sulfation of GAG was relevant for 
binding, sodium chlorate treatment could decrease the in itia l1251 IGFBP-2 association to cell membranes 
whether it was bound or covalently cross-linked to the membranes. However, we believe that the bands 
shown in Fig 3.3.1.a.7 represent a residue o f tracer physically trapped in the pellet or even derived from 
tube walls irrespective o f the presence o f the pelleted cells. Based on these results any further speculation 
on the role o f GAG sulfation on the interaction o f IGFBP-2 with cell membranes, would be unwarranted. 
Similarly, the investigation on the possible interaction o f IGFBP-2 with integrins remained inconclusive.
3.3.1.b Detection of endogenous IGFBP-2 associated to the cell surface.
3.3. l.b . 1 125I  IGFs cross-linking studies on Clone 9  a n d M C 3 T 3 -E l membranes.
Most o f  the evidence on IGFBP-2 binding to cell surfaces reported in the literature has been 
obtained with an indirect technique, such as cell membrane 125I IGF-I or II affinity labelling and cross- 
linking (Reeve et al., 1993; Russo et al., 1995; Russo et al., 1997; and recently Bradshaw et al., 1999). 
We applied the 1251 IGF-I and IGF-II cross-linking technique to Clone 9 membranes and Fig 3.3.l.b. 1 a 
and b show an autoradiograph o f affinity labeled complexes formed and electrophoretically separated on a 
12% reducing gel. In addition to the size o f the complexes, information on the identity o f  the bands was 
derived from the competition pattern obtained when cold IGF-I, IGF-II, des(l-3) IGF-I or insulin were 
included during the cross-linking reaction.
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F ig  3.3. l.b. I
125I-IGF cross-linking to Clone 9 cell m em branes
complex
C-l IGF- I * IGFBP 2 IGF-I *
complex
c - l IGF-II* IGFBP-2- IGF-II*
400ug o f  C lone 9 membranes were cross-linked with 125 I IGF-1 (Fig a) or II (F ig b)in the 
presence or in the absence o f  lug/m l cold IGF-I, d e s ( l-3 )  IGF-I. IGF-II or lOug/ml insulin. 
Control sam ples o f  IGF tracer cross linked in the absence (c-l IGF-I. c-l IGF-II) or in the 
presence o f  IGFBP-2 were included.
Affinity labeled sam ples were electrophoresed on a 12% gel under reducing conditions 
and dried gels w ere exposed  directly to autoradiographs or analyzed with the phospho-im ager.
125I IGF-I cross-linking, in the absence o f  cold competitors, showed a major 36kDa and a 130kDa 
band. The latter likely represents the complex between tracer and IGF-IR a  subunit as it has the expected 
size and is competed by cold IGF-I, IGF-II, des(l-3)IGF-I and insulin. All these peptides are known to 
bind to the IGF-I receptor, although IGF-II and insulin have a 10 and 500 fold reduced affinity 
respectively (Nissley et a l ,  1991). The major band detected by the tracer, in the absence o f competitors, 
migrated with an apparent Mr o f approximately 36kDa and it was accompanied by a fuzzy shadow just 
above it (38kDa). These bands are believed to represent the complexes formed between radiolabelled IGF- 
I (7.5 kDa) and cell surface associated IGFBPs. The competition pattern obtained in the presence o f cold 
IGFs, IGF analogue or insulin, supports this hypothesis. The appearance o f the 38kDa band was inhibited 
by cold IGF-I and II, but not by insulin, which does not bind to IGFBPs. Des(l-3)IGF-I, which has a 50 
fold reduced affinity for IGFBPs (Heding et al., 1996, Oh et al., 1993a), did not compete with 
radiolabelled IGF-I. Interestingly, in the presence of the IGF-I analogue, the band appeared more intense 
and defined, and migrated with a slightly higher Mr (similarly to the 38kDa shadow that was evident when 
the tracer was used in the absence o f  any competitor or competed by insulin). As a control for the cross- 
linking reaction, 1251 IGF-I was incubated with DSS in the presence or in the absence of recombinant rat 
IGFBP-2. IGF-I tracer alone did not form any complex (and the only band evident in the lane is the one 
corresponding to the tracer itself which can also be seen in all other tracks), while the 1251IGF-I-IGFBP-2 
cross-linked complex migrated as a double band o f about 38-40kDa.
In the 125I IGF-II cross-linking blot, a high background, probably due to the quality o f IGF-II 
tracer, makes it more difficult to distinguish the bands clearly, but a very similar competition pattern is 
apparent. Again 125 I IGF-II cross-linked with a protein o f a high Mr (130 kDa), whose appearance was 
competed by cold IGF-I, -II, des(l-3)IGF-I and partially by insulin. The 36kDa band was the major band 
detected and it was inhibited by cold IGF-I and -II, but not by insulin and des(l-3)IGF-I. Again des(l-
3)IGF-I produced a band shift from 36 to 38 kDa. 1251 IGF-II incubated with DSS did not produce any 
complex, whereas when cross-linked with IGFBP-2 a single 40 kDa band was evident.
In conclusion, 1251 IGF-I and IGF-II cross-linking experiments were able to detect at least one 
IGFBP (o f estimated 30-32 kDa) associated with Clone 9 cell membranes.
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3.3. L b .2 D etection  o f  IG FBP-2 a sso c ia ted  to Clone 9  m em branes b y  125I  IG F -I ligan d b lo t an d  
anti IGFBP-2 W estern blot.
Proteins in Clone 9 plasma membrane preparations were separated by electrophoresis and 
transferred to a membrane which was subsequently cut in two halves in order to be differentially 
processed for 125 IGF-I ligand or anti IGFBP-2 Western blot (respectively a) and b) in Fig 3.3.l.b .2). 125I 
IGF-I tracer clearly identified a band with the same electrophoretical characteristics as the recombinant 
rIGFBP-2 control (34kDa), and another fainter band just below it. The highest radioactivity was associated 
with the migration front o f the gel. The presence o f IGF-binding protein species on the cell membranes 
already shown with cross-linking experiments was confirmed by ligand blotting which does not require 
chemical cross-linking o f 125I IGF-I binding to the membrane. The identification o f the binding protein 
species was first attempted with an anti IGFBP-2 Western blot for two reasons: i) IGFBP-2 was the only 
binding protein secreted by Clone 9 cells in CM, ii) the protein detected on 1251 IGF-I ligand blots showed 
the same electrophoretical characteristic as the IGFBP-2 control. The anti IGFBP-2 antibody displayed 
only a diffuse reactivity at 36 and 32kDa in the Clone 9 membranes lane. Fig 3.3.1.b.2b,2 shows another 
anti IGFBP-2 western blot on a crude preparation o f Clone 9 cells. In this case the band shows a more 
distinct shape, but it is faint. This figure also shows that the IGFBPs found on the cell surface are not a 
contamination from soluble binding proteins possibly present in the supernatant.
While comparing ligand and Western blotting autorads at different exposure times, it was noted 
that the two methods had equivalent reactivity for the IGFBP-2 control, but that the anti IGFBP-2 
antibody had a lower sensitivity than the IGF-I tracer for the 36kDa membrane protein. This led us to 
hypothesise that the image obtained in IGF-I ligand blots could be either due to a totally different IGFBP 
or it could represent the sum o f overlapping IGFBP bands with similar electrophoretic mobility. Excluding 
IGFBP-3 (a doublet o f around 40kDa) and IGFBP-4 (a 24-28 kDa doublet), IGFBP-1, 5, or 6  can all 
migrate similarly to IGFBP-2 in electrophoresis. As Clone 9 cells are a rat liver cell line and hepatocytes 
have been reported to secrete principally IGFBP-1 and 2 (Menuelle et al., 1995; Scharf et al., 1995; Hazel 
et al., 1998), we sought to further analyse the membranes used in ligand blots in an anti rat IGFBP-1 
Western blot (data not shown). This antibody, which in a previous experiment was able to recognise 
IGFBP-1 in the CM o f a rat hepatoma cell line (H411E), failed to detect any bands in the Clone 9
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Fig 3.3.l.b.2.b.2
IGFBP-2 associated to Clone 9 cell membrane
Anti IGFBP-2 Western blot
IGFBP-2 super C lone9 
m em br
The picture shows an anti IGFBP-2 western blot o f a sample o f Clone9 
m em brane preparation and an equivalent volum e o f the supernatant derived 
from the last centrifugation step o f m em brane preparation. Sam ples were 
First electrophoresed on a 12% g e l , blotted and then processed for 
W estern blotting. (Anti IGFBP-2 at 1:2000 dilution; anti rabbit-H RP 
second antibody at 1:5000 dilution)
Fig 3.3.1.b.2.b3
125IGF-I ligand blot of Clone 9 cell 
conditioned medium
125IG F-I ligand blot o f  C lone9 cell conditioned medium. The picture show s a single  
IGF-binding protein species o f  approximately 32kDa. A sm aller fragment (20kD a approx.) 
is also evident.
(from  Dr J. Beattie, with perm ission)
membrane track, and did not react with the IGFBP-2 control. As will be shown in the following 
experiments we also tested anti IGFBP-5 with Clone 9 membrane associated binding proteins.
Repeated analysis o f  Clone 9 cell conditioned medium by ligand blotting over a period o f several 
years in our laboratory has revealed only one major binding protein species at Mr o f approximately 32kDa 
(Fig 3.3.1.b.2.c). This band has never presented as a doublet and this protein corresponds to IGFBP-2, as 
identified by Western blotting (data not shown). In addition, using an “in house” anti-IGFBP-5 antibody 
we have no conclusive evidence for the presence of IGFBP-5 in medium conditioned by Clone 9 cells.
In conclusion, the presence o f Clone 9 membrane-associated IGFBPs was confirmed in 125 IGF-I 
ligand blots. Anti IGFBP-2 Western blots suggested that IGFBP-2 could be present as one o f the species.
3.3.1. b. 3 Anti IG FBP-2 a n d  5 im m uno-precipitation(IP) o f  so lu b ilized  Clone 9 a n d  M C3T3-E1  
mem branes. D etection  o f  p rec ip ita ted  pro tein s b y 125I  IG F -I ligan d blot.
Solubilized Clone 9 and MC3T3-E1 membranes were immuno-precipitated with anti IGFBP-2 or 
anti IGFBP-5 antibodies and the immune complexes were pelleted with Pansorbin. Immuno precipitated 
IGFBPs were detected in 125I IGF-I ligand blots (Fig 3.3.1.b.3.a and 3.3.l.b .3.b). A sample o f crude 
membrane preparation (i.e. non immune precipitated), and recombinant rIGFBP-2 or rIGFBP-5 were also 
included. Recombinant rIGFBP-2 (non immune-precipitated), migrated as a single band o f 34kDa, 
recombinant rIGFBP-5 migrated as an equally intense doublet o f 33-35kDa. In the literature IGFBP-5 has 
been reported either as doublet or as a single band (Camacho-Hubner et al., 1992; Tonner et al., 1997). 
Whether the two bands result from different IGFBP-5 transcripts or postranslational modifications 
(IGFBP-5 is O glycosylated and phosphorylated) or whether they have a different biological functions is 
not known.
In the upper autoradiograph (Fig 3.3.l.b .3%), Clone 9 membranes (non immune-precipitated) directly 
analysed by ligand blotting showed a 34kDa band accompanied by a 28kDa band, substantially 
reproducing the results shown earlier in Fig 3.3.1.b.2.a. After solubilization o f the membranes and 
immuno-precipitation o f cell surface-associated IGFBP with anti IGFBP-2 antibodies, a single 34kDa 
band appeared. This band was more intense than the corresponding band in crude membrane preparations, 
indicating that the immuno-precipitation had a concentrating effect. Anti IGFBP-5 immune precipitated a 
doublet formed by a faint upper band (34kDa) and a more abundant band o f slightly smaller size. No
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Fig 3.3. Lb.3
IP of solubilised Clone 9 and MC3T3-E1 membranes 
followed by 1251 IGF-I ligand blot
a) Clone 9 cells
SM Clone9 - C lone 9 C lone9 _  C lone9 IG FBP-2 IGFBP-5 
m em b Pan sorb me mb me mb
Ab aB P -2  aB P -2  aB P -5  aB P -5
b) MC3T3-E1 cells
SM M C M C M C M C IGFBP-5 IGFBP-2
mem b Pansorb m em b m em b
Ab aB P -2  aB P -2  _  aB P -5  aB P -5
Solubilised m em branes from Clone 9 or M C3T3-E1 cells were im m une- precipitated with 
anti IGFBP-2 or anti IGFBP-5 antibody and pelleted by the addition o f Pansorbin. Sam ples 
were then run in a 12% gel under non reducing conditions. A fter blotting, the m em branes 
were processed for an l23I IGF-I ligand blot as described in M ats.&  M eths.
bands appeared when Pansorbin was incubated with solubilized membranes without the antibodies, nor 
when anti IGFBP-2 antibodies were pelleted with Pansorbin, in the absence of membranes. In the track 
containing anti IGFBP-5 alone a faint reactivity was detectable.
The bottom gel (Fig 3.3.Lb.3.b) shows an identical experiment performed on MC3T3-E1 cell 
membranes used as a control. In this case, the direct ligand blot on the crude plasma membrane 
preparation detected two feint bands at 34kDa and 30kDa while the darkest band was associated with the 
migration front o f the gel. Anti IGFBP-2 antibody was essentially unable to immuno-precipitate any 
proteins from solubilised MC3T3-E1 plasma membranes, nor showed any reaction when precipitated with 
Pansorbin in the absence o f membranes. However, when anti IGFBP-5 antibody was incubated with 
solubilised MC3T3-E1 membranes, it was able to precipitate a doublet which co-migrated with the 
smallest band o f the IGFBP-5 control and resembled the doublet immunoprecipitated from Clone 9 
membranes. However the same, but much less intense, doublet band showed when anti IGFBP-5 antibody 
was precipitated with Pansorbin in the absence o f  membranes, indicating that perhaps some binding 
proteins were present in this antibody preparation and led to a background activity. Nevertheless, the 
presence o f Clone 9 or MC3T3-E1 membranes had a distinct effect on the amount of binding protein 
immuno-precipitated by anti IGFBP-5 antiserum.
In conclusion by anti IGFBP-2 immune precipitation o f solubilized Clone 9 membranes we were able to 
determine, at least, in part the identity o f  membrane associated IGFBPs. The same experiment performed 
with anti IGFBP-5 antibody was more equivocal although it suggests that more than one IGFBP may be 
present on the surface o f Clone 9 cells.
3 .3 .l .b .4 DISCU SSIO N
In this section we presented the results o f studies undertaken to detect endogenous IGFBP-2 
associated with Clone 9 cell membranes.
First, we affinity labelled Clone 9 cell membranes with1251 IGF (cross-linking Exp 3.3. l.b. 1), as 
it seemed to be a well reported method for studies on membrane-bound IGFBP-2. In addition, this 
technique provides a general picture o f all IGF-binding sites available on the cell surface, including IGF- 
IR, IGF-IIR, insulin R and IGFBPs.
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The figures shown (Fig 3.3. l.b. 1 a and b) are representative o f  a series o f cross-linking studies 
we undertook on Clone 9 or on MC3T3-E1 cells. While IGF receptors were always easily revealed, 
detection o f cross-linked complex between IGF tracer and cell associated IGFBPs was only shown 
distinctively by using membrane preparations that were 5 times more concentrated than that reported in 
the literature (80-lOOpg/pl). In both IGF-I and IGF-II cross-linking experiments, a 36-38kDa complex 
was apparent Although the band migrated slightly fester than theoretically expected (Mr o f 38-40kDa), 
the competition pattern obtained in the presence o f cold des (1-3)IGF-I and insulin indicated that the 
complex was indeed formed by the tracer and an IGFBP. When a high concentration (lOpg/ml) o f insulin 
was added (which has low affinity for IGF-IR and does not bind to IGFBPs), it competed with 125I IGF 
binding to IGF-IR, but it did not displace the tracer from the 36-3 8 kDa band. Similarly, des(l-3)IGF-I, 
which has normal affinity for IGF-IR but reduced affinity for IGFBPs, competed IGF-I/II tracer binding to 
IGF-IR, but not to IGFBP. However, unlike insulin, des IGF-I seemed to cause a small upward shift o f the 
lowest part o f the IGF-IGFBP complex so that the band migrated as a single 38kDa species. The protein 
shift could be simply due to a technical artifact with no biological meaning or it might be an indication o f  
the multiple nature of the 36-38kDa protein species. Des(l-3)IGF-I has reduced affinity for IGFBPs, but it 
still retains a residual binding capacity that can vary for different IGFBPs (Oh et al., 1993 a, Mohan et al., 
1995; Heding et al., 1996). Therefore, i f  the 36 and 38kDa bands represented two different membrane 
associated IGFBPs, it is possible that des(l-3)IGF-I was able to bind to the smaller IGFBP, while it was 
unable to displace the tracer from the larger IGFBP.
Not only was the cross-linking technique useful in detecting membrane associated IGFBPs, but, 
as already mentioned, it also provided information on the IGF receptor profile in Clone 9 cells. In all 
experiments carried out in both Clone 9 and MC3T3-E1 cells, a 130kDa band appeared (Fig 3.3.l .b .l.a), 
which, as confirmed by the competition pattern, represented the a  subunit o f the IGF-IR. Conversely, the 
identification o f the high Mr radioactive band at the top o f gel is not straight forward as its size and the 
competition pattern are not clearly detectable. In a previous experiment, where Clone 9 membranes were 
125I IGF-I cross-linked and electrophoresed on a 7.5 % reducing gel, the Mr o f this band was estimated to 
be approximately 270kDa (data not shown), but unfortunately no IGF-II tracer or cold IGF-II were used at 
that time. A comparison between the competition patterns o f IGF-I and IGF-II cross-linking experiments
125
would be very informative as the two tracers have different affinities for the IGF-IIR. Mr estimates for the 
IGF-IIR ranges between 260 kDa (Sepp-Lorenzino, 1998) and 215kDa, this latter being reported for IGF- 
IIR in Clone 9 cells (Matovcik et al., 1990). Therefore the 270kDa band we detected in 125I IGF-I cross- 
linking experiments might be too large (even after subtraction o f 7.5kDa for tracer Mr) to coincide with 
this IGF-IIR description. It is possible that this band was a 270kDa dimer o f two IGF-IR a  subunits as 
reported by Bradshaw et al. (1999).
The identity o f Clone 9 membrane-associated IGFBPs was, at least in part, clarified with 
immunoprecipitation experiments. Anti IGFBP-2 antibody incubated with solubilized Clone 9 membranes 
precipitated a protein, which displayed the same electrophoretic characteristics as recombinant rIGFBP-2 
and was able to bind 125I IGF-I in ligand blots. When the immune precipitation was carried out with anti 
IGFBP-5 antisera a doublet appeared, with the upper band having the same Mr as IGFBP-2 and the lower 
band slightly smaller. As already noted in paragraph 3.3.l.b .2, the same double band appeared faintly in 
the anti IGFBP-5 alone track, in the absence o f Clone 9/MC3T3-E1 membranes. Although the amount o f  
immunoprecipitated IGFBP indisputably increased in the presence o f membranes, suggesting that an 
additional source of immunoprecipitable IGFBP-5 had been provided, it cannot be excluded that 
membrane components might simply facilitate the precipitation o f immunocomplexes already present in 
the serum. However, the presence on Clone 9 membranes o f an IGFBP, smaller and less abundant than 
IGFBP-2 seems consistent with the pattern o f membrane-associated IGFBPs detected in Fig 3.3. l.b .2.a. 
Moreover the double band detected in 125 IGF-I ligand blots with the ECM preparation o f Clone 9 cells 
seems to support also the presence o f two IGF binding species.
Lastly, though our results show quite clearly the presence of IGFBP-2, and possibly IGFBP-5, on Clone 9 
cell membranes they do not directly prove that the binding proteins are chemically bound to the 
membranes. Plasma membranes were prepared using a method described in the literature for this type o f  
study. Contamination from CM can be excluded as the cell plates were washed three times before cell 
lysis and scraping. In addition, no IGFBPs were revealed in the supernatant from the membrane pellet 
after the last centrifugation using Western blotting. It is a different matter to prove that IGFBP-2 was 
chemically bound to the membranes and not simply physically associated with it. The first section of  
experiments where 1251 IGFBP-2 was used as a probe to detect membrane binding, could have clarified
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this point, but unfortunately the high background binding o f the tracer to plastic rendered the results 
uninterpretable. It may be possible with further research to identify the binding molecule(s) for IGFBP-2 
in Clone 9 cells. As already mentioned, Russo and co-workers (1997) reported that IGFBP-2 in rat 
olfactory bulbs binds to cell surface GAGs, mainly chondroitin and kearatan sulphate, which are the most 
abundantly expressed GAGs on these membranes. First, they demonstrated IGFBP-2 bound to purified 
GAGs in vitro. Then, they showed that in solubilised olfactory bulb membranes, an anti IGFBP-2 
antibody was able to co-immune-precipitate IGFBP-2 associated to a 200kDa molecule, which was 
recognized by anti chondroitin sulphate antibodies in Western blotting. As we had no information on the 
nature o f the GAGs present on Clone 9 membranes, we tried to visualize any coimmunoprecipitated 
protein by reprobing the 125 I IGF-I ligand blot shown in Fig 3.3.J.b.2 a and b with 125 I IGFBP-2. 
Unfortunately, the only band that appeared was the 150 kDa anti IGFBP-2 antibody (data not shown). 
Negative results could be due to the inability o f  125I IGFBP-2 to bind to any co-precipitated protein in 
ligand blots. Alternatively, the conditions (1% Triton, 1% Na cholate) used to solubilize Clone 9 
membranes before the incubation with anti IGFBP-2 may lead to the dissociation o f IGFBP-2 from its 
cognate membrane binder.
In conclusion, in this experimental section we demonstrated that IGFBP-2 is associated with 
Clone 9 cell membranes and we provided some evidence that IGFBP-5 may also be present. In addition, 
we showed that Clone 9 cells express IGF-IR.
3.3.2 Clone 9 cell responsiveness to IGF stimulation.
Once we had demonstrated the association of IGFBP-2 to Clone 9 cell membranes, we needed to 
establish whether Clone 9 cells were a suitable model for investigating IGFBP-2 modulation o f IGF 
action. The first requirement was to demonstrate cell responsiveness to IGFs. Therefore we developed 
both a short term (signal transduction events) and a long term (MTT assay) assay to show IGF 
responsiveness o f Clone 9 cells.
3.3.2.1. Signalling studies
The aim of our signalling studies was simply to identify a measurable effect triggered by IGF 
stimulation. As one o f the earliest events that follows the interaction o f growth factors with their receptors
127
Fig 3.3.2.1.
Tyrosine phosphorylation induced by IGF treatment 
in Clone 9 cells
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1:1000)
is protein phosphorylation o f the receptor and cytoplasmic protein substrates, we tested the effect o f  a 2 - 
lOmin stimulation o f Clone 9 cells with IGF-I, IGF-II, des(l-3)IGF-I or insulin.
In the upper anti-phospho-tyrosine Western blot (Fig.3.3.2.1.a), Clone9 cells were stimulated for lOmin 
with a high (100 ng/ml) concentration o f IGF-I or des(l-3)IGF-I or with (100 and lOOOng/ml) insulin. The 
figure shows very clearly that IGF-I and des(l-3)IGF-I treatment induced the appearance o f a tyrosine 
phosphorylated protein with a Mr o f approximately 180kDa. This band was absent in the control lane and 
it was just detectable in insulin treated cells, surprisingly with no differences whether 100 or lOOOng/ml 
insulin was used. Under our experimental conditions, IGF-I, des(l-3)IGF-I or insulin treatments did not 
seem to stimulate tyrosine phosphorylation o f any other protein, as determined by Western blots.
We then designed a dose-response experiment, in which Clone 9 cells were stimulated for 2min with 1-10- 
lOOng/ml o f IGF-I, IGF-II, and des(l-3)IGF-I. Results are shown in Fig 3.3.2.7b. It can be observed that 
the phosphorylated band was not apparent after stimulation o f Clone 9 cells with 1 and 10 ng/ml IGF-I and 
IGF-II, but both peptides used at lOOng/ml induced phosphorylation o f the 180kDa protein. Conversely, 
lOng/ml o f des(l-3)IGF-I were sufficient to stimulate tyrosine phosphorylation o f this protein, an effect 
which seems to increase at lOOng/ml. We noticed that anti-phosphotyrosine Western blotting could 
occasionally be influenced by non-homogeneous reactivity o f the ECL reagents in different areas o f the 
membrane blots. Therefore it might be misleading to draw definitive conclusions on relative potencies of  
IGF-I and II at lOOng/ml or to exclude that IGF-I could have some effects also at lOng/ml.
The identity o f the 180kDa phosphorylated protein remains unknown. We postulated it could represent the 
activated form o f IRS-I, because one o f the earliest events that follow IGF-IR stimulation by IGF-I is the 
phosphorylation o f the 165-185kDa insulin receptor substrate protein, IRS-I (De Meyts et a l., 1994; Rubin 
and Baserga, 1995). Therefore, we tested this hypothesis by anti IRS-I Western blotting (data not shown). 
Lysate samples from Clone 9 cells, treated +/- lOng/ml IGF-I, II or des (1-3)IGF-I were electrophoresed. 
Unfortunately using a rabbit polyclonal anti-rat IRS-I antibody we were unable to detect a protein o f the 
expected size (165-185kDa). Instead a 95kDa band appeared in all tracks (data not shown).
In conclusion, we found that Clone 9 cell responsiveness to acute IGF treatment could be 
revealed by the induction o f tyrosine phosphorylation o f a 180kDa protein species.
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3.3.2.2. MTT assay
In order to identify other parameters located down stream in the IGF signalling cascade, we tested 
i f  the MTT assay, a metabolic/mitogenic bioassay, was exploitable for measuring Clone 9 cell 
responsiveness to IGF treatment. As explained in the Materials and Methods section the MTT assay 
measures the amount o f yellow MTT, tetrazolium salt, which is transformed to an insoluble, purple, 
formazan compound by metabolically active cells. In Fig 3.3.2.2.a the effects o f  24h incubations of Clone 
9 cells with 5, 50, 500ng/ml of IGF-I, IGF-II or insulin are presented. 8  replicates for no-treatment 
controls and for each dose o f hormone treatment were measured Hormone concentrations are indicated on 
the X axis and the absorbance at 620nm on the Y axis. Each plotted point represents the mean value and 
the standard deviation. In the first experiment it appeared that both IGF-I and des(l-3)IGF-I were potent 
cell stimulators, both active at 5ng/ml. At 50ng/ml their effect increased and it reached a plateau at 
50Qng/ml. Insulin was less potent and did not reach the stimulation level o f the other two growth factors 
even at 500ng/ml. In Fig 3.3.2.2. b are presented the results o f an identical experiment, except that cells 
were allowed to grow for 48h. The picture is similar to that at 24hr, except for a higher activity for insulin, 
which at 500ng/ml, showed the same potency as IGF-I and des(l-3)IGF-I.
Fig 3.3.2.2.c shows a 24 h MTT assay in Clone 9 cells treated with 1, 10 and lOOng/ml of IGF-I, 
des(l-3)IGF-I or IGF-II. In this experiment, insulin treatment was substituted with IGF-II as the direct 
comparison between the IGFs, and the IGF-I analogue, was more relevant for our research. We intended 
to test i f  the apparent difference in cell responsiveness observed between IGF-I and des(l-3)IGF-I 
treatment at 5ng/ml was amplified at lower treatment concentrations (lng/ml). It should be noted that in 
our MTT assay, after hormonal treatment, cells are cultured for 24-48 h. During this time cells grow and 
produce IGFBPs that, accumulating in the CM, can inhibit cell growth stimulated by IGF, but not by 
des(l-3)IGF-I as it has almost no affinity for IGFBP. We considered that 5ng/ml of IGF-I (see 
Fig.5.3.2.2.a) might be almost sufficient to saturate IGFBP binding capacity and overcome their inhibitory 
effect. Indeed, in the 24h assay, IGF-I and des(l-3)IGF-I and IGF-II potency at lng/ml varied remarkably, 
des(l-3)IGF-I being the most potent, followed by IGF-I and finally IGF-II. In particular the difference 
between IGF-I and des (1-3)IGF-I hormone treatment resulted in statistically highly significant results. 
The results o f the MTT assay fo r  the two treatments IGF-I and des(l-3)IGF-I at concentrations o f  lng/ml
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Fig 3.3.2.2 MTT assay  on Clone 9 cells
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and lOng/ml were analysed with MTNITAB version 11.27 using a 2 way ANOVA with replications. The 
interaction between the hormones and the concentrations was significant (P=0.007), indicating that the 
difference between the two treatments is dependent on the concentration. We then performed an 
independent sample t-test to compare the effect o f IGF-I and des(l-3)IGF-I at each o f  the two 
concentrations. The metabolic/mitogenic effect o f  the two hormones on Clone 9 cells, as determined with 
the MTT assay, was significantly different at the concentration o f lng/ml (P<0.001), but not at lOng/ml 
(P=0.071).
IGF-II was less efficient than IGF-I in stimulating Clone 9 cells. This was not surprising as IGF-II 
(compared to IGF-I) has at least 10 times lower affinity for the IGF-IR (Nissley et al., 1991). Moreover, 
IGFBP-2 has been reported to have higher affinity for IGF-II than IGF-I (Rosenfeld et al., 1989; Roghani 
et al., 1991; Oh et al., 1993a). As a consequence IGF-II may be sequestered by IGFBP-2 more efficiently 
and thus interact less with the IGF-IR.
Fig 3.3.2.2.d shows a 48h MTT assay in which Clone 9 cells were treated with l-10-100ng/ml 
IGF-I, IGF-n, des(l-3)IGF-I. Again des(l-3)IGF-I was the most potent peptide in stimulating Clone 9 
cells at all concentrations tested. In this experiment the effect o f IGF-I or IGF-II treatment were 
indistinguishable. Both peptides showed lower potency than des(l-3)IGF-I at each concentration tested. In 
this case the 2 way ANOVA test with replication on IGF-I and des(l-3)IGF-I at 1 and lOng/ml showed that 
the interaction between hormones and the concentrations was insignificant (P=0.542 ), which indicates 
that the difference between desIGF-I and IGF-I was the same no matter what the concentration was. This 
analysis also indicates that the two hormones were different (P<0.001) and that they stimulated Clone 9 
cell growth in a concentration dependent fashion (P=0.010 for concentration effect).
In conclusion Clone 9 cell responsiveness to IGFs can be conveniently measured by 24-48h MTT 
bioassay. The difference between IGF-I and des(l-3)IGF-I treatments can be usefully exploited to derive 
the role o f IGFBPs in modulating IGF action.
3.3.2.3 Characterisation of IGF production in Clone 9 cells
Samples of 48h concentrated CM from Clone 9 cultures were electrophoresed on 16% acrylamide 
gels under non reducing conditions, blotted, and analysed by anti-IGF-I and anti-IGF-II Western blotting 
(Fig 3.3.2.3a and 3.3.2.3. b). In the (upper) anti IGF-I Western blot, a single band, which showed identical
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Fig 3.3.2.S.
Clone 9 cells secrete IGF-I
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Freeze- dried, dialysed and concentrated conditioned m edium  from Clone 9 
cells was run in a 16% acrylam ide gel under non reducing conditions.
Increasing am ounts o f standard IGF-1 and II were also included in order to check the 
cross reactivity o f the antibodies. After blotting, the m em branes were processed for 
W estern blotting using either a  IGF-I (fig a) or a IG F -II (fig b) as the first antibody
migration characteristics as the hIGF-I standard, appeared in the Clone 9 CM lane. In the lanes where 
IGF-I was run at high concentration, a 14kDa Mr band was evident and may represent a peptide dimer. 
However, anti IGF-I antibodies clearly cross-reacted with hIGF-II. Therefore, we tested whether the band 
detected in Clone 9 CM was actually IGF-I or IGF-II with an anti IGF-II Western blot. Anti-hIGF-II 
polyclonal antibody, which does not cross react with human or rat IGF-I (<1%), specifically detected 10- 
100-1000 ng hIGF-II but did not recognise any bands in the IGF-I control or in Clone 9 CM lanes. 
Combining the results o f the two Western blots, we conclude that Clone 9 cells secrete IGF-I, but not IGF- 
II.
3.3 .2 .4  D ISCU SSIO N
The results presented in this section represent the preliminary steps necessary to establish a cell 
model in which the modulation o f IGF action by IGFBP-2 could be studied. Our cross-linking 
experiments demonstrated that Clone 9 cells express IGF-IR and by Western blotting it was demonstrated 
that the cells secrete IGF-I in the conditioned medium. The presence o f most of the elements o f the IGF 
axis (IGF-I, IGFBP/s, IGF-IR and, as reported in the literature, IGF-IIR) indicated that the growth factor 
might play a functional role in the Clone 9 cell line. We found that these cells were responsive to IGF and 
that anti phospho-tyrosine Western blotting and MTT assays were suitable methods to measure the effect 
o f  treatments. Some differences between the two methods should be highlighted.
Protein phosphorylation (paragraph 3.3.2.1) in response to IGF signalling is an acute event, 
which follows a few minutes incubation with hormone and it is principally influenced by the 
affinity/capacity o f  the binding sites available on the cell monolayers and the availability o f signalling 
proteins in the cells. Before hormone treatment, cell plates are washed so that the only IGFBPs present are 
those associated with the monolayer. In Clone 9 cells, des(l-3)IGF-I, at lOng/ml, appeared to be more 
potent than IGF-I in stimulating the phosphorylation o f a 180kDa protein species (Fig. 3.3.2./.b). This 
difference between the two growth factors, which have equal affinity for IGF-IR, might be attributed to 
the inhibitory effect that monolayer associated IGFBPs exert on IGF-I but not on des(l-3)IGF-I. The 
lesser response o f Clone 9 cells to IGF-II treatment in comparison with IGF-I and des(l-3)IGF-I can be 
explained by its reduced affinity for the IGF-IR. In addition, although our charcoal-binding assay data
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disagree, it has been reported that IGFBP-2 affinity for IGF-II is higher than its affinity for IGF-I, 
therefore IGFBPs present on the monolayer could sequester IGF-II from IGF-IR more efficiently.
Unlike anti phospho-tyrosine Western blotting, the MTT assay (paragraph 3.3.2.2) measures a long term 
effect o f  IGF stimulation. After hormonal treatment, Clone 9 cells are grown for 24-48h and their 
metabolic-mitogenic response is directly assessed, without the intervention o f any washing step. As a 
consequence, nutrient concentration in the CM will be gradually reduced, while cell metabolism products 
will accumulate, including secreted IGFBP-2. In this assay, the higher potency displayed by des(l-3)IGF-I 
in comparison to IGF-I analogue might be due to the inhibitory effect exerted on IGF-I by the total amount 
o f  soluble and monolayer associated IGFBPs. Although this assay cannot discriminate between the 
components o f the IGFBP population, it has the advantage o f ease, reliability and ability to detect an IGF 
effect at concentration as low as lng/ml.
Some aspects o f  the MTT assays require elaboration. In both the 24h and 48h MTT assays (Exp. 3.3.2.2. a, 
b, c and d), at low concentrations (l-5ng/ml), des(l-3)IGF-I appeared to be more potent than IGF-I in 
stimulating a metabolic/mitogenic cell response. As already mentioned this could be due to the fact that at 
these concentrations IGFBP-2 exerts its inhibitory effect on IGF-I but not on des(l-3)IGF-I. On the 
contrary, in 24h MTT assays (Exp. 3.3.2.2.a and c) the effect o f the two hormones becomes 
indistinguishable at higher concentrations (10-50-100-50Qng/ml). In the two 48hr assays (3.3.2.2.b and
3.3.2.2. d ) the trend of the cellular response to high doses o f hormone stimulation is not consistent. In Exp
3.3.2.2. b stimulation of Clone 9 cells with 50-500ng/ml o f IGF-I was equivalent to the effect o f des(l- 
3)IGF-I, whereas in Exp 3.3.2.2.d IGF-I remained less potent than des(l-3)IGF-I at all concentrations 
tested, even at lOOng/ml. These differences may be due to experimental variability and more experiments 
would be required to accurately define Clone 9 cell responsiveness at high hormone doses. However, we 
focused our experiments on the ability o f  IGFBP-2 to modulate the effect o f  IGF-I (but not des(l-3)IGF- 
I), and were therefore interested in activity at low concentration of hormone.
The final aim o f our project was to create a modified Clone 9 cell subclone, whose expression of 
endogenous IGFBP-2 was impaired by the expression o f antisense IGFBP-2 RNA. In this respect we 
believe that anti-phosphotyrosine Western blotting and the MTT assays would prove to be suitable in 
order to investigate the effects o f IGF treatment in wt and modified cells. In addition, the finding that
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Clone 9 cells secrete endogenous IGF-I could be exploited to compare the ability o f IGFBP-2 to modulate 
basal cell growth in wt and antisense transfected cells.
133
3.3.3 Development of a cellular model to investigate IGFBP-2 biological functions.
Once we had identified the parameters for measuring Clone 9 cell responsiveness to IGFs, we 
proceeded to isolate a population o f modified Clone 9 cells, whose IGFBP-2 expression would be 
inhibited by using an antisense RNA technique. We intended to compare these modified Clone 9 cells 
with their wt counterparts, in order to clarify some aspects o f  IGFBP-2 biological functions. As controls, 
we transfected Clone 9 cells with sense IGFBP-2 or pcDNA3 vector alone, and we also included 
sense/antisense IGFBP-5, as we were interested to investigate whether the increased or inhibited 
expression o f IGFBP-2 or 5 could differentially affect cell growth or signal transduction.
3.3.3.1 C loning IGFBP-2 an d  IG F B P S  into the pcD N A 3 expression vec to r  in sense/anti sense  
orientations.
Fig 3.3.3.1 shows an EcoRlor Hind III restriction digestion o f recombinant pcDNA3 expression 
vector carrying DNAs for IGFBP-2 or IGFBP-5 inserted in either a sense or antisense orientation with 
respect to the CMV promoter. As IGFBP-2 and IGFBP-5 cDNAs had been cloned into an EcoRl site in 
pcDNA3, the digestion o f the recombinant vectors with the same endonuclease released inserts o f the 
expected size. Digestion with Hind HI was used to check the gene orientation o f the insert in the vector. 
This enzyme cuts the pcDNA3 plasmid once and linearizes it. There is a unique Hind III restriction site at 
the 5 ’end o f the IGFBP-2 cDNA and also at the 3 ’ end o f the IGFBP-5 cDNAs. Therefore it was possible 
to deduce the orientation o f the inserts from the size o f released DNA fragments. The expected fragment 
sizes are summarised in the table shown in Fig 3.3.3.1
It is clear from the data presented in this picture that we had produced recombinant pcDNA3 plasmids 
carrying IGFBP-2 or IGFBP-5 cDNAs inserted in either orientation.
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Fig 3.3.3.1
Cloning IGFBP-2 and 5 in the sense/antisense 
orientation into pcDNA3 expression vector
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3 .3 .3 .2  Prelim inary experim ents to evaluate the grow th  rate in Clone 9  cells transfected with  
sense/an tisense IGFBP-2 or cDNA3 vector alone.
The growth rate o f Clone 9 cells transfected with either sense or antisense IGFBP-2 constructs or 
with pcDNA3 vector alone was assayed in a time course experiment under basal conditions (i.e. in the 
absence o f  exogenous growth factors. For each cell line, the averaged values o f 24 replicates and standard 
deviations at each time point were plotted (Fig 3.3.3.2). On the X axis is indicated the time (from 0 to 72 
hr at 12hour intervals), and on the Y axis is expressed the absorbance measured at 620nm. After an initial 
recovery phase, the three cell lines, show distinct time-dependent growth. We took into account that the 
initial density o f  the cell suspensions used for plating could be slightly different for each o f the Clone 9 
transfected lines. For this reason, we established the MTT reactivity o f each cell line just after cell 
attachment to the plates (time 0 ), and we aimed to calculate the individual growth rates rather than 
comparing the absolute values obtained at each time point. Statistical analysis o f the data was performed 
with GENSTAT 5 version 4.1. using multiple linear regression with groups. The shape o f the growth 
curves was not significantly different (i.e. they were parallel) in the 3 cell populations o f Clone 9 cells 
(transfected with sense/antisense IGFBP-2 or pcDNA vector alone) indicating that the growth rate o f the 
cells was not specifically affected by the DNA constructs used for transfection.
In conclusion, in this preliminary time-course experiment, sense/antisense-IGFBP-2 or pcDNA transfected 
Clone 9 cells, when cultured under basal conditions in 0.1% FBS over a period o f 72hr, show the same 
growth rate (as measured by MTT assay).
3 .3 .3 .3 .1251 IG F -I charcoal binding assa y  on C M  sam ples fro m  Clone 9  cells transfected with  
sense/antisense IGFBP-2 or pcD N A  vector alone.
A preliminary assessment o f the efifect/s that transfection o f Clone 9 cells with different 
constructs had on the expression o f IGFBP-2 was carried out using the charcoal binding assay. Equal 
volumes o f serum-free media conditioned for 24h by Clone 9 cells transfected with sense, antisense 
IGFBP-2 constructs or pcDNA vector alone, were examined for their 125I IGF-I binding capacity. In Fig
3.3.3.3 increasing volumes of CM are indicated on the X axis, while on the Y  axis is reported 125 I IGF-I 
binding expressed as a % o f the blank value, as described in Materials and Methods (paragraph 2.1.3). CM 
from antisense IGFBP-2 transfected cells showed a decreased IGF-binding activity in comparison with
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CM from pcDNA3 or sense IGFBP-2 transfected cells. In addition, sense-transfected cells appeared to 
secrete approximately twice as much IGFBPs into conditioned medium when compared to pcDNA 
transfected cells.
3.3 .3 .4  D ISCU SSIO N
IGF stimulation o f growth has been reported in numerous cell types. In body tissues and many 
cultured cells, endogenous IGFBPs act as modulators o f IGF mitogenic actions. The indirect effect exerted 
on cell growth by treatment with exogenous IGFBPs has also been extensively reported (Jones and 
Clemmons, 1995a). Based on this evidence, it has been postulated, and in some cases demonstrated that, 
both the overexpression or the inhibition o f  expression o f specific IGFBP genes can affect cell 
proliferation. Accordingly, using this hypothesis we tested i f  in Clone 9 cells (a cell line responsive to 
IGF mitogenic stimulation), the inhibition o f endogenous IGFBP-2 expression influenced the rate o f cell 
growth. Preliminary results from the time course experiment presented here (paragraph 3.3.3.2), show that 
under basal conditions (in the absence o f added IGFs), the transfection o f  Clone 9 cells with either 
sense/antisense IGFBP-2 or pcDNA3 vector alone did not differentially affect cell growth under our 
culture conditions. Many interpretations o f this finding are possible, but it should be noted that this was 
the result o f a single experiment. It is essential to confirm this result and to characterize in more detail the 
level o f  inhibition o f expression before drawing any conclusions.
In cells that produce endogenous IGFs and that are responsive to the mitogenic effect o f IGF, 
transfection with antisense IGFBP constructs has been reported to stimulate cell proliferation after a 
variable time and under different culture conditions. Corkins et al. (1995) showed a 35% increase in cell 
growth in a rat intestinal epithelial cell line (IEC-6 ) transfected with antisense IGFBP-2 after 3 days 
culture in 5% FBS. The same research group (Parks et al., 1999) recently reported that human colon 
carcinoma (Caco-2) cells transfected with antisense IGFBP-3 displayed an increased growth rate, 
compared to pcDNA3-transfected cells, after only 8  days in culture (either in serum free or serum 
containing medium). On the other hand, the effect on cell growth o f overexpression o f sense IGFBP-2 has 
also been investigated. Human embryonic kidney fibroblasts stably transfected with IGFBP-2, displayed 
impaired cell growth after 5 days o f  culture, compared to control cells (Hoflich et al., 1998). After 3 day 
of culture, rat glioma cells (C6 ) transfected with IGFBP-2 cDNA and expressing a high level o f protein,
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grew at the same rate as control cells, while identically transfected clones expressing low level o f  IGFBP- 
2 displayed impaired growth (Bradshaw et al., 1999). A  direct comparison o f the effects o f  sense or 
antisense transfection may not be appropriate. In the antisense technique, the expression o f the targeted 
gene is generally not completely abolished. In the cases above, with antisense IGFBP-2 and IGFBP-3, 
(Corkins et al., 1995; Parks et al., 1999) a 54 and 55 %  reduction o f the corresponding mRNAs was 
observed, respectively. In the case o f IEC6  cells transfected with the antisense IGFBP-2 construct, the 
concentration o f IGFBP-2 in CM was reduced by 6 8 % after 6 - 8  days o f culture. A 60% reduction of  
IGFBP-3 RNA and 80% decrease in protein concentration was obtained by using antisense IGFBP-3 
oligodeoxynucleotides (ODN) (Oh et al., 1995). However the use o f antisense oligonucleotides, is a 
different technique which transiently inhibits the expression o f a target gene. As a consequence, freshly 
transfected cells are needed for every experiment and a wide variability in the inhibition o f gene 
expression is commonly experienced. For this reason many researchers prefer to create cell lines stably 
transfected with antisense constructs. O f course, not even this technique is devoid o f  drawbacks. The 
transfected foreign gene is integrated randomly into the cellular genome and the location site o f  
integration plays an essential role in the level o f expression o f the exogenous DNA. However, as most of 
the expression vectors carry a neomycin-resistance gene, transfected cells can be selected in the presence 
o f  a specific drug (usually G418), and a clonal population can be grown separately from a single resistant 
cell. After the assessment o f the efficiency o f  the reduction o f mRNA transcription and protein expression, 
the best clones can be chosen and expanded
Our experiment 3.3.3.2 was carried out with a mixed population o f stably transfected cells. Although this 
might not be an ideal situation because the overall inhibition o f gene expression corresponds only to the 
average between highest and lowest antisense mRNA expressing cells, Corkins et al. (1995) successfully 
demonstrated that a non-clonal population o f IEC cells transfected with antisense IGFBP-2 grew faster 
than control cells.
With regard to the efficiency o f  the inhibition o f  IGFBP-2 expression achieved in antisense- 
transfected Clone 9 cells, although encouraging, only a limited amount o f information on the total IGF- 
binding capacity o f the CM can be derived from the charcoal binding assay and more detailed analysis are 
necessary. Not only should the specific decrease o f IGFBP-2 in the conditioned medium be verified by
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Western blotting, but also any changes in general protein secretion or in the expression o f other classes of  
IGFBPs should be carefully analysed. In fact, the overexpression or the inhibition o f the expression o f one 
specific IGF-binding protein can induce a compensatory cellular response resulting in an alteration of the 
IGFBP profile or even inducing IGF expression (Bradshaw et al., 1999; Park, 1999).
In the case o f the MTT experiments what may be required in order to see an effect, is the use o f a 
clonal population o f cells whose IGFBP-2 expression is greatly inhibited. However, while our study was 
progressing, most reports on the use o f a sense or antisense strategy to highlight the role IGFBP-2 on cell 
proliferation supported an inhibitory effect for IGFBP-2 on cell proliferation (Corkins et al., 1995; Hoflich 
et a l ,  1998; Bradshaw et al., 1999). These results are in line with the well documented general inhibitory 
effect o f IGFBP-2 on IGF action and do not support its role as a positive regulator of cell growth. This 
latter hypothesis arose from early reports showing synergistic effects o f IGFBP-2 on IGF metabolic or 
mitogenic action in different cell systems (Bar et a ,  1989; Boumer et al., 1992) and it was corroborated 
by the finding that many tumours express high levels o f  IGFBP-2 (Elmlinger et al., 1998, Mishra et a l ,  
1997; Cohen et al., 1993; Fuller et al., 1999; Ho and Baxter, 1997b; Kanety et al., 1993, Kanety et al., 
1996; Karasik et al., 1994). Moreover, Slootweg et al. (1995) described an IGF-independent effect of 
IGFBP-2 in rat osteosarcoma cells. Hoflich et al. (1998) investigated if  the high level o f expression of 
IGFBP-2 in tumours could be indicative o f its involvement in the pathogenesis or in the progression of  
tumour growth. In light o f the growth inhibitory effect, which is obtained either by overexpressing 
IGFBP-2 in human fibroblasts, or by adding medium conditioned by these cells to colon carcinoma cells, 
the authors suggested an alternative interpretation. Rather than a synergistic effect on IGF-stimulated 
growth, the increased secretion o f IGFBP-2 in the CM o f cultured tumour cells should be seen as a cellular 
defensive reaction aiming to limit the high level o f  proliferation.
O f course, the lack o f evidence o f a positive role for IGFBP-2 in transfection studies is not 
sufficient to exclude the occurrence o f this effect. For example, none of the systems used could really 
discriminate between the action o f soluble or membrane-associated IGFBP-2. This is a difficult area to 
address. The higher potency shown by des(l-3)IGF-I compared to IGF-I on the stimulation o f tyrosine 
phosphorylation o f a 180kDa protein in wild type Clone 9 cell, could be exploited for the purpose. As 
mentioned above, in the tyrosine phosphorylation assay the conditioned medium is discarded and only the
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monolayer adherent IGFBPs are present. We have hypothesised that these immobilized IGFBPs may be 
responsible for the impaired effects o f IGF-I compared with its analogue des IGF-I. A  cell system devoid 
o f  immobilized IGFBPs (antisense IGFBP-2 transfected Clone 9 cells) would be an appropriate model to 
test this hypothesis. If the difference between IGF and des IGF was not apparent, it would be additional 
proof o f  the inhibitory effect played by membrane-associated IGFBP-2 in wt Clone 9 cells. If, instead, the 
difference between IGF and des(l-3)IGF persists in the absence o f IGFBP-2 expression, it may be due to 
the presence o f an additional IGFBP associated to the monolayer (IGFBP-5 for example), or due to 
completely unrelated reasons. We have shown some limited evidence suggesting Clone 9 cells secrete 
IGFBP-5 (paragraph S. 3. l.b. 3), which is known to associate to the cell membrane and to ECM. In this 
respect, i f  the secretion o f this binding protein by Clone 9 cells can be confirmed, the effect o f  alternative 
suppression of the IGFBP-2 or the IGFBP-5 gene may be helpful in elucidating the specific role played by 
each IGFBP in this cell model system.
139
4. G en era l d is c u s s io n
It is not the intention of this final chapter to repeat the discussion o f the experimental results 
obtained in the current work. These are fully described at the end o f each experimental section. Instead we 
intend to conduct a broader discussion o f two particular areas of the current work, namely a comparison o f  
the IGF axis we have described for Clone 9 cells and that which exists in primary cultures o f  hepatocytes, 
and also some further considerations as to the use o f antisense technology in relation to the experimental 
systems.
The work undertaken in this study has provided a large range o f useful information on various 
biological aspects o f IGFBP-2, and at the same time it has lead to an enrichment o f our knowledge in 
different research areas. We started from DNA cloning and mutagenesis and then, introducing for the first 
time the use of the baculovirus expression system in our Institute, we expressed wt and mutant IGFBP-2 
proteins and we compared their affinity for IGF. During this first part o f the project we also produced and 
purified wt IGFBP-2 (and its PGD mutant) which we utilised in the second part o f our research aiming to 
investigate IGFBP-2 association with the plasma membrane of cultured cells. In this area we tried many 
different approaches and we finally succeeded in demonstrating the association o f endogenous IGFBP-2 to 
cell membranes o f Clone 9 cells, an adult rat liver cell line, that secrete only IGFBP-2 into CM. We then 
moved to the last part o f our project, investigating the role o f endogenous IGFBP-2 in modulating the 
IGF-IGF-R axis. We established two bioassays which helped to enlighten different aspects o f IGFBP-2 
modulation o f Clone 9 cell responsiveness to IGFs. In our acute, cell signalling-type bioassay, IGF action 
is probably influenced by monolayer-associated IGFBPs, while in our long-term cell proliferation assay, 
both soluble and monolayer-associated IGFBP-2 can affect growth factor activity. We observed that in the 
Clone 9 cell line, des(l-3)IGF-I, an IGF-I analogue with normal affinity for IGF-IR and decreased affinity 
for IGFBPs, appeared more potent than IGF-I in stimulating both protein phosphorylation and cell 
proliferation. These results led us to hypothesise that the negative modulation o f IGF-I action could be due 
to the presence o f endogenous IGFBP-2, regardless o f its soluble or monolayer association. According to
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this hypothesis, in the absence o f  the endogenous binding protein, the activity o f IGF-I and des(l-3)IGF-I 
would be expected to be similar. We worked to create a cellular model suitable to test this hypothesis, by 
transfecting Clone 9 cells with an antisense IGFBP-2 construct. At this time, only preliminary results have 
been obtained from our antisense IGFBP-2 transfected Clone 9 cell model. Further investigation is 
required to establish die level o f  inhibition o f IGFBP-2 gene expression achieved and the effect that this 
inhibition has on cell growth in our Clone 9 cell model.
The Clone 9 cell line was derived from normal adult rat liver (Weinstein et al., 1975). The cells 
display an epithelial phenotype with a cuboidal or polygonal cell shape, and grow tightly packed, but not 
overlapping, in discrete colonies which eventually become confluent. When the cell line was originally 
established, selection o f these cells from liver primary culture was facilitated i) by low cell density plating, 
which enables the detection o f epithelial clusters over the widely spreading fibroblasts, and ii) by using a 
medium with a low percentage o f FBS (3-5%), which favours growth o f epithelial over fibroblastic cells. 
Weinstein and coworkers excluded the possibility that Clone 9 cells underwent tumour transformation, 
because no viral particles were detected in the cell cytoplasm and because cells were unable to grow in 
soft agar. However, Clone 9 cells lacked hydrocortisone-inducible tyrosine aminotransferase, which is 
typical o f hepatocytes and which is also retained in hepatoma cells (Weinstein et al., 1975). Therefore the 
authors concluded that Clone 9 cells were likely to be derived from hepatic parenchyma cells although an 
origin from bile duct epithelial cells could not be excluded. As Clone 9 cells are often referred to as 
“hepatocytes” (Matovcik et al., 1990; Brown et al., 1986) and as the cells, which are commercially 
available, displayed the expected phenotype, we would have probably continued to consider them as 
hepatocytes if  some o f our results had not suggested otherwise.
The IGFBP secretion profile o f  the different liver cell types has been characterised in detail by 
Scharf et al. (1995). Adult rat hepatocytes secrete IGFBP-1, 2 and 4 (in decreasing order of abundance), 
and do not produce IGFBP-3. Fat-storing cells secrete IGFBP-2 and 4, while endothelial cells and Kupffer 
cells produce IGFBP-2 and 3. The authors suggest that this compartmentalization o f IGFBP secretion 
might have the function o f preventing intracellular formation o f 150kDa ternary complex in the 
hepatocytes which secrete both ALS subunit and IGF-I, but not IGFBP-3. Also Schmid et al. (1992)
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reported that adult rat hepatocytes secrete a major 32kDa IGFBP and a lesser amount o f IGFBP-2. In 
contrast to these reports, other authors claim that IGFBP-1 is undetectable in normal adult rat liver, and its 
secretion is only apparent in regenerating liver (Mohn et a l., 1991). Foetal rat hepatocytes secrete IGFBP- 
1, -2 and -4 similarly to what was reported by Scharf in adult rat hepatocytes (Menuelle et al., 1995).
In Clone 9 cell conditioned medium only one band o f approximately 32-34kDa was detectable by 
IGF-I ligand blotting. In agreement to what previously shown by Yang et al. (1990), we identified this 
protein as IGFBP-2, as it reacted with an anti IGFBP-2 (but not by anti IGFBP-1 antibody), in Western 
blotting (data not shown). Conversely, on Clone 9 cell membranes, in addition to IGFBP-2, another 
IGFBP o f  slightly smaller Mr was revealed and our immune precipitation data suggest this protein might 
be IGFBP-5. The difference between IGFBP profile in Clone 9 cells (IGFBP-2) and that described in the 
literature for hepatocytes (IGFBP-l>IGFBP-2>IGFBP-4) might reflect an adaptation o f the cell line to 
culture conditions and does not exclude the possibility that the two cell types have the same histological 
origin. In this respect it should be noted that IGFBP secretion in hepatocytes varies under different 
conditions, such as foetal life (Menuelle et al., 1995), liver regeneration (Mohn et al., 1991), and various 
tumour states (hepatoma cell lines, Yang et ar/.,1990 and Scharf et a /.,1998).
We then compared the IGF-IGF-R axis o f hepatocytes and Clone 9 cells. Primary cultures of 
human hepatocytes, express IGF-I but not IGF-IR. Conversely, they express IGF-IIR, but not IGF-II 
(Scharf et al., 1998). The expression o f IGF-I and the lack o f the expression o f IGF-IR receptor, though 
characteristic o f adult human and rat hepatocytes (Schmid et al., 1992; Scharf et al., 1998), cannot be 
adopted as a marker for hepatocytes as it is a reversible condition. For instance, IGF-IR is expressed in 
foetal hepatocytes, in regenerating liver (after hepatectomy) and in some hepatoma cells (Caro et al., 
1988). Furthermore, PLC cells (human hepatoma cells) express both IGF-I and IGF-II receptors and none 
of the IGF peptides (Scharf et al., 1998). Our data show that Clone 9 cells express IGF-I and IGF-IR and, 
although we did not obtain definitive evidence o f the IGF-IIR, our results are not inconsistent with its 
presence, which has previously been described in this cell line (Matovcik et al., 1990 and Brown et al., 
1986).
Several studies have been published which aimed to identify the receptor responsible for 
mediating IGF action in hepatocytes, but results were not always directly comparable, due to the different
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experimental conditions utilised. Scharf et al. (1996) reported that in adult rat hepatocytes insulin and 
IGF-I decreased IGFBP-1 and IGFBP-2 secretion, but they upregulated IGFBP-4. Based on the lower 
potency displayed by IGF-I in comparison to insulin, the authors postulated that the insulin R mediated the 
action of both hormones. Raper et al. (1995) showed that both IGF-I and IGF-II (at a concentration o f  
2nM) stimulated 3[H]thymidine uptake in adult rat hepatocytes, but the two peptides acted through 
different mechanisms. IGF-I elevated cellular cAMP levels and its action was decreased by somatostatin 
(SS14) and by a specific antagonist o f the adenyl cyclase signal transduction pathway (2’-5’ 
dideoxyadenosine, DDA). Conversely, IGF-II-stimulated thymidine uptake was not accompanied by an 
increase o f  cAMP and was unaffected by the addition o f these two compounds. In addition, 125I IGF-II 
binding to the hepatocytes was specific and it was likely to be mediated by IGF-IIR (as it was competed 
by IGF-II, but not by IGF-I or insulin). 125 I insulin also bound specifically to its receptor and it was 
significantly displaced by IGF-I, but not by IGF-II. The authors concluded that, IGF-IR expression being 
very low in adult liver hepatocytes, the IGF-I-stimulated increase in cAMP and thymidine uptake might be 
partially mediated through the insulin receptor, while IGF-II, which did not bind efficiently to the insulin 
receptor, might act through IGF-IIR. Also Kimura and Ogihara (1998) reported that IGF-I and IGF-II 
stimulate DNA synthesis and cell proliferation through two different mechanisms in primary culture o f  
adult rat hepatocytes. IGF-I induced DNA synthesis was increased by cAMP-elevating agents, by an a r  
adrenoceptor agonist and by phorbol myristate acetate (PMA). IGF-I signalling was mediated by tyrosine 
kinase, phospholipase C, PI(3)K and p70 S6 K. In contrast, IGF-II stimulated DNA synthesis was inhibited 
by cAMP-elevating agents, by an a r adrenoceptor agonist and by PMA. IGF-II signalling was mediated 
by Gi protein, MAP kinase and p70 S6 K. IGF-II was 100 fold more potent than IGF-I in inducing DNA  
synthesis and, while IGF-I-stimulated cell proliferation was inhibited by high cell plating density, IGF-II 
action was unaffected. Moreover, although in this paper the nature o f the receptors mediating IGF effects 
was not specifically addressed, the authors reported that IGF-I-induced thymidine uptake in adult rat 
hepatocytes was inhibited by the addition o f an anti IGF-IR antibody , and IGF-II action was antagonised 
by an anti IGF-IIR, but not vice versa.
Despite the suggestions o f Raper (1995) and Kimura and Oghiara (1998) o f an involvement of  
IGF-IIR as a mediator o f IGF-II signalling, a signal transduction pathway for the IGF-IIR has not been
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convincingly demonstrated. Both IGF-I and IGF-II actions are believed to be mediated principally through 
the IGF-IR. An alternative mediator o f the biological effects o f  IGF-II in foetal rat hepatocytes has been 
suggested by Menuelle et al.(1995). The authors propose that in these cells, both IGF-II and insulin- 
stimulated glycogen synthesis is mediated by the insulin receptor. More recently, the same group of 
researchers has expanded this study, showing that in the same cell type, insulin and IGF-II also induced 
DNA synthesis. In this case, insulin appeared to act through its own receptor, while IGF-II was more 
likely to act through the IGF-IR (foetal rat hepatocytes express IGF-IR) (Menuelle et al., 1999). However 
in this case, the attempt to discriminate between signals occurring through the insulin or the IGF-I receptor 
might appear slightly artificial, as when both receptors are expressed in a cell type, they may form hybrid 
receptors (Siddle et al., 1999). The hypothesis o f IGF-II signalling through the insulin receptor finds 
strong support in the study o f Morrione et al., 1997, who demonstrated IGF-II ability to stimulate cell 
proliferation in R-/IR fibroblastic cells. These cells were originally derived from igflr nullizygotes (thus 
lacking IGF-IR) and have been transfected to obtain overexpression o f the insulin receptor. In this model, 
both insulin and IGF-II (at 50ng/ml) stimulated cell proliferation, DNA synthesis, insulin receptor 
autophosphorylation and phosphorylation o f IRS-1, the major protein substrate o f the insulin receptor. In 
contrast, IGF-I, even at concentrations as high as 200ng/ml, foiled to stimulate R-/IR cell proliferation. 
The authors suggest that the observed difference in functionality between the two IGFs can be explained 
by considering their relative affinity for the insulin receptor. IGF-II affinity for the insulin receptor is only 
1/10 o f that of insulin, whereas IGF-I binding to the insulin receptor is 50-100 times lower than insulin 
(DeMeyts et al., 1994).
In Clone 9 cells, IGF-I was generally more effective than IGF-II or insulin in stimulating either 
proliferation or protein phosphorylation. 125I IGF-I or 125I IGF-II affinity labelling o f Clone 9 membranes 
revealed the presence o f the 130kDa a  subunit o f IGF-IR. We believe that IGF-IR receptor is the main 
mediator o f IGF-I and IGF-II biological actions in Clone 9 cells. However, the expression o f insulin 
receptor on Clone 9 cells was not specifically investigated and in the light o f recent findings (Morrione et 
al., 1997; Menuelle et al., 1999) the involvement o f insulin receptor in the mediation o f  insulin and IGF-II 
effects on Clone 9 cells cannot be excluded.
144
In summary, Clone 9 cells have been found to be a suitable cellular model for studying some of 
the IGFBP-2 biological functions o f IGFBP-2 as this cell line expresses all components o f the IGF-IGFR- 
IGFBP axis, and especially cell membrane associated IGFBP-2. However, whether Clone 9 cells can be 
considered a physiological model for adult rat hepatocytes is another question and this would require a 
specific histological characterisation o f these cells.
Our choice o f studying IGFBP-2 function by following a “lack o f a function” (gene expression 
inhibition by antisense mRNA), was dictated by our main aim to investigate the role played by the 
IGFBP-2 fraction which is associated to the cell membranes. The IGF inhibitory effect o f soluble IGFBP- 
2 is already well established. To investigate the role o f cell membrane associated IGFBP-2 we could either 
increase or decrease the amount o f this IGFBP bound to the cell surface. As we were unable to detect cell 
surface binding o f exogenous IGFBP-2, the utilisation o f methods based on the addition of the binding 
protein to cell monolayers were precluded. Thus, we decided to block endogenous IGFBP-2 production by 
Clone 9 cells by transfecting them with an antisense IGFBP-2 construct. We attempted to deduce some 
useful information on the role o f endogenous (soluble and monolayer-associated) IGFBP-2 by comparing 
cell growth of wt Clone 9 cells or antisense transfected, either following IGF treatment or under basal 
conditions. In the latter case, the endogenous production o f IGF-I might act in an autocrine fashion to 
sustain Clone 9 cell proliferation, and therefore its modulation by endogenous IGFBP-2 might be of 
physiological significance. Moreover, it might be possible that, in the absence o f endogenous IGFBP-2 (in 
antisense transfected cells), the binding o f exogenously added protein is more easily demonstrated. In this 
case it could be possible to treat antisense transfected Clone 9 cell monolayers with IGFBP-2 and study 
the specific role o f the monolayer-associated protein on cell growth avoiding the interference o f  the 
soluble IGFBP-2. On the other hand, we planned to elucidate the specific role o f monolayer-associated 
IGFBP-2 by comparing wt and antisense transfected Clone 9 cells in IGF-stimulated protein 
phosphorylation assays (where, under our experimental conditions, only monolayer associated IGFBPs are 
present). O f course all these future experiments are based on the assumption that the transfection of Clone 
9 cells with antisense IGFBP-2 drastically suppresses the expression o f the endogenous binding protein.
Although we describe the use o f full length antisense IGFBP-2 stably transfected into Clone 9 
cells via a pcDNA3 expression vector, from a practical point o f view, due to the progress made in
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antisense technology and the knowledge achieved in this field, there is a large range o f options available to 
maximise the efficiency o f  inhibition o f gene expression. For example, a choice could be made on whether 
pre-mRNA rather than mature mRNA should be targeted. It has been proposed that the subnuclear 
localization in which the antisense molecule interacts with its target can affect the efficiency o f  expression 
inhibition. Chuang (1992) suggests that targeting antisense oligos to spliceosomes could prevent 
intracellular degradation and increase the chances o f meeting the target sequence. Alternatively, inhibition 
o f gene transcription could be achieved by directing triple helix-forming-oligonucleotides to the gene 
promoter region. IGFBP-2 promoter has been studied in mouse (Landwehr et al., 1993), rat (Brown and 
Rechler, 1990), human (Binkert et al., 1992), pig (Song et al., 1993) and chicken (Schoen et al., 1995). It 
lacks TATA or CAAT motifs, but in the proximal region upstream o f the 5’end o f the gene several G/C 
boxes have been identified and shown to mediate basal IGFBP-2 promoter activity (Boisclair et al., 1993; 
Kutoh et al., 1993). Recently, other more upstream sequences able to augment basal IGFBP-2 promoter 
activity have been identified in liver derived cells and even the presence o f a gene transcription silencer 
has been demonstrated (Badinga et al., 1998; Kutoh et al., 1999). The latter acts as a negative modulator 
o f IGFBP-2 expression in proliferating BRL-3 A cells (a rat liver cell line) cultured at low density. In the 
same cell line, IGFBP-2 expression increases when confluence is reached and cells are arrested at the 
border between G l/S  phase possibly by activating an enhancer element which counteracts the silencer 
function. Nuclear factors interacting with the silencer and enhancer DNA regions have been identified and 
their role as a repressor and an activator has been suggested. In the light o f these findings other methods of 
blocking IGFBP-2 expression could be considered. If the identification o f the repressor is achieved, it 
might be possible to increase the intranuclear concentration o f  this factor and possibly potentiate its 
transcription silencing activity. An alternative strategy may be to transfect the cells with double stranded 
DNA “decoys”, which, reproducing transcription factor binding site sequences, might sequester these 
factors and inhibit transcription. A more definitive solution would be to employ cells derived from 
IGFBP-2 knock out mice. These were established by Wood et al., (1993) and were shown not to display 
any obvious change in phenotype. However, the authors have suggested that the lack o f IGFBP-2 might be 
masked by a compensative effect from the other class o f IGFBPs. This possibility should be also taken 
into account if  such a model was chosen to test IGFBP-2 functions.
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Considerations o f this type are important in the current work, as initial observations from 
populations o f Clone 9 cells stably transfected with antisense IGFBP-2 indicate that general protein 
secretion by these cells is decreased questioning the specificity achieved by the full length antisense BP-2 
construct. Experiments in this area are continuing in our laboratory.
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Abstract
U sing m onolayer cultures o f  costal chondrocytes established from four w eek old  Clun Forest lam bs, w e have demonstrated  
that, under serum free conditions the ce lls  release three IGFBPs (32, 29 and 21 kD a) into the m edium . The m ost abundant o f  
these —the 32 kDa BP —w as show n to be IG FBP-2 by Western blotting. Furthermore w e demonstrate that the leve ls  o f  IGFBP- 
2 in conditioned m edium  are acutely increased (6 , 12 and 24 h time points) fo llow ing  treatment o f  ce lls  w ith bovine GH ( 1 -  
100 ng/m l).
In a parallel set o f  experim ents, using ovine fibroblasts (derived from derm is) w e show  that IG FBPs o f  Mr 32 , 29 and 21 
kDa are also secreted by this cell type. H ow ever the relative abundance o f  these B Ps differed from that seen in the chondrocyte 
cultures, w ith the 21 kDa sp ecies now  the m ost abundant. In addition, prolonged exposure o f  autoradiographs indicated that 
fibroblasts secreted a higher Mr IGFBP (m ost probably ovine B P-3) that w as not detected in any o f  our chondrocyte cultures. 
M ost significant how ever w as the demonstration that bGH did not dramatically affect the levels o f  IGFBPs in fibroblast cell 
cultures. We conclude that GH stim ulates BP-2 production from chondrocytes and this is a cell-type specific effect in as much  
as it is not replicated in cultures o f  dermal fibroblasts. (M ol C ell B iochem  162; 145—151, 1996)
Key words', ovine chondrocytes, growth horm one, IGFBPs
Abbreviations'. BCIP — 5-brom o-4-chloro-3-indolyl phosphate; CM -  conditioned medium; DM EM  — D u lb ecco ’s M odified  
Eagles M edium ; FCS — foetal c a lf  serum; IGF — insulin-like growth factor; IGFBP — insulin-like growth factor binding pro­
tein; H B SS -  H anks’ Balanced Salt Solution; GH — growth hormone; N B T  -  nitroblue tetrazolium; SFM  — serum  free m e­
dium; T B S — tris buffered saline
Introduction
The insulin-like growth factors (IGF-I and IGF-II) are small 
(7.5 kDa) polypeptides w hich display m itogenic, differentiat­
ing and m etabolic activities (review ed in ref [1]). In vitro and 
in vivo these actions are m odulated by non-covalent associa- 
tior with well-characterised IGF binding proteins (IGFBPs),
six o f  w hich have been cloned for both rat and human [2], 
Association o f  IGFs with their binding proteins has been re­
ported to enhance [3] or inhibit [4] their activities.
One o f  the m ost important functions o f  IGF-I, in associa­
tion with pituitary growth hormone (G H ), is the regulation 
o f  longitudinal skeletal growth in m am m als, a process which  
is principally achieved by the differentiation, clonal expan­
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sion and subsequent ossification  o f  chondrocyte populations 
w ithin the epiphyseal growth plates [5 -7 ]. Although the ex ­
act role o f  GH and IGF-I in this process is still not clearly 
defined, it is evident that in the case o f  the latter horm one its 
activity at the growth plate w ill be influenced by the pres­
ence, locally  o f  the IG FBPs d iscussed  above. Very little data 
is available on IGFBP production by growth plate chondro­
cytes and even  less on the hormonal regulation o f  secretion  
o f  these proteins from this cell type. B ecause o f  this w e have 
in vestigated  the secretion  o f  IG FBPs from differentiated, 
m onolayer cultures o f  ovine costal chondrocytes. We report 
that under our serum -free culture conditions, chondrocytes 
release principally IG FBP-2 ( -3 2  kDa) with lesser amounts 
o f  a 29  and 21 kD a IGFBP. Further, w e demonstrate that in 
this culture system  bovine GH stim ulates (2-fo ld  increase) 
the secretion o f  IG FBP-2. We discuss our results in the con­
text o f  a p oss ib le  interplay betw een GH and IGF-I in the 
regulation o f  grow th plate m etabolism .
Materials and methods
For tissue culture, D M EM , H am ’s F12 and foetal ca lf  serum  
w ere from  G ibco  BRL (Inchinnan, Scotland). P en ic illin / 
streptom ycin , H anks’ balanced salt so lu tion  and trypsin- 
EDTA w ere from ICN B iom edicals (B ucks, England). C ol- 
lagenase w as from  B oehringer (S u ssex , England), D N ase  
from Sigm a (D orset, England) and donor c a lf  serum from  
Tissue Culture Services (TCS - Bucks, England). T issue cul­
ture p lasticw are w as from C oStar U K  (E ssex , E ngland); 
A lcian  B lue, protam ine sulphate, activated charcoal, goat 
anti-rabbit IgG alkaline phosphatase conjugate and reagents 
for e lec trop h oresis w ere from  S igm a. Rabbit an tibovine  
IG FBP-2 w as from TCS. This is a polyclonal rabbit antibody 
raised to bovine IG FBP-2 purified from the M D BK  cell line. 
It cross-reacts w ith ov ine B P-2 and show s < 0.5 % cross­
reactivity w ith IG FBPs 1, 3, 4 and 5 [8]. Recom binant hu­
man (rh) IGF-I w as from Bachem  UK (E ssex, England) and 
recom binant bovine growth horm one (rbGH-Met-1 . . . Leu 
127, lot no M -l 1 8 -0 8 3 0 8 ) w as a g ift from Dr R C ollier, 
M onsanto Corp, St Louis, MO, U SA . Electrophoresis appa­
ratus Protean Ilx i was from B io-R ad (Herts, England) and 
blotter m odel TE42 w as from H oeffer Scientific Instruments 
(San Francisco, U SA ).
Cell culture
Costal chondrocytes w ere prepared from the growth plates 
o f  4  w eek old  m ale lambs. A fter removal o f  the rib cage each  
individual rib together w ith the jo in t above the growth plate 
w as separated and scraped free o f  all tissue using a scalpel.
The growth plates (12 per anim al) are about 1 -2  mm thick, 
m ilky in colour and easy to separate from the adjoining bone. 
They were removed sterilely and washed tw ice in Petri dishes 
with 10 m l D M E M /H am ’s F I2 m edia with no serum. The 
growth plates w ere pooled and chopped into 1 m m  sq p ieces  
using a scalpel and then added to a sterile enzym e solution — 
0.12%  collagenase, 0.02%  D N A se in 20  ml D M EM /H am ’s 
F12 with 10% donor c a lf  serum. This d igestion  w as left at 
37°C for 18 h after w hich time m ost o f  the chondrocytes were 
isolated from the cartilage. C ells w ere w ashed x 3 seeded into 
75 cm 2 flasks and frozen after 7 days in culture and one pas­
sage. For experim ental purposes costal chondrocytes were 
seeded into 12-w ell tissue culture plates at 105 ce lls /w ell in 
com plete m edium  (D M E M /10% F C S/100  units m l-1 p en icil­
lin/streptom ycin). Cultures w ere m aintained at 37°C  in a hu­
m idified atmosphere o f5 % C 0 2, for either 7 or 14 days. Prior 
to the experim ents, cells were w ashed (x  2 in H ank’s B uff­
ered Salt Solution H B SS) and incubated w ith 500  ul fresh 
SFM  ± bovine GH (bG H —final concentration 0 -1 0 0  ng/m l). 
Incubation w as continued for 6—72 h, fo llow in g  w hich  m e­
dium was rem oved, centrifuged briefly to rem ove cell debris 
and stored at -2 0 °C .
In order to confirm  maintenance o f  chondrocyte phenotype 
in m onolayer culture, cells w ere stained for the presence o f  
proteoglycan using A lcian B lue according to Lindhal et al. 
[7]. To investigate the sp ec ific ity  o f  the effects o f  GH on  
chondrocyte cultures, replicate experim ents w ere performed  
on cultures o f  sheep dermal fibroblasts. T hese w ere estab­
lished from explants o f  skin rem oved from the inguinal re­
gion. Explants (approxim ately 1 mm sq p ieces) w ere incu­
bated in D M E M /10% FC S/100 units m l'1 Pen Strep in 10 cm  
tissue culture dishes. After 5 -6  days in culture, fibroblasts 
w ere observed grow ing at the borders o f  explants. A t this 
stage explants w ere picked from the culture with a scalpel and 
fibroblasts w ere allow ed  to grow  to confluency. C ells were 
passaged with trypsin-EDTA and maintained in DM EM  10% 
FCS 100 U m l-1 Pen Strep. C ells  o f  various passage were 
stored in liquid N 2 using D M EM :FC S:D M SO  (50:40:10) as 
cryo preservant. For experim ental purposes, fibroblasts were 
used betw een passage 2—5 and chondrocytes at passage 2 or 
3. N o differences in IGFBP secretion w ere evident in differ­
ent passages. The hormonal treatment, incubation conditions 
and m edium  collection  procedures w ere identical for chon­
drocyte and fibroblast cultures.
Western ligand blotting
This was performed according to the m ethod originally de­
scribed by Hossenlopp et al. [9]. 80 ul o f  conditioned medium  
(C M ) was incubated w ith 20 ul x 5 strength non-reducing  
sam ple buffer (312 .5  mM Tris.Cl pH 6 .8 , 10% (w /v) SD S, 
50% (v/v) g lycerol, 50 ug/ml brom ophenol blue) at 100°C
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for 3 min. Electrophoresis w as for 4—5 h at 60 m A  on a 12% 
polyacrylam ide gel in a running buffer com prising 25 mM  
Tris.Cl (pH 8 .3 ), 192 m M  g lycin e, 0.1%  (w /v) SD S. G els 
w ere blotted at 130 m A  for approxim ately 16 h (at 4°C ) in 
15 m M  Tris (pH 8.3) 120 mM  glycine, 5% (v /v) methanol. 
F ollow ing transfer, blots ( 1 6 x 1 4  cm ) were incubated in Tris- 
Saline (TS — 150 mM  N aC l, 10 m M  Tris.Cl (pH 7.4)) con­
taining 3% (v /v ) N P -40  for 30  m in, TS — 1% B SA  for 2 h 
and TS -  0.1 % Tween for 10 min. B lots w ere hybridised in 2 
ml TS — 1% B S A  0.1%  Tween containing 2 x 106cpm l25I- 
IGF-I for 16 h at 4°C . A fter w ashing — 2 x 1 5  min in TS -  
0.1 % Tween and 3 x 1 5  m in in TS, autoradiographs w ere ob­
tained by exposure to Fuji x-ray film  in a cassette contain­
ing Dupont Cronex L i-Plus intensifying screens.
Im m unoblotting
CM w as processed  exactly  as described for ligand blotting  
w ith the exception  that m edium  w as prepared in reducing  
sam ple buffer containing 5% (v /v) 2-m ercaptoethanol — fi­
nal concentration. F ollow ing  electrophoresis and transfer to 
nitro-cellulose, mem branes w ere b locked by incubation for 
30 min at room  temperature in TS containing 2% (w /v) Mar­
vel. Rabbit anti-bovine IG FBP-2 w as diluted 1:2000 in TS — 
0.2%  M arvel and incubated for 2 h. A fter 4 x 1 0  min w ashes 
in TS, second antibody (goat anti-rabbit IgG alkaline p hos­
phatase conjugate) diluted 1:1000 in TS -  0.2% M arvel was 
added and incubation w as continued for a further 2 h. B lots 
w ere again w ashed for 4 x 15 min in TS and colour develop­
m ent was brought about by incubation in 0.1 M Tris.Cl (pH  
9.5) containing 0.1 M N aCl 5 m M  M gC l2, .066% (w /v) N BT  
and .033% (w /v ) BCIP. BCIP and N B T  w ere added from 50  
m g/m l stock solutions in 100% and 70% dim ethylformamide 
respectively. C olour developm ent w as m onitored over a 3 0 -  
60 min period and the reaction w as terminated by w ashing  
blots in TS.
lodination
5 ug o f  IG F -1 w as iodinated to a specific activity o f  5 0 -1 0 0  
uC i/ug using the Iodogen coated tube m ethod [10]. Labelled  
peptide was separated from free 125I by gel filtration over a 
Sephadex G -10 colum n.
Solution p h a se  assay o f  IG F  binding proteins
This was perform ed as described originally by Conover et al. 
[11] with slight m odifications. B riefly, varying volum es o f  
chondrocyte conditioned m edium  (1 0 -1 0 0  ul) w ere added to 
100 ul o f  50  m M  Tris.Cl (pH 7 .4), 0.5%  B S A  (assay buffer)
containing 125I-IGF-1 (2 5 ,0 0 0  cpm  per tube). Total volum e  
w as made up to 300 ul w ith  unconditioned m edium . B ind­
ing o f  tracer was a llow ed to proceed overnight at 4°C . F ol­
low ing incubation, assay tubes w ere p laced  on ice and 600  
ul o f  a solu tion  contain ing 1% activated  charcoal (S igm a  
Product N o C -5385), 0 .2  m g/m l protam ine sulphate in assay  
buffer w as added. After a further 10 m in incubation on ice, 
charcoal w as pelleted by centrifugation at 3000  rpm for 10 
min. The supernatant, w hich  contains the 125I-IGF-I - IGFBP  
com plexes w as decanted. Charcoal pellets w ere counted and 
bound 125I-IGF-I calculated by subtracting cpm  in pellets from  
added l25I-IGF-I counts.
Statistics
Data on binding o f  l25I-IGF-I to chondrocyte m onolayer CM  
in solution phase are presented as m ean ±  S .D . (n = 3), where 
n is the number o f  culture w ells treated with the indicated con­
centration o f  bGH. D ifferences betw een untreated and GH- 
treated cultures w ere analysed by Student’s /-test.
Results
Figure 1A indicates the results o f  a ligand blot o f  CM  from  
m onolayers o f  sheep grow th plate chondrocytes stim ulated  
with varying concentrations (0 -1 0 0  ng/m l) o f  bGH for 6, 12 
or 24 h (for experim ental details see M aterials and m ethods 
section). Under our culture conditions, these ce lls  secrete 3 
main IG FBPs at Mr 32, 29  and 21 kDa. It is a lso  apparent 
that, for the m ost abundant 32 kD a IGFBP, GH has a stim u­
latory effect. A lthough it appears in Fig. 1A that the levels  
o f  the 29 and 21 kDa IG FBPs appear to be regulated in line 
with the 32 kDa protein, this w as not a consistent observa­
tion. The identity o f  this 32 kD a IGFBP w as established as 
IG FBP-2 after b lotting w ith rabbit anti-bovine B P -2 (Fig. 
IB ). In addition, it is clear that the levels o f  BP-2 determ ined  
by im m unoblot vary in parallel w ith  those seen  in the ligand  
blot. It should be noted that the ligand- and im m unoblot rep­
resent gels containing different sam ples (from  the sam e w ell) 
and is not a single nitrocellulose blot probed sequentially with  
l25I-IGF-I and anti-BP-2 antibodies. It is also clear from Fig. 
1B that neither the 29  kD a nor the 21 kD a IGFBP react with  
the anti-BP-2 antiserum suggesting that either these are not 
fragm ents o f  the 32  kD a B P -2  or, i f  th ey  are, that the 
epitope(s) recognised by this antiserum have been lost. A t 32 
kDa, our observation o f  the Mr for the ovine BP-2 agrees w ell 
with 30.9  kDa calculated from the published sequence o f  this 
BP [12]. Attem pts to identify the 29 and 21 kDa bands by 
im munoblotting w ere unsuccessful. N either o f  these proteins 
reacted with polyclonal antiserum to human BP- 1, B P-4 or
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Fig. I . L igand b lo t (A ) and  im m unoblo t (B ) o f  cond itioned  m edium  from chondrocy te  m onolayer cu ltu res treated  w ith vary ing  am ounts o f  bG H  for e ither 
6 h (lanes 1 -4 ), 12 h (lanes 5 -8 )  o r 24 h (lanes 9 -1 2 ) . C oncen tra tions o f  bG H  are 0 (lanes 1, 5 and 9); 1 ng/m l (lanes 2, 6 and 10); 10 ng/m l (lanes 3, 7 and 
11) and 100 ng/m l (lanes 4, 8 and 12). Lane C con ta ins 10 ul o f  m edium  conditioned  by the rat liver tum our cell line -  C lone  9 w hich  secre tes the  30 kDa 
IG FB P-2 exclusive ly  [24]. N ote that rum inan t BP-2 at 32 kDa has a h igher M r than the rat protein. For the im m unoblot, key to the legend is as for ligand blot. 
T he b lo ts show n are  rep resen ta tive  o f  dup licate  blo ts carried  out on tw o separate  experim ents. 80 ul o f  cond itioned  m edium  w ere analysed  by both ligand- 
and im m unoblo t as described  in M aterials and m ethods.
BP-5. (Antiserum to BP-6 was unavailable to us at this time). 
They are also unlikely to represent fragments o f  BP-3. In 
respect of  the 29 kDa BP, it should be noted that on prolonged 
exposure o f  the autoradiograph, this band frequently pre­
sented as a doublet (data not shown). Stimulation o f  the 
IGFBP levels at the 6, 12 and 24 h time points was mirrored 
by our solution phase IGFBP data (Fig. 2). At 1 and 10 ng/ 
ml bGH for each o f  the 6, 12 and 24 h time points, p < 0.01 
(compared to IGFBP levels in control wells). At 100 ng/ml 
bGH p < 0.05 compared to corresponding controls for each 
o f  the time points. This fact, together with the level o f  l25I- 
IGF-I binding by CM suggested to us that little IGF-I/IGF- 
11 was released by these cells. This was confirmed following 
assay o f  acid gel filtration fractions from CM. We would 
emphasise that this stimulation o f  IGFBP secretion by GH 
is not simply a result o f  an increase in cell number following 
hormone treatment. At the range o f  GH concentrations used 
in the present study no increase in cell number was seen (data 
not shown).
A major concern during the monolayer culture o f  chondro­
cytes is the well-reported dedifferentiation o f  the cells that 
occurs on serial passage [13], Although we always worked 
with passage 2 or 3 cells, we were careful to confirm chondro- 
cvtic phenotype by staining for proteoglycan with Alcian
Blue. Despite this and in order to confirm the specificity o f  
the effect o f  GH on monolayer cultures of  chondrocytes, we 
conducted parallel experiments with sheep dermal fibro­
blasts. We present the results o f  these experiments in Fig. 3A 
and this data should be compared with that presented in Fig.
1 A. It is immediately obvious that there are differences in the 
nature and relative intensities o f  the various IGFBP species. 
For example the ratio o f  21 kDa to 29 or 32 kDa protein is 
much higher in the fibroblast conditioned medium than in the 
chondrocyte conditioned medium. In addition there appears 
to be very little consistent effect o f  bGH on the levels o f  any 
o f  the IGFBP species in fibroblast cultures. In order to con­
firm these differences in expression o f  IGFBPs between 
fibroblasts and chondrocytes  we over-exposed  an au to ­
radiograph o f  a ligand blot with CM from both fibroblast and 
chondrocyte CM (Fig. 3B). As well as the previously de­
scribed differences in IGFBP secretion pattern we also found 
in fibroblast conditioned medium an IGFBP at a higher Mr. 
This we suspect to be ovine BP-3, although confirmation o f  
this will be by blotting with specific anti-serum. Neverthe­
less, we believe that the data presented in Fig. 3 confirm, 
especially in the context of IGFBP secretion, the phenotypical 
and biochemical d ifferences between our fibroblast and 
chondrocyte cultures.
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F ig  2. S o lu tion  phase  assay  for IG FB P concen tra tion  in cond itioned  m edium  from chondrocy te  m onolayers. C ells w ere treated  w ith 0 , 1, 10 o r 100 ng/m l o f  
bG H  and m edium  w as rem oved  a fte r 6, 12 o r 24 h for dete rm ina tion  o f  IG FB P levels by so lu tion  phase assay. R esults are  p resen ted  as a %  o f  contro l values 
(zero  bG H ) and represen t the m eans ± S.D. o f  d e te rm inations  on 3 d ifferen t w ells for each bGH concen tra tion  at each tim e point. For experim en tal d e ta ils  see 
M aterials  and M ethods section .
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Fig. 3. A L igand blot analy sis  o f  CM  from  fib rob lasts  m onolayers treated  w ith vary ing  am ounts o f  bG H  for c ithe r 6 h (lanes I 4 ). 12 h (lanes 5 8) or 24 h 
(lanes 9 - 12). C o n cen tra tio n s  o f  bG H  are 0 (lanes 1 ,5  and 9); I ng/m l (lanes 2, 6 and 10); 10 ng/m l (lanes 3, 7 and 11) and  100 ng/m l (lanes 4. 8 and 12). As 
in Fig. I . lane C con ta in s C lone 9 cell cond itioned  m edium . B O verexposu re  o f  a ligand blot analysis  o f  CM from unstim ula ted  fib rob lasts  (lane  I = 50 ul; 
lane 2 = 100 ul) o r ch ondrocy tes  (lane 3 = 50 ul; lane 4 = 100 ul). E xperim ental deta ils  as described  in M aterials  and M ethods section .
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In terms o f  bGH stim ulation o f  IGFBP-2 levels, w e show  
clear effects at each o f  the 6, 12 and 24 h tim e points. It is 
important to note, how ever, that by 48 and 72 h the effects 
o f  bGH w ere less marked and this should therefore be re­
garded as an acute effect o f  bGH in this culture system . In 
addition, although w e describe the results o f  experim ents on 
chondrocyte m onolayers w hich w ere grown in culture for 7 
days, essentially the sam e results were obtained in cells grown 
for 14 days. A ssay  for IGF-I and IGF-II in acid gel filtration 
fractions o f  m edium  from treated and untreated cells revealed  
that lev e ls  o f  these peptides w ere below  the sensitivity o f  the 
radio-im m unoassays used to detect them.
Discussion
T here is very  little  data on the secretion  o f  IG FB Ps by  
chondrocytes in culture. Froger-Gaillard et al. [14] working  
w ith rabbit articular chondrocytes reported a main IGFBP  
species o f  30  kDa w ith lesser amounts o f  a 24 and 20 kDa 
species. A lthough GH had no effects on these ce lls  (isolated  
from 2 -3  month old  rabbits), these authors also reported the 
absence o f  IG FBP-3 in CM cultured by these cells. In a more 
recent study o f  bovine chondrocytes derived from adult and 
foetal articular cartilage and foetal growth plate cartilage and 
using either h igh-density m onolayer culture or suspension  
culture in alginate beads, O lney eta l.  [15] reported secretion  
o f  IG FBPs o f  Mr 33 kDa (B P -2) and at 29 and 24 kDa. This 
is sim ilar to the 32 kD ovine BP-2 and 29 and 21 kDa IGFBPs 
w e report in the present study. It should be noted, however, 
that this latter study also indicated the presence o f  BP-3 in 
CM from these cell types.
Our observation o f  the up-regulation o f  IG FBP-2 by bGH  
is novel and runs som ew hat against the current orthodoxy. 
In vivo, hypophysectom y results in a 1 0 -20  fold increase in 
IG FBP-2 m R N A  in liver suggesting a negative regulation by 
GH in vivo  [16]. H ow ever, the fact that treatment o f  these  
hypophysectom ised rats with a combination o f  GH, cortisone, 
te s to stero n e  and T4 p artia lly  reduced  hepatic  IG F B P -2  
m R N A  levels towards normal but treatment with GH alone  
led to a further increase in hepatic m R N A  levels over and 
above that seen in hypophysectom ised  rats led the authors to 
conclude that factors other than GH w ere important in regu­
lating IGFBP-2 m R N A  levels. Although the sam e work iden­
tified  insulin and nutritional state as important regulators o f  
IG FBP-2, relatively little e lse is known o f  in vivo and more 
especia lly  in vitro regulation o f  IG FBP-2. H opefully, as the 
promoter region o f  the IG FBP-2 gene is now  being analysed  
and transcription factor binding sites identified [ 17, 18], more 
inform ation w ill be forthcom ing in this area. A lthough the 
physiological significance o f  the local production o f  IGFBPs 
in the growth plate remains unknown, tw o recent studies with
a 25 kDa IGFBP purified from am niotic fluid (m ost likely  
B P-1) and IG FBP-4 (purified from a human osteosarcom a  
cell line) were shown to inhibit the basal- and IGF-stimulated 
growth o f  chick pelvic cartilage explants [ 19 ,20]. These find­
ings may suggest a som ew hat unusual hypothesis that GH 
(norm ally considered an anabolic horm one for the growth  
plate) has an inhibitory effect by stimulating IGFBP-2 release 
and inhibiting the autocrine/paracrine activity o f  IGF. It must 
be borne in m ind, how ever, that p h y sio lo g ica l e ffects  o f  
IGFBPs are probably specific  to the particular form o f  BP  
present. C learly the hypothesis that BP-2 has an inhibitory  
effect on the growth parameters o f  these ce lls  requires to be 
tested directly. A lthough this area requires further exam ina­
tion such an inhibitory effect o f  GH w ould clearly negate any 
stimulation o f  IGF-I secretion at the level o f  the growth plate. 
One clue to these possib le contradictory effects o f  GH may 
com e from the reported subtle differences in GH action in d if­
ferent regions o f  the growth plate. This was alluded to briefly 
in the introduction with GH acting on those ce lls  w ithin the 
stem cell layer o f  the growth plate to stim ulate differentia­
tion and IGF-I acting on differentiated cells to cause m itogen- 
esis. GH is reported as having little effect on these d ifferen­
tiated cells and even as having an inhibitory effect on colony  
formation from these ce lls  o f  the interm ediate zone o f  the 
growth plate [7]. One possib ility  is that this inhibitory effect 
o f  GH may be m ediated via the stim ulation o f  IGFBP-2 pro­
duction by these ce lls . N ote, how ever, that in our study w e  
used cells derived from the entire growth plate and therefore 
the relative abundance o f  each cell type is unknown. Clearly  
further experiments with enriched cell populations may prove 
fruitful. One w ay to exam ine these possib ilities in vivo would  
be to detect im m unohistochem ically  IG FB P-2 production  
throughout the region o f  the growth plate fo llow ing treatment 
with GH. A s alluded to previously, there is ev id en ce  that 
under som e circum stances IGFBPs may potentiate the actions 
o f  IGFs. It is possib le that GH m ight therefore enhance the 
e ffe c ts  o f  loca l IG Fs by stim u la tin g  the prod u ction  o f  
IGFBPs. In addition given  that IG FBP-2 has a higher affin­
ity for IGF-II than IGF-I [21] local changes in IGF-I/IGF-II 
ratios resulting from increases in IG FBP-2 may a lso  have 
physiological relevance.
Our solution phase data in Fig. 2 demonstrate a bell-shaped  
dose response curve for GH stim ulation o f  IG FBP-release, 
with an optimum effect achieved at around 10 ng/m l and a 
reduction in IGFBP release at 100 ng/nl rbGH. Such data is 
consistent with other tissue culture system s w hich dem on­
strate this type o f  response w hen challenged  with varying  
doses o f  rbGH [22, 23]. This has been rationalised on the 
basis o f  the stoichiom etry o f  interaction betw een GH and its 
receptor being 1:2. A t high concentrations o f  GH it is postu­
lated that nonsignalling 1:1 com plexes betw een hormone and 
receptor m ay form, leading to a decrease in b iological s ig ­
nal. Clearly the exact nature o f  the GH dose-response curve
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obtained w ill be dependent on the density o f  GHR present.
In summary, w e have demonstrated that rbGH stim ulates 
the secretion  o f  IG FB P-2 by m onolayer cultures o f  ovine  
chondrocytes. G iven  the ease  w ith w hich  IG FBPs can be 
quantitated in con d itio n ed  m edium  and the fact that the 
growth plate is a c lassica l target tissue for GH action, w e  
believe that such a system  may provide a relevant, robust and 
high throughput in vitro b ioassay for GH agonists/antago­
nists. This possib ility  is currently being exam ined.
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218) of rat insulin-like growth factor binding protein (IGFBP)-5 are 
important determinants in binding IGF-I
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ABSTRACT
The highly conserved N- and C-terminal domains of 
IGFBPs are believed to participate in IGF binding, 
but only recently have some of the critical residues in 
the IGFBP sequence involved in ligand binding been 
identified. Here we describe two highly conserved 
amino acids in the C-terminal domain of rat IGFBP-5 
that are involved in binding IGF-I. Site-directed 
mutagenesis was used to produce two mutants, 
G203K and Q209A, of rIGFBP-5. Relative to wild- 
type rIGFBP-5, an 8-fold reduction in affinity for 
human IGF-I was found for recombinant G203K 
protein in both IGF-I ligand blots and solution phase 
ligand binding assays, and a 7- and 6-fold reduction 
for Q209A respectively. This shows that Gly203 and 
Gln209 in IGFBP-5 are important determinants in
binding IGF-I, and due to their complete 
conservation in all IGFBP sequences, we suggest that 
they are likely to be involved in binding IGF-I in all 
six binding proteins. In addition, these two non-basic 
residues lie within the ECM binding region (201-218) 
of IGFBP-5, demonstrating that the C-terminus 
contains partially overlapping IGF-I and ECM 
binding sites. We therefore propose that heparin 
binding to basic amino acids in IGFBP-5 between 
201-218 may physically occlude subsequent 
interaction between IGF-I and Gly203/Gln209, and 
that this may explain previous work of others 
showing reduced affinity of ECM-bound IGFBP-5 
for IGF-I.
INTRODUCTION
The mitogenic and metabolic effects of insulin-like 
growth factors (IGFs) are mediated mainly through 
the type 1 IGF receptor, which is found on the 
surface of most cell types (recently reviewed in 
Butler et al. 1997). In turn, the bioavailability of 
IGFs is regulated by a family of IGF-specific 
binding proteins (IGFBPs; reviewed in Clemmons
1997). As the affinity constants of the IGFBPs are 
between 2- and 50-fold greater for binding IGFs 
than that of the IGF type 1 receptor, they can 
modulate IGF action by controlling the distribution 
of IGFs in biological fluids.
Comparisons of IGFBPs 1-6 indicate a high 
degree of conservation in the N- and C-terminal 
regions. Of particular note are the largely conserved 
cysteine residues throughout IGFBPs 1-6 of all 
species sequenced so far. A non-conserved region
separates the N- and C-terminal domains. Both the N- 
and C-terminal cysteine-rich domains of IGFBPs are 
believed to participate in IGF binding. This is 
suggested by the observations that N-terminal 
cysteine-rich domains of IGFBP-1 (Huhtala et 
al. 1986), IGFBP-3 (Sommer et al. 1991), IGFBP-4 
(Chemausek et al. 1995), and IGFBP-5 (Andress et 
al. 1993) and C-terminal cysteine-rich domains of 
IGFBP-2 (Wang et al. 1988; Ho & Baxter 1997) and 
IGFBP-3 (Binoux et al. 1991) all possess residual 
IGF binding activity. Despite this, to date only a 
limited number of mutational analyses of IGFBPs 
have been aimed at the identification of IGF binding 
domains.
Earlier work has shown that IGFBP-5 binding to 
extracellular matrix (ECM) results in a reduction in 
its affinity for IGF-I and enhancement of IGF-I 
biological actions (Andress & Bimbaum 1992; Jones 
et al. 1993). This was confirmed by experiments
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demonstrating that incubation of IGFBP-5 with 
glycosaminoglycans (GAGs) resulted in a 17-fold 
decrease in the affinity of IGFBP-5 for IGF-I (Arai 
et al. 1994). Amino acid substitution and peptide 
competition experiments have identified a sequence 
rich in basic amino acids in IGFBP-5 (between 
Arg201 and Arg218) that is involved in both 
heparin and ECM binding (Arai et al. 1996; Parker 
et al. 1996.), and it was proposed that heparin 
binding to this region may produce a 
conformational change in IGFBP-5 that results in a 
reduction of affinity for IGF-I (Arai et al. 1996). 
More recently, a systematic mutational analysis of 
this region has identified Arg207 and Arg214 as the 
most critical basic amino acids for binding ECM 
(Parker et al. 1998), and, in addition, has shown 
that mutation of 9 out o f the 10 basic amino acids in 
this region had no effect on IGF-I binding.
Recently, work from several laboratories has 
begun to identify the specific amino acids in the 
IGFBP molecule that do contribute to IGF binding. 
At the N-terminus of bovine IGFBP-2, it was 
shown that Tyr60 was protected against iodination 
upon binding of IGFBP-2 to IGF-II (Hobba et al. 
1996). Subsequently, the same group demonstrated 
that substitution of tyrosine-60 with alanine or 
phenyalanine leads to a 4.0- and 8.4-fold reduced 
affinity for IGF-I respectively, and a 3.5- and 4.0- 
fold reduced affinity for IGF-II respectively (Hobba 
et a/. 1998). One suggestion is that the hydroxyl 
group of Tyr60 may participate in hydrogen bond 
formation that is important for the initial complex 
formation with IGF-I, and that this may be a 
common mechanism for all the IGFBPs, (with the 
exception of IGFBP-1 which has an alanine residue 
at the equivalent position). In support of this, others 
have carried out nuclear magnetic resonance 
spectroscopy on a bacterially expressed N-terminal 
fragment of IGFBP-5 (residues 40-92). From this 
work it was proposed that the primary IGF binding 
domain comprises Val49, Tyr50 (equivalent to 
Tyr60 in IGFBP-2), Pro62 and Lys68 to Leu75, 
where the conserved Leu and Val residues localize 
in a hydrophobic patch on the surface of the 
IGFBP-5 protein (Kalus et al. 1998). However, 
these researchers also demonstrate that the N- 
terminal fragments of IGFBP-5 have a 10 to 200- 
fold lower affinity for IGFs than the full length 
protein, which agrees well with the reported 
reduced affinities of other C-terminally truncated 
fragments of IGFBP-3 (Clemmons 1993) and 
IGFBP-5 (Andress et al. 1993). This indicates that 
other residues at the C-terminus of the IGFBP
proteins may be involved in the additional 
stabilization of IGF complex formation that leads to 
the very high affinity of binding.
Deletion between residues Cys205 to Val214 at the 
C-terminus of human IGFBP-4 has recently been 
shown to cause a 6-fold reduction in affinity for 
binding IGFs (Qin et al. 1998). It is conceivable 
however that deletion of one of the very highly 
conserved cysteines in this region leads to a major 
change in the secondary structure of the C-terminal 
domain, as the six cysteines at the C-terminus of 
bovine IGFBP-2 (bIGFBP-2) have been shown by 
Forbes et al to form disulphide bonds between 
consecutive residues (Forbes et al. 1998). These latter 
researchers also demonstrated that truncation of 48 
residues from the C-terminus of bIGFBP-2 had no 
effect on IGF binding (equivalent to residue 200 in 
human IGFBP-4), suggesting that residues which 
contribute to IGF binding differ between IGFBP-2 
and -4. However, greater reduction in affinity for 
both IGFs was observed when 63 residues were 
deleted from the C-terminus of IGFBP-2, with a 
greater effect on IGF-II binding (up to 80-fold). This 
therefore identifies a critical region between amino 
acids 222-236 of bIGFBP-2 involved in binding IGFs 
(Forbes et al. 1998).
This critical region of bIGFBP-2 corresponds to 
amino acids 201 -216 in the rat IGFBP-5 (rIGFBP-5) 
sequence, which lies within the basic heparin binding 
region of the protein. Alignment of amino acid 
sequences for all six binding proteins from several 
species revealed that there are completely conserved 
glycine and glutamine residues (GIy203 and GIn209 
in rIGFBP-5) within this region (Fig 1A), which, in 
turn, suggests an important conserved function for 
these amino acids. Using site directed mutagenesis, 
we have made two mutants of rIGFBP-5 (G203K and 
Q209A), and examined their affinity for binding 
human IGF-I (hIGF-I). We report here that the 
individual mutations both cause an approximately 8- 
to 7-fold reduction in affinity for hIGF-I as shown 
both by IGF-I ligand blotting and solution phase 
ligand binding assays. The implications of these 
findings for IGFBP-5 interaction with both IGF-I and 
ECM are discussed.
MATERIALS AND METHODS
Site-directed mutagenesis
The full-length cDNA for rIGFBP-5 in pGEM®-7$f 
(Promega), containing both initiator and signal 
peptide, was kindly provided by Dr S. Guenette, Los
Journal o f Molecular Endocrinology (1999) 23, 117-123
Rapid Communication
Table 1. Affinity of wtIGFBP-5. G203K and Q209A for hIGF-I
Western Analysis Scatchard Analysis
Protein Estimation of protein 
concentration (us/ml)
Affinity for hIGF-1: 
% wt
Estimation of protein 
concentration (us/ml)
Affinity for hIGF-I: 
K0 (nM)
wt BP-5 5.5 100 6.3 0.154
G203K 6.9 12.5 8.1 1.25
Q209A 7.8 15.0 11 0.84
Kd values were obtained by Scatchard analysis of binding data as described in the Methods section.
Angeles. It was subcloned into the EcoRI restriction 
site of pFastBac® (Gibco-BRL) for eventual 
expression in the baculovirus system. Site-directed 
mutagenesis was then performed at two separate 
sites on the rIGFBP-5 cDNA using the Gene 
Editor® in vitro mutagenesis system (Promega). For 
the G203K mutation, the oligonucleotide 5’- 
CC AACTGT G ACCGC AAAAA ATT CT AC AAG A
GAAAGC-3’ was used, which created a unique Apol 
restriction site, and for Q209A it was 5’- 
GATTCTACAAGAGAAAGGCATGCAAGCCTTC 
TCGTGG-3’, which created a unique SphI restriction 
site. The products of the initial mutagenesis reactions 
were transformed into E. coli ESI301 mutS, a repair 
minus strain, to avoid selection against the desired 
mutations. Following mutagenesis, the DNA was
G203 0209
Cysteine-Rich Nan-Conserved Cysteine-Rich
N-Tenmnal Domain Central Domain C-Terminal Domain
BP5 rat (197) PhCDRKGFYKRKQCKP(212)
BP1 human (179) PhCNKNGFYHSRQ£ET(194)
BP1 bovine (183) PhCNKNGFYHSKQ£ET(183)
BP1 rat (192)PhCNKNGFYHSKQCET(207)
BP2 human (224) PhCDKHGLYNLKQCKM(239)
BP2 rat (205) PhEDKHGLYNLKQ£KM(220)
BP3 human (211) Pf£DKKGFYKKKQCRP(225)
BP3 bovine (211) PNCDKK5FYKKKQCRP(225)
BP3 pig (207) P>CDKKGFYKKKQ£RS(222)
BP3 rat (212) PfCDKKGFYKKKQCRP(226)
BP4 human (182) PhCDRNGNFHPMQCHP(I97)
BP4 bovine (182) PhCDRNGNFHPHQCHP(197)
BP4 rat (178) PNCDRNGNFHPKQ£HP( 193)
BP5 human (197) PbCDRKGFYKRKQ£KP(212)
BP6 human (166) PN£DHRGFYRKRQCRS(181)
BP6 rat (149) PhCDLRGFYRKQQCRS(164)
-  COOH
B 201 -Arg-Lys-Gly-Phe-T yr-Lvs-Arg-Lvs-Gln-Cys-Lys-Pro-Ser-Arg-Glv-Arg-Lvs-Arg-218
FIGUREl
A. C-terminal amino acid sequences of IGFBP. At the top is a schematic representation of the three structural domains of the IGFBPs. The relative 
location of the conserved glycine and glutamine residues are shown above the C-terminal domain, and the substituted amino acids below. The box 
underneath shows a line-up of the amino acid sequences for this C-terminal region in all six IGFBPs from several different species. The residue 
number at the start and end of each sequence is indicated in brackets. The conserved cysteines are underlined and the G203 and Q209 are in bold.
B. Amino acid sequence of the 201-218 region of IGFBP-3. Basic amino acids are underlined and Gly203 and Gln209 are in bold.
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maxi-prepped using the Qiagen Plasmid Maxi Prep 
Kit and manually sequenced using the T7 
Sequenase™ version 2.0 DNA sequencing kit 
(Amersham Life Sciences), which verified that the 
correct mutations were present.
Baculovirus expression
Expression of recombinant IGFBPs in the insect 
cell-baculovirus system was carried out using the 
Bac-to-Bac® system (Gibco-BRL), which employs 
the techniques of Lucklow et al. 1993 to produce 
recombinant virus. Conditions for expression were 
the same as that in the manufacturer’s guide, with a 
chosen multiplicity of infection of 5. Sf9 insect 
cells (Spodoptera frugiperda) were grown in Sf-900 
II medium (Life Technologies). 50 ml suspension 
cultures were grown in spinner flasks (Techne) and 
culture supernatant containing secreted IGFBP 
protein was harvested 24 to 28 hours after infection, 
depending on the optimum level of expression of 
the individual protein. Supernatants were 
concentrated using 20 ml Ultrafree-20® (Millipore) 
columns and aliquots were frozen in liquid nitrogen 
and stored at -70  °C.
IGF-I Ligand Blotting
Proteins were electrophoresed on 12% acrylamide 
SDS gels under non-reducing conditions and 
subsequently transferred to nitrocellulose 
membranes. Ligand blots were performed 
according to the method described by Hossenlopp 
et al. 1986 , using IGF-I (GroPep) radiolabelled to a 
specific activity of approximately 100 jiCi/pg. 
Following ligand analysis the same blots were used 
for immunodetection.
Immunoblotting
Western blotting of wt IGFBP-5, G203K and 
Q209A was performed to monitor protein loading 
of samples which had previously been subjected to 
ligand blot analysis. Immunodetection was with a 
sheep antibody raised in our laboratory to 
baculovirus-expressed wt rIGFBP-5 protein 
provided by Dr Sean Guenette (John Wayne Cancer 
Institute, Los Angeles). First antibody was used at a 
dilution of 1:2000 and anti sheep-HRP conjugate at 
1:20,000. Reactivity was determined using 
Enhanced Chemiluminesence (ECL) (Amersham) 
and densitometric analysis (Molecular Dynamics).
Quantitation of wt IGFBP-5, G203K and Q209A in 
baculovirus supernatants was achieved by Western 
blot/densitometry using as standard wt IGFBP-5 
supplied by Dennis Andress (Veterans Affairs 
Medical Center, Seattle). Care was taken to operate 
with standards and samples within the linear range of 
the ECL/Film response methodology. Using this 
technique protein concentrations of 5.5, 6.9 and 7.8 
pg/ml were found for wt IGFBP-5, G203K and 
Q209A respectively (Table 1).
Solution Phase Assay of IGFBP activity
Activity of wt IGFBP-5, G203K and Q209A were 
assessed in solution by the method described by 
Conover et al. 1989. Amounts of wt, G203K and 
Q209A proteins were present in assay tubes such that 
approximately 20% of added ,25I-IGF-I (25-30,000 
cpm) was bound. Affinity of wt and mutated IGFBP- 
5 proteins was assessed by Scatchard analysis of 
binding curves obtained following addition of 
increasing concentrations of unlabelled IGF-I. 
Protein concentrations as estimated by Scatchard are 
6.3, 8.1 and 11 |ig/ml for wt IGFBP-5, G203K and 
Q209A respectively (Table 1).
RESULTS AND DISCUSSION
Two amino acids in the C-terminus of IGFBPs 
(Gly203 and Gin 209 in IGFBP-5) are completely 
conserved between all six binding proteins from all 
species sequenced to date (Fig 1A). In this work, we 
demonstrate that these residues in rIGFBP-5 are 
important determinants in binding IGF-I. Wild-type 
IGFBP-5 and the two mutants G203K and Q209A 
were probed with l25I- labelled IGF-I in ligand blots, 
and the same blots were subsequently probed with a 
sheep anti-IGFBP-5 polyclonal antisera (Fig 2A). 
The IGFBP-5 doublet produced by expression in the 
baculovirus system is a common feature from several 
laboratories (personal communications Dr D. 
Andress, Dr S. Guenette), including commercially 
available hIGFBP-5 (Austral Biologicals), and this 
may be the result of inefficient cleavage of the 
mammalian signal peptide during secretion. 
Nevertheless, BiaCore analysis of the wt IGFBP- 
5/hIGF-I and -II  interaction recorded a single 
association and dissociation event (data not shown), 
suggesting that the IGFBP-5 doublet represents a 
single species with respect to IGF-I binding. Also, 
the strong recognition of the mutant proteins with our 
IGFBP-5 antibody demonstrates their immunological 
integrity. Densitometry was carried out on ligand and
Journal o f Molecular Endocrinology (1999) 23, 117-123
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A B
wt G203K Q209A
G203 K Q209A
Anti-rIGFBP-5
FIGURE 2. Western analysis of wild-type and mutant protein.
A. Both autoradiographs were produced from a single western blot. The upper autoradiograph is a ligand blot of wt rlGFBP-5 protein 
and the two mutant proteins G203K and Q209A probed with lUI-hIGF-I. The lower autoradiograph is the same blot subsequently 
probed with sheep anti-rIGFBP-5 polyclonal antisera.
B. Histogram showing the results of a densitometric analysis of the upper autoradiograph in 2A (n = 2 + range).
western blots from two separate experiments and 
the ratio between the strength of signal in ligand 
and western blot determined (Fig 2B; Table 1). This 
demonstrated that, relative to wt IGFBP-5, G203K 
and Q209A have an 8- and 7-fold reduction in 
affinity for IGF-I respectively.
This is in very strong agreement with the IQ 
values derived from solution phase binding assays 
for these three proteins (Fig 3; Table 1). The IQ of 
wt IGFBP-5 in our experiments is also in agreement 
with previous results using mammalian and yeast 
expressed protein (Kiefer et al. 1992), but we 
demonstrate that, relative to wt IGFBP-5, G203K 
and Q209A have a 8- and 6-fold reduction in 
affinity for IGF-I respectively (Table 1). Forbes et 
al 1998 demonstrated up to an 80-fold reduction in 
IGF-II affinity when the equivalent amino acids 
(222-236) were deleted from bIGFBP-2. This larger 
reduction in affinity may be a result of differential 
IGF-I and -II recognition. Alternatively, loss of 
both conserved amino acids may explain the larger 
effect. The affinity of a double mutation in rlGFBP- 
5 (G203K, Q209A) for both IGF-I and -II is the 
subject of ongoing research in our laboratory. Note, 
however, that the C-terminal truncated bIGFBP-2 
proteins may have lost other residues involved in 
IGF binding. Indeed, smaller truncations did appear 
to alter IGF binding specificity selectively,
suggesting that other more C-terminal residues may 
be involved in differential IGF-I and -II recognition 
(Forbes et al. 1998).
A myriad of functions has now been ascribed to the 
basic amino acid rich region between Arg201 and 
Arg218 in IGFBP-5. In addition to heparin and ECM 
binding (Arai et al. 1996; Parker et al. 1996), this 
region has been implicated in binding to the acid 
labile subunit (Twigg et al. 1998), the putative 
IGFBP-5 receptor (Andress 1998), plasminogen 
activator inhibitor-I (Nam et al. 1997), and has even 
been postulated to have strong homology to a nuclear 
localization signal (Schedlich et al. 1998) and the 
DNA-binding domains of several transcription 
factors (Schedlich et al 1998; Turner & Tijan 1989). 
Recently, a systematic mutational analysis of this 
region, using either single or combined substitutions 
of basic amino acids, has identified the critical 
residues involved in ECM binding (Parker et al.
1998). While some of these mutations displayed 
major reductions in ECM binding, they were shown 
to have little effect on IGF-I affinity, and it was 
concluded that the 201-218 region was not involved 
in binding IGF-I.
It is, therefore, of major significance that two of the 
non-basic amino acids lying within this region have 
now been shown to be involved in IGF-I binding. In 
the linear sequence, Gly203 and Gln209 flank a
Journal of Molecular Endocrinology (1999) 23, 117-123
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FIGURE 3. Regression lines drawn through the data obtained 
by Scatchard analysis of hIGF-I binding to wt IGFBP-5 (solid 
line: y = -0.0063x + 0.95 (r = -0.94)), G203K (dashed line: y = 
-0.0008x + 0.23 (r = -0.96)) or Q209A (dotted line: y =
-0.0012x + 0.47 (r = -0.77)). IGFBPs were present at 1.1,6.9 
and 7.4 ng/tube for wt, G203K and Q209A respectively. Kd 
values were determined from these plots and are as indicated 
in the Figure. This experiment was performed twice and 
similar results were obtained in each instance.
critical residue involved in ECM binding (Arg207), 
and, in turn, are themselves flanked by other basic 
residues which play a part in this interaction (Fig 
IB). In addition, a helical wheel prediction of the 
201-218 region of IGFBP-5 (Parker et al. 1998), 
places Gly203 adjacent to the critical ECM binding 
residues, while Gln209 is flanked by two further 
basic residues elsewhere in the wheel. Thus, we 
have demonstrated that IGF-I and ECM binding 
sites in IGFBP-5 are in very close proximity and 
may partially overlap.
This has important implications for the function 
of IGFBP-5. Heparin or ECM binding to the basic 
amino acids in the 201-218 region of IGFBP-5 may 
physically occlude any subsequent interaction 
between Gly203/Gln209 and IGF-I. This would 
offer an alternative explanation for the observed 
reduced affinity of ECM/GAG bound IGFBP-5 for 
IGF-I (Andress et al. 1992; Jones et al 1993.; Arai 
et al. 1994), rather than a heparin induced 
conformational change in IGFBP-5 which alters an 
IGF binding domain elsewhere in the protein. The 
lower affinity of ECM-bound IGFBP-5 for IGF-I 
may be biologically important for obtaining the 
correct balance between soluble IGF-I available for 
binding the type 1 IGF receptor and a reservoir of 
immobilised IGF-I protected from proteolysis while 
bound to the ECM.
In summary, we have identified two highly 
conserved C-terminal residues in IGFBP-5 involved 
in IGF-I binding. Due to the complete conservation 
of these two amino acids in all IGFBP sequences, 
we suggest that they are likely to be involved in
binding IGF-I in all six of the binding proteins. 
Overlap of these residues in IGFBP-5 with other 
amino acids between 201-218, that have been shown 
to be involved in ECM binding, suggests their 
involvement in the interaction between IGFBP-5, 
ECM and IGF-I.
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Characterization of the IGF axis in 
a rat liver-derived epithelial cell line
Silvia Bramani, Gordon J. Allan and James Beattie
Hannah Research Institute, Ayr KA6 5HL, UK
Summary We have used the techniques of chemical cross-linking, W estern blotting and immunoprecipitation-ligand 
blotting to dem onstrate that insulin-like growth factor binding protein-2 (IGFBP-2) is associated with plasm a 
m em branes of an epithelial cell line derived from rat liver a s  well a s  being secreted into the medium by these cells. We 
dem onstrate that these cells secrete  IGF-I, but not IGF-II into serum  free medium. Evidence from signalling, cell 
proliferation and cross-linking experiments indicate that these cells also express cell surface IGF-I receptors. 
D ose-response  experiments indicate an enhanced biological activity of the IGF-I analogue des (1-3) IGF-I com pared 
to wild-type IGF-I in both acute signalling experiments and longer-term (24 h) mitogenic assays. As this IGF-I analogue 
has lower affinity for IGFBPs, we believe that in this cell culture system , activity of IGF-I may be attenuated in the long 
and short term by the accumulation of IGFBP-2 in conditioned medium and by the p resence of IGFBP-2 associated 
with the cell m em brane and/or ECM.
©  1999 Harcourt Publishers Ltd 
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INTRODUCTION
The in su lin -like grow th factors (IGF-I and -II) are sm all 
polypeptides w h ich  h ave im portant m etabolic  and  
grow th prom otin g  action s (review ed in  ref. 1). In b io log i­
cal flu ids on ly  a sm all proportion o f  th e  IGFs ex ist in  a 
free form, w ith  th e  m ajor fraction o f  c irculating IGFs 
b eing  b o u n d  to  h igh-affin ity  carrier proteins -  th e  IGF 
binding proteins (IGFBPs). To date, six  such  b ind ing  pro­
teins h ave b een  identified  and clon ed  for b oth  rat and  
h u m an s2. In addition, a fam ily o f four low -affin ity IGF 
binding proteins has recently b een  described3. T he six  
high-affin ity  IG F B P s(l-6) are characterized by a h igh  
degree o f  structural similarity. T his is typically  apparent 
by the con servation  o f cy ste in e  residu es in  th e  prim ary 
structure, all o f w h ich  are invo lved  in  d isu lph ide b ond  
form ation and w h ich  are in  turn b elieved  to  be im portant 
in form ing a m olecu lar 'scaffold' for th ese  proteins. 
A lthou gh  n o  X-ray crystallographic structure is available
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for any o f the IGF b ind ing  proteins, recent ev id en ce  from  
peptide m apping and proteolysis stu d ies4 su ggests  a 
three-dom ain  m od el for th ese  proteins w ith  cystein e-rich  
N- and C- term inal dom ains b ein g  con n ected  by a central 
h in ge region.
In a functional sense, IGFBPs h ave traditionally b een  
v iew ed  as a reservoir o f  polypeptid e grow th factor, 
buffering tissu es from th e h yp og lycem ic  effects o f large 
circulating levels o f  IGF-I. Recent m olecu lar and cellular  
studies, how ever, have led to a refinem ent o f th is v iew  
and have postu lated  activ ities o f IGFBPs, w h ich  h ave  
included  h orm on e-in d ep en d en t effects3. One major area 
o f research has b een  d eve lop ed  fo llow ing th e  reports o f  
in teraction  o f IGFBPs w ith  various e lem en ts o f  the extra­
cellular m atrix and cell m em bran es6 7. Interactions w ith  
ECM are b elieved  to  take place v ia  positively-charged  
con sen su s heparin-b ind ing seq u en ces present in all 
binding proteins excep t IGFBP-4. Such b ind in g  is 
believed  to  affect the b io log ica l properties o f  th e  IGFBP 
proteins by altering affinities for IGFs and by protecting  
BPs from  degradation by locally  produced  proteases*'9. 
Clearly th is m eth od  o f m od u lating  IGFBP activity could  
have im portant b io logical im plications in regu lating the  
supply o f IGF polypeptide to  target tissues.
1096-6374/99/060425+09 $18.00/0 ©  1999 Harcourt Publishers Ltd
426 S. Bramani et al.
For IGFBP-1, interaction  w ith  cell m em brane integrin  
a 5P, (via a C -term inal RGD seq u en ce  in th e  b in d in g  pro­
tein) has b een  reported, and IG F-independent effects o f  
BP-1 on  ce ll m igration w ere d o cu m en ted 6. In addition, 
IGFBP-3 and IGFBP-5 h ave a lso  b een  reported to  a ssoc i­
ate w ith  cell m em brane protein  or g lycosam in og lycan  
recep tors10". Like IGFBP-1, IGFBP-2 also p o ssesses a C- 
term inal RGD integrin  b in d ing  m otif, a lth ou gh  to  date  
no in teraction  w ith  th is c lass o f  cell surface b ind in g  m ol­
ecu le  has b een  proposed  for th is particular b ind ing  pro­
tein. N otw ithstan d ing  th is, lim ited  reports h ave  
su ggested  that IGFBP-2 is in d eed  identifiable in plasm a  
m em brane preparations12-14. In order to  provide further 
support for th is p h en o m en o n  and address its b io log ica l 
sign ificance, w e h ave  in vestigated  th e  association  o f  
IGFBP-2, secreted  b y  a rat liver ep ithelia l ce ll line, w ith  
m em branes derived  from  m onolayer culture o f th ese  
cells. By th e  u se  o f various tech n iq u es w e clearly d em on ­
strate su ch  an association  and  provide further support 
for th e  h yp oth esis  that IGFBP-2 b inds to  p lasm a m em ­
branes. Further, w e dem onstrate th e  secretion  o f  IGF-I by  
th ese  cells and th e  p resence o f  functional IGF-I receptors  
in  ce ll m em branes. In addition, w e describe experim ents  
w h ich  su ggest an im portant role for secreted , and per­
haps m em b rane-associated  IGFBP-2 in th e  au tocrine reg­
u lation  o f  th e  cell response to  IGF-I.
MATERIALS AND METHODS
Materials
The rat liver ep ithelia l cell line (C lone 9) w as obta ined  
from  th e European C ollection  o f A nim al Cell C ultures 
(ECACC Cat N o CRL1439) at Salisbury, U K 15; reagents for 
tissu e  culture w ere from  Gibco, (Inchinnan, UK); tissue  
culture p lastic w as from  Costar (Bucks, UK); m in i-gel 
electrophoresis and b lo ttin g  equ ipm ent w as from  
BioRad, Herts, UK; BCA protein  reagent w as from  Pierce 
(Chester, UK); E nhanced  C h em ilu m in escen t R eagent 
(ECL), Hyperfilm , H ybond-C  and PVDF m em branes w ere  
from  A m ersham  (Bucks, UK); MTT (thiazolyl b lue) w as 
from  Sigma; rabbit p o lyclonal an ti-bovine IGFBP-2 and  
an ti-p h osp h otyrosin e  m o n oclon a l antibody 4G 10 w ere  
from TCS B iologicals (Bucks, UK); rabbit polyclonal anti­
hum an  IGF-I w as a gift from  NIADDK (Bethesda, USA) 
and rabbit p o lyclon al an ti-hu m an  IGF-II w as from  
GroPep Pty (Adelaide, Australia); horse radish peroxidase  
(HRP) conju gated  secon dary  antibod ies w ere from  
Sigma; pansorbin w as from  C alb iochem  (N ottingham , 
UK, Cat N o 507861); h  IGF-I, hIGF-II and des (1 -3 ) IGF-I 
w ere from  GroPep Pty (Adelaide, Australia); bovin e  
insu lin  w as from  Sigma. All o th er reagents w ere o f  ana­
lytical grade. B aculovirus derived recom binant rat 
IGFBP-2 w as p rodu ced  in  our laboratories.
METHODS
Cell culture and plasma membrane preparation
C lone 9  cells w ere grow n in  Ham s F I2 conta in ing  2 mM  
glutam ine, 10% FCS, Penstrep and p lated  in  10 cm  Petri 
dishes. W hen  con flu en ce w as reached, cells w ere w ashed  
w ith  H anks Balanced Salt Solution  (HBSS) and serum - 
starved overn ight in  serum  free m ed iu m  (SFM -  H am s 
F I2 /  0.1% BSA/ 2 m M  glutam ine). Enriched cell m em ­
brane preparations w ere prepared as described  by  
W oodw ard et a l.16. M onolayers w ere w ash ed  tw ice w ith  
ice cold  PBS and cells w ere d etached  from  plates in  h yp o­
ton ic  buffer [1 mM EDTA, 1 mM  N a bicarbonate (pH 7.4) 
2 mM  PMSF, 3 pM leupeptin , 16 pM aprotinin, 50 0  pM  
NaVoJ T he cell su sp en sion  w as h o m o g en ized  (Polytron  
10 s) and centrifuged  at lOOOg at 4°C for 10 m in. The 
supernatant from  th is first sp in  w as centrifuged  at 15 00 0  
g  for 5 m in. To produce an enriched  plasm a m em brane  
preparation, th e  15 0 0 0  g  supernatant w as centrifuged  at 
50  0 0 0  g  for 9 0  m in. M em branes w ere resuspend ed  in  10 
mM  Tris pH 7.4 in  th e  p resen ce o f protease inhibitors, the  
protein  concentration  w as determ ined  w ith  BCA protein  
assay  and a liquots w ere stored  at -  20°C  prior to  further  
analysis.
Western and ligand blotting
C oncentrated  sam ples o f  th e  enriched  plasm a m em brane  
preparations w ere subject to  electrophoresis on  12% 
non-red u cin g  SDS ge ls and transferred to  H ybond C 
m em branes. Ligand b lots w ere perform ed essen tia lly  
accord ing to  th e  m eth od  described  b y  H ossen lop p  e ta V 7 
Briefly, m em branes w ere w ash ed  in  3% N P4() in  Tris 
buffered-saline [TBS -  10 mM  Tris 6 0  mM  NaCl (pH 7.4)] 
for 30  m in, TBS -  1% BSA for 2 h  and TBS -  0.1% T w een  
(TBS-T) 20  for 10 m in. M em branes w ere hybridized  
overn ight w ith  l25I-IGF-I ( -1 .5  x 106 cpm) in  1 -2  m l 
TBS -  1% BSA, 0.1%  T w een 20  at 4°C. T lie m em branes  
w ere th en  w ashed  in TBS -T (3 x 15 m in) and 2 x 1 5  m in  
in  TBS. M em branes w ere dried and exp osed  to  X-ray film  
for periods o f  up to  10 days. For W estern blots, m em ­
branes w ere b locked  in  3% BSA-TBS-T and incubated  
w ith  a rabbit po lyclonal aIGFBP2 Ab 1:2000 (in 1% BSA- 
TBS-T) for 1 h, w ashed  in TBS-T ( 3 x 1 5  min), incubated  
w ith  an arabbit-H RP (1:5000 in 5% non-fat dried m ilk in  
TBS-T) for l h  and w ash ed  (3 x 15 min; TBS-T) again. 
Protein bands w ere v isu alized  by ECL detection .
Immunoprecipitation of membrane associated IGFBP-2 
T he im m unoprecip itation  o f so lub ilized , C lone 9 plasm a  
m em branes w as perform ed as a m odification  o f a m eth od  
previou sly  d escr ib ed 1’. 8 0 0  pg o f plasm a m em branes  
w ere so lu b ilized  by treatm ent for 1 h  at 4°C in 4 0 0  pi 
buffer A (50 mM Tris pH 7.4, 150 mM NaCl, 0.01%  N aN v 
0.8 m g/m l pepstatin , 2 m g/m l aprotinin, 2 m g/m l
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leupeptin , 1% Triton x-100 , 1% Na cholate). 4 0 0  pi o f  
buffer B (20 mM Tris HC1 pH  7.5, lO m M  M gCl2, 0.2%  
BSA) w as added  and sam ples centrifu ged  at 28  5 0 0  x  g  
for 30  m in  at 4°C. T he supernatants w ere transferred to  
fresh tu b es  and rotated overn ight at 4°C w ith  10 pi anti- 
b ov in e  IGFBP-2. T he an tibod ies w ere precipitated by  
th e  ad d ition  o f  50  pi Pansorbin and centrifugation  at 
6 0 0 0  x  g  for 10 m in. T he resu ltant pellet w as w ashed  
th ree tim es w ith  buffer A and resu sp en d ed  in  50  pi o f 2X 
n on -red u cin g  sam ple buffer, left on  ice  for 3 0  m in, then  
b oiled  for 3 m in. Sam ples w ere analysed  by ligand b lo t­
ting  w ith  l25I-IGF-I as described  above.
Detection o f IGF-I and IGF-II in Clone 9 cell conditioned 
medium
C onfluent m onolayers o f C lone 9  cells (4 x 107 cells) w ere 
allow ed  to  con d ition  serum  and protein  free m ed ium  
(~ 130 ml) over a period o f 24  h. The vo lu m e o f m ed iu m  
w as red u ced  in  tw o stages by freeze-drying to approxi­
m ately  5 m l and d ialysed  ex ten sive ly  against 10 mM  Na  
ph osp h ate  (pH 7). Sam ples (10 pi) o f concentrated , d ial­
ysed  m ed iu m  w ere subject to  n on -red u cin g  SDS-PAGE 
(16% polyacrylam ide gels) a lon g  w ith  IGF-I and IGF-II 
standards before transfer to PVDF m em branes. Blots w ere  
probed w ith  rabbit an ti-h u m an  IGF-I (diluted 1:2000 in  
TBS-T) before d evelop m en t w ith  anti-rabbit HRP conju ­
gate (1:5000) in  TBS-T and ECL reagent. IGF-II was 
detected  w ith  a rabbit p o lyclon al an ti-hum an  IGF-II in 
th e  sam e m anner on  parallel b lots.
Effect o f hormones on tyrosine phosphorylation in Clone 9 
cells
C onfluent m onolayers o f  C lone 9 cells in 10-cm  tissue cu l­
ture d ish es w ere starved overnight in serum  free media. 
Prior to horm onal stim ulation, m edia was rem oved and 
the cell m onolayers w ere w ashed  on ce w ith  HBSS. Cells 
w ere th en  treated w ith either IGF-I, des (1 -3 ) IGF-I or IGF- 
II (1 -1 0 0  ng/m l) or insulin  (100 or 1000 ng/m l) in 5m l o f  
fresh serum  free m ed ium  for periods o f 2, 5 or 10 min. At 
the end o f  th is incubation  period, m edium  was rem oved, 
m onolayers w ashed  tw ice w ith  ice-cold  PBS and cell 
lysates w ere prepared as described p reviou sly1*. Lysates 
were run on  SDS-PAGE (7.5% gels) under reducing cond i­
tions and transferred to  H ybond C or PVDF m em branes. 
The profile o f tyrosine-phosphorylated  proteins was deter­
m ined by im m unob lotting  w ith  the anti -  pY M ab 4G 10  
(1:5000 in  TBS-T) w ith  detection  by anti-m ouse HRP con ­
jugate (1:20 00 0  in TBS-T) and ECL
Cell proliferation assay
To m easure the m itogen ic  response o f  C lone 9 cells to  
different po lypeptide h orm ones, cells w ere trypsin ized  
from stock  cu ltures and seed ed  in 96-w ell tissu e  culture  
plates at a d en sity  o f  6  x  103 ce lls /w ell in 50  pi o f  H am s
F I2 / 0.1% FCS/PenStrep. After overn ight incubation  
(37°C, 5% C 0 2), cells w ere treated  for 2 4 - 4 8  h  w ith  a 
further 50  pi o f  H am s F 12/ 0.1 %FCS/ Penstrep conta in in g  
various concentrations o f IGF-I, IGF-II, d e s ( l-3 )  IGF-I or 
insu lin  as described in Fig. 5 (A,B). At th e  en d  o f  th e  in cu ­
bation  period, 10 pi o f stock  MTT (3-[4,5-D im e- 
thylth iazol-2-yl]-3 ,5-d iphenylform azan) -  5 m g  per m l in 
RPMI 1640 m ed ium  w /o  P h en o l Red w as added to  each  
well, and in cu bation  w as co n tin u ed  for a further 3 h. 
Following so lub ilization  o f  dye b y  the add ition  o f  150 pi 
of 0 .05 M HC1 in isopropanol, absorbance o f m icrotitre  
w ells was determ ined  at 6 2 0  nm . M itogen ic/m etab olic  
activities o f added polyp ep tides w as m easured  by  
increased  absorbance at th is w avelen g th  (see Fig. 5 A,B).
Cross-linking
106 cpm  125I-IGF-I or ,25I-IGF-II w ere in cu b ated  w ith  4 0 0  
pg m em brane protein  in a total v o lu m e o f  1 m l o f  reac­
tion  buffer (RB) — 5 mM  Tris.Cl (pH 7.4) con ta in in g  0.5%  
(w/v) fatty acid  free BSA— in th e  p resence or ab sen ce o f  
com p etin g  u n lab elled  h orm one [IGF-I, IGF-II, des (1 -3 )  
IGF-I or insulin: 1 pg/tube]. R eactions w ere rotated at RT 
for 3 h  fo llow ed  by cen trifugation  (10 0 0 0  g, 10 min). 
Supernatants w ere discarded, pellets w ash ed  by resu s­
p en sion  in  1 m l o f  RB and re-centrifuged. Finally, pellets  
w ere resu sp en d ed  in  BSA-free RB and cross-link in g  was 
ach ieved  by th e  addition  o f  50  pi o f 4 0  m M  DSS in an h y­
drous DMSO and incubation  at 4°C  for 15 m in. T he reac­
tion was q u en ch ed  by the addition  o f  2 0 0  pi 50  mM  
Tris.Cl (pH 7.4) 5 mM EDTA. C entrifugation  was repeated  
as described above, m em brane pellets resu sp en d ed  in  
SDS sam ple buffer b oiled  for 3 m in  and resolved  on  12% 
gels under reducing cond ition s. Gels w ere C oom assie  
Blue stained, dried and u sed  for direct autoradiography.
lodination
IGF-I and IGF-II w ere iod inated  by the Iodogen  coated  
tube m eth od  to  a specific activ ity  o f - 1 0 0  p C i/u g19.
RESULTS
In initial experim ents to  characterize com p on en ts o f  th e  
IGF axis in th e  C lone 9  cell line, w e exam in ed  the recep­
tor profile o f  th e  cells. In Fig. 1 w e sh o w  the results o f  
cross-link ing exp erim ents w ith  preparations o f C lone 9 
cells p lasm a m em branes and l25I-IGF-I. Tw o major bands  
w ere d etected  at Mrs o f  approxim ately 36  and 120 kDa. 
T he patterns o f com petition  during cross-link ing experi­
m ents indicated  that th e  h igher Mr band represented  th e  
a -su b u n it o f  th e  IGF-I receptor and in d eed  C lone 9  cells 
respond  to IGF-I (see below ). T he low er Mr band was 
com p eted  o n  co -in cu b ation  w ith IGF-I and IGF-II, but 
n ot w ith  des (1 -3 ) IGF-I or insulin . Such a pattern o f com -
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F ig . 1 Cross-linking of ,25I-IGF-I to Clone 9 cell p lasm a 
m e m b ra n e s .  106 cpm  125I-IGF-I w a s  cross-l inked to 400 pg  of Clone 
9 cell p la sm a  m em b ra n e s ,  a s  described  in Materials and  Methods. 
Incubations w ere  performed in the a b s e n c e  of competitor or in the 
p r e s e n c e  of 1 pg  IGF-I, d e s (1 -3 )  IGF-I, IGF-II or  insulin a s  
indicated. Labelled b a n d s  w ere  d e tec ted  by phosphorim ager .  The 
location of putative cross-linked IGFBP ( -3 6  kDa) and  the a-  
subunit  of the IGF-I receptor  a re  indicated by broad and  thin arrows 
respectively. Control exper im en ts  show  the pattern ob ta ined  after 
cross-linking ,25I-IGF-I to baculovirus-derived recombinant rat 
IGFBP-2 (Bac) or cross-linking labelled IGF-I a lone  (label). This 
exper im ent w a s  re p e a te d  three times.
petition is characteristic of the  IGFBP family. Cross-link­
ing experim ents with i2!SI-IGF-II also indicated the  pres­
ence of this IGFBP species and  dem onstra ted  an identical 
pattern of  com petition to that observed with I2SI-IGF-I 
cross-linking. In addition, a very h igh Mr band is appar­
ent w hich shows characteristics of the  IGF-II/mannose-6- 
phospha te  receptor (data not shown). These data 
therefore suggest tha t Clone 9 cells express IGF-I recep­
tors and probably also IGF-II receptors. A lthough we did 
not perform any cross-linking experiments with l2SI- 
insulin, the  results of ou r  ho rm one  s timulation experi­
ments (see later) indicate that insulin receptors are ei ther 
missing or present at a very low abundance .
Repeatedly dur ing  the course of these experiments 
with plasma m em brane  preparations, it was evident that 
a lower Mr band  ( - 3 0 - 4 0  kDa) was specifically labelled 
following e ither  ,2rT-IGF-I or l25I-IG F-I I cross-linking. As 
cross-linked IGF-IGFBP complexes would be predicted to 
have an Mr of this order  and as com petition analysis sug­
gested tha t  this species may be a m em ber  of the  IGFBP 
family, we conduc ted  fu rther  experim ents to test the 
hypothesis  tha t  an  IGFBP(s) was associated with the 
plasma m em brane  of Clone 9 cells. In Fig. 2 we present 
the results of a ligand blotting experiment, where solubi­
lized m e m brane  preparations have been probed with l25I- 
IGF-I. Two IGFBP species are evident (lane 2). The higher 
Mr b inding protein migrates at the  same location as bac­
ulovirus-derived rat IGFBP-2, and  along with o thers  we 
have dem onstra ted  previously tha t  Clone 9 cells produce 
IGFBP-2, and  experim ents to date suggest that this is the
M r-
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Fig . 2 Prote ins in solubilized Clone 9 cell m e m b ra n e s  w ere 
s e p a ra te d  by e lec trophoresis  and  transferred  to Hybond C 
m e m b ran es .  Ligand blotting w as  perform ed with ,25I-IGF-I and  
identified an  IGFBP (lane 2), which co-migrated  with recombinant 
baculovirus der ived rat IGFBP-2 (lane 3). To confirm the identity of 
this IGFBP, solubilized m e m b ra n e  p repara t ions  w ere subjec t  to 
immunoprecipitat ion with polyclonal rabbit anti-bovine IGFBP-2, a s  
described  in Materials and  Methods. S u b s e q u e n t  blotting of 
immunoprecip ita tes  with ,25I-IGF-I confirmed the  p re se n c e  of 
IGFBP-2 in cell m e m b ra n e s  (lane 1: thick arrow). Note the 
p r e s e n c e  of a smaller Mr IGF-I binding s p e c ie s  p resen t  in non- 
immunoprecip itated m e m b ra n e s  (lane 2: thin arrow). This 
exper im ent w a s  rep ea ted  th ree  t imes with identical results in ea c h  
cas e .
only b inding protein species present in m ed ium  condi­
tioned by this cell line.20' 22 We hypothesized, therefore, 
that this m em brane  associated IGFBP could also be 
IGFBP-2. To confirm this, we performed im m unoprecip i­
tation experiments with solubilized Clone 9 cell m em ­
branes and  anti-bovine IGFBP-2 antiserum. This 
an tiserum  recognizes IGFBP-2 from several species 
(including rat) with only minimal cross-reactivity with 
o ther  IGFBPs2'. Ligand blot of the resultant im m une  
complex identified the cell-associated IGF b inding pro­
tein as IGFBP-2 (lane 1). The smaller Mr IGF binding 
protein fragment was not im m unoprecip i ta ted  with anti- 
BP2. This smaller Mr fragment does not appear consis­
tently, and  its identity is currently  unknow n.
We were interested in exam ining w hether  IGFBP-2 
could potentially affect the response of Clone 9 cells to 
exogenous IGF-I. Preliminary evidence from o u r  cross- 
linking studies indicated the  presence in cell m em branes  
of IGF-I receptors. We therefore conduc ted  horm one 
stimulation experiments using cu l tu res  of Clone 9 cells. 
We designed two different experimental models to work 
within. Initially, we exam ined the acu te  effects of IGF-I, 
des (1-3) IGF-I, IGF-II and insulin in the stimulation of 
protein tyrosine phosphorylation  in Clone 9 cells over 
a short time course. In Fig. 3 we present results of
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Fig . 3 Clone 9 cell m onolayers  were t rea ted  with 100 ng/ml IGF-I, 
d e s  (1 -3)  IGF-I or insulin (100 and  1000 ng/ml) After preparation 
of cell lysa tes,  tyrosine phosphorylated  proteins w ere  de tec ted  by 
blotting with the anti-phosphotyrosine antibody 4G 10  a s  descr ibed  
in Materials a n d  Methods.  The arrow indicates the IGF-I a n d  d e s  
(1 -3)  IGF-I specific induction of a - 1 8 0  kD tyrosine-phosphorylated  
protein. Insulin at 100 or 1000 ng/ml h ad  no effect on the level of 
tyrosine phosphorylation of this protein. This exper im ent w as  
re p e a te d  three  times.
anti-phosphotyrosine blots of cell lysates following treat­
m ent of cultures with IGF-I, des (1-3) IGF-I or insulin. 
IGF-I and  des (1-3) IGF-I (100 ng/ml for both) were 
found to stimulate the tyrosine phosphorylation  of a pro­
tein of Mr ~ 180 kD, whereas insulin, even at two phar­
macological doses, had little effect on the tyrosine 
phosphorylation  of this protein. Although we have pos­
tulated that this protein is a m em ber  of the insulin recep­
tor substra te  family (IRS), we have to date, been unable 
to precipitate this species with commercial anti-IRS 1 
antisera. However, this data confirms the  presence in 
Clone 9 cells of functional IGF-I receptors and may sug ­
gest a relative paucity of insulin receptors, (although this 
would require further confirmation by, for example b ind­
ing and /o r  cross-linking s tudies with radio-labelled 
insulin). In addition, dose-response  studies with both 
IGF-I and  des (1-3) IGF-I indicated that the latter ho r­
m one (which binds poorly to IGFBPs) was more active in 
stim ulating  the tyrosine phosphorylation  of this protein 
(Fig. 4) at concentrations of 10 and 100 ng/ml (see 
Discussion)
These results were confirmed both  in terms of activity 
profiles and dose-responses in a separate bio- assay sys­
tem where the metabolic/mitogenic activity of horm ones  
was tested by the MTT assay system (Fig. 5). This for- 
mazan dye-based m ethod for the  examination of the 
mitogenic/metabolic activities of horm ones has been 
used previously in the context of IGF ligands2-1. Again, 
IGF-I and des (1-3) IGF-I dem onstra ted  considerable 
activity in this assay, whereas insulin (Fig. 5A) and IGF-II
C 1 10 100 1 10 100 1 10 100
* IG F -I  * * D E S  * * IG F -II  ►
B lo t a n t i-p Y
Fig . 4 D o s e -d e p e n d e n c y  of induction of 180 kDa tyrosine 
phosphoryla ted  protein by IGF-I, d e s  (1 -3)  IGF-I and  IGF-II. 
Confluent layers of Clone 9 cells w ere  t reated  with polypeptide 
ho rm ones  (1, 10 or 100 ng/ml) for 5 min. After preparation of cell 
lysates,  pa tterns of tyrosine phosphory la ted  proteins w ere d e tec ted  
a s  for Fig. 4 by blotting with 4G 10 Arrows indicate the dose -  
de p e n d e n t  stimulation of tyrosine phosphorylat ion of 180 kDa 
protein by both IGF-I and  the d e s  (1 -3)  ana logue .  This experiment 
w a s  rep ea ted  twice.
(Fig. 5B) had stimulatory effect only at h igher concen tra­
tions (which probably indicates cross-reactivity of these 
horm ones at the  IGF-I receptor). These results paralleled 
those of the signalling experim ents described in Figs 3 
and 4 in respect of the  activity of IGF analogues. Indeed, 
we were interested to note the  apparen t increased activ­
ity of the  des (1-3) IGF-I ana logue in this metabolic 
assay, which dem onstra ted  a m uch  higher  activity at 
lower concentra tions (1 ng/ml) than  IGF-I itself (Fig. 5B).
The potential biological significance of these results 
was further suggested by the  dem onstra tion  that Clone 9 
cells secrete IGF-I bu t not IGF-II into su rround ing  
m edium  (Figs 6 A and B). Western blot analysis of co n ­
centrated  m edium  clearly indicated a protein reactive 
with polyclonal anti-IGF-I an t iserum  (Fig. 6A, lane 4). 
A lthough IGF-II cross-reacts to a certain degree with the 
anti-IGF-I antiserum  (lane 5), m ed ium  conditioned by 
Clone 9 cells does not react with anti-IGF-II antisera (Fig. 
6B). We conclude that Clone 9 cells secrete IGF-I but not 
IGF-II into serum free medium. Clearly, therefore, the 
potential exists for locally produced IC.F-I to act in an 
au tocrine fashion at the IGF-I receptor (which we have 
shown to be functional in this cell line; Figs 3-5).
DISCUSSION
There are only limited reports of IGFBP-2 interaction 
with cell m em branes or com ponen ts  of the extra-cellular 
matrix. By a process of in vitro au torad iography  with l2M- 
IGF-I, and im m unohistochem istry  with an anti-IGFBP-2 
specific polyclonal antiserum, Russo et al.'2 reported the 
presence of IGFBP-2 in the  mitral cell layer of the rat 
olfactory bulb. These findings were confirmed by the 
subsequen t im m uno  precipitation of cross-linked l2T  
IGF-I-1GFBP complexes from solubilized olfactory bulb 
m em branes with polyclonal anti-IGFBP-2 antisera. 
Despite the fact that IGFBP-2 contains a consensus RGD 
integrin binding sequence, IGFBP-2 association with
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Fig. 5 An MTT metabolic/ proliferation a s s a y  following t rea tm ent 
of subconfluent  cultures of Clone 9 cells. (A ) Cultures w ere  t reated  
with IGF-I (•), d e s  IGF-I (■) or insulin (A) at  the indicated 
concentrat ions. After 24 h incubation,  microtitre p la tes  w ere 
p ro c e ss e d  for MTT a s s a y  a s  descr ibed  in Materials and  Methods.  
(B ) Cells w ere t rea ted  with IGF-I (•), d e s  IGF-I (■) or IGF-II (A) at 
the indicated concen tra t ions  a n d  p ro c e s s e d  for MTT a s s a y  a s  
described  in (A). For both (A ) a n d  (B ) the n um ber  of da ta  points at 
ea c h  horm one concentrat ion  = 8. R esults  a re  e x p re s s e d  a s  m e a n  ± 
SE. T h e s e  exper im ents  w ere r e p e a te d  at least three  times. The 
results of the MTT a s s a y  for the two t rea tm en ts  IGF-I a n d  des lG F- 
I, at concen tra t ions  1 an d  10 ng/ml (Fig. 5B), w ere  an a ly sed  with 
MINITAB version 11.2 / using a two-way ANOVA (with replications). 
The interaction be tw een  the h o rm o n es  and  the co ncen tra t ions  w a s  
significant ( P =  0.007), indicating that the difference b e tw een  the 
two trea tm ents  is d e p e n d e n t  on  the concentrat ion. W e then 
performed in dependen t  sa m p le s  /-tests to c o m p are  the effect of 
IGF-I and  deslGF-l  at e a c h  of the two concentrat ions.  The 
metabolic/mitogenic effect of the two ho rm o n es  on Clone 9 cells, 
a s  de term ined  with the MTT assay ,  w as  significantly different at the 
concentration of 1 ng/ml (P  < 0.0001), but not at 10 ng/ml (P  =
0.071).
olfactory bulb  m em branes  was not affected by the  pres­
ence of an RGD -  contain ing  peptide. However, im m u n o ­
precipitation of BP-2 revealed the  presence of a 
co-im m unoprecipitat ing  200 kDa proteoglycan contain­
ing chondroit in  sulphate. Indeed, in the same study it 
was reported that,  in vitro, IGFBP-2 b o u n d  to the gly- 
cosaminoglycans- chondroitin-4 and  -6 sulphate, keratan  
sulphate and heparin, leading to the  suggestion that BP- 
2 may associate with these molecules on the cell m em ­
brane or in the  extracellular matrix. In contrast, using an 
in vitro assay based on the binding of IGFBP-2 to
A  M r(k D a)
x  -■■•mt.
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Fig . 6 S erum  an d  protein free medium w a s  conditioned by 
confluent m onolayers  of Clone 9 cells for a  period of 24 h (A) IGF-I 
in concen tra ted  conditioned m edium (CM) w a s  identified by 
W estern  blotting a s  described  in Materials a n d  Methods. Clearly 
evident is IGF-I derived from Clone 9 cell conditioned medium 
(lane 4) together  with 1000 ng (lane 1), 100 ng (lane 2) and  10 ng 
(lane 3) of IGF-I s tandard .  (B) In parallel blots, IGF-II w a s  de tec ted  
by probing with a  polyclonal rabbit an ti-human IGF-II antiserum. 
This exper im ent w a s  re p e a te d  twice.
heparin-Sepharose beads, it was dem onstra ted  that 
IGFBP-2 bound  to heparin and heparin  sulphate, but 
not to chondroit in  sulphate-A or -C or to derm atan  
su lpha te”. Glearly, the exact com ponen ts  of the ECM/cell 
m em branes  responsible for the binding of IGFBP-2 
require furthe r  elucidation. The effect of IGFBP-2 associ­
ation with com ponen ts  of the  cell m em brane  or extracel­
lular matrix on the  subsequen t IGF-IGFBP interaction 
are also a subject of controversy. For example, whereas 
IGFBP-2 binding to chondroitin-6- su lphate  has been 
reported to lower the  affinity of the b inding protein for 
IGF-I by a factor of 3 '2, ano ther  s tudy  has reported that 
precomplexation of IGFBP-2 with e i ther  IGF-I or IGF-II is 
obligatory for the subsequen t b ind ing  of the complex 
with heparin or the  extracellular matrix com ponen ts”.
Clearly, the  presence of cell surface -  associated 
IGFBP-2 together  with the  IGF-1 receptors on the cell 
m em brane  of Clone 9 cells has im portant consequences 
in the response of cells to local IGFs. In a similar vein, 
Reeve et al. '3 dem onstra ted  the  differential distribution
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o f  m em bran e-associated  IGFBP-2 b etw een  sm all cell and  
n on -sm all cell lu n g  carcinom a cu ltu res (SMLC and  
NSCLC). SCLC cells, con ta in in g  abundant m em brane  
associa ted  IGFBP-2 responded  less w ell to ex o g en o u s  
IGF-I in  term s o f  stim ulation  o f  DNA syn th esis than  the  
NSCLC cu ltures, w h ich  con ta in  eq u iva len t levels o f cell 
m em b rane IGF-I receptors b u t little m em b ran e-associ­
ated  IGFBP-2. T he find in gs o f su ch  stu d ies im ply an 
inh ib itory  role for m em b rane-associated  IGFBP-2 and  
confirm  th e  w eigh t o f  ev id en ce  currently available in the 
literature in relation  to  th is particular b ind ing  protein  
(review ed in ref. 25). Similarly, in our current study, we 
find that th e  u se  o f th e  non-IG FBP-binding IGF-I ana­
logu e  des (1 -3 ) IGF-I sh ow s a greater activity over IGF-I 
in  b oth  lon g-term  (24 h) m itogen ic  assays (Fig. 5) and in 
short-term  signalling  experim ents (Figs 3 and 4). In the  
longer-term  m itogen ic  assay, it is clearly possib le that 
secreted  IGFBP-2 m ay accum ulate in the cond ition ed  
m ed iu m , bath in g  th e  cells to an exten t such  that activity  
o f ex o g en o u s IGF-I is com prom ized . Over the shorter 
cou rse  o f IGF-I signalling  experim ents, how ever, it is p os­
sib le that th e  predom inant inhibitory action on IGF-I 
activ ity  is affected  by m em brane (ECM )-associated  
IGFBP-2, a lth ou gh  th is clearly is an h yp oth esis w hich  
requires further investigation .
A lth ou gh  IGF-II is reported to  have a tw o-fold  low er  
affinity for th e  IGF-I receptor than th e  h o m o lo g o u s IGF-I 
ligand, w e b e lieve  th e  activ ity  o f  IGF-II at th e  IGF-I recep­
tor is further com prom ised  in our experim ental system  
by th e reported h igh er affinity o f  BP-2 for IGF-II. In addi­
tion, reports on  relative affinities o f  IGF-I and IGF-II for 
th e IGF-I receptor are largely d ocu m en ted  for h o m o lo ­
g o u s  hu m an  system s. W hether th is h o ld s for th e  rat pro­
teins rem ains to be fully substantiated .
The rat liver cell line u sed  in  th is current study  is 
derived  from  th e liver o f  an adult Sp ragu e-D aw ley  rat26. 
It is ep ithelia l in character and h as b een  dem onstrated  
previou sly  to  secrete IGFBP-2 into serum  free m ed iu m 20. 
O ther param eters o f th e  IGF axis are poorly characterized  
in rat liver cell lines, therefore our observations o f  the  
presence o f  function al IGF-I receptors and the secretion  
o f IGF-I (but n ot IGF-II) by  C lone 9 cells are o f som e sig ­
nificance. T his latter property is shared by primary cu l­
tures o f  rat hepatocytes, a lth ou gh  it is generally  believed  
that leve ls  o f  IGF-I receptors in  adult h ep atocytes are low  
and are increased  on ly  under con d ition s o f hepatic  
regeneration  or during fetal grow th .27 In th e  con tex t o f  
IGFBP secretion , w hereas C lone 9 cells secrete on ly  (or 
predom inantly) IGFBP-2, a spectrum  o f IGFBPs -  in clu d ­
ing IGFBP-1, -2 and -4—are produced  by adult rat h ep ato ­
cytes in cu ltu re2”. To our know ledge, there has b een  no  
report o f  association  o f any IGFBPs w ith  th e  surface o f  
h ep atocytes. Our com parison  o f the com p on en ts o f the  
IGF axis in  C lone 9 cells, and that pu b lish ed  to date for
primary cu ltures o f hepatocytes, em p h asize  th e  epithelial 
rather than  parenchym al nature o f th is ce ll line. This is 
confirm ed by our proliferation stu d ies (Fig. 5A), w here  
insu lin  is m u ch  less active than  either IGF-I or des (1 -3 ) 
IGF-I in a 2 4 -h  MTT assay. Such a pattern o f  reactivity is 
characteristic o f in su lin  acting th rou gh  th e  IGF-I recep­
tor, for w h ich  it d isp lays a low er affin ity than  for the  
h o m o lo g o u s insu lin  receptor. This is con firm ed  by the  
signalling experim ents reported in Fig. 3, w here IGF-I 
and des (1 -3 ) IGF-I are able to  stim u late th e  tyrosine  
p hosphorylation  o f 180 kDa protein  at d o ses  o f 100 
ng/m l, but insu lin  at concen trations o f  up  to  1000 ng/m l 
has little effect on  th e  tyrosine p h osp h ory la tion  o f  this 
protein. Our observations on  th e proliferative effect o f  
IGF-II in  C lone 9 cells cu ltures also im ply  that th e  action  
of th is polypeptide is via th e  IGF-I receptor, confirm ing  
th e  route o f action  described  by o th er  grou p s for the  
m itogen ic effect o f  th is p o lypeptide in  cu ltu res o f  rat 
hepatocytes, a lth ou gh  others h ave su g g ested  d ivergent 
m echan ism s for IGF-I and IGF-II m ito g en esis29-30.
Clearly it w ould be o f interest to identify th e  com p o­
n en ts ) in the m em brane o f  C lone 9 cells responsib le for 
interaction with BP-2. One problem  associated  w ith th is is 
the probable saturation o f BP-2 b in d ing  sites b y  en d oge­
nously-produced  IGFBP-2. In an attem pt to  overcom e this, 
w e are creating C lone 9 cell lines w h ich  are stable trans- 
fectants w ith  anti-sense constructs o f  rat IGFBP-2. As well 
as addressing the difficulties indicated above, such  cell 
lines sh ou ld  help  in confirm ing th e  sign ificance o f the  
autocrine secretion o f IGF-I in th e regulation  o f cell 
growth. It has been  reported very recently that hum an  
em bryonic k idney fibroblasts transfected w ith a m ou se  
IGFBP-2 expression  vector, and w h ich  su bsequently  
express h igh  levels o f mIGFBP-2, have slow er grow th  
curves than  non-transfected cells31. Additionally, and sim i­
larly to our findings, the sam e study reports an enhanced  
activity for an alternative non-IGFBP b in d in g  IGF-I ana­
logu e (long R3 IGF-I) in stim ulating grow th  o f  IGFBP-2 
transfected cells arguing for th e action  o f  IGFBP-2 as a 
negative regulator o f  cell grow th. Further ev id en ce  in sup­
port o f th is hypothesis is provided by th e  observation  that 
the rat intestinal epithelial cell line IEC-6 stably trans­
fected w ith an anti-sense rat BP-2 expression  construct 
displays increased grow th k inetics and grow th  arrested 
m axim um  density  com pared to non-transfected  cells32. In 
this study, the authors w ere unable to  dem onstrate an 
association  o f IGFBP-2 w ith cell m em branes. However, 
their data confirm ed earlier results w h ich  indicated that 
IGF-I an alogues with reduced b inding affinity for IGFBPs, 
stim ulated cell grow th m ore potently than  native IGF-I in 
this cell line,33 a lthou gh  the authors did n ot investigate 
the association  o f  IGFBP(s) w ith  cell m em branes. Together 
w ith our current observations, these data support a role 
for IGFBP-2 as an autocrine regulator o f cell grow th.
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To con clu d e, in relation to  the IGF axis in th e  rat liver 
derived ep ithelia l cell line C lone 9, w e h ave dem onstrated  
that:
(1) This ce ll line con ta ins functional IGF-I receptors and  
responds to  IGF-I and d es (1 -3 ) IGF-I acu tely  (2 -1 0  
m in) by increasing the leve l o f tyrosine  
p hosp h ory la tion  o f  a - 1 8 0  kDa protein, and  
chronically  (24 h) by stim ulatin g  m itogen esis as 
determ ined  by MTT assay.
(2) IGFBP-2 is secreted  into th e  m ed ium  o f C lone 9 
cells, and a proportion o f  th e  b ind ing  protein  
associa tes w ith th e  plasm a m em brane o f th ese  cells.
(3) Secreted  and m em b ran e-b ou nd  form s o f IGFBP-2 
m ay inhib it th e  activ ity  o f  IGF-I, as ev id en ced  from  
th e  greater p o ten cy  o f  th e  non-IGFBP b ind ing  
an alogu e des (1 -3 ) IGF-I in b oth  signalling and  
m itogen ic  assays.
(4) T his m ay have ph ysio log ica l relevance in the  
co n tex t o f  IGF-I action  in an autocrine sense, as w e  
dem onstrate that C lone 9  cells secrete IGF-I b u t not 
IGF-II in to  con d ition ed  m edium .
We b elieve  that th is cell line m ay represent a u sefu l 
m odel to investigate further local regu lation  and action  
o f com p on en ts o f  th e  IGF axis.
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